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This thesis aimed to address a number of unanswered research questions in 
Addison’s Disease:  investigate whether autoimmunity is the predominant cause 
of Addison’s disease in South Africa and if a human leukocyte (HLA) DQ antigen 
association exists; the extent to which lipids, lipoproteins and biochemical markers 
of cardiovascular disease are abnormal; the degree to which replacement doses 
of hydrocortisone are supra-physiological; the impact of glucocorticoid receptor 
(GCR) polymorphisms on risk factors, markers of cardiovascular disease and 
replacement doses of hydrocortisone. 
Patients 
A national database of patients with Addison’s disease was compiled from primary 
care, referral centres and private practices. 148 patients {97 of European descent 
(white), 34 of mixed ancestry, 5 Asian and 12 black African} were matched with 
controls for gender and ethnicity.
Methods 
Demographic and clinical data were elicited using questionnaires. Anthropometric 
data were recorded and blood was drawn. The causes of Addison’s disease 
were investigated using a specific algorithm.  Lipids, lipoproteins and markers 
of cardiovascular disease were assessed. Salivary cortisol day curves were 
evaluated in 31 Addison’s patients on usual hydrocortisone doses and control 
subjects. The role of the GCR polymorphisms was explored to determine its 
influence on metabolic parameters and hydrocortisone dose.
Results 
Fifty one percent of patients’ Addison’s disease was autoimmune in origin. Either 











cohort, while 23% had both. None of the Asian or black patients had detectable 
evidence of autoimmune disease. Overall 8% had tuberculosis, 4% had 
adrenoleukodystrophy, 1% had ACTH-resistance syndrome and 6% had X-linked 
adrenal hypoplasia. HLA DQB1*0201 predominated in the autoimmune group. 
Almost 50% had hypertriglyceridaemia, 65% had hypercholesterolaemia,  about 
75% had low high density lipoprotein cholesterol (HDLC) and 75% had elevated 
low density lipoprotein cholesterol (LDLC). Highly sensitive C-reactive protein 
(hs-CRP) was increased in both white and mixed ancestry patients, compared to 
controls. The Framingham risk >20% in 10 years was found in 36% of the cohort. 
The Addison’s patients had significantly higher first and second peak salivary 
cortisol concentrations, and median and interquartile range (IQR) salivary cortisol 
area under the curve (AUC) than the controls’ endogenous cortisol profiles. The 
AUC correlated with the peak salivary cortisol concentrations in patients, (r = 
0.87; p = 0.0001) and controls (r = 0.74; p = 0.0001). The GCR ER22/23EK 
heterozygous polymorphism was associated with an elevated BMI in patients 
(29.4 versus 24.7 kg/m2; p = 0.02) and healthy controls (26.3 versus 24.2 kg/m2; 
p < 0.0001) but with a lower HDLC in patients, than controls. Neither the BcII nor 
the N363S polymorphisms were associated with any significant alteration in the 
metabolic traits examined.
Conclusions 
The lower prevalence of Addison’s disease in South Africa than Western countries 
is concerning since patients could be dying undiagnosed. Enhanced awareness 
of this highly treatable condition is warranted. Autoimmunity predominated in 
patients mostly of European descent (white), but none of the Asian or black 
patients had either detectable adrenocortical or 21-hydroxylase autoantibodies 
necessitating further local studies to understand whether there is a true ethnic 
predilection for autoimmune Addison’s disease. A low threshold is required 
for screening, intervention and follow-up of all patients for cardiovascular risk 











physiological concentrations of salivary cortisol on hydrocortisone replacement 
should prompt clinicians to screen patients for side-effects. The association 
between the ER22/23EK polymorphism and elevated BMI in both patients and 
controls requires confirmation in a large sample. Further local and international 
studies are warranted to corroborate the findings of this large sub-Saharan study 




















Introduction to primary hypoadrenalism and its possible complications
Chapter 1
Introduction to primary hypoadrenalism and its 
possible complications
1.1 Introduction
Addison’s disease was first described in 1855 by Thomas Addison at Guy’s 
hospital as a disease that caused the symptoms of “general languor and debility, 
remarkable feebleness of the heart’s action, irritability of the stomach, and a 
peculiar change of colour in the skin, occurring in connection with a diseased 
condition of the supra-renal capsules”.1 This was an era in which biochemical 
testing and confirmation were not available.  Addison’s disease was invariably 
fatal, but despite the fact that life-saving glucocorticoid (GC) replacement 
therapy has been available since 1949, multiple challenges remain with respect 
to its management.2 At least two famous people are said to have had Addison’s 
disease.  A posthumous diagnosis was made in Jane Austen by the symptoms 
and signs that she had exhibited during her lifetime.3 President John F Kennedy 
also suffered from Addison’s disease.  There has been debate as to whether this 
illness affected his performance as a president.4 5 
This overview is intended to review the literature that underpins the work conducted 
for this thesis. Due to the divergent nature of the fields that it covers, it is inevitable 
that it is voluminous. The clinical aspects of primary hypoadrenalism are first 
summarized. This is followed by a description of the anatomy and embryological 
aspects of adrenal gland development. The aetiology of primary hypoadrenalism 
is then discussed. As autoimmunity represents an important underlying cause, 
the pathogenesis of autoimmunity is described, highlighting the normal defences 
against autoimmunity and why these should fail. As autoimmune primary 
hypoadrenalism frequently occurs as part of a cluster of autoimmune endocrine 
conditions, the clinical aspects of autoimmune polyglandular syndromes are 
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then reviewed. In view of patients with Addison’s disease not having the same life 
expectancy as the background population, the possible impact of GCs on lipids 
and lipoproteins was considered next. This is followed by an appraisal of the 
methods used for monitoring GC replacement therapy in primary hypoadrenalism 
and in particular, salivary cortisol in this regard. A review of how the presence 
of glucocorticoid receptor (GCR) polymorphisms may impact on GC action 
concludes the literature overview.
1.2 Clinical presentation
Addison’s disease may present either with acute or chronic primary adrenal 
insufficiency, which have substantially different features.
1.2.1 Acute primary adrenal insufficiency
Acute primary adrenal insufficiency is characterised by orthostatic hypotension, 
agitation, confusion, circulatory collapse, abdominal pain and fever. Acute adrenal 
decompensation is caused by haemorrhage per se, or rarely by bleeding into 
metastases of the adrenal glands, often precipitated by coexistent acute infection 
leading to death if left untreated.6 7
1.2.2 Chronic primary adrenal insufficiency
The diagnosis of chronic primary adrenal insufficiency is frequently preceded by 
a history of prolonged hyperpigmentation, malaise, fatigue, anorexia, weight loss, 
gastrointestinal disturbance, and joint and back pain. Patients may crave salt 
and develop unusual food preferences, such as drinking the brine surrounding 
pickles.8 Hyperpigmentation is the most frequently encountered sign. It is more 
easily recognised in the sun-exposed areas of the face, neck and arms, and 
also occurs on areas that are subject to trauma such as the knees and knuckles. 
However hyperpigmentation may be more difficult to recognise in darker-skinned 
races, as the palmar creases and mucous membranes are often normally 
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should alert clinicians to the possibility of Addison’s disease. However, increasing 
pigmentation of the skin is not diagnostic of primary hypoadrenalism.9  Scalp hair 
may also become darker, new naevi may be observed10  and calcification of the 
cartilage of the ear may occur.11
Primary autoimmune adrenal insufficiency may exist as a component of 
autoimmune polyglandular syndrome (APS). Vitiligo may be demonstrable 
in up to 9% of patients with APS1 and 5% of patients with APS2. An unusual 
manifestation of vitiligo is that scalp hair although hyperpigmented initially, may 
ultimately lose its pigmentation.10
Hyponatraemia, hypoglycemia, hyperkalaemia, unexplained eosinophilia and mild 
pre-renal dysfunction are together highly suggestive of primary hypoadrenalism.12 
13  Although the finding of recurrent hypoglycaemia in a type 1 diabetic should 
alert a clinician to the possibility of Addison’s disease, it is an uncommon cause 
of recurrent hypoglycaemia (1%).14 15
1.3  Anatomy and embryology of the adrenal glands
The adrenal glands are small triangular glands; one located above each kidney. 
The left adrenal gland is crescent-shaped and the right gland is pyramidal in 
shape (Figure 1). Both glands are surrounded by firm fibrous capsules that often 
merge with the perinephric capsules. The adrenal glands are supplied by the 
phrenic artery, the abdominal aorta and the renal arteries.16 The veins draining 
the adrenal glands are the shorter right adrenal and the left longer adrenal veins. 
Variations of venous drainage and arterial supply are known to occur, and one case 
of the right middle adrenal artery arising from the right renal artery was recently 
documented.17 The major lymph vessels drain the medulla and subcapsular 



































Figure 1: The anatomy of the adrenal glands.  The arterial supply, venous drainage and relations 
of the adrenal glands are shown.  Adapted from Human anatomy Martine FH, Timmons MJ, 
Robert MB et al, 2006  The endocrine system, the adrenal gland Chapter 19, Figure 19.9 page 
513. Berriman L Daryl Fox San Francisco Fifth edition.19
The adrenal glands have a larger outer cortex and a smaller inner medulla. 
The glands measure between 3 cm and 4 cm at their longest diameters, have 
a mass of between 5 to 7g,20 and have a yellow colour imparted by the rich 
lipids within the cortices. The adrenal medulla, by contrast, is reddish-brown.21 
In most mammals, the adrenal cortex consists of an outer zona glomerulosa, 
intervening zona fasciculata and an inner zona reticularis. A narrow population of 
stem cells surrounds the zona glomerulosa, facilitating progressive development. 
This population of cells may ultimately give rise to adrenocortical neoplasia.22
1.3.1 Embryological development of the adrenal glands
The mesodermal ridge gives rise to both the kidneys and adrenal cortices, 
which helps to explain their close anatomical proximity. At around the fourth 
week of gestation, the coelomic epithelial cells and the underlying mesonephric 
mesenchymal cells migrate from the mesonephros to form the most rudimentary 
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of large polyhedral cells of coelomic mesothelium. Primitive sympathetic cells 
migrate with nerve tracts to form the adrenal medulla. In the seventh week in 
utero, the paraganglionic cells replicate and differentiate and by the eighth week, 
discrete foetal gonadal and adrenal tissues are discernible, which then develop 
as separate entities thereafter (Figure 2).  Between the eighth and ninth weeks 
of gestation, adrenal glands are encapsulated, which results in a distinct organ 

























Figure 2: The significant events in the early human adrenal gland development. a) The adrenal 
cortex develops from the intermediate mesoderm. b) The intermediate mesoderm contains 
adrenogonadal progenitor cells, which give rise to steroidogenic cells of the adrenal gland and 
gonads.  The cells due to become adrenal tissue migrate retroperitoneally to the upper pole of 
the mesonephros. c) At about 5 weeks, the adrenal and gonadal primordial develop as separate 
entities. d) Between 8 and 9 weeks, the adrenal gland becomes encapsulated and already 
exhibits a foetal and definitive zone. Adapted from Ferraz-de-Souza B, Achermann JC. Disorders 
of adrenal development. 2008. Endocrine development. 13:19-3223
The human foetal adrenal gland comprises two distinct zones; the foetal zone 
and the definitive zone. The former accounts for 80-90% of the adrenal cortex 
at term and is responsible for the elaboration of mainly androgens, especially 
dehydroepiandrosterone (DHEA). The definitive zone is responsible for producing 
cortisol. A transitional zone exists between these two zones and is capable of 
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has a persistent postnatal layer adjacent to the medulla known as the X zone. 
In many respects, the X zone is similar to that of the foetal adrenal tissue.  The 
development of the adrenal cortices is different in mice and humans as CYP17 
is expressed only transiently in the former, explaining why mice adrenal glands 
produce primarily corticosterone rather than androgens.22   At birth the significant 
reduction in adrenal volume is matched by a rapid reduction in the levels of 
androgens. A specific molecular clock has been proposed to direct the number 
of cell divisions that facilitates involution of the foetal zone.  Foetal pituitary 
adrenocorticotrophic hormone (ACTH) is responsible for the phenomenal growth 
of the foetal zone,25 while insulin-like growth factor (IGF II), fibroblast growth factor 
and epidermal growth factor mediate growth of the foetal adrenal gland.26   The 
development of the vascular network may be facilitated by vascular endothelial 
growth factor (VEGF) and angiopoietins.27
1.3.2   Molecular aspects of adrenal development
The molecular underpinnings of adrenal development are highly complex, rapidly 
expanding and in the last two years alone (between August 2008 and August 2010) 
51 publications were identified in a Pubmed search. The formation of the primitive 
adrenogonadal primordia (AdP), occurs under the influence of transcription factors 
empty spiracles2 (Emx2), Lin 11 Islet 1 and Mec-3 homeobox gene 1 (Lim1), 
Wilms tumour 1 (Wt-1) and wingless-type MMTV integration site family member 4 
(Wnt4).28  Figure 3 demonstrates the various combinations of transcription factors 
that direct the development of undifferentiated primordial cells to form the adrenal 
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Figure 3: Molecular and genetic aspects in adrenal gland and gonadal development. Adapted 
from Principles of Molecular Medicine pg 410, Marschall Stevens Runge, Cam Patterson.28 
Transcription factors Emx2, Lim1,Wt-1 and Wnt4 are critical for the development of the 
adrenogonadal primordium. This forms following amalgamation of primitive mesoderm and 
coelomic epithelium. Thereafter various combinations of transcription factors will direct the fate 
of the undifferentiated primordial cells along one or a number of pathways to form the adrenal 
cortex, kidney, bipotential gonad and internal reproductive tract primordia. Factors highlighted in 
bold are involved in human development.
Abbreviations: 
DAX1 dosage-sensitive-sex-reversal-adrenal hypoplasia congenita locus on the X-chromosome 
gene 1, Emx2: empty spiracles 2, Hoxa1: homeobox A 1, Lhx9: lim homeobox gene 9, Lim: 1 
Lin11 Islet 1 and Mec-3 homeobox gene 1, Sf1: steroidogenic factor 1, Wt-1: Wilms tumour 1, 
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The AdP has its origins at the primitive urogenital ridge29 and its formation is 
critically dependent on the expression of the nuclear receptor steroidogenic 
factor 1 (Sf1).30 Both these primitive organs appear to arise from a single group of 
cells because they stain immunohistochemically strongly positive for Sf1.29  The 
bilateral AdP then divide into the foetal adrenal and the gonadal primordia. Wnt4 
is critical for this separation of the AdP.
Foetal zone specific Sf1 enhancer (FadE) is specific for adrenal development, as it 
is absent in the gonadal primordium.29  The AdP expresses Wt-1 and Wnt4, which 
have been found to be crucial in the differentiation of both adrenocortical and 
gonadal stromal cells.31 32  The Wnt pathway regulates proliferation, specification 
of cell fate, stem cell maintenance and differentiation. Wt-1 is responsible for 
the molecular specification of the adrenal primordia by up-regulation of Sf1. 
Development of the adrenal primordia is directed through the up-regulation of 
Sf1 by Wt-1, transcriptional co-activator CREB-binding protein/P 300-interacting 
transactivator, with ED-rich tail, 2 (Cited2). As the adrenal primordia separate 
from the AdP, they are subject to the action of a transcription complex containing 
the homeobox protein [(PKNOX1, homeobox gene 9b and pre-B-cell leukaemia 
homeobox 1 (Pbx1)] and their principal function is to maintain Sf1 foetal zone 
expression.30 33 
It has been suggested that stem cells within the capsule give rise to the definitive 
cortex in response to a number of morphogenic signals.33   Simultaneous with 
the transcriptional cascade, mesenchymal cells that are Sf1 negative coalesce 
to form a capsule around the foetal cortex (Figure 4). As soon as the capsule is 
complete, the adult cortex develops in the intervening tissue between the capsule 
and foetal cortex. Following various mitogenic stimuli, the capsule undergoes 
symmetrical division, developing another capsule cell, which in turn produces 
a subcapsular progenitor cell. The capsule and subcapsular population of cells 
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receptive to ACTH and angiotensin II signals, which direct the differentiation of 
these cells to producing steroids.33 
Sf1/adrenal 4-binding protein (Ad4BP) like other nuclear hormone receptors, 
has an N-terminal zinc finger DNA-binding domain, a ligand-binding domain 
and a C-terminal AF-2 activation domain.34  Sf1 actively promotes a variety of 
steroidogenic enzymes following ACTH stimulation and is essential not only for 
providing the subcapsular cells with their ability to proliferate, but is also essential 
in interacting with other transcription factors.33 
Sf1 also interacts with transcription factors cyclic AMP response element 
binding protein and β-catenin. Pbx1 is a downstream mediator of Sf1-dependent 
proliferation of subcapsular cells. DAX1 (dosage-sensitive sex reversal, adrenal 
hypoplasia congenita critical region, on chromosome X gene 1) positive together 
with Sf1 positive progenitor cells are responsible for transiently amplifying non-
steroidogenic cells.33  Investigation of patients with adrenal hypoplasia congenita 
has revealed that nuclear receptors Sf1, DAX1, and the Pbx1 play pivotal roles 
in the development of the adrenal cortex. The homeobox genes are thought to 
induce the Ad4BP/Sf1 expression in the intermediate mesoderm and interact with 
Pbx1, critical in the early development of adrenal development.30  FadE functions 
to fine-tune expression of the Ad4BP/Sf1.30  The amount of Ad4BP/Sf1 expressed 
will ultimately determine the size of the mature adrenal gland. Interestingly, 
DAX1 and Sf1 mutations produce a similar clinical picture of X-linked adrenal 
hypoplasia congenita, suggesting their interaction. The DAX1 gene product acts 
as a repressor of Sf1 transactivation, preventing transcription. By contrast, ACTH 
stimulation inactivates DAX1 and initiates steroidogenesis.33 
Wnt signalling is crucial in the canonical and planar polarity pathway (Figure 4). In 
the absence of Wnt ligands, β-catenin is found predominantly in the cell membrane 
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accumulates in the cytoplasm and nucleus, resulting in the activation of various 
genes including Sf1 and DAX1, suggesting that β-catenin has an important role 
to play in adrenal cortex development through proliferation, specification of cell 
fate, stem cell maintenance and differentiation.35 36   As Wnt4 is a secreted protein 
with a critical role in female genital and adrenal gland development, disruption of 
this protein in a mouse model resulted in abnormal differentiation of the adrenal 
cortex and sex-reversal.37   Aberrant migration of adrenocortical cells into the 
developing gonad was observed in the absence of Wnt4.38
Very large quantities of inhibin-α are produced by the foetal adrenal gland, 
which ensures adrenal specification and unresponsiveness to human chorionic 
gonadotropin-mediated ovarian development.33 
All GATA transcription factors are zinc finger transcription factors that bind to 
specific DNA sequences. GATA-4 has been detected exclusively in the foetal 
adrenal gland and has been shown to work in concert with Sf1 for adrenocortical 
development.22 GATA-4 plays an essential role in upregulating inhibin-α, 17 
α-hydroxylase (CYP17) and steroidogenic acute regulatory protein (StAR). 
Ad4BP/Sf1 is expressed in three zones of the adrenal cortex and is critical for the 
regulation of the genes encoding the steroid hydroxylases.39
Sonic hedgehog (Shh) is a signalling glycoprotein that is known to have a key 
morphogenic function in organogenesis including limb development.40 It binds to 
a receptor of Patched 1 (PTCH1) and Smoothened (SMO), which in turn activates 
the downstream pathway of glioma associated oncogene homologue (Gli)1, Gli2 
and Gli3 transcription factors. Shh is expressed by relatively undifferentiated 
steroidogenic cells and is involved in the expansion of the progenitor pool in the 
adrenal capsule. Sf1 positive adrenocortical cells expand the cortex by producing 
Shh upon the adrenal capsule.41 The subcapsular cells gain Sf1 expression, but 
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Figure 4: Molecular aspects of adrenal cortical cell development. Adapted from Kim AC, Barlaskar 
FM, Heaton JH, Else T, In search of adrenocortical stem and progenitor cells 2009 Endocrine 
Reviews pages 241-263.33   Stem cells within the capsule give rise to the definitive cortex. 
Mesenchymal cells negative for Sf1 (steroidogenic factor-1) coalesce to form a capsule around 
the foetal cortex. Following mitogenic stimuli, the capsule produces another capsule cell, which in 
turn produces a subcapsular progenitor cell. ACTH and angiotensin II direct the differentiation of 
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transcription, while ACTH inactivates the former. Sf1 interacts with other transcription factors 
for adrenocortical development. Wnt signalling is crucial in the canonical and planar polarity 
pathway. Wnt4 is involved in female genital development. Large quantities of inhibin-α ensure 
adrenal rather than ovarian development. GATA-4 plays a role in up-regulating inhibin-α, CYP17 
and StAR (steroidogenic acute regulatory protein) and is thus critical for up-regulating the genes 
encoding the steroid hydroxylases.  Shh (Sonic hedgehog) is a glycoprotein and has a key 
morphogenic function. Shh is expressed by relatively undifferentiated steroidogenic cells and 
expands the progenitor pool in the adrenal capsule. The subcapsular cells gain Sf1 expression, 
but have limited steroidogenic potential. They continue to proliferate and migrate towards the 
corticomedullary boundary acquiring full steroidogenic activity. E: Oestrogen; T: testosterone 
AR: androgen receptor; GR, glucocorticoid receptor; GC: glucocorticoid. FSH: follicle stimulating 
hormone; LH: luteinising hormone 
1.3.3    Foetal production of cortisol and dehydroepiandrosterone (DHEA)
StAR, 11 beta-hydroxylase, 17α-hydroxylase, 3 β-hydroxysteroid dehydrogenase 
and 21-hydroxylase enzymes have been detected by immunohistochemistry at 50-
52 days postconception. The presence of high concentrations of transient nerve 
growth factor IB-like (NGFI-B) through its regulation of type 2 3 β-hydroxysteroid 
dehydrogenase, along with early ACTH secretion from the pituitary in the first 
trimester may be responsible for the earl  production of cortisol,42 while epidermal 
growth factor (EGF) may be responsible for promoting adrenocortical growth.43 
Taken together it appears as though the combination of NGFI-B and ACTH are 
critical in the early development of a functioning hypothalamic-pituitary adrenal 
(HPA) axis, but the mechanisms that regulate NGFI-B expression and the 
precise order in which control occurs remain uncertain.42  The volume of steroid 
hormones produced is influenced by the arterial perfusion of the adrenal, which in 
turn is affected by the prevailing partial pressure of oxygen, endothelin and nitric 
oxide. ACTH exerts a vasodilator action on the arteries, which supply the adrenal 
cortex. The zona glomerulosa is able to release epoxyeicosatrienoic acids (EETs) 
in response to ACTH secretion. These EETs induce vascular smooth muscle 
relaxation and ultimately lead to growth of the adrenal cortices.44  Concomitantly 
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as the onset of the second trimester. Large volumes are first secreted during the 
second and third trimesters by the adrenal cortices.42 46
1.4 Aetiology of Addison’s disease
Although an increasing prevalence of primary adrenal insufficiency has been 
reported in Western countries over the past four decades, it is unclear whether 
this constitutes a true rise in prevalence or heightened awareness.47 48   Our 
understanding of the aetiology of Addison’s disease has evolved over time.  In 
the latter half of the 20th century it has been a decline of Addison’s disease 
attributed to tuberculosis from 33% to 2.6%, while the majority are now thought to 
be autoimmune in origin.49  Indeed, it is only since the discovery of specific adrenal 
autoantibodies that a definitive diagnosis of autoimmune Addison’s disease could 
be made. Autoimmune Addison’s disease is the most common form of primary 
adrenal insufficiency in Western countries, accounting for 68-94% of cases, even 
though this has sometimes been assessed by adrenal autoantibody assays run 
in excess of 10 years after the onset of clinical disease.48-51   In an Italian study, 
70% of patients with previously designated idiopathic Addison’s disease, with a 
disease duration of less than 20 years, were positive for adrenal autoantibodies, 
which is consistent with an autoimmune aetiology.52 Positive adrenocortical 
autoantibodies (ACA) and 21-hydroxylase autoantibodies were reported in up to 
90% of patients with recent-onset autoimmune Addison’s disease, compared with 
0.3% among healthy Italian control subjects.53-55
Autoimmune Addison’s disease may occur as an isolated condition or in association 
with the APS. In childhood,6 49 APS1 occurs in association with hypoparathyroidism 
and mucocutaneous candidiasis and in adulthood APS2 occurs in association 
with type1 diabetes mellitus (T1DM) and autoimmune thyroid disease.56
A wide variety of infections have been ascribed to cause Addison’s disease. Of 
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histoplasmosis, coccidiomycosis and blastomycosis, occur relatively rarely.6 
In most recent Western series, tuberculosis accounts for 15% of all Addison’s 
disease cases.55  Adrenal insufficiency secondary to histoplasmosis is extremely 
rare,57  but asymptomatic infection of the adrenal glands by histoplasmosis occurs 
more commonly and should be considered in the differential diagnosis of enlarged 
adrenal glands.58 59  Adrenal involvement due to Cryptococcus neoformans, 
Toxoplasma gondii, Mycobacterium avium-intracellulare and Kaposi’s sarcoma, 
usually in an in immunocompromised state, arise from human immune deficiency 
virus (HIV) infection.60  Hyponatraemia may be falsely attributed to gastrointestinal 
involvement, particularly severe diarrhoea, rather than to hypoadrenalism 
secondary to HIV infection.61 62  In one study, frank hypoadrenalism in advanced 
HIV was reported as remarkably uncommon.61  End-stage acquired immune 
deficiency syndrome (AIDS)-associated opportunistic infections, for example 
cytomegalovirus (CMV) or Mycobacterium avium-intracellulare, may impair 
adrenal function by direct invasion of the adrenal cortex. CMV may remain latent 
for many years and become activated in an immunocompromised individual. 
CMV may affect the retina, oesophagus and the interstitium of the lungs. Thus, 
these coexisting conditions may suggest that CMV may be the underlying cause 
for Addison’s disease.63  A single case report has described Addison’s disease in 
a paediatric patient with CMV and HIV-1 co-infection.64
The adrenal glands are frequently infiltrated by metastatic and lymphomatous 
spread from primary carcinomata of the lung, breast, kidney, bladder, pancreas, 
melanomata and haematological malignancies, and hypoadrenalism can 
occur.65 This was recognised as early as 1855 by Addison, who first suggested 
that adrenal metastases could induce adrenal insufficiency, but the prevalence 
of hypoadrenalism in this context is remarkably poorly documented.66 At least 
90% of the adrenal glands need to be replaced by tumours in order for primary 
hypoadrenalism to result. Although it is mandatory to exclude adrenal dysfunction 
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may persist, despite significantly enlarged adrenal glands.67-70  Interestingly, many 
of these patients demonstrate a paradoxical supra-normal cortisol response to 
ACTH stimulation testing, which is thought to be the result of chronic stress.71
Lung cancer is the leading cause of cancer mortality in most countries, with the 
global incidence increasing by 0.5% per year.72  In a series of 500 consecutive 
cancer autopsies, 42% of metastatic lung cancers involved the adrenal glands. 
This high prevalence of adrenal metastases may reflect the rich sinusoidal blood 
supply and high local concentration of GCs, which may promote implantation 
of metastases.73 There are sparse data on the prevalence of hypoadrenalism 
in metastatic bronchogenic carcinoma. Redman and colleagues,74 reported a 
33% prevalence of hypoadrenalism in 15 patients with a variety of metastatic 
carcinomas (including lung, colon, gastric, ovary and an unknown primary) and 
bilateral adrenal enlargement on CT scan. However, the criteria for hypoadrenalism 
used (cortisol increment of <150 nmol/L or a peak cortisol concentration <415 
nmol/L), do not accord with accepted criteria for primary adrenal insufficiency.47 75 
Lutz and colleagues76 employed more conventional diagnostic criteria and studied 
patients with either unilateral (n = 8) or bilateral (n = 9) adrenal metastases, not 
exclusively bronchogenic, and found no evidence for overt hypoadrenalism.76 
Several factors may potentially account for under-reporting of hypoadrenalism 
associated with metastatic carcinoma. Firstly, since the symptoms of adrenal 
insufficiency are similar to those of extensive metastatic disease, adrenal 
insufficiency is seldom considered in a patient whose condition is progressively 
deteriorating with increasing anorexia, malaise and weight loss.77 Secondly, 
the treatment of metastatic cancer of the lung with GCs may mask the state of 
adrenal insufficiency. Thirdly, since the syndrome of inappropriate anti-diuretic 
hormone (SIADH) is often encountered in small-cell carcinoma, hyponatraemia 
may be incorrectly attributed to SIADH rather than primary adrenal insufficiency.78 
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manifestation of cancer and of malignancies initially presenting as an Addisonian 
crisis.79 80  To address this uncertainty, the prevalence of hypoadrenalism using 
validated diagnostic criteria in patients with advanced (stage III or IV) bronchogenic 
carcinoma and were not pre-selected for adrenal metastases, was investigated. 
In this cohort of 30 subjects, two patients had definitive evidence for adrenal 
insufficiency, with the peak cortisol of 536 and 545 nmol/L, associated with a 
raised plasma ACTH concentration of 131.4 pmol/L and 10.5 pmol/L, respectively 
(normal 2.2-10.0 pmol/L) following a 250 µg ACTH stimulation test.  The overall 
prevalence of adrenal insufficiency was 6.7% in the series (95% confidence 
interval 0.8%-22.1%),7  which was in contrast to the 33 % reported by Redman 
et al.74 
Adrenoleukodystrophy (ALD) is a rare X-linked condition (1:20 000 males) 
characterised by a deficiency of peroxisomal membrane ALD protein, which 
transports activated acyl-CoA derivates into the peroxisomes, where they are 
shortened by beta-oxidation. The ALD protein, which is similar to the adenosine 
triphosphate (A.T.P.)-binding cassette transporter super family of proteins, 
is encoded by the ALD gene mapped to Xq28.81 This deficiency results in 
accumulation of very long chain fatty acids (VLCFAs) in the blood, adrenal gland, 
brain, testis, and liver.82 The ensuing demyelination may evoke an autoimmune 
reaction.83   The adrenal glands may sustain damage by VLCFA accumulation, 
inducing cell membrane microviscosity and subsequent alterations in ACTH 
action.84
The presentation of ALD may vary widely, with six distinct described types ranging 
in decreasing order of severity down to asymptomatic individuals. The childhood 
cerebral type is the most devastating form. It occurs in 31-35% of patients with 
ALD, and is characterised by adrenal insufficiency and progressive relentless 
neurological dysfunction, often presenting with cognitive and gait disturbances, 
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cerebral form occurs in 6-12% of patients with ALD and resembles the child-type 
in which spinal cord, peripheral nerve and psychiatric symptoms predominate. 
However, its progression is far slower than the childhood cerebral form.85-87 
Adrenomyeloneuropathy occurs in 40-46% of patients with ALD and typically, 
the age of onset is between 20 years and 40 years of age. It has a reduced 
propensity to affect cortical function, and a greater tendency to affect the long 
ascending and descending tracts of the spinal cord, inducing inter alia urinary 
and erectile dysfunction along with hypoadrenalism.88 Approximately 10-20% of 
X-linked ALD patients have primary adrenal insufficiency without neurological 
involvement and a proportion may be entirely asymptomatic, despite very high 
levels of VLCFA. Female carriers may have neurological involvement due to non-
random X inactivation, with a similar clinical picture to adrenomyeloneuropathy, 
but a slower rate of progression and rarely, adrenal involvement.85  A proportion of 
patients with Addison’s disease due to ALD without neurological damage exhibit 
increased VLCFA and their brothers also demonstrate increased VLCFA.82 
Although dietary restriction of VLCFA, particularly hexacosanoic acid (C26:0) may 
normalise plasma VLCFA, it does not produce a significant clinical improvement 
and the ongoing deterioration may be accounted for by an autoimmune process.83 
Sarcoidosis has previously been suggested as a cause of Addison’s disease. 
However, some reports suggest that the sarcoidosis may have been coincidental, 
as the Addison’s disease coexisted with another autoimmune gland failure 
compatible with Schmidt’s syndrome.89
The triple A or Allgrove’s syndrome is an autosomal recessive disorder, 
characterized by the triad of achalasia cardia, alacrima and ACTH-resistant 
adrenocortical insufficiency. It is also known as the achalasia-Addisonianism-
alacrima syndrome (AAAS) and results from mutations on chromosome 12q13.90 
The antiphospholipid syndrome may result in primary hypoadrenalism, either due 
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vascular occlusion of the adrenal vessels, or secondary to anticoagulant therapy 
in the presence of antiphospholipid antibodies. Autoimmune mechanisms could 
also be causative in association with the antiphospholipid syndrome.91  Intra-
adrenal haemorrhage may hinder normal steroid hormone production within the 
adrenal cortex, infrequently resulting from long-term anti-coagulation therapy.6 
Haemorrhaging of the adrenal cortices has been demonstrated following 
prophylaxis with anti-coagulation for joint replacements.92 It has been postulated 
that a stressed adrenal gland, that is significant ACTH stimulation, may be more 
predisposed to haemorrhage if anticoagulation is concurrently administered.93
A rare cause of primary adrenal insufficiency is Erdheim-Chester disease, which 
is a non-Langerhans form of histiocytosis, characterised by xanthomatous 
infiltration of tissues with foamy histiocytes. The pituitary gland is the most 
common gland to be affected and primary hypoadrenalism has been documented 
rarely. In the largest case series (n = 22) of Erdheim-Chester disease, adrenal 
enlargement was detected in seven cases (31.8%), but only one patient had 
adrenal insufficiency.94
Mutations in transcription factors responsible for normal adrenal gland 
development have been found to induce a familial syndrome of congenital adrenal 
hypoplasia. These include mutations of any of the following: DAX1 [dosage-
sensitive sex reversal, adrenal hypoplasia congenital (AHC), critical region on the 
X chromosome, gene-1, NR0B1/AHC] and steroidogenic factor-1 (Sf1, NR5A1 
and Ad4BP.95 96 Males with congenital adrenal hypoplasia usually present in 
infancy or early childhood with salt-losing primary adrenal failure, recognised by 
profound hyponatraemia, global GC deficiency in infancy and arrested puberty 
because of associated hypogonadotropic hypogonadism.96   Duplication of the 
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The Smith-Lemli-Opitz syndrome is a genetic disorder resulting from 
7-dehydrocholesterol reductase mutations in the gene DHCR7 producing growth 
failure, mental retardation and craniofacial malformations. Moreover some 
mitochondrial DNA deletions resulting in the Kearn’s Sayre syndrome may cause 
external ophthalmoplegia, retinal degeneration, cardiac conduction defects 
and other endocrinopathies.2  Several drugs have been implicated in causing 
adrenal insufficiency with glucocorticoid treatment being the most common and 
exposing it on withdrawal.  Other drugs include anticoagulants which may induce 
adrenal haemorrhage, while aminoglutethamide, ketoconazole, fluconazole and 
etomidate are able to inhibit specific enzymes of cortisol synthesis.  Moreover, 
phenobarbital, rifampicin and phenytoin inter alia have resulted in activation of 
cortisol metabolism.98
1.4.1 Pathogenesis of autoimmunity 
The cardinal function of the immune system is to protect an organism from 
infection. Vertebrates have developed a large range of T-cell and B-cell receptors 
that alert an organism to infectious agents. Once an offending agent has been 
identified, there are multiple mechanisms with which an organism can defend 
itself. The particular mechanism it selects depends on the site and the type of 
prevailing infectious agent. For example, if the offending agent is in the blood 
circulation, antibodies are likely to provide protection.99 Separate immune defence 
mechanisms operate in humans. The most rudimentary system or innate immunity 
functions to defend the organism against oxidative stress, but must discriminate 
between foreign and self. The most sophisticated immune defence system 
relies on clonal selection of specific antibodies.100 Since natural killer (NK) cells 
share characteristics of both innate and adaptive immunity including harbouring 
memory of a previous exposure to specific antigen, execution of a brisk response 
to a pathogen and secretion of interferon-γ in response to a cognate ligand, it 
could be considered to act as a bridge between innate and adaptive immune 
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Although a relatively small proportion exists in blood, the remainder represents a 
formidable subset of intraepithelial lymphocytes, capable of recognising inter alia 
small bacterial phosphoantigens. Some of the γ-δ T-cells require induction prior 
to their involvement in effector function, and this prepared state may represent 
innate immunity. As their responses are both compatible with innate- and antigen-
specific, they also have the ability to provide intermediate protection between 
innate and adaptive immunity.102
Although diversity is ensured by multiple rearrangements of genes, there is a risk 
of producing antibodies or T-cell clones that react with self components of the 
host organism. Enormous diversity of the T-cell receptor functions is achieved 
through the random rearrangements of both α- and β- genes. These rearranged 
segments of genes are ultimately spliced together, generating functional mRNA, 
and in turn, multiple permutations of α- and β- protein chains.103  Immunoglobulins 
are produced by B-cell lines, which originate in the bone marrow and then reside 
in either the spleen or peripheral lymph glands. As in the case of T-cells, multiple 
genes are responsible for the diverse repertoire of antibodies. The κ and γ 
genes encode light chains, while a single gene family is responsible for encoding 
heavy chains. The variable region (V) is responsible for binding directly with the 
antigen.104
Elimination of T-cells that are directed at the self occurs in the thymus and is 
referred to as negative selection.105 Certain subsets of T-cells directed at self may 
escape elimination, due to some autoantigens not being detected in the thymus.105 
106  Autoreactive B-lymphocyte elimination occurs in the bone marrow.107  Central 
and peripheral tolerance ensures that immune cells react intensively with foreign 
antigens, but weakly with self antigens. Autoreactive cells not eliminated by either 
of these two mechanisms may induce autoimmunity.
1.4.2 Recognition of a foreign or harmful antigen 
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the thymus where they evolve into mature T-cells. The thymus facilitates the 
production of various T-cell receptors. Early T-cells differentiate into either CD4 
or CD8 cells.108  The vast majority of mature T-cells are tolerant to self antigens. 
T-cells react to foreign antigens that are bound to the major-histocompatibility 
complex (MHC).109 T-helper cells are stimulated by antigen-presenting cells 
(APCs), such as macrophages and dendritic cells. Various chemokines follow 
initial contact with an antigen.110  T-helper cells also stimulate B-lymphocytes 
to evolve into immunoglobulin-producing plasma cells. Mature B-lymphocytes 
are able to migrate from the bone marrow to peripheral lymphoid tissue. The 
primary follicles within the lymphoid tissue are dedicated areas where class 
switching may occur. This is a process where B-lymphocytes, in a heightened 
state of stimulation can change their immunoglobulin class production.111  Most 
B-lymphocytes may become resting cells and serve as memory cells, which are 
fundamental in ensuring a class switch of immunoglobulins with re-stimulation by 
the same antigen.112
T-cells, but not B-cells require the antigen to be bound to the MHC, which is a 
series of over 150, interconnected genes with a critical role in the presentation of 
antigens.113   MHC is divided into three complexes. Class I and II are responsible 
for antigen presentation114  and class III MHC proteins will be discussed below. 
Foreign antigens or proteins are fragmented within the cells and part of the protein 
is then displayed in the cell membranes of the MHC. Class I MHC proteins for 
example, HLA-A, HLA-B and HLA-C are ubiquitous, are found on virtually all 
cells and have the ability to present peptides, derived from the cell cytoplasm, 
to CD8 T cells.  This is sometimes referred to as the cytosolic or endogenous 
pathway.115 T-cells are also designed to destroy endogenous antigens, which are 
presented through the class I MHC. Viruses or malignant cells, which present 
abnormal antigens through the former mechanism, may be eliminated by lysis.116 
NK cells are not HLA-A restricted. They produce cytokines, such as interferon 
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express HLA class I molecules. Some viruses escape CD 8+ class I expression. 
Genes encode HLA-A, B, C and CD1 regions.117  MHC class Ib protein HLA-E has 
a specialised function that permits cell recognition by NK cells, but it also has the 
ability to interact with the T-cell receptor.118
By contrast, MHC class II molecules are found only on specialised cell types 
that function as APCs, including macrophages, dendritic cells, Langerhans cells, 
activated T-cells and B-cells coded by HLA-DP, HLA-DQ and HLA-DR loci.119  The 
antigens or proteins presented on class II molecules are derived from extracellular 
proteins, lipids and polysaccharide entities. The class II MHC has the ability to 
present peptides from the extracellular and intravascular spaces to CD4 T-cells.120 
The DQ locus consists of two closely related genes, the DQA1 and DQB1, which 
are responsible for two separate glycoproteins; α and β respectively. Allelic 
variation of the HLA-DQB1 is of interest, as it modifies the peptide-bound cleft, 
responsible for presentation of antigens, eliciting a powerful T-cell response.121 
CD1 protein is also an APC molecule of phospholipid antigens, which permits 
interaction with the T-cell receptor.122 The CD1 pathway is a unique one for 
presentation of lipids and glycolipid antigens by CD1 molecules to specific CD1-
restricted T-cells, such as NK. CD1 are “non-classical“ HLA class I molecules 
with limited diversity. CD1-restricted T-cells perform effector and helper activity. 
Principally, they interact with macrophages, dendritic cells, NK cells, B- and 
T-cells, contributing to both the innate and adaptive responses.119
The class III region spans about 700 genes and encodes for tumour necrosis 
factor α and β (TNF-α and β), as well as factors related to complement. This 
region encodes genes that can escalate the inflammatory and immunological 
response.123  The enzyme 21-hydroxylase is also encoded by the class III region 
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In order for T-cells to become activated, APCs must present an antigen within the 
MHC and it should be followed by interaction of co-stimulatory molecules. These 
two signals result in proliferation of T-cells, interleukin-2 (IL-2) production and the 
elaboration of the product of the bcl-2 proto-oncogene (Bcl-xL), which is an anti-
apoptotic protein.125  126  T-cells may be activated by T-helper cells expressing CD4 
surface proteins, which in turn stimulate cytotoxic T-cell production.    They do this 
by binding of CD40 on APCs with CD154 found on T-helper cells, permitting direct 
stimulation of T-cytotoxic cells by APCs.127 128 Another molecule found on T-cells 
is the CD28 homolog cytotoxic T-lymphocyte antigen (CTLA-4 or CD152), which 
functions to suppress T-cell activation and may play a role in the susceptibility to 
various autoimmune diseases.129 
Similar to T-cells, B-cells also require at least two signals to become activated. 
Antigens may stimulate B-cell production directly and T-helper cells are also 
involved in stimulating B-cell production through the interaction of CD154 on 
T-helper cells with CD40 on B-cells.130 This engagement is a powerful stimulus for 
cytokine production by T-helper cells, which is essential for isotype switching and 
formation of germinal centres in lymphoid tissues. When B-cells encounter an 
immunoglobulin, internal B-cell mechanisms are activated and the immunoglobulin 
serves as an antigen receptor. Subsequently, the degraded protein is transmitted 
onto the cell surface, which is presented within the MHC II molecule and permits 
recognition by cytotoxic T-cells. These degraded proteins have the ability to 
stimulate B-cells, which in turn are able to produce appropriate antibodies.131 
Adaptive immunity is programmed to identify specific molecules and relies on 
a large number of receptors. As soon as T-cells recognise foreign antigens, a 
series of adaptive responses are directed at these antigens. Adaptive responses 
can usually take from days to decades to initiate, and require a combination 
of B- and T-cells. The armamentarium used to eliminate the foreign antigen 
includes antibodies; cytotoxic T-cells (CTL); classical complement activation; 
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is crucial that the immune response is highly specific against foreign antigens 
and not against self antigens. Under normal physiological conditions, there are a 
number of checks and balances designed to eliminate cells aimed at self. Under 
most circumstances, these processes preclude the evolution of an autoimmune 
process. 
 
1.4.3 Prevention of immune responses against self
1.4.3.1 T-cell tolerance 
An active state called tolerance, is designed to prevent an autoimmune reaction 
against self antigens.133  As previously discussed, cell receptors and antibodies 
are subject to hypermutation. These random changes may inadvertently result in 
components of the immune system, directed at self, producing an autoimmune 
response.134  T-helper cells mature in the thymus and during development are 
exposed to a vast variety of self antigens.135  Clonal deletion is the active process 
in which maturing T-cells are eliminated if they bind to any of the self antigens, 
provided that the self antigen is presented within the MHC. The vast majority of 
developing T-cells undergo apoptosis within the thymus.  The remaining mature 
T-cells that are not eliminated by clonal deletion leave the thymus gland tolerant of 
self antigens. This active process is often referred to as central T-cell tolerance.136 
Those maturing T-cells (pre-T-cells) that are positively selected as a consequence 
of their low avidity to MHC-self peptide complexes, increase expression of T-cell 
receptors and express either as CD4 or CD8. T-cells are also eliminated if they 
have a high avidity for the MHC-presented self peptide. This process of negative 
selection may be achieved through apoptosis, tumour necrosis factor receptor, 
Fas-associated death domain (FADD), or through activation of the Bcl-2 family 
members, with consequent release of Caspase 9.137  The factors that determine 
the low versus high affinity to T-cell receptors are still unknown. T-cells are also 
activated through the co-stimulatory pathway CD28 and CD80/CD86 on APCs. 
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for these important steps as blocking these co-stimulatory pathways abolishes 
the autoimmune processes.138   As negative selection of auto-reactive T-cells is 
imperfect, autoimmunity may result.  Anergy is the mechanism by which peripheral 
tolerance results from the lack of responsiveness to a self antigen. Regulatory 
T-cells in the form of suppressor T-cells will also function to maintain peripheral 
tolerance.139   Auto-reactive T-cells may be eliminated by clonal deletion, which 
is a modified form of apoptosis in which auto-reactive cells may have escaped 
elimination.140   Self antigens may protect against autoimmunity by inducing 
ignorance to which T-cells do not respond.141   A shift from a Th1 response to a Th2 
response may also suppress auto-reactive inflammatory T-cells, as Th1 responses 
predominate in the context of autoimmunity.142   Peripheral tolerance may also be 
achieved through T-cell active suppression, but the precise mechanism of this is 
still under review. Natural (innate) or adaptive T-regulatory cells that can suppress 
via direct cell-to-cell contact, or via release of immune suppressive cytokines IL-10 
or TGFβ, have been described. A deficiency in the number of T-regulatory cells or 
function has been described, as playing an important pathogenic role in various 
autoimmune diseases, including T1DM. Autoimmunity may thus be prevented if 
T-regulatory cells successfully antagonise the self-reactive response. However, 
autoimmunity may occur if the T-regulatory cell response is overwhelmed 
through inherent defects in the number of regulatory cells, function or persistent 
chronic inflammation and consequent negative effect on function. Self reactive 
T-cells may also acquire resistance to the effect of T-regulatory cell mediated 
control.143   A novel pro-inflammatory T-cell subset (Th17) producing IL-17, which 
is a family of cytokines that include IL-17A IL-17B, IL-17C, IL-17D, IL-17E and IL-
17F, stimulates neutrophils to the site of inflammation and produce antimicrobial 
proteins, specifically against Candida and Staphylococcus species. A pathogenic 
role for Th17 has been suggested in autoimmune animal experiments such as 
collagen induced arthritis and in human autoimmune diseases, for example 
rheumatoid arthritis, psoriasis, multiple sclerosis and uveitis.  Enhanced Th17 cell 
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The role of Th17 in autoimmune Addison’s disease is still speculative  and further 
research is required to establish this definitively.145
1.4.3.2 B-cell tolerance
The bone marrow is the active site, where central B-cell tolerance is instituted. 
The pre-B-cells are able to rearrange B-cell receptors in a specific sequence, 
beginning with heavy chain immunoglobulin gene rearrangement followed by 
rearrangement of the light-chain. Deletions of clones of immature B-cells, which 
bind to self antigens, may also be achieved through apoptosis. Editing is the 
process by which immature auto-reactive B-cells escape apoptosis by undergoing 
further  rearrangement of  the  light  and heavy chains.146   B-cell tolerance is a vital 
link in the chain in the  armamentarium  against  autoimmunity.  In the  absence 
of stimulation  by an antigen, mature  B-cells are eliminated by activated T-cells 
through the  Fas-Fas  ligand  and CD40-CD154 interactions.147
1.4.3.3 Pathophysiology of autoimmunity
It is generally assumed that autoimmunity is initiated by activation of the CD4 
helper T-cells, which in turn react with a specific autoantigen. An external microbial 
antigen may induce molecular mimicry due to similarity between this antigen 
and an autoantigen.148   Lipopolysaccharides, derived from infectious microbial 
agents, act as an adjuvant to immune responses. This is accomplished by their 
binding toll-like receptors to macrophages or dendritic cells, in order to enhance 
natural immunity and inflammatory cytokine production.149
The adaptive immune system makes the assumption that all exogenous 
antigens are potentially foreign and harmful. It uses specific surface receptors 
to discriminate between self and foreign antigens.150  Impairment of the Fas-Fas 
ligand interaction results in failed apoptosis and consequent autoimmunity.151 
Autoimmunity is often the consequence of failed active suppression, predominant 
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been considered important in the pathogenesis of autoimmunity152  especially the 
MHC.153   A third of T-helper cells is constituted by a subset of T-helper 17 cells 
(Th17) and appear to be involved in the development of autoimmune diseases. 
Th17 cells offer dichotomous immunological function of either protection or 
immunopathogenesis. T-regulatory cells have an important role in defending 
against autoimmunity, through the release of IL-10 and transforming growth 
factor β (TGFβ). It is interesting that TGFβ also permits expansion of T-regulatory 
cells. There is a reciprocal relationship between T-regulatory cells and Th17.154 
Impaired control by T-regulatory cells on Th17 has been implicated in the evolution 
of autoimmunity.155 
Evolution of T1DM is strongly influenced by environmental factors as well as genetic 
factors. For example, 90% of patients with T1DM harbour a particular DQ B1 allele 
of MHC. Certain HLA alleles may even offer protection against autoimmunity. 
For example DQw1.2 is associated with a lower incidence of T1DM.156  There is 
overwhelming evidence for DQ alleles being the most important, but not the only 
markers of susceptibility to autoimmune disease157  through their ability to alter the 
conformation of the antigen binding site.156  Environment also plays an important 
role in the pathogenesis of autoimmunity, as evidenced by the investigation of 
T1DM monozygotic twins, which demonstrates concordance of less than 50%.158 
Coxsackie B-virus, avoiding breast-feeding, introduction of certain foods, birth 
weight and maternal islet autoimmunity are thought to confer the highest risk 
for T1DM.159  Epidemiological evidence supports a link between vinyl chloride, 
silica, exposure to certain metals,  polycyclic  hydrocarbons,  mycotoxins and 
autoimmunity, through molecular mimicry, alteration of lymphocyte signalling and 
interference in the development of tolerance to self antigens.160  Autoimmunity 
can only result when naive T-cells with auto-reactive potential are exposed 
to exogenous peptides. T-helper cells stimulate B-cells which in turn produce 
antibodies and result in tissue damage through the complement pathway. On the 
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presented via the MHC class I molecule.161
Data from a variety of sources have ensured that Addison’s disease fulfils the 
criteria of an autoimmune condition. This includes the initial discovery of ACA 
in 1957,162 the diffuse mononuclear cell infiltration of the adrenal glands, along 
with atrophy of the adrenal glands, the presence of a cell-mediated immune 
reaction163 and induction of Addison’s disease in animals, using cortex extracts 
and various steroid enzymes as self antigens, presented in association with 
the MHC.  Despite attempts to induce Addison’s disease in animals by using 
autoantigens or steroid enzymes, these have been unsuccessful as they have 
differed from human disease, in that these failed to induce diffuse atrophy of 
the adrenal cortices and no regeneration nodules were reported.164 Additionally, 
there has been lack of biochemical confirmation of adrenal insufficiency following 
adrenal antigens.165 
1.5 Pathogenesis of autoimmune Addison’s disease
In non-APS1, certain HLA genes are required for the development of autoimmune 
Addison’s disease, but it also requires the presence of certain environmental 
triggers. Activated T-lymphocytes are programmed to discern adrenocortical 
antigens presented in MHC class II molecules. T-helper lymphocytes induce 
cytotoxic T- and B-lymphocytes by secreting interleukin-2 (IL-2) and other 
lymphokines, which in turn result in ACA and 21-hydroxylase autoantibody 
production. T-cell mediated destruction of the adrenal glands is identified by the 
presence of the latter antibodies in serum.49
1.5.1  Autoimmune Addison’s disease
Autoimmune Addison’s disease may occur as part of the APS or alone.166  In 
addition to ACA, several autoantibodies have been detected as being associated 
with Addison’s disease due to the dysregulation of antibody production.167  It is 
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autoimmune Addison’s disease. Steroid-cell producing autoantibodies (StCA) 
and 17 α-hydroxylase autoantibodies were found, for example, in association 
with the development of coexistent Addison’s disease and hypergonadotrophic 
hypogonadism.168  Although the presence of circulating adrenal autoantibodies 
suggests an autoimmune aetiology, occasionally autoantibodies have been 
found in patients with tuberculous adrenalitis, especially in low titres.54 169 The 
levels of autoantibodies fluctuate in concert with disease activity and remit during 
signs of biochemical remission of adrenal dysfunction. Thus, the reliability of 
adrenal autoantibody assessment may be influenced by the time elapsed since 
the diagnosis of hypoadrenalism.170-172 
1.5.1.1 General statements with respect to autoimmune conditions
A greater frequency of autoimmune conditions occurs in women and in association 
with the presence of certain human leukocyte antigen (HLA) alleles.173  The 
targets in autoimmune endocrinopathies are sometimes an enzyme or cell 
surface receptor (Table 1). A number of molecular biological factors facilitating an 
autoimmune process in Addison’s disease are likely; such as molecular mimicry, 
cytotoxic T-lymphocyte antigen-4 (CTLA-4) polymorphisms and aberrant induction 
of T-cell help. Polymorphisms in the 3’-promoter region and 5’-untranslated region 
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Table 1: Confirmed and suspected autoantigens found in autoimmune endocrine conditions 
frequently associated with autoimmune Addison’s disease.175
Disease Confirmed Autoantigens Putative Autoantigens
Addison’s disease P450c21 P450c17, P450 scc
Hashimoto thyroiditis Thyroid peroxidaseThyroglobulin








Premature gonadal failure P450 c17P450 scc
Pernicious anaema H+/K+ATP aseIntrinsic factor
Myasthenia gravis Acetylcholine receptor-α-chain
Vitiligo TyrosinaseTyrosinase related protein-2





P450c17: 17 alpha hydroxylase autoantibodies
P450 scc: P450 side-chain cleavage autoantibodies
ICA69: islet-cell autoantibodies
3BHSD:  3-β -hydroxysteroid dehydrogenase 
IA-2 insulinoma antibodies 2
GAD 65: glutamic acid decarboxylase 65
Adapted from Paediatric Endocrinology 2008 M Sperling, WB Sanders Philadelphia Autoimmune 
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1.5.1.2 Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) functions as a co-stimulatory 
molecule, but it also has an important inhibitory action on T-cell activation.176  Two 
sequential steps are required for activation of T cells. The first is the presentation 
of a foreign antigen by HLA class II molecules on the APCs to the T-cell receptor-
CD3 complex. A co-stimulatory signal is required between CD28 on T-cells and 
the CD80/86 on APCs. CTLA-4, which is a homolog of CD28, also binds CD80/86, 
but with considerably greater affinity than CD28, which inhibits T-cell activation. 
Figure 5 demonstrates the known actions of CTLA-4.177  A CTLA-4 polymorphism 
has been thought to confer susceptibility to autoimmune Addison’s disease, 
particularly in association with APS.178   An analysis of CTLA-4 polymorphisms, 
in both an Italian cohort and a meta-analysis of European Addison’s subjects, 
indicates an association of CTLA-4+49 with proven autoimmune Addison’s 
disease, independent of HLA class II genes.179 It has been suggested that this 






































antigen taken up in 
APC and partially 
digested
Figure 5: The inhibitory action of CTLA-4 on T-cell activation. (i) CTLA-4 likely competes with 
CD28 for CD80/86 ligands, inhibiting the co-stimulatory effect of CD28. (ii) CTLA-4 may have an 
inhibitory action on Lck, Fyn and ZAP-70 protein kinases, which are important in phosphorylating 
tyrosine residues of the TCR-CD3 complex. (iii) CTLA-4 may interact with TCR-CD3 complex at 
the immunological synapse to disrupt T-cell activation by binding and blocking the immunoreceptor 
tyrosine-based activation motif (ITAM).
Abbreviations:
APC: antigen presenting cell 
CTLA-4: cytotoxic T-cell associated 4
MHC: major histocompatibility complex 
TCR:T-cell receptor 
Adapted from HLA, CTLA-4 and PTPN22: the shared genetic master-key to autoimmunity? Brand 
O, Gough S and Heward J Expert Reviews in Molecular Medicine 2005, volume 7 page 1-15.177
1.5.2  Autoantibodies in autoimmune polyglandular syndromes (APS)
Antibodies in certain autoimmune conditions, for example Graves’ disease or 
myasthenia gravis are directly pathogenic, while islet cell cytoplasmic (ICA) 
and glutamic acid decarboxylase 65 (GAD65) autoantibodies in T1DM are not 
necessarily so.180 Nevertheless, demonstration of these autoantibodies in the 
asymptomatic individual has important predictive value, as it establishes increased 
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1.5.2.1 Positive autoimmune markers for Addison’s disease
Previous studies have shown both 21-hydroxylase autoantibodies and ACA are 
found in autoimmune Addison’s disease, and in the majority their presence is 
an excellent discriminator of autoimmune versus non-autoimmune Addison’s 
disease. Yet occasionally, they may be present in very low titres in non-autoimmune 
Addison’s disease, in particular unequivocal post tuberculous Addison’s disease.54 
169 170 182  Several studies have demonstrated excellent concordance between 
these autoantibodies, which remain detectable for at least two years after the 
onset of autoimmune Addison’s disease.49 
1.6  Autoantibodies in Addison’s disease
The various autoantibodies found in association with Addison’s disease will be 
discussed below. While the predominant expression of IgG1 isotypes suggests 
a Th1 response, a small subset of patients with Addison’s disease demonstrate 
IgG4 predominance suggesting a Th2 response in the latter small group.
1.6.1  Adrenocortical autoantibodies (ACA)
Seminal work by Anderson et al in 1957, using the indirect fluorescent antibody 
technique, recognised that the association of Hashimoto’s thyroiditis and 
Addison’s disease produced an antibody to adrenal tissue.162  ACA are specific 
to the adrenal glands and capable of binding to the three layers of the adrenal 
cortex. Immunofluorescence produces a homogenous staining pattern of 
the cytoplasm.49  ACA have a positive predictive value for the development of 
autoimmune Addison’s disease, which is greater in children than in adults.183   In 
one study, a single patient with adrenal insufficiency related to adrenal tuberculosis 
demonstrated a positive complement fixation test, but failed to stain positive for 
the adrenocortical secretory cells by immunofluorescence. This suggested a false 
positive complement fixation test.182   ACA are detectable 15 years after the onset 
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20%.172
1.6.2 Steroid-cell producing autoantibodies (StCA)
Steroid-cell producing autoantibodies (StCA) are not specific to the adrenal glands. 
They have been found in the presence Addison’s disease, often in association 
with hypergonadotrophic hypogonadism, particularly in women, but they have 
also been found in men.49   StCA are polyclonal IgG, producing an identical 
immunofluorescent pattern to ACA and have been found to be positive in 28% of 
unselected cases of autoimmune Addison’s disease.49 184  It has been suggested 
that StCA are useful in detecting autoimmune Addison’s disease patients at risk 
for subsequent primary ovarian insufficieny (POI).185
1.6.3 17 α-hydroxylase autoantibodies
17 α-hydroxylase autoantibodies are detected using S-labelled recombinant 
antigens.53  They react with 17 α-hydroxylase enzyme and are also not specific 
to the adrenal glands, as they can also react with the testes and ovaries.186 
17 α-hydroxylase was the first autoantigen recognised in the sera of patients 
with APS1.187  There is an increased likelihood of detecting this antibody in 
autoimmune Addison’s disease associated with both concurrent and subsequent 
development of (POI).53 185  Krohn et al showed that the presence of 17 
α-hydroxylase autoantibodies is associated with autoimmune Addison’s disease 
in children suffering from APS1188  but subsequent work by Betterle et al indicates 
that 21-hydroxylase autoantibodies may be far more important as a marker of 
autoimmune Addison’s disease in children.183 
1.6.4 21-hydroxylase autoantibodies
The enzyme 21-hydroxylase is unique to the adrenal cortex and is located primarily 
within the zona glomerulosa.189 The presence of 21-hydroxylase autoantibodies 
associated with clinical primary hypoadrenalism is diagnostic for autoimmune 
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decrease with disease duration, as only 50% are still positive 20 years after the 
onset.190  The higher the titre, the greater the risk of the development of Addison’s 
disease in the future.191   In a multivariate analysis to determine at-risk individuals, 
high antibody titres versus medium-low titres were found with imminent evolution 
of autoimmune Addison’s disease.192  21-hydroxylase autoantibodies are positive 
in 80% of APS1 and APS2.190  Overwhelmingly, 21-hydroxylase autoantibodies are 
IgG1.  A minority are IgG2 and IgG4, supporting a predominant Th1 immunological 
response.145  While the predominant expression of IgG1 isotypes suggests a Th1 
response, a small subset of patients with Addison’s disease demonstrate a IgG 4 
predominance suggesting a Th2 response.193
1.6.5  Antibodies to P-450 side chain cleavage enzyme (P-450 scc)
Antibodies to P-450 scc in isolated Addison’s disease occur at considerably 
lower prevalence rates than 21-hydroxylase autoantibodies, but are similar to 
17 α-hydroxylase autoantibodies.194 The presence of P-450 scc autoantibodies 
is highly correlated with autoimmune Addison’s disease and POI.49 Of 263 Italian 
subjects with autoimmune Addison’s disease, 35 (13%) had APS1, 107 (41%) 
had APS2, 13 (5%) had APS4 and 108 (41%) had isolated autoimmune Addison’s 
disease.49 The respective proportions of hypergonadotrophic hypogonadism and 
positive P-450 scc antibodies were 60% and 80% in APS1, 9% and 40% in APS2, 
61% and 40% in APS4 and 0% and 20% in isolated autoimmune Addison’s 
disease. In a study of APS1 by Soderbergh et al, P-450 scc occurred in 79% 
of patients with hypogonadism and an odds ratio of 6.8 for the association with 
Addison’s disease.195  Patients with POI and Addison’s disease, in association with 
either APS1, APS2 or APS4 had positive P-450 scc antibodies in 93%, which was 
virtually identical to the prevalence of ACA and 21-hydroxylase autoantibodies in 
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1.6.6 The occurrence of other autoantibodies
As Addison’s disease frequently coexists with a cluster of other autoimmune 
conditions, it could be expected that multiple antibodies are discerned in serum; 
thyroglobulin and thyroperoxidase antibodies are the most frequently found. In 
an unselected group of 212 Polish patients with Addison’s disease, (comprising 
58 due to tuberculosis, 148 due to autoimmune and six with other adrenal 
disorders), 51 (24%) had positive microsomal antibodies and 67 (32%) had 
antithyroperoxidase antibodies.196 In a cohort of 91 Dutch patients of whom 83 
patients were considered to have autoimmune adrenalitis, 38 of these had at least 
one other autoimmune disorder. In addition to adrenal autoantibodies, microsomal 
antibodies occurred in 58%, antithyroglobulin in 23.4%, parietal cell antibodies in 
19.8%, pancreatic islet-cell autoantibodies in 6.2% and ovarian antibodies in 3.7% 
of women50 higher than the prevalence of other clinical autoimmune conditions. 
Autoimmune thyroid disease occurred in 26.5%, pernicious anaemia in 4.8%, 
T1DM in 1.2% and POI 7.3%.51  In 1975, Irvine et al showed similar results to the 
Dutch study in 174 patients with autoimmune Addison’s disease the prevalence 
of antithyroid autoantibodies was 59.7%, parietal cell antibodies was 28.7% 
and anti-ovarian antibodies was 22.9%.197   In a review of APS in association 
with T1DM, which examined Belgian, Swedish and USA cohorts, Addison’s 
disease occurred in 12-14%.  Of the Addison’s patients, 5% had positive tissue 
transglutaminase antibodies, 83-90% had 21-hydroxylase autoantibodies, and 
primary hypothyroidism was present in 14-21%, whereas anti-thyroperoxidase 
antibodies were present in 23-40%, Graves’ disease was present in 10-20% and 
parietal cell antibodies were present in 6%. In the respective general populations, 
tissue transglutaminase occurred in 0.5-1%, 21-hydroxylase occurred in 0-0.6% 
and parietal cell antibodies 2.5-12%.198 Individuals with autoimmune hepatitis and 
positive liver kidney microsomal 1 antibodies are prone to develop associated 
polyendocrinopathies, especially APS1. This is likely because of sequence 
homology between 21-hydroxylase and an enzyme P4502D6 expressed by 
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1.6.7 Rationale to measure adrenal autoantibodies
Measurement of these autoantibodies helps to establish their prevalence in the 
healthy background population, the underlying aetiology of the adrenal failure 
and may identify patients at risk of Addison’s disease, and so potentially avoid a 
life-threatening adrenal crisis.49 The early detection of antibodies alerts physicians 
and so may help to avoid the full blown disease. Apart from parietal cell antibodies, 
the remaining autoantibodies occur at a sufficiently greater rate among Addison’s 
patients than the general population, corroborating their usefulness as a screening 
tool.200 The simultaneous presence of ACA and 21-hydroxylase autoantibodies 
in an individual with primary hypoadrenalism confirms autoimmune Addison’s 
disease with 99% certainty.55 
1.7 Clinical aspects of autoimmune adrenal gland failure
It is generally held that Addison’s disease develops in association with other 
endocrinopathies in up to 50% of cases and 59% was found among 263 Italian 
autoimmune Addison’s disease patients.49 In order to diagnose APS1, two of 
the following criteria are needed: adrenocortical failure or serological evidence 
of adrenalitis, hypoparathyroidism and mucocutaneous candidiasis, while 
APS2 comprises adrenocortical failure with either autoimmune thyroid disease 
and/or T1DM. Three further polyglandular autoimmune syndromes have been 
described. In APS3 both autoimmune Addison’s disease and hypoparathyroidism 
are absent; while in APS4 autoimmune Addison’s disease occurs in the absence 
of both T1DM and autoimmune thyroid disease.  The subdivisions of APS3 and 
APS4 are not universally used, and the majority distinguish APS as either APS1 
or APS2, based on their respective ages of onset. The immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is a rare primary 
immune deficiency disease, manifesting in infancy and results in severe 
enteropathy, villous atrophy, dermatitis, T1DM and thyroiditis, and is caused by 
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the development and function of regulatory T-cells, inducing profound immune 
dysregulation.201  Due to its rarity and its unlikely cause for Addison’s disease in 
South Africa, it will not be discussed further.
1.7.1 Autoimmune polyglandular autoimmune syndromes
The clinical characteristics of each of the autoimmune polyglandular syndromes 
will be discussed below.
1.7.1.1 Autoimmune polyglandular syndrome (APS1)
Finland has the highest incidence of APS1 in the world and yet only 100 
patients have been documented so far in a population of 5 million.202 The major 
manifestations of APS1 are mucocutaneous candidiasis, which occurs within the 
first two years of life, hypoparathyroidism and adrenal insufficiency, chronologically 
usually following this order.175 187  Minor endocrinological components of APS1 
include primary hypogonadism and T1DM. Non-endocrinological manifestations 
include periodic malabsorption, gastric parietal cell atrophy, pernicious anaemia, 
hepatitis, alopecia, vitiligo, dental enamel hypoplasia, pancreatic exocrine 
dysfunction and keratopathy,49 203  (Table 2).
Addison’s disease occurs in more than 85% of patients and hypoparathyroidism 
usually presents before puberty.49  Up to 64% of a Finnish cohort had  these three 
major components of APS1 by the age of 30 years. Primary hypogonadism was 
the next most frequent manifestation, occurring in 60% of females and 14% of 
males. Up to 30% of patients had periodic malabsorption, gastric parietal cell 
atrophy, hepatitis, alopecia and vitiligo, in various combinations and at various 
time intervals. Of 263 Italian patients with Addison’s disease occurring as part 
of APS (APS1, APS2, and APS4) or isolated Addison’s disease, 100% had both 
21-hydroxylase and ACA, 80% exhibited StCA, 80% had either 17 α-hydroxylase 
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Addison’s disease occurs in more than 85% of patients and hypoparathyroidism 
usually presents before puberty.48  Up to 64% of a Finnish cohort had  these three 
major components of APS1 by the age of 30 years. Primary hypogonadism was 
the next most frequent manifestation, occurring in 60% of females and 14% of 
males. Up to 30% of patients had periodic malabsorption, gastric parietal cell 
atrophy, hepatitis, alopecia and vitiligo, in various combinations and at various 
time intervals. Of 263 Italian patients with Addison’s disease occurring as part 
of APS (APS1, APS2, and APS4) or isolated Addison’s disease, 100% had both 
21-hydroxylase and ACA, 80% exhibited StCA, 80% had either 17 α-hydroxylase 
and/or P-450 scc autoantibodies.  Addison’s disease is highly prevalent in APS1 
and was recorded in 100% of this series.48 
1.7.1.2  Autoimmune polyglandular syndrome 2 (APS2)
The presence of autoimmune Addison’s disease with either autoimmune thyroid 
disease or T1DM, constitutes APS2. Minor components include, inter alia vitiligo, 
chronic atrophic gastritis, hypergonadotropic hypogonadism, chronic hepatitis 
and Sjogren’s syndrome.49 (Table 2). The prevalence varies from 1.5-4.5 per 100 
000 inhabitants, with mainly females being affected.187   Thyroid autoimmune 
disease may be any of Hashimoto’s thyroiditis, primary myxoedema, symptomless 
thyroiditis and Graves’ disease. In a study by Neufeld et al, one of these thyroid 
manifestations occurred in 69% of patients with APS2, while T1DM occurred 
in 52% of the same cohort.166  Among 107 Italian subjects with APS2, the 
prevalence of the minor components ranged from 1-11%, while T1DM occurred 
in 28%.49  ACA and/or 21-hydroxylase autoantibodies were detectable in 100% of 
these cases, but StCA, 17 α-hydroxylase and/or P-450 scc autoantibodies were 
present in about 40% of the cases, in contrast to APS1 where the latter three 
autoantibodies were positive in about 80%.49  The evolution of APS2 occurs with 
T1DM preceding Addison’s disease, but autoimmune thyroid disease may occur 
prior, at the same time, or after the onset of Addison’s disease.204 There is merit in 











Introduction to primary hypoadrenalism and its possible complications
other endocrinopathies could facilitate prompt introduction of potentially lifesaving 
therapy. Although APS2 is inherited in an autosomal dominant pattern, multiple 
genotypes may predispose an individual to developing it, including HLA-B8, HLA 
DR3, HLA-DR 4, microsatellite polymorphism in the MHC class I chain-related 
(MIC-A) and CTLA-4, but results of studies are inconsistent.49 
Table 2: The expected prevalences of autoimmune phenomena in autoimmune polyglandular 
syndromes (APS)175
APS1 APS2
Type 1 DM 4-18% 41-52%
Autoimmune thyroid 
disease 8-40% 70%
Pernicious anaemia 12-15% 2-25%
Gonadal failure








Autoimmune hepatitis 10-15% Rare
Malabsorption 10-18% Rare
Abbreviations:
APS1: autoimmune polyglandular syndrome type 1
APS2: autoimmune polyglandular syndrome type 2
T1DM: type1 diabetes mellitus
Adapted from Paediatric Endocrinology 2008 M Sperling, WB Sanders Philadelphia Autoimmune 
polyglandular syndromes Haller MJ, Winter W E, Schatz DA, page 770-787175
1.7.1.3 Incomplete autoimmune polyglandular syndrome 2 (absence of 
Addison’s disease)
Incomplete APS2 is diagnosed in the absence of autoimmune Addison’s disease, 
but it coexists with T1DM and autoimmune thyroid disease, or in a sibling that 
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disease and positive ACA in an individual, should be considered as incomplete 
APS2.49 166 
1.7.1.4   Autoimmune polyglandular syndrome 3 (APS3)
Autoimmune thyroid disease, in association with other autoimmune diseases and 
in the absence of both Addison’s disease and hypoparathyroidism, is designated 
as APS3. Since it can occur with T1DM, autoimmune gastrointestinal involvement, 
autoimmune dermatological or an autoimmune connective tissue disorder, it may 
be sub-categorised by the presence of any of these aforementioned autoimmune 
conditions.49 
1.7.1.5 Autoimmune polyglandular syndrome 4 (APS4) (autoimmune 
Addison’s disease in the absence of both autoimmune thyroid disease and 
type 1 diabetes mellitus) 
The combination of autoimmune Addison’s disease and other autoimmune 
endocrinopathies, in the absence of both autoimmune thyroid disease and T1DM, 
constitutes APS4. The occurrence of ACA and 21-hydroxylase autoantibodies 
at the onset of Addison’s disease is usually 100%. The autoimmune features 
include, inter alia; vitiligo, alopecia, chronic gastritis, pernicious anaemia, 
hypergonadotrophic hypogonadism and lymphocytic hypophysitis.49 187 
1.7.2 Genetics of autoimmune polyglandular syndromes
The mode of inheritance differs between APS1 and APS2.
1.7.2.1 Genetic predeterminants of APS1
Specific components of the immune system, including: the thymus, lymph nodes, 
and peripheral blood cells including the CD14 positive monocytes, but not 
CD4 T-cells, express the AIRE gene. As the protein product of the AIRE gene 
is a transcription factor that functions to up-regulate certain organ-specific self 
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negative selection of organ-specific thymocytes.200  Transgenic mice with specific 
deletion of the insulin gene in medullary thymic epithelial cells, which express 
AIRE, develop autoimmune diabetes and insulitis, despite normal expression of 
insulin in the beta-cells. This latter experiment emphasises the role of the normal 
AIRE gene in maintaining central tolerance. APS1 is monogenic, resulting from 
mutations in the AIRE gene and is inherited in an autosomal recessive fashion. 
These mutations result in decreased expression of the transcription factor and 
diminished presentation of self antigens by the medullary thymic epithelial and 
dendritic cells to developing T-cells. This results in reduced central tolerance to a 
number of self antigens (Figure 6).205  The most common is the R257X mutation 
responsible for 82% of Finnish and the majority of Italian APS1 alleles.187  Other 
frequently encountered mutations that have been described include C311Y, 
P326Q and L397fsX478.145  The L323fsX373 mutations of AIRE have been found 
to occur in Britain in association with APS1.206  21-hydroxylase, thyroid peroxidase 
and inter alia thyroglobulin are under the transcriptional control of AIRE.174  High 
titres of antibodies to interferon-α and/or interferon-ω have been detected in 




























Figure 6: The mechanisms of the autoimmune regulator (AIRE) in preventing autoimmunity. 
Adapted from Mathis D, Benoist C.A decade of AIRE. Nat Rev Immunol. 2007;7(8): 645-50.208 
The function of the autoimmune regulator (AIRE) is to promote transcriptional activity of numerous 
chromosomal locations, with a view to stimulating expression of genes by medullary epithelial cells 
(MECs) in selected tissues. The antigens that are identical to peripheral self in MECs are presented 
to immature thymocytes either directly or by uptake of antigens released from MECs by thymic 
dendritic cells (DC).  The differentiating T-cells, which recognise these antigens are removed by 
apoptotic clonal deletion. Some T-cells may survive by evolving regulatory cell function. Mutations 
in AIRE gene result in decreased expression of the transcription factor and less presentation of 
self antigens by the medullary thymic epithelial and dendritic cells to developing T-cells, which 
results in reduced central tolerance to a number of self antigens.
1.7.2.2 HLA (human leukocyte antigen) 
This refers to a group of genes spanning 700 kilobases, located on chromosome 
6p21.3 region-encoding cell surface and antigen presenting-proteins (Figure 
7). Patients with certain HLA antigens have a higher propensity of developing 
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erythematosus (SLE) and myasthenia gravis. In the case of T1DM, 40-50% of 
the genetic risk may be explained by the DQ locus. An α- and β-chain of the MHC 
class II facilitate nine pocket-binding clefts; some are considered major and some 
minor. These create unique peptide binding patterns for various MHC molecules. 
The major MHC-binding pockets harbour polymorphic side-chain residues that 
determine which peptides will bind.209 
chromosome 6
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Figure 7: Gene map of the human leukocyte antigen (HLA) region. Adapted from Mehra NK, Kaur 
G. MHC based vaccination approaches: progress and perspectives. Expert Rev Mol Med. 2003 
Feb 24;5(7):1-17. 210The HLA region traverses 700 kilobases on the short arm of chromosome 6. 
HLA class I molecules restrict CD8 cytotoxic lymphocyte function and control immune responses 
against endogenous antigens and virally infected targets. HLA class II molecules are involved 
in the presentation of exogenous antigens to T-helper cells.  The HLA class III region contains 
multiple genes encoding proteins that are not involved in cell-mediated immunity, but modulate 
immune responses using tumour necrosis factor (TNF), heat shock proteins and complement.
The α- and β-chains are encoded by HLA-DQA1 and HLA-DQB1, respectively and 
are both located on chromosome 6p21.3. Significant variation is likely to occur as 
normal individuals produce two α-and 2 β-chains. Thus, each person has four HLA-
DQ isoforms. Each individual HLA-DQ isoform can present different antigens to 
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turn signals B-cells to produce antibodies.211 When there is a breach in tolerance, 
autoimmunity may result. HLA-DQ alleles influence susceptibility to T1DM and it 
is interesting that HLA DQB*0602 is protective.212 Nevertheless, through linkage 
disequilibrium studies, it appears that particular DR/DQ allelic combinations are 
associated with autoimmune diseases.213
1.7.2.3 Genetic predeterminants of APS2
Autoimmune endocrinopathies arise because of immune-mediated destruction 
of either a single target endocrine gland or multiple endocrine glands. The 
development of APS requires a genetic susceptibility, an environmental trigger, 
active autoimmunity and metabolic derangements. Other genes and transcription 
factors, aside from HLA, are to a lesser degree responsible for the development 
of autoimmune endocrinopathies. APS2 appears to occur sporadically or 
in families of patients with APS2 and associates with HLA-DQB*0201 and 
DQB*0302. The HLA-DRB1*03-DQA1*0501-DQB1*0201 haplotype has such a 
strong association, that in all probability, could be considered a genetic marker 
for the APS2. HLA-DR3/DQ2 appears to be strongly associated with APS2 and 
even more consistently than HLA-B8 when it occurs as part of the HLA-B8-DR3 
haplotype.210 In a study of HLA genotypes DQ8/DQ2, consisting of DRB1*0404/
DQ8 with DRB1*0301/DQ2 was present in 14 of 21 (67%) patients with Addison’s 
disease and 8 of 12 (67%) with T1DM mellitus compared to 0.7% of the general 
population. This finding may be influenced by the common association of T1DM 
and adrenal autoimmunity, especially in the context of APS2. The genetic risk 
of Addison’s disease associated with HLA is complex. In addition to DQB1 
polymorphisms, HLA DRB1*0301, DQA1*0501, DRB1*0401, DQA1*0301 are 
positively associated while DRB1*0403 is negatively associated with Addison’s 
disease.214 Additionally, an association exists between the retrovirus-like long-
terminal repeat (LTR) DQ-LTR13 and the development of autoimmune Addison’s 
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In addition to HLA genes, two non-HLA genes, such as the MHC class I chain-
related A (MICA) 5.1 allele and the protein tyrosine phosphatase non-receptor type 
22 (PTPN22) genes, may predispose a person to developing APS2. Specifically, 
the MICA 5.1 allele is associated with a genetic risk for Addison’s disease, which is 
explained by the loss of the membrane-binding region of the protein and defective 
interaction with another integral membrane protein (NKG2D) critical for thymic 
maturation of T-cells. The combination of the microsatellite allele 5.1 located in 
class I of the HLA antigen and HLA DR3/DQ2 appear to be quite important in the 
genetic risk of autoimmune Addison’s disease is identified in a group of Italian 
patients.216 The PTPN22 gene appears to regulate T-cell receptor signalling and 
a polymorphism within this gene, resulting in a gain of function, yields decreased 
T-cell receptor signalling and increased risk of autoimmune disorders.174  SNP’s of 
the PTPN22 gene have demonstrated conflicting associations with autoimmune 
Addison’s disease and in a large cohort of UK entirely subjects, a specific SNP 
C185T was found to occur more commonly in autoimmune Addison’s disease 
versus healthy control subjects (12.2% vs. 7.8%; p < 0.008). A meta-analysis 
of three further patient cohorts indicated an OR of 1.44, CI (1.21-1.72) for 
autoimmune Addison’s disease.217  Class II expression on APCs including B-cells, 
monocytes, dendritic cells and activated T-cells, is under the control of the class II 
transactivator. Two European studies have demonstrated the genetic association 
between polymorphisms of the class II transactivator and the development of 
autoimmune Addison’s disease, independent of HLA gene markers, by conferring 
variations in the level or tissue selectivity of MHC class II expression.190 Class II 
expression is under control of the MHC class II transactivator encoded by the 
MHC2TA gene. An A-G SNP was suggested to confer susceptibility to autoimmune 
diseases. Both heterozygous and homozygous polymorphisms of the rs3087456 
SNP have been associated with a genetic risk of autoimmune Addison’s disease.218 
In addition, a C-type lectin domain family 16, member A (CLEC 16A) was found 
to be independently associated with Addison’s disease, after having been found 
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have reported an association between vitamin D receptor and the cytochrome 
P450 family, subfamily B, polypeptide 1 (CYP27B1) gene, as well as the NACHT 
leucine-rich-repeat protein 1 (NALP1) gene in the predisposition to APS2.145   As 
shown HLA alleles are not the only genetic influence in the development of APS2 
and genome-wide scans may be necessary in the future to determine the likely 
additional genetic risk of developing this condition. 
 Indeed several negatively associated genetic markers have been identified. HLA 
DRB1*0403 is a strongly protective marker for both T1DM and Addison’s disease 
in Italy.220 Several HLA class II including DRB1*01-DQA1*01-DQB1*0501 and 
DRB1*13-DQA1*0103-DQB1*0603 were negatively associated with Addison’s 
disease.221
1.7.3 Genetic predeterminants of type 1 diabetes mellitus, as an example
The major genetic determinants of T1DM are located within the MHC on 
chromosome 6p21.3. Specifically, class II genes encoding HLA-DR and HLA-
DQ contribute the most towards the susceptibility of developing T1DM through a 
simple recessive inheritance pattern.222 223  More than 90% of Caucasian patients 
with type 1A diabetes have either DR3,DQ2 (DQ2 = DQA1*0501, DQB1*0201) or 
DR4,DQ8 (DQ8 = DQA1*0301, DQB1*0302) haplotypes.223   Between 30% and 
50% of patients with type 1A diabetes are heterozygotes for DR3 DQ2 /DR4 DQ8 
compared with 2.4% of the general population.224  In Denver, Colorado only 2% of 
newborns are HLA DR3/DR4 heterozygotes, whereas 30% of children with type 
I A diabetes have this genotype.225  By contrast, specific DR and DQ alleles in an 
autosomal dominant pattern can confer protection against evolution of type 1A 
diabetes. The most common protective alleles are DQA1*0102 and DQB1*0602. 
This was determined by the finding that approximately 20% of control populations 
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1.8 Screening for primary adrenal failure
The short synthetic adrenocorticotrophin (ACTH) is regarded as the most reliable 
diagnostic test for chronic adrenal hypofunction. Indeed its excellent sensitivity 
and specificity has confirmed its use in screening for hypoadrenalism in persons 
at risk for developing Addison’s disease.228
The adrenal cortex, responsible for the release of cortisol and androgens, is 
under the negative feedback control of ACTH, while the release of aldosterone is 
controlled by the renin-angiotensin II system. Progressive functional deterioration, 
as in autoimmune destruction of the adrenal cortex, results in diminished 
function adrenal reserve as shown by reduced plasma concentration of cortisol 
and aldosterone in association with an increased ACTH and renin release.49 
The inability of the adrenal cortex to respond to synthetic ACTH may be due in 
part to the cortex being maximally stimulated by endogenous ACTH. Synthetic 
ACTH injected intravenously or intramuscularly, irrespective of whether the 1 µg 
or 250 µg doses are administered, is vastly supra-physiological.  Subjects who 
have either basal or stimulated cortisol levels of >500 nmol/L do not have overt 
Addison’s disease.2 229  The short synthetic ACTH stimulation test can be used 
to diagnose primary and secondary hypoadrenalism.  A meta-analysis showed 
that the low-dose (1 µg) and the standard dose (250 µg) ACTH stimulation test 
performed similarly, but the receiver operating curves using the 1 µg performed 
slightly superiorly in ruling out HPA insufficiency. However, the differences were 
clinically unimportant.230 
Betterle et al, proposed that subclinical autoimmune adrenalitis may evolve 
through 3 defined stages: stage 1 where both ACTH and basal cortisol levels 
are normal, with concomitant elevated plasma renin activity and reduced or 
normal aldosterone levels; stage 2, when ACTH levels are normal, but the peak 
stimulated cortisol level is reduced, and stage 3 when the ACTH level is elevated 
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pregnancy, infection or trauma coexist in stage 3 of subclinical disease, overt 
clinical hypoadrenalism may manifest. Adrenal cortical mass declines throughout 
these predetermined subclinical stages.49  Subclinical hypoadrenalism should be 
considered when the ratio of ACTH to cortisol is increased. This is evidence in 
early autoimmune primary adrenal insufficiency, where patients exhibit reduced 
sensitivity to low-dose ACTH stimulation.231
The presence of either circulating ACA or 21-hydroxylase antibodies however 
does not invariably indicate that adrenalitis or incipient hypoadrenalism will 
occur. For example, a baby born to a mother who had ACA and 21-hydroxylase 
autoantibodies, Addison’s disease, and co-existing hypothyroidism (APS2), did 
not develop either clinical or subclinical hypoadrenalism until 34 months of age, 
suggesting that an additional factor other than positive adrenal autoantibodies 
is required to induce Addison’s disease.232  In Padua, Italy, the cumulative risk 
for developing autoimmune Addison’s disease was 48.5% among ACA positive 
subjects,191  identifying a sub-group in whom screening needs to be performed.
1.8.1 Hypothesis of adrenal failure and genetic predisposition in South 
Africa
In a South African retrospective analysis of 50 patients who presented to a 
teaching hospital with acute Addison’s disease, autoimmunity as a cause was 
uncommon.233  However, it is hypothesised that autoimmunity in a large South 
African cohort with Addison’s disease may be far more common if defined by 
the presence of circulating ACA and 21-hydroxylase autoantibodies. Moreover, 
certain HLADQB1 genotypes may predispose people to autoimmunity Addison’s 
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1.9 Lipids, lipoproteins and markers of cardiovascular disease in 
primary hypoadrenalism
1.9.1 Introduction
It has been contended that survival of patients with Addison’s disease on 
replacement therapy has been comparable to that of the background population. 
The overall mortality rate was the same in a Norwegian study as the background 
population, a sub-group of Addison’s patients younger than 40 years of age, 
particularly in males, was at risk of premature death due to infections, sudden 
death and acute adrenal failure.234  On the other hand, a  Swedish publication 
reviewing death registers documented a relative risk of death of 2.19 for all causes, 
indicating a two-fold risk for premature death, in appropriately treated Addison’s 
disease patients.  The risk ratio for death from cardiovascular disease (CVD), the 
leading cause of death, was 1.97 for men and 2.31 for women, with ischaemic 
heart disease, followed by cerebro-vascular disease.235  Moreover, a similarly 
conducted Swedish study of primary autoimmune adrenal failure corroborated a 
more than double mortality rate secondary to CVD.236  The Norwegian study was 
based on a population registry, on the other hand both Swedish studies were 
based on registries of hospitalised patients and the accuracy of either diagnosis 
or aetiological classification were not verified. The reasons for this accelerated 
mortality associated with CVD were not investigated. It is possible that Addison’s 
disease per se may have contributed to the excess mortality, although exposure 
to supra-physiological GCs with resultant hypertension, T2DM and obesity with 
centralisation of body fat and abnormal plasma lipids may be contributors.237 The 
role of these factors has not been explored in Addison’s disease. However, GC 
replacement dose reduction from 30 mg to 15 mg in hypopituitary patients has 
not invariably resulted in an improved CV risk factor profile.238  GC replacement, 
irrespective of the dose, may fail to mimic endogenous cortisol levels with supra-
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yielding yet another explanation for accelerated CVD. 239
In contrast to hypopituitarism, there is a paucity of studies appraising CVD 
risk in primary hypoadrenalism, apart from the study by Giordano et al, which 
demonstrated higher total cholesterol (TC) and TG levels, than controls in a study 
of 38 Addison’s patients.240 In another study, DHEA administered to Addison’s 
patients resulted in no improvement in lipids and lipoproteins, although these were 
not abnormal at base-line.241  A meta-analysis demonstrated a higher mortality 
rate, especially among women with hypopituitarism, due to inter alia CVD.242  GH 
deficiency is the most likely culprit for accelerated CVD in hypopituitarism judging 
by the large number of CVD risk factors that normalise on GH replacement, 
independent of the dose of GC replacement.243
The traditional risk factors for CVD and cerebral vascular disease include 
hypertension, tobacco exposure, hypercholesterolaemia and diabetes mellitus.244 
More recently, inflammation has been implicated in the pathogenesis of 
atherosclerosis. Several serum markers of inflammation have been proposed to 
indicate or play a role in the pathogenesis of atherosclerosis.245
A brief overview of lipid and lipoprotein metabolism and the effects of GCs will 
follow. Lipids and lipoproteins are dynamic in nature and are subject to multiple 
fluxes, with influences at multiple points in their metabolism. Not only genetic 
variations, but also environmental factors influence the steady state and response 
to a given stress. It is therefore not always possible to predict confidently a net 
effect of a single stimulus.
1.9.2 Lipoprotein metabolism
1.9.2.1 Introduction to lipid metabolism
Lipoproteins transport lipids from their sites of production and are modulated 
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pathways involved in lipoprotein metabolism; (i) the post-prandial pathway for 
chylomicrons, which transport dietary lipids, (ii) the constitutive pathway involving 
very low density lipoprotein (VLDL) for TG transport, (iii) the provision of LDL 
cholesterol, and  (iv) the reverse cholesterol transport system, which involves 
HDL.246 These pathways and the reported effects of GCs are shown in Figure 8.
1.9.2.2 Post-prandial pathway of chylomicrons for dietary lipid transport
Chylomicrons consist of 85-90% TG and are produced in the epithelial cells of 
the small intestine. Their apoproteins (apo) are mainly B48, apoAI and apoAIV. 
Hydrolysis of TG in chylomicrons occurs at the vascular endothelium where 
lipoprotein lipase is anchored on cells by heparan sulphate proteoglycans. This 
results in remnants, which are now proportionately richer in cholesterol esters. 
These chylomicron remnants by virtue of their large size, have low atherogenic 
potential, though they may still penetrate the arterial wall. The chylomicron 
remnants, which possess apoE, are cleared rapidly by the liver from plasma, by 
their ability to interact with remnant receptors in the liver. 247 248
1.9.2.3 The constitutive pathway of VLDL
The liver secretes VLDL, which comprises 55% TG, 20% cholesterol esters, 15% 
phospholipids and 10-15% protein. Its production and secretion is enhanced by 
uptake and circulation of free fatty acids (FFA), whether generated by intravascular 
lipolysis or by adipocytes. VLDL is assembled on apoB100.249 250  The cholesterol 
TG phospholipid components of VLDL may be produced de novo by the liver or 
could be re-used from uptake of lipoproteins. The TG content of VLDL is also 
hydrolysed by lipoprotein lipase. TG in VLDL remnants is hydrolysed by hepatic 
lipase, forming progressively smaller particles and becoming richer in cholesterol, 
first as intermediate dense lipoproteins (IDL) and ultimately as LDL.251
 
1.9.2.4 The LDL pathway
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35% cholesteryl ester, 10% free cholesterol, 10% TG and 20% phospholipids. The 
remaining 25% is protein; almost completely apoB100. The vast majority of LDL 
is taken up in hepatocytes, through the LDL receptors. Plasma LDL concentration 
may be raised by increased production of VLDL or through decreased clearance 
by down-regulation of LDL receptors. ApoE-containing lipoproteins (remnants) 
compete with LDL for uptake at LDL receptors on the hepatocytes.252 
1.9.2.5 The reverse cholesterol transport system involving HDL
High density lipoprotein (HDL) is the smallest of the lipoproteins. About half 
comprises lipids, 25% phospholipid and 15% cholesteryl ester. Free cholesterol 
and TG both constitute 5%. The remaining half is made up of proteins apoAI and 
apoAII are the major apolipoproteins of HDL. The liver secretes apoAI-containing 
phospholipid discs, as nascent or immature HDL particles. The intestine is also 
able to synthesise small particles that contain apoAI. Additionally, HDL may result 
from the metabolism of chylomicrons and VLDL through lipolysis.253  The enzyme 
lecithin-cholesterol-acyl-transferase (LCAT) esterifies cholesterol to a long 
chain fatty acid from phospholipids in the shell around the particles. Migration of 
cholesteryl esters to the core leads to a spherical particle that is viewed as a more 
mature form (HDL3). With progressive increase in size, LCAT transforms HDL3 
into the larger and less dense HDL2. Cholesteryl ester transfer protein (CETP) 
transfers cholesteryl ester from HDL2 to VLDL and IDL, permitting the delivery of 
cholesterol to the liver by this route. In exchange, HDL receives TG.253  Hepatic 
lipase hydrolyses the TG and thus regenerates the smaller HDL3 particle for 
more cycles of cholesterol esterification and enlargement, followed by lipolysis. 
Exchange of TG into LDL could result in a similar modulation of LDL to a smaller 
particle. The esterification of surface-free cholesterol in HDL creates space for 
more free cholesterol to be accepted from cells or other lipoproteins.  HDL can 
also deliver cholesterol directly to the liver, leading to the secretion of cholesterol 
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1.10 Lipid changes with corticosteroid use
1.10.1 Lipid pathways affected by glucocorticoids
Despite the frequency with which pharmacological doses of GCs are used, there 
are surprisingly few publications on their effects on lipid metabolism.  The effects 






























































































































Figure 8: A schematic view of lipoprotein metabolism and where points of interaction with 
glucocorticoids have been reported in the literature. Adapted from Marais AD Lipids, lipoprotein 
metabolism and their derangements. South African Heart Journal September 2005, volume 2 
number 3 page 8-18. 246
Abbreviations:
Ai: apolipoprotein–AI 
HDL3: high density lipoprotein 3 
HDL2: high density lipoprotein 2











Introduction to primary hypoadrenalism and its possible complications
C: cholesterol 
BA: bile acid 
TG: triglyceride 
NEFA: non-esterified fatty acids
apoE: apolipoprotein E 
B100: apolipoprotein B100
Cii: apolipoprotein CII
LDL: low density lipoprotein 
LDLR: low density lipoprotein receptor 
LRP: low density lipoprotein receptor protein 
CM: chylomicron 
LPL: lipoprotein lipase 
CETP: cholesterol ester transfer protein 
HL: hepatic lipase 
LCAT: lecithin cholesterol acyltransferase
SRB1: scavenger receptor B1
ABCA1: adenosine binding cassette transporter A1 
VLDL: very low density lipoprotein
FA: fatty acids
These effects are also summarised in Table 3. Reference numbers provided in the table are also 
given in red print and appear in the reference list.
Dyslipidaemia and hypertension are the most significant CV adverse effects 
resulting from pharmacological doses of GCs.255  The precise mechanisms by 
which GCs alter lipid metabolism are not clear. There are conflicting data about 
GC action on lipids and lipoprotein metabolism. Changes in lipid profiles in 
humans have been documented on varying doses of prednisone.256-259  The major 
changes that have been reported are: elevated VLDL and TG either increased or 
decreased high-density lipoprotein cholesterol (HDLC) and increased low-density 
lipoprotein cholesterol (LDLC).
1.10.1.1 Animal studies concerning lipid changes and steroid use
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atherosclerosis, raised plasma TG significantly, but not the TC concentration260 
suggesting an increased production of TG-rich VLDL or possibly decreased 
metabolism. GCs reduce hepatic lipase activity and thereby reduce the 
metabolism of HDL2 to HDL3, resulting in elevated HDLC. Rats exposed to 
dexamethasone and triamcinolone have shown increases in TC and TG, but 
these findings were not duplicated with hydrocortisone.261  When hydrocortisone 
was administered to rats at a fixed dose of 100 µg/g of body weight, there was 
a reduction in total plasma cholesterol. Plasma apoAI was increased and apoE 
was decreased, but a differential effect was noted on plasma apo levels using 
hydrocortisone, triamcinolone and dexamethasone. The greatest increases 
were observed in apoAI, using triamcinolone and dexamethasone. The latter 
also yielded the largest increase in apoAIV, and triamcinolone caused the 
greatest increase in apoE levels. In contrast, the greatest reduction in plasma 
apoE levels was found in rats receiving hydrocortisone.261  Decreased remnant 
clearance would raise plasma TG, and could provide particles similar to LDL and 
promote atherosclerosis. Reaven et al, demonstrated that methyl-prednisone 
administered to normal rats for 8 days resulted in increased levels of TG and 
almost double the amount of the plasma cholesterol.262  A reduction in lipoprotein 
lipase activity from adipocytes was reported to occur in response to GCs, resulting 
in an increase in TG and a decrease in HDLC.263 Plasma apoE levels decreased 
on exposure to hydrocortisone, either as a consequence of decreased hepatic 
secretion or increased catabolism of apoE-containing lipoproteins. Additionally, 
lower production of apoE by extra-hepatic tissues has been suggested.264 Various 
organs, including the brain, spleen and kidney produce apoE, where its major 
function is thought to be the redistribution of cholesterol from cells with excess to 
those that require cholesterol.264  Plasma apoAI has been found to increase with 
most GCs, but the effect is considerably greater on exposure to triamcinolone 
and dexamethasone, resulting in increased HDLC.261 264   An increase in hepatic 
apoAI mRNA has also been documented in cultured rat hepatocytes exposed 
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in rats, following administration of methyl-prednisolone to account for elevated 
levels of LDL and TC.266
1.10.1.2 Human studies concerning lipid changes and steroid use
A positive correlation has been shown between plasma LDLC and endogenous 
plasma cortisol in healthy men aged between 52 years and 67 years of age.267 
Unless other changes occur in Addison’s disease, it can be speculated that GC 
deficiency will lower LDLC. GCs alter plasma lipids within 14 days.259   A study 
examining the acute effects of dexamethasone (3 mg), administered twice daily 
(equivalent to an acute stress), to young men aged between 19 years and 39 
years of age on CVD bio-markers, reported lower hs-CRP levels, increased HDLC 
and no alteration in LDLC, FFA and TG.268  In the post-cardiac transplantation 
setting, GCs have also been found to reduce hepatic lipase activity and impair 
CETP, and thereby could raise HDLC and reverse cholesterol transport.269 
Another study reported that GCs reduced the level of hepatic lipase activity.268 
Beentjes et al found that GC prescription in hypopituitary patients resulted in 
low VLDL, reduced LDLC, and reduced LCAT and CETP.270  Serum lipid levels 
were evaluated among US adults, using GCs in the third National Health and 
Nutrition Examination Survey (NHANES), which demonstrated that GC use was 
associated with higher HDL levels and lower ratios of total cholesterol-to-HDL.271 
Both GC use and endogenous hypercortisolism such as Cushing’s disease, have 
resulted in elevated TC and LDLC. 272
Based on animal and human studies, exposure to GCs may produce either 
increased or decreased HDLC and could disrupt reverse cholesterol transport 
flux. Some studies corroborate up-regulated hepatic LDL receptor activity, which 
explains a decrease in LDLC. 273 274  While GCs are known to have pleiotropic 
actions on multiple physiological and pathological processes, it would appear that 
there could be varied responses to the lipid and lipoprotein homeostasis and that 
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in Table 3, as can be best deduced from the various strategies used to identify 
lipoproteins and mechanisms of change.
Table 3: Changes in lipid and lipoprotein metabolism attributable to glucocorticoid treatment
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(contains apo AI and 
substrate for LCAT & 
CETP)
256 259 261 263-265 271 272
256low-dose glucocorticoids in 
women with rheumatoid arthritis 
apoAI was unchanged, but HDLC 
increased by 15%
260apoAI increased by 18% 
and HDLC increased by 28% 
following prednisone after 2 
weeks
261apoAI increased with 
hydrocortisone, triamcinolone 
and dexamethasone variably, 
but only dexamethasone 
increased apoAIV in rats
265apoAI increased after exposure 
to dexamethasone
268increase of HDLC by 10%
269increased phospholipids, 
unesterified cholesterol and 
apoE, reduced CETP& hepatic 
lipase, LCAT unchanged
271apoAI significantly higher 
among glucocorticoid users; 
atheroprotective ratios in elderly
273increased after corticotropin 
and dexamethasone in healthy 
humans




References for studies: human256 259 267-272, rodent261-263 265, rabbit260
References in superscript
1.10.2 Medical conditions due to steroid excess
Dyslipidaemia, hyperglycaemia and hypertension are the most significant CV 
adverse effects that result from pharmacological doses of GCs.279  Cushing’s 
syndrome provides a pathological state in which to evaluate lipid abnormalities 
in relation to excess steroids. The earliest work from 1983 reported markedly 
elevated mean levels of TC, TG, LDLC and HDLC, prior to treatment in 11 
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removal of the autonomous cortisol secreting tumour.280  It was suggested that 
hypercortisolism stimulates the production of hepatic VLDL particles.281 Lipid 
abnormalities, that are: elevated TC, LDLC and TG, but a low HDLC, have also 
been found in sub-clinical Cushing’s syndrome.281 282
1.10.3 Medical conditions requiring glucocorticoids for therapy
Lower than normal HDLC levels are seen in untreated rheumatoid arthritis patients 
and the inflammation per se, may induce these abnormalities,283 as part of the 
short-term acute phase encountered in the majority of subjects. Rheumatoid 
arthritis may represent a unique clinical scenario where some of the adverse 
lipid profile may be dampened by GCs.256   Rheumatoid arthritis represents an 
independent risk factor for CVD. In a recent meta-analysis of 24 studies involving 
111 758 patients there was a significant increase of CVD. The mortality from CVD 
and cerebrovascular disease in this meta-analysis increased by 59% and 50% 
respectively, compared with the general population.284 Reported changes in the lipid 
profile in rheumatoid arthritis include increased or decreased cholesterol levels, 
but it should be borne in mind that the populations differed in terms of disease 
activity, and not all patients were treated with GCs.285-288  Patients with rheumatoid 
arthritis were reported frequently to have high TC and LDLC, and decreased 
HDLC.256 289  On the other hand, a reduction in plasma apoB100 concentration 
has been identified among patients with active rheumatoid arthritis.290  This may 
well reflect an acute phase response.
A rise in TG suggests VLDL overproduction, with consequent exchange of TG 
into HDL and remodelling, explaining small HDL particle size and low HDLC. 
Similarly, LDL would remodel into smaller particle size. Frequently low doses of 
GCs (5 mg prednisone) are administered over a long period of time to rheumatoid 
arthritis sufferers. One study reported increased HDLC in response to GCs, 
without affecting the TC, TG and IDLC. Higher HDLC was attributed to a rise in 











Introduction to primary hypoadrenalism and its possible complications
Accelerated atherosclerosis has been attributed to SLE itself and/or to the GC 
therapy. Recent exposure to GCs, along with an increased activity index in SLE, 
conferred the greatest risk for atherosclerosis.291
Hypopituitarism differs from Addison’s disease, in that growth hormone deficiency, 
exposure to radiation and multiple endocrine deficiencies may coexist. Some 
reports show that hypopituitary patients on conventional replacement therapy 
(hydrocortisone, thyroxine and sex steroids) are subject to increased morbidity 
and mortality as a consequence of accelerated atherosclerosis276 292 but the exact 
pathophysiology is unknown. Hypopituitary patients who were thought to be 
optimally replaced by their individual clinicians, {mean total daily hydrocortisone 
dose of 27 mg (with a range from 12.5 mg to 35 mg)}293 had adverse lipid profiles 
of increased TG, increased TC and increased LDLC, compared to the controls.276 
The authors speculated that the hydrocortisone replacement may have contributed 
to these abnormal lipid profiles. A cyclic variation in TG was identified among 
women. It was lowest between 01h00 and 07h00 and highest between 07h30 
and 20h30. Additionally, minor elevations in TC were observed postprandially.276 
A reduction in hydrocortisone doses from 20-30 mg per day to 10-15 mg per 
day resulted in an average loss of 7.1 kg of body fat in 11 patients not receiving 
growth hormone. The TC and TG decreased significantly, indicating the beneficial 
effect of reducing GC replacement doses on lipid profiles, independently of growth 
hormone supplementation.275 The coronary risk in growth hormone-deficient 
hypopituitary patients has been attributed to abnormal lipid profiles.277  Males 
had raised BMI, TC, LDLC and TG, compared to the controls. Among females, 
the BMI and TG were significantly raised, while the HDLC was lower compared 
to the controls in hypopituitary patients receiving growth hormone.278 294   Various 
doses of hydrocortisone supplementation in growth hormone-replaced patients 
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1.11 The relationship between diabetes mellitus, dysglycaemia 
and abnormal lipid profiles
Either T1DM or T2DM can coexist with Addison’s disease as part of APS and 
the metabolic syndromes respectively. Abnormal lipid metabolism, usually 
manifested as hypertriglyceridaemia, is frequently encountered in diabetes and 
is a function of glucose control.295   The risk of CVD events in diabetics is the 
lowest when the glucose level is between 4.0 mmol/L and 4.9 mmol/L.296  The 
EDIC study demonstrated the benefits of good glycaemic control and reduction 
of CVD events, even though the glycosylated haemoglobin A1C (HbA1C) did not 
differ between the group with initial optimal glycaemic control compared to the 
less intensively treated group.297
Hypertriglyceridaemia, the commonest lipid disorder among diabetics, is 
established as an independent risk factor for CVD.298 299  In the UK Prospective 
Diabetes Study (UKPDS), the clinical risk factors in newly diagnosed T2DM 
at diagnosis were compared with age-matched normal subjects who did not 
have any first-degree relative with diabetes. The diabetic patients were more 
overweight and the TG levels were higher.300  The Fenofibrate Intervention 
and Event Lowering in Diabetes (FIELD) investigators examined the effect of 
Fenofibrate on reducing the CVD events in diabetes. The combination of TG 
>2.3 mmol/L and low HDLC levels, conferred the greatest risk of CVD at 17.8% 
at 5 years.301   Patients with impaired glucose tolerance were also found to have 
increased TG, as shown in the Diabetes Epidemiology Collaborative Analysis of 
Diagnostic Study in Europe (DECODE), which explored the relationships between 
lipid levels and glucose status in European subjects without a prior history of 
diabetes. Age is an important pre-determinant of fasting hypertriglyceridaemia.302 
It has been shown that TG >1.7 mmol/L occurs in up to 30% of individuals that 
are 20 years of age and continues to rise to about 43% for those that are 50 
years of age and over, irrespective of diabetic status.303  HDLC is frequently low in 
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fasting glucose had lower HDLC concentrations and higher TC/HDLC ratios than 
compared to the controls.304
1.12 Biochemical markers of cardiovascular inflammation
A number of inflammatory serum markers predict CVD. Of more recent interest 
are: highly sensitive C-reactive protein (hs-CRP), serum amyloid A (SAA) 
and lipoprotein-associated phospholipase A2. Numerous cross-sectional and 
longitudinal studies have identified CRP as a predictor for CVD. hs-CRP is 
associated with a 2-3 fold increase in the prevalence of myocardial infarction, 
stroke and peripheral vascular disease305 and predicts CVD events in patients 
with or without antecedent events.306  Its function as a reliable predictor for CVD 
events has been verified through studies such as the West of Scotland Coronary 
Atherosclerosis Prevention Study (WOSCOPS)307 and the Framingham heart 
study.308 Patients with the metabolic syndrome have higher levels of hs-CRP, 
than those without the metabolic syndrome.309  The relationship between the 
individual components of the metabolic syndrome and hs-CRP was investigated. 
In a cross-sectional multicentre study, a population-based survey was conducted 
to determine the prevalence of CV risk factors among 1344 subjects who fulfilled 
the Adult Treatment Panel (ATP) III diagnostic criteria for the metabolic syndrome. 
The prevalence of the metabolic syndrome was 30.9% (95% confidence interval 
28.4%-33.3%). Each individual component, except for HDLC, was associated 
with an elevated hs-CRP, with waist circumference exhibiting the strongest 
association with hs-CRP.  Moreover, a gradual increase in the log transformed 
levels of hs-CRP was observed, with an increasing number of components of the 
metabolic syndrome. 310
Serum amyloid A (SAA) is linked to atherosclerosis risk. SAA leads to expression 
of proteinases, which degrade extracellular matrices.311  The concentration of 
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enriched in HDLC at the expense of apoAI. Phospholipase A2 enzymes hydrolyse 
phospholipids, generating lysophospholipids and FFA.312  Lipoprotein associated 
phospholipase A2 is preferentially found on small LDL.313
Non-esterified fatty acids (NEFA) are released from adipose tissue by the action 
of hormone sensitive lipase. This enzyme is not suppressed in diabetics and 
NEFA concentration may parallel that of deteriorating glycaemic control.314  The 
association of hormone-sensitive lipase and NEFA is strong.315  An association 
also exists between high NEFA in offspring and increased risk of CVD in their 
parents. NEFA may have a direct pro-arrhythmogenic effect and predispose 
individuals to sudden cardiac death presumably arrhythmogenic by shortening 
the action potential duration, through activating the A.T.P.-sensitive potassium 
channels.314   As circulating NEFA are to a large extent influenced by the adrenergic 
tone, it is possible that the adrenergic stimulation may be the cause for the pro-
arrythmogenic effect. 
1.13 Framingham risk assessment
TThere is universal appreciation that being male, advancing age, elevated 
blood pressure, tobacco use, dyslipidaemia   and   diabetes  mellitus are major 
contributors to the development of CVD. The overall vascular risk increases 
synergistically when multiple risk factors are present.316 The Framingham risk 
score for predicting CVD has demonstrated validity among Whites, African 
Americans, Europeans and Asians.317 The current Framingham risk score was 
derived from a population of 5 000 individuals in the Framingham community, 
taking age, blood pressure, TC, HDLC and tobacco exposure into consideration.318 
A 10-year risk of CVD >20% demands aggressive management. However, in 
certain settings, the Framingham risk assessment may be inaccurate. Studies 
have shown that patients with SLE and rheumatoid arthritis have a higher than 
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coronary artery calcification and higher Framingham risk scores, with the absolute 
risk underestimated by the Framingham risk score calculation alone.320 Diabetes 
is now recognised as a secondary prevention equivalent.321
1.14 Normative lipid data for South Africa
South Africa has a heterogeneous population in which different communities 
display not only different CVD event rates, but also varying lipid profiles.322 10-
20 years ago, a number of localised population-based studies were conducted 
but these did not consider the effect of substantial urbanisation among the black 
population and the changing lifestyles of many South Africans. South Africa is 
burdened by the HIV epidemic.  This adds further CV risk by the deranged metabolic 
profile, associated with highly active antiretroviral therapy. The  dyslipidaemia 
associated with antiretroviral therapy manifests as a high triglyceride/low-HDLC 
syndrome, and in severe cases may present as a chylomicronaemia syndrome.323  
Current lipid profiles and CVD risk in different communities in South Africa are not 
available for specific comparisons with Addison’s disease subjects in this study. 
By assuming that European and North American data apply,302 324  risk estimates 
can be used as a guide, even if they are not absolutely reliable.
1.15 Dyslipidaemia and cardiovascular risk in Addison’s disease
Dyslipidaemia may be heterogeneous in origin in patients with Addison’s disease. 
Incidental lipid disorders can occur that are unrelated to Addison’s disease, for 
example: familial combined hypercholesterolaemia (2% of any population) or 
familial hypercholesterolaemia (0.2% of most populations), but some founder 
effects exist in the South African population for familial hypercholesterolaemia.325 
Incidental disease states, such as nephrotic syndrome, hypothyroidism or 
diabetes may produce dyslipidaemias. The underlying aetiology of Addison’s 
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phase reaction with reduced HDLC and by contrast, chronic tuberculosis may 
induce a rise in HDLC as patients are treated with rifampicin. Similarly, other 
microsomal enzyme inducers including: phenytoin and alcohol are known to raise 
HDLC (Table 4).326
Table 4: Possible causes for lipid derangement among patients with Addison’s disease
Primary Secondary










Related to underlying 
aetiology of Addison’s 
disease *
•	Autoimmune diabetes or 
primary hypothyroidism
•	Tuberculosis acute or 
chronic or its therapy 
(rifampicin increases HDL)
•	Adrenoleukodystrophy






* Conditions that may cause Addison’s disease and affect other organ systems that modulate 
lipoprotein metabolism
Addison’s disease has not traditionally been viewed as an independent CVD 
risk factor, and lipids and lipoproteins have not been studied in any depth in 
this condition. A single study examined lipid profiles of 54 Addison’s patients 
in response to DHEA supplementation. The baseline and standard error of the 
mean (SEM) TC was 4.45 (0.22) mmol/L, TG was 1.23 (0.14) mmol/L, HDLC 
was 1.27 (0.08) mmol/L and LDLC was 2.57(0.15) mmol/L, and no differences 
in lipid profiles were found between the placebo and DHEA treatment groups 
after 6 months and 12 months.241  In a recent study by Giordano et al, 18 of the 
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hypertriglyceridaemia, compared to 8 controls, but none of the patients or controls 
had an HDLC <1.03 mmol/L or an LDLC >4.91 mmol/L.240  It is conceivable that 
patients with Addison’s disease have lipid abnormalities, which place them at 
increased risk for CVD and the GC replacement may also impose additional 
CVD risk. Patients with Addison’s disease may also have altered markers for CV 
inflammation that result from the disease or its treatment, and the value of these 
markers needs to be assessed.
1.16 Therapy for Addison’s disease
Patients with Addison’s disease require lifelong GC replacement therapy. This 
usually takes the form of hydrocortisone. Endogenous cortisol production, 
determined by stable isotope dilution mass spectrometry in healthy individuals, is 
only 6-11 mg/m2/day,327  but the ideal hydrocortisone replacement dose remains 
to be determined. Suggested doses vary from 30 mg of hydrocortisone to as little 
as 12.5 mg per day, divided in two or three daily doses.322 329  In general, clinicians 
rely on empiric doses, which vary substantially according to the practice at a 
particular centre. Over-replacement with hydrocortisone may result in accelerated 
bone loss, premature atherosclerosis and the metabolic syndrome.235 330-332   On 
the other hand, insufficient hydrocortisone supplementation results in chronic 
symptoms of fatigue. There is evidence to support the idea, that irrespective of 
the dose of hydrocortisone replacement, patients have subjective impaired health 
quality.333
Conventional hydrocortisone replacement is non-physiological, as it is well 
absorbed in the small and large intestines, inducing high peaks that are followed 
by rapid elimination. This results in intermittent low trough levels require two to 
three doses per day. In addition, inter-individual differences in the absorption 
and metabolism of hydrocortisone, results in uniform doses being inappropriate 
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replacement, normal physiology is not restored.333  Consequently, there is 
ongoing research to improve hydrocortisone administration and replacement, by 
prolonging its bio-availability.335
CVD has been linked to increased cortisol levels. Hypertension, increased heart 
rate, increased TC, LDLC, fasting insulin and glucose, have all been reported 
to correlate with endogenous cortisol levels. A positive correlation has also 
been found between the number of carotid atherosclerotic plaques, measured 
by ultrasonography and endogenous cortisol exposure in an elderly population, 
independent of the number of coexisting CVD risk factors.336  There is uncertainty 
as to the degree of either exogenous or endogenous cortisol exposure that results 
in harmful effects. In patients with hypoadrenalism, the most significant barrier 
to monitoring therapy with GCs is that no single test exists that reliably reflects 
adequacy, over-replacement or under-replacement.
1.16.1 Pharmacokinetic principles of monitoring and interpretation of drug 
levels 
A priori assumptions are made with respect to drug monitoring, namely that there 
is inter-individual variation and that the drug levels found in plasma correlate 
much more closely with the therapeutic effect and toxicity than the dosage. For 
many drugs, therapeutic effects are not easily measured and utilising blood 
concentrations may be helpful in making dosage adjustments.337  The standard 
definitions used in pharmacokinetic studies are given in Table 5.
After a patient ingests a single oral dose of medication, the peak level is referred 
to as the maximum concentration, Cmax, or the maximum systemic exposure. The 
time at which Cmax occurs is called tmax or the time of maximum exposure. Both 
Cmax and tmax are highly dependent on how quickly the drug enters and is eliminated 
from the body. There is individual variation in the absorption, metabolism, 
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weight, gender, general state of health, genetic factors and drug interactions.337 
Drug concentrations may be measured in certain circumstances in whole blood, 
serum saliva or urine. The specific timing of the sample is likely to influence the 
interpretation of the drug concentration. The anticipated response of a drug is 
generally based on the concentrations determined by steady state samples or 
samples taken at specific time points after the dose. While hydrocortisone has 
excellent bioavailability after being administered orally, it has a half life of 1.8 
hours and therefore does not reach a steady state using 2-3 daily doses.338
Drugs with a narrow therapeutic window (the blood concentration between 
the minimum effective and the maximum tolerated concentrations), require 
monitoring and dosage adjustments, in order to limit toxicity. For example, dosage 
adjustments for the aminoglycosides should ensure that the peak concentration 
is exceeded, while the trough concentration is below the threshold for toxicity.339 
The optimum therapeutic blood concentration range or therapeutic window in 
which most people will be effectively treated without suffering from toxicity, have 
been determined for many drugs, for example digoxin and lithium carbonate.337
1.16.1.1 Exposure-time profiles
The overall exposure to a drug is measured by the area under the concentration-
time profile (AUC), also known as a systemic exposure-time profile, which is a 
composite of the rate and extent of drug input, distribution and elimination (Figure 
9). AUC is derived from concentration time data. It takes cognisance of how much 
of the drug is introduced and cleared from the plasma compartment, irrespective 
of the rate at which it is absorbed into the plasma compartment. The usual way 
to determine AUC is by approximating the area between the measurements as 
trapezoids and summing up the areas of successive trapezoids.   AUC may also 
guide dosing, for example, it may provide information on the maximum tolerated 
exposure and it is frequently referred to as AUC dosing. Drug AUC values can 
































Figure 9:  Pharmacokinetic data derived from an exposure time profile. The AUC (area under 
the concentration-time) correlates with exposure to a substance. The therapeutic window or 
therapeutic range is the optimal concentration at which is efficacy is most likely. The lower limit 
minimum effective concentration (MEC) is usually the concentration at which 50% of subjects 
have a therapeutic response. The upper limit minimum toxic concentration (MTC) is usually the 
lowest concentration at which the toxic effects predominate. The Cmax (maximum concentration) 
of a substance is usually the highest total concentration of a drug or endogenous substance in 
plasma measured over a period of time.  For an oral drug where the absorption into the plasma 
from the gut and clearance from the plasma via the kidney or liver compete, the maximum 
concentration, Cmax occurs when these rates are equivalent. The tmax (time) after administration 
of the drug occurs when the maximum concentration is reached following an extravascular dose. 
Adapted from Rowland M, Tozer T. Clinical pharmacokinetics; concepts and applications. Third 
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The maximum concentration of a substance, measured during 
a defined interval. (For an oral drug, absorption processes 
increase the plasma concentration; distribution to other tissues 
from the plasma compartment and clearance from the plasma 
via the kidney and liver reduce plasma concentrations; the 
maximum concentration, Cmax occurs when these rates of 
drug transfer into and out of the plasma compartment are 
equivalent.)
tmax
The time after administration of the drug when the maximum 
concentration is reached following an extravascular dose. 
More simply: the time of Cmax
Trough levels 
(Cmin)
The minimum concentration observed over a period of time. 
(Usually this is the concentration in the plasma at the time just 
before the following dose, but can refer to any point in time 
when the concentration is lowest as in the case of endogenous 
substances.) 
Area under the curve 
(AUC)
Area under the concentration versus time curve; usually the 
plasma drug concentration curve and this correlates with 
exposure to a substance.
The measure will vary according to the method of derivation.
Therapeutic window
The therapeutic window or therapeutic concentration range 
is the optimal concentration at which is efficacy is most likely.  
The lower limit is usually the concentration at which 50% 
of subjects have a therapeutic response.  The upper limit 
is usually the lowest concentration where the toxic effects 
predominate. Many prefer the term ‘target drug concentration 
range’ and this would be that concentration range where most 
patients would have a satisfactory treatment response without 
unacceptable toxicity.
Clearance (CL)
Total elimination of a substance from the body either by 
diffusion, excretion, renal filtration or metabolism (this would 
be referring to CL from the body). Often one mechanism of 
elimination predominates and therefore clearance refers to the 
elimination via that organ – for example kidney or liver. This is 
usually defined in terms of the volume of plasma (or defined 
compartment/tissue/body) cleared of the drug per unit time.
Bioavailability
The fraction of substance dose which reaches the systemic 
circulation. The lost fraction is the result of incomplete 
absorption and/or pre-systemic metabolism.
Adapted from Clinical pharmacokinetics: concepts and applications Rowland M, Tozer TN. 1995 
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1.17 Monitoring of the adequacy of replacement in Addison’s 
disease
A number of measures have been used to examine the adequacy or otherwise of 
replacement therapy in Addison’s disease; none is ideal. These methods will be 
briefly discussed.
1.17.1 Use of plasma ACTH as a marker of hydrocortisone adequacy in 
primary hypoadrenalism
ACTH under normal physiological conditions is released in a pulsatile fashion, 
under control of hypothalamic corticotropin releasing hormone. The diurnal rhythm 
of ACTH release ensures that there is a peak before awakening and a continued 
decline as the day progresses. The episodic release of ACTH is independent of 
circulating levels of cortisol, and is not related to the levels of cortisol just prior 
to its release. It has a short plasma half life of 7-12 min inducing a wide range of 
concentrations of cortisol.161
The studies that utilise plasma ACTH as a marker of the adequacy of GC 
replacement in primary hypoadrenalism have yielded highly variable results. 
Feek et al showed that the morning plasma ACTH in Addison’s disease patients, 
measured on the day that they were asked to omit their doses (equivalent to a 
total daily dose 20 mg daily of hydrocortisone) was either elevated, normal or 
suppressed.340  In five healthy Addison’s patients, presumed to be on adequate 
hydrocortisone replacement therapy (ranging from 15-30 mg daily), the ACTH 
was markedly elevated between 08h00 and 09h00, but was similar to control 
levels between 12h00 and 02h00.341  On the other hand, it has been suggested 
that ACTH suppression below the reference range is indicative of over-exposure 
to GCs.342 One of the explanations for the frequent lack of ACTH normalisation 
with replacement doses of GCs, is the reduced sensitivity of the pituitary gland 
to cortisol inhibition, which stems from the loss of negative feedback before the 
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TSH (which has a half life of 50-60 min and is under feedback inhibition of thyroid 
hormone) is accepted as a marker of adequacy of thyroxine replacement,161 
ACTH should not be used to monitor adequacy of GC replacement. It could also 
reflect the differences in the robustness of TSH and ACTH assays as well as 
stability of the hormone following sampling, since ACTH is more labile than TSH.
1.17.2 24-hour urine cortisol for the monitoring of hydrocortisone 
replacement therapy
The 24-hour urine cortisol measurement has limited value in monitoring and 
adjusting therapy for patients with Addison’s disease.  It is a gross reflection 
of hydrocortisone, because the peaks are ignored and it merely reflects a 
measure of total exposure.343  In one small study of nine patients with primary 
hypoadrenalism on usual replacement doses, the urinary free cortisol (UFC) 
levels were in the range obtained from a large number of healthy controls.344 
However, in another study, the UFC levels were above the reference range.343 
These discrepant findings attest to the poor reliability and reproducibility of this 
modality for monitoring. Additionally, cortisol-binding globulin (CBG) is saturated 
rapidly after absorption of GCs. This leads to enhanced renal elimination of 
GCs, resulting in higher concentrations of UFC compared to healthy subjects, 
which makes it difficult to compare with the usual reference range.345  Overall, 
the 24-hour urine collection has multiple drawbacks, including accuracy of urine 
volume collections, making it an unsuitable method of monitoring adequacy of 
replacement therapy.
1.17.3 Plasma cortisol for the monitoring of hydrocortisone replacement 
therapy
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1.17.3.1 Single measures of plasma cortisol-peak
Monitoring hydrocortisone replacement therapy using cortisol peak levels have 
revealed that the vast majority of patients have supra-physiological peak levels, 
occurring 1-2 hours after the morning dose, followed by hypocortisolaemia.346 
Li Voon Chong et al showed that the peak cortisol measured 2 hours after the 
morning dose was higher in patients taking 20 mg of hydrocortisone compared 
with those taking 10 mg.329 Children with ACTH deficiency on hydrocortisone 
replacement had persistent supra-physiological peaks of cortisol, irrespective of 
whether the morning dose was adjusted for body surface area.346 
1.17.3.2 Plasma cortisol day curves
Plasma cortisol day curves were first introduced in 1977. Plasma samples drawn 
hourly over a 5-hour period showed considerable inter-individual variation at both 
peak and 5-hour levels.347  In 1978, patients on twice daily hydrocortisone were 
found to exhibit higher plasma concentrations between 08h00 and 12h00, and 
between 17h00 and 18h00 compared to control levels but plasma cortisol levels 
were undetectable between 03h00 and 08h00.341  A three-times daily regimen 
of hydrocortisone was able to partially correct the prolonged nadir of plasma 
cortisol during the cortisol day curve seen with the twice-daily regimen.334 Howlett 
et al performed serum cortisol measurements at 09h00, 12h30 and 17h30 on 
hypoadrenal patients’ usual hydrocortisone replacement doses with  the optimum 
replacement dose defined as the dose required to achieve a urinary free cortisol 
(UFC) and a 09h00 plasma cortisol level within reference range for the normal 
population.  It was also revealed that following the peak cortisol levels, there are 
5-7 hours of decline to below 100 nmol/L, which lasts until the next dose.348  The 
aim of a structured scoring system was to assess the clinical quality of replacement 
together with timed repeated plasma cortisol measurements. In this system 
fatigue or loss of energy, nausea, weight loss, hyperpigmentation, hypoglycaemia, 
hyponatraemia or hyperkalaemia suggested under-replacement, while insomnia, 
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hypernatraemia, hypokalaemia and elevated blood pressure suggested over-
replacement. Lower scores correspond with lower plasma cortisol concentrations 
and higher scores correspond with with higher plasma cortisol concentrations343 
suggesting that a positive relationship exists between clinical parameters and 
cortisol concentrations during a plasma cortisol day curve. Peacey et al found 
that plasma cortisol day curves correlated with UFC levels and bone turnover 
markers in Addison’s disease and hypopituitarism. At the beginning of the study, 
the mean total hydrocortisone dose was 29.5 mg and markers of bone turnover 
were increased. When the total dose of hydrocortisone was reduced to a mean of 
20.8 mg in order to limit the harmful effect of GCs on bone, osteocalcin increased, 
but N-telopeptide of type I collagen (NTX) remained unchanged. 349
Plasma cortisol day curves have inherent problems. The major drawbacks are 
the frequent blood sampling and admission to hospital, even for part of a day, 
resulting in inconvenience to the patient, and therefore these curves are not widely 
used. In addition, plasma cortisol relies on the hydrocortisone being absorbed 
systemically, equilibrating with CBG and does not reflect an instantaneous 
measure of free cortisol.350  CBG levels vary widely among individuals351 and may 
increase with increased duration of treatment with hydrocortisone, which may 
also contribute to the poor reliability of using plasma cortisol day curves.
1.17.3.3 Plasma cortisol day profiles and area under the curve
The AUC has also been used to estimate cortisol exposure. Mah et al showed that 
during the time period 08h00-14h00, it was possible to adjust the hydrocortisone 
dose so that the AUC was similar for patients and controls. Further, profiles were 
less variable when using a dose of 0.12 mg/kg of hydrocortisone and a single blood 
sample taken 4 hours after the initial dose of hydrocortisone could predict the 
AUC, which could be used to alter replacement doses.350  Thomson et al reported 
significant inter-individual variability in plasma cortisol AUC, measured 15 min, 30 
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ingestion in patients.352 Charmandari et al showed that using plasma AUC in 
patients with congenital adrenal hyperplasia, despite a high bioavailability with 
oral hydrocortisone, intravenous hydrocortisone induced a significantly higher 
Cmax at 10 min, compared to oral hydrocortisone, which reached its peak cortisol 
concentration at 180 min.  In both cases serum cortisol was undetectable 6 hours 
after the initial administration of hydrocortisone.353 
1.17.4 Other biochemical markers for evaluating cortisol exposure
Remarkably, long-term cortisol exposure has been examined using the cortisol 
content of human hair as a biomarker.  It is not a routine test, but it may in time 
become a successful, non-invasive alternative to salivary and plasma cortisol.354
1.18 Salivary cortisol as a means of monitoring replacement 
therapy in Addison’s disease
Monitoring salivary cortisol will be introduced followed by a discussion on technical 
factors and previous studies of salivary cortisol in Addison’s disease.
1.18.1 Introduction
There are numerous advantages to using saliva for monitoring drugs or hormones. 
Saliva is readily accessible, it is a relatively small reservoir for antigens and as a 
result, the risk of contracting HIV and hepatitis infections is much lower than for 
blood. Analytes are stable at ambient temperature for about 7 days, limiting the 
need for refrigeration. It is more convenient for patients than plasma samples, 
as multiple samples can be collected at their homes and it does not require 
supervision by a professional.355
Salivary cortisol is a non-invasive accurate measure of endogenous free cortisol 
production and it has found favour in various fields such as sports physiology, 
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through the acinar cells of the salivary glands and the rate at which they are found 
in saliva is independent of the amount of salivary flow.355 357  However, minor 
abrasions of the gum mucosa can induce contamination by blood, which could 
falsely elevate salivary cortisol.355  Steroids are lipophilic and are transferred 
rapidly through the saliva. A significant proportion of cortisol is converted to 
cortisone by 11 beta-hydroxysteroid-dehydrogenase-II, yielding an inactive keto-
form. Hirasawa et al confirmed immunoreactivity of both 11 beta-hydroxysteroid-
dehydrogenase-II and mineralocorticoid receptors in submandibular and parotid 
salivary glands.358 The degree to which this enzymatic reaction occurs is often 
ignored, which could potentially explain some of the discrepant results in the 
literature with respect to cortisol. In order to obviate this uncertainty,  it  is important 
to verify  that the assay used has minimal cross-reactivity  with cortisone.359 
As there is comparatively minimal 11 beta-hydroxysteroid-dehydrogenase-I in 
salivary glands, salivary cortisone predominates over salivary cortisol from local 
production and salivary cortisol has been suggested to be a good reflection of 
serum cortisol.360 361
Salivary cortisol correlates well with an individual’s degree of stress and socio-
economic status. In two groups representing divergent socio-economic classes, 
the lower socio-economic status group had a higher stress index and salivary 
cortisol, compared with the higher socio-economic class.362  In a pilot study 
in young males with violent and aggressive behaviour, salivary cortisol was 
reproducible from week to week, implying that a single day curve may be of 
value in assessing the HPA.363  Salivary cortisol could be considered an ultra-
filtrate of plasma cortisol as saliva is usually free of CBG and thus measures 
free cortisol.364  Salivary cortisol has specific advantages over plasma cortisol 
in pregnancy and patients using oral contraceptives or hormonal replacement 
therapy, where the CBG levels are likely to be elevated. Salivary cortisol has also 
been extensively used to exclude Cushing’s syndrome, and more recently it has 
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cortisol can be used in basal and stimulated conditions, as it does not require 
equilibration with CBG.367   Salivary cortisol has emerged as an important analyte 
to monitor conditions ranging from frank excess, example Cushing’s disease to 
subtle degrees, of HPA activation or depression.368
Several studies have shown a correlation between salivary cortisol and several 
metabolic abnormalities.369 370  A rise in salivary cortisol was positively associated 
with BMI, waist-to-hip ratio, random blood glucose (RBG), insulin and TG, and 
with abdominal obesity in men.368   Among type 2 diabetics, women with the 
highest cortisol profiles had the highest fasting, postprandial glucose and HbA1C. 
In addition, systolic and diastolic blood pressures were correlated with cortisol 
levels.371
Multiple authors have shown an association between cortisol hyper-secretion and 
the development of clinical depression.372 373  People at risk of depression due to 
a positive family history have demonstrated increased salivary cortisol levels.  In 
keeping with a previous finding of a negative correlation between plasma cortisol 
levels and bone mineral density (BMD), similarly increased salivary cortisol levels 
and reduced BMD at all  sites were demonstrated in depressed  individuals.374  By 
contrast, in elderly women from Helsinki, salivary cortisol samples throughout a 
24-hour period did not demonstrate a relationship between HPA activity and the 
development of the metabolic syndrome.375
Although a positive correlation between salivary cortisol and serum cortisol exists 
in most studies, correlation coefficients vary from r = 0.62 to r = 0.86.376 377   An 
overall correlation of simultaneous measures of serum with salivary cortisol was 
found to be r = 0.62; p=0.0001 in healthy subjects, and patients with Addison’s 
disease, pseudo-Cushing’s and Cushing’s syndrome.  Wong et al, found that total 
plasma cortisol was highly correlated with salivary cortisol (r = 0.7) in hypoadrenal 
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in CBG (peak in the early afternoon and attenuation of free cortisol) and variable 
binding of cortisol, due to diurnal variation may be potential causes for the variable 
relationship between salivary and serum cortisol.378  Healthy subjects‘ morning 
serum cortisol in one study is about 20 times greater than that of simultaneously 
sampled salivary cortisol, and in the afternoon serum cortisol is about 27 times 
greater than salivary cortisol.379 Despite the multiple influences that could modify 
the relationship between serum and salivary cortisol, one study demonstrated an 
excellent correlation throughout the 24-hour period.380   Overall, the relationship 
between saliva and serum cortisol is not always constant and is influenced by the 
time of sampling.
1.18.2 Devices for the collection of salivary cortisol
Saliva is most commonly collected by chewing on salivettes or by collecting 
passive drool in plastic tubes. It has been reported that the concentrations of 
salivary cortisol generated, were lower when collected in salivettes, compared 
with the passive drool technique collected into microcentrifuge tubes. However, 
salivettes exhibited better correlation with total plasma and free plasma cortisol 
compared to collecting saliva using the passive drool technique.380   Similarly, 
when using 6 time points between 08h00 and 23h00, the salivettes correlated 
better with plasma free and total plasma cortisol compared to the passive drool 
technique.381   As results may be influenced by the particular collection device, the 
same device should be used throughout studies.382
1.18.3 Technical factors associated with salivary cortisol collection
One of the problems with saliva analysis is that the steroid of interest may coexist 
with a difficult matrix, requiring physical or chemical disruption. Freezing and 
thawing cycles, and centrifugation are used to break up mucins.383   A significant 
decrease in the concentrations of salivary cortisol were detected in the samples 
that were thawed and refrozen up to five times, but thawing twice did not induce 
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tobacco or gingivitis may falsely elevate salivary cortisol. A useful method of 
determining whether saliva is contaminated by blood, is to quantify the volume of 
sex-hormone binding globulin (SHBG) and CBG.385  Exogenous GCs may also 
contaminate saliva.383   Many authors have confirmed the stability of salivary 
cortisol for up to 3 months at -20°C. Storage at -80°C may prolong the durability of 
the samples even further. An increase in cortisol in response to chronic smoking 
has been reported and it is thought to be the result of activation of the HPA. 
Smokers exhibited higher levels of salivary cortisol throughout the day, despite 
being carefully controlled for social status, health behaviour and stress reporting 
in one study.386  The collection process for salivary cortisol also demands some 
dietary restrictions as certain chemicals may influence the measured cortisol 
concentrations.387  For example, lemon juice intended to stimulate saliva may 
cause a false increase in salivary cortisol.388
An advantage of using salivary cortisol is it can be performed in the comfort of 
patients’ homes, rather than requiring admission to hospital, obviating spurious 
rises in levels of cortisol associated with stress caused by being admitted to 
hospital.  Sheer et al showed that the salivary cortisol on awakening was two 
times higher in subjects admitted to hospital, three times higher at the morning 
peak and five times higher at late night sampling, compared to those subjects 
who collected saliva at home.389
1.18.4 Monitoring of hydrocortisone using salivary cortisol in Addison’s 
disease patients
Despite salivary cortisol being easily obtained, there are concerns relating to its 
wide variability.  Two authors have suggested that measuring salivary cortisol 
is not of value in assessing GC adequacy, because of the significant variability 
observed.352 376  Free cortisol levels fluctuate considerably during the day, 
suggesting that salivary cortisol may be no more accurate than plasma cortisol in 
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Løvås K et al evaluated the potential for using salivary cortisol measurements in 
assessing the adequacy of GC replacement in patients with Addison’s disease, 
after taking either oral cortisone acetate or intravenous hydrocortisone. Salivary 
and plasma cortisol were highly correlated, (r = 0.83-0.98, p <0.002), but a morning 
dose of 12.5 mg of cortisone acetate generated a wide distribution in salivary 
cortisol concentrations.377   Salivary cortisol AUC has a poor predictive value for 
plasma cortisol AUC and consequently, it was suggested that salivary cortisol 
could not be used to make individual adjustments to hydrocortisone doses.352 
Hydrocortisone is the favoured GC used in congenital adrenal hyperplasia (CAH) 
caused by 21-hydroxylase deficiency, due to its short half life and neutrality with 
respect to longitudinal growth.392 393 The usual profile after taking oral hydrocortisone 
is that the peak plasma cortisol is reached 1-2 hours after administration in the 
morning, followed by a non-exponential decline indicating that a non-sustained 
level of cortisol prevails after taking oral hydrocortisone.239  Groschl et al examined 
the pharmacokinetic profile of a single dose of hydrocortisone in ten children and 
adolescents with salt-wasting CAH and compared it to that of healthy volunteers, 
aged between 18 years and 29 years of age. The patients with CAH had different 
cortisol profiles from the healthy volunteers; as they reached a maximum salivary 
cortisol concentration within 15 min after taking oral hydrocortisone, while the 
healthy volunteers reached their maximum concentrations only between 15 min 
and 30 min. This suggests that the metabolism of hydrocortisone is rapid in patients 
with CAH, due to lower levels of CBG and consequently accelerated clearance 
rates. Although it was unclear whether the BMI and the dose of hydrocortisone/m2 
differed between the patients and controls to account for the differential clearance 
rates in these two groups it is also uncertain, whether this rapid rate of clearance 
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1.19 Improvements with respect to hydrocortisone replacement 
therapy
Experts have suggested hydrocortisone doses should be between 20 mg and 30 
mg per day, divided in two or three daily doses.348  An intravenous programmed 
hydrocortisone infusion was set up to mimic the circadian rhythm of cortisol 
secretion. The overall mean 24-hour cortisol exposure was similar for the patients 
on conventional oral therapy and infusion therapy, but the patients on infusion 
therapy were exposed to higher concentrations between 21h00 and 09h00. 
These results indicate the potential to improve therapy, by focussing on delayed 
absorption.394  Modified hydrocortisone release tablets administered 15-20 mg 
at 23h00 and 10 mg at 07h00, provided the most physiological excursions of 
cortisol, compared to healthy controls.395   Another hydrocortisone formulation 
administered to healthy subjects, providing 15 mg with a 50% delay in release, 
was able to match normal cortisol profiles.396  A novel once daily modified 
release hydrocortisone tablet with combined immediate and extended release 
characteristics has been developed to achieve a more physiological cortisol 
profile reproducing the normal circadian profile better than immediate release 
hydrocortisone. The pharmacokinetic profiles indicate that the gastrointestinal 
absorption was rapid with a high bioavailability and the variability was less than 
indicated by immediate release hydrocortisone formulations. This preparation 
has completed phase III studies.397  Overall, the benefits seen with the delayed 
release are the lower peak levels and the absence of sub-physiological cortisol 
levels as seen using conventional replacement modalities.
1.20 Monitoring of salivary cortisol, using the area under the 
curve 
The AUC for salivary cortisol is a useful surrogate measure of exposure to either 
endogenous or exogenous cortisol. In chronic fatigue sufferers and healthy 
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former was lower compared to the healthy controls.398 Inhaled GCs have the 
potential to suppress the HPA and despite the recommendation for frequent 
monitoring of serum cortisol levels, the ideal modality for monitoring has not 
been established.  153 patients with moderate asthma were randomly assigned 
to receive fluticasone propionate in varying doses, flunisolide or prednisone. 
An 08h00 salivary cortisol, 24-hour UFC and 22 hour serum cortisol AUC were 
performed. A positive correlation was found between the 08h00 salivary cortisol 
and serum cortisol AUC (r = 0.51; p = 0.0001), as well as with the serum cortisol 
performed at the same time, (r = 0.55; p = 0.0001). The salivary cortisol measured 
once at 08h00 showed a 50% decline in the plasma cortisol AUC for a 22-hour 
period.399
There is consensus that the salivary cortisol AUC was the most promising 
measure in order to link cortisol levels and psychological functioning. Increased 
salivary cortisol AUC concentrations have been related to psychosocial measures 
for example anxiety, hostility and lack of calmness. Stone et al suggested that in 
order to evaluate exposure, more salivary cortisol measures per day are better 
than fewer400 and at least four or five are recommended. To obtain an accurate 
AUC samples taken 1 hours, 4 hours, 9 hours and 11 hours after waking have 
been shown to provide reasonable assessment of the AUC. Other researchers 
have recommended six samples taken at immediately on waking, before getting 
out of bed, 45 minutes after waking, between 16h00 and 18h00, 18h00 and 
21h00 and between 21h00 and bedtime. The frequent sampling, especially 
during the early part of the day, ensures that the morning cortisol awakening 
response (CAR) is adequately measured, that the afternoon-evening slope is 
demonstrated and finally that the evening nadir is confirmed.401 A multidisciplinary 
collaboration of leading scholars examining socio-economic status and health, 
known as the MacArthur Network has suggested a single day, six-sample 
protocol with samples taken at awakening, 45 minutes, 2 1/2 hours, 8 hours and 
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levels during waking hours.402   Alterations in the CAR have been documented in 
disease states. Normally, the peak concentration occurs about 30 minutes after 
waking, but significant variability in the CAR has been encountered in breast 
cancer sufferers.403  The normal circadian rhythm may be disrupted prior to the 
diagnosis of either diabetes or hypertension.404 Obesity too is known to exhibit a 
blunted salivary cortisol response, with overall lower morning levels.405
An elevated CAR has been associated with social stress, depression and chronic 
work overload, while a reduced response can be anticipated with persistent 
pain.406  The variation in the magnitude of responses between individuals, following 
different stressful situations or tests, is marked. In contrast to pharmacological 
stimulants, for example administration of ACTH or corticotrophin releasing 
hormone, psychological stress tasks have differing potential to evoke stress 
responses. The abundance of psychology literature has shown that certain 
individuals respond differently depending on whether the stressor is isolated 
with acute hyper-responsiveness or a recurrent insult, manifesting with hypo-
responsivity. Inconsistencies in results may be attributable to the highly varied 
responses and heterogeneity of the study design.407
1.20.1 Hydrocortisone during stress and mineralocortioid replacement
At least a doubling of the dose of hydrocortisone is warranted in most mild illnesses. 
In life-threatening situations, the dose of hydrocortisone should be increased to 
100 mg, three times daily.  Major surgical procedures, sepsis or severe trauma 
demand significant escalation of hydrocortisone replacement, but this may be 
reduced gradually, depending on a favourable patient response. On the other 
hand, a Cochrane review examining the need for supplemental steroids for surgical 
patients with adrenal insufficiency, showed inadequate evidence to support or 
refute the use of supplemental peri-operative steroids in these patients and that 
the maintenance dose may be sufficient.408   Mineralocorticoids are essential for 
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is possible by evaluating plasma sodium, potassium and renin activity assays. An 
elevated plasma renin activity in an Addison’s patient may indicate inadequate 
mineralocorticoid substitution, while elevated blood pressure, peripheral oedema 
and sodium retention may indicate over-replacement. The usual dose of 9-alpha-
flouro-hydrocortisone is between 50 µg and 200 µg per day. Patients are at risk of 
developing hyperkalaemia and hypotension, should this be discontinued.229
1.20.2 Rationale for measurement of salivary cortisol day curves in 
Addison’s disease 
Salivary cortisol is easily accessible and reflects both circulating free and total 
serum cortisol. Thus salivary cortisol day curves, could be used to determine 
whether Addison’s patients on their usual doses of hydrocortisone are exposed 
to higher concentrations of cortisol than healthy subjects’ endogenous cortisol 
levels and whether higher exposure translates into metabolic abnormalities. 
1.21 The effect of glucocorticoid receptor polymorphisms on 
sensitivity to cortisol in relation to Addison’s disease
1.21.1 Introduction 
Cortisol exerts multiple pleotropic actions that are critical for metabolic, 
physiological and stress-related conditions.409 The actions of cortisol are diverse, 
and include CV immune and metabolic actions, as well as regulation of cellular 
growth and proliferation. Cortisol also exerts negative feedback action on the HPA, 
which is fundamentally important in regulating its secretion. Multiple psychiatric 
and psychological disorders arise from over-activation of the HPA.410   Adipocyte 
differentiation, for example which increased fat mass and predisposition to insulin 
resistance, is also influenced by cortisol. As cortisol has a permissive effect on 
catecholamines, increased lipolysis and circulating FFA levels may result during 
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The biological response to cortisol is influenced by the level of GCs and the 
sensitivities of the individual glucocorticoid receptors (GCRs).413 The biological 
response is also influenced by the availability of prevailing cortisol and the extent 
to which cortisol is bound to CBG. 11 beta-hydroxysteroid-dehydrogenase-I 
converting enzyme determines the ratio of active versus inactive intracellular 
cortisol and is consequently capable of altering the biological response.414   The 
response that an individual patient exhibits to either physiological or supra-
physiological GCs is not uniform and may differ even within tissues of the same 
individual.415  Similarly, the same stressor evokes different stress responses in 
different people, invoking the possibility of individual sensitivity to cortisol. Plasma 
cortisol levels do not invariably correlate with the functional effects on the target 
tissues, as considerable variability is observed among subjects using GCs in 
relation to therapeutic efficacy and development of side-effects.416  On binding of 
GCs to their glucocorticoid receptor (GCR) apparatus, the GCR evokes biological 
changes on the target tissues. Multiple functional polymorphisms within the GCR 
may explain the differential sensitivities of patients to GCs.
1.21.2 The glucocorticoid receptor
Survival of the mammalian species is critically dependent on the GCRs, as 
shown by GCR gene knockout mice experiments in which these mice die soon 
after birth.417 418  The GCR is a member of the steroid hormone receptor-binding 
super family and common to all these receptors are an N-terminal transactivating 






























Figure 10:  Schematic representation of three single nucleotide polymorphisms in the glucocorticoid 
receptor that have been examined in this study.  Adapted from Koeijvoets KC, van der Net JB, 
van Rossum FC, Steyerberg EW et al, Two common haplotypes of the glucocorticoid receptor 
gene are associated with increased susceptibility to cardiovascular disease in men with familial 
hypercholesterolaemia. J.Clin. Endocrinol. Metab. 2008 93:4902-4908.420
A, C, G = DNA base changes.
The human GCR consists of nine exons, located on chromosome 5 (5q31) and is 
encoded by the gene nuclear receptor subfamily 3, group C, member 1 (NR3C1).421  
Alternative splicing of the GCR messenger ribonucleic acid (mRNA) produces two 
distinct products namely GCR-α and GCR-β. GCR-α and GCR-β both contain 
exons 1-8, but they differ due to alternative splicing of exon 9, which produces 
a 5.5-kb and 4.3-kb mRNA, respectively.422  Several polymorphisms have been 
reported in the GCR gene, which occur in different regions and so affect the GCR 
function in different ways (Figure 10). The ER22/23EK polymorphism results 
in GCR reduced sensitivity, while both N363S and BclI polymorphisms lead to 
enhanced sensitivity. The altered sensitivity imparted by GCR polymorphisms is 
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of the GCRs occurs through the binding of cortisol and the translocation of this 
entire complex to the nucleus, where it binds to specific DNA sequences and 
activates transcription of a wide variety of GC responsive genes.418 423
When cortisol binds to GCR-α, an initial conformational change results, with 
consequent exposure of its nuclear localisation signal and subsequent nuclear 
entry, aided by the protein product, importin. Cis-regulation is achieved through 
direct interaction between GCR-α and DNA. By contrast, interaction between 
GCR-α and other transcription factors gives rise to transregulation.415 GCs 
mediate their anti-inflammatory action through the transrepressive effects, 
which are the processes that inhibit cellular migration and humoral immunity, 
and transactivation enhanced production of lκβ (specific inhibitor of transcription 
factor nuclear factor κβ) results.424  When cortisol binds to the GCR, the activated 
GCR complex up-regulates the expression of anti-inflammatory proteins in the 
nucleus and may simultaneously suppress the pro-inflammatory proteins in the 
cytoplasm. This is achieved by preventing translocation of other transcription 
factors from the cytoplasm into the nucleus. Transactivation is a process by which 
the GCR homodimerises, translocates into the nucleus and then binds to specific 
DNA response elements, activating gene transcription. Each cell type may have 
any unique biological response to GCs. Transcription factors NF-κβ or AP-1 are 
able to transactivate various genes in the absence of an activated GCR. On 
the other hand, the activated GCR can bind with these transcription factors and 
prevent them from targeting specific genes. This process is called transrepression. 
Transactivation and transrepression may each have adverse and beneficial effects. 
Examples of adverse effects resulting from transrepression include HPA axis 
insufficiency and susceptibility to infections, while diabetes, glaucoma and skin 
atrophy result from transactivation adverse effects. The beneficial effects of GCs 
may also result from transrepression (for example, inflammatory gene inhibition, 
immune cell migration and suppression of carcinogenesis), and transactivation 
(for example up-regulation of anti-inflammatory lipocortin-1, secretary leukocyte 
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The GCR-α is the most comprehensively studied protein product of the GCR gene 
family, because of its functional importance to the steroid binding activity.426 The 
protein product GCR-β  does not bind to either synthetic or endogenous GCs. Its 
principal action is to antagonise GCR-α and to modulate the cortisol response.418 
GCR-β exists in considerably lower concentrations than GCR-α consequently, 
low GCR-α: GCR-β ratios are thought to play a role in the development of GC 
resistance.427
The severest form of altered receptor function is generalised GCR resistance, 
arising from diminished transactivation of the GC-responsive mouse mammary 
tumour virus (MMTV) promoter.428  This is a rare, familial or sporadic condition, in 
which the target tissues display either general or partial insensitivity to GCs and 
a compensatory increase in ACTH levels.429  The clinical picture may vary from 
a complete lack of symptoms to overt clinical GC deficiency, despite elevated 
compensated plasma cortisol and ACTH levels. This excessive ACTH secretion 
results in adrenal hyperplasia, and increased production of adrenal steroids and 
mineralocorticoids.428
1.21.3 Glucocorticoid receptor polymorphisms
The marked variation in patients’ clinical responses and susceptibility to 
developing GC side effects is well recognised, but there is debate as to whether 
this is modified by gender and age.428 430-434
Several GCR polymorphisms have been reported. The most common include: 
BclI, ER22/23EK and N363S, which have been investigated extensively in the 
context of metabolic syndromes. The BclI polymorphism is due to an intronic 
C-to-G nucleotide change that appears 646 base pairs (bp) downstream from 
exon 2 and involves a BclI restriction site in intron 2. The ER22/23EK is due to 
changes in codons 22 and 23 (GAG AGG to GAA AAG allele). The ER22/23EK 
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is silent as the change from GAG to GAA still codes for glutamic acid (E to E), 
while the change in codon 23 AGG to AAG, changes the amino acid from arginine 
to lysine (R to K).  The N363S polymorphism is found in exon 2, resulting in a 
change from asparagine to serine (N to S).419  In addition to these functional 
polymorphisms, there are a large number of other polymorphisms that do not 
appear to affect function.435
The precise mechanism accounting for the increased sensitivity of  BclI to GCs is 
not known. No alteration in GCR pre-mRNA has been identified, but it is speculated 
that this polymorphism is linked to variations in the promoter region, resulting 
in an increased expression or increased stability of the GCR gene.436  Using 
binding studies with {(3)H}-dexamethasone, Russcher et al,437 demonstrated that 
15% more of a less active transcriptionally active isoform was produced by cells 
harbouring the ER22/23EK polymorphism. Using microarray gene technology, 
the N363S polymorphism was shown to regulate a different set of genes, which 
accounts for a differential effect of dexamethasone in cells harbouring this 
polymorphism.437 Transfection experiments indicated that a number of genes 
are up-regulated in the presence of this polymorphism.438 In addition, the N363S 
polymorphism induced a small increase in the transactivating capacity of the GC 
response element-luciferase reporter.439
1.21.3.1 Prevalence of glucocorticoid receptor polymorphisms 
Ethnicity appears to have a major influence on the prevalence of GCR 
polymorphisms. Caucasian controls were selected and matched for asthmatics in 
Poland to determine whether an association exists between GCR polymorphisms 
and response to GCs. The frequency of the  BclI (G allele) was 38% and the (C 
allele) was 62% in this Polish cohort.440  Among Polish healthy control subjects, 
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The reported frequency of the N363S (G allele) is 3-7% in Dutch, Anglo-Celtic 
and French Caucasian populations from Europe.443-445  By contrast, a significantly 
lower prevalence of the N363S (G allele) was found in South Asians (0.3%) living 
in the United Kingdom (35% Indians, 42% Pakistanis and 19% Bangladeshis).446 
Among Brazilian subjects, the prevalence of the N363S (G allele) has been 
reported as 3.4%, while prevalence of up to 19% has been reported in an 
Australian population based study.447  A recent Polish study of healthy control 
subjects, indicated that the G allele of the N363S polymorphism occurred at a 
frequency of 10%.441
There are only occasional studies in South Africa that examined the prevalence 
of these polymorphisms. In her dissertation in 2007, Jennings et al found that 
the prevalence of the BclI (G allele) polymorphism among normal weight and 
obese Black South African women subjects was 82% and 81%, respectively. 
The G allele of the N363S polymorphism to date has only been reported in the 
minority of black Africans, but as far as is known, this polymorphism has not yet 
been investigated in South Africa.448 There is also no record of the ER22/23EK 
polymorphism being investigated in South Africa. See (http://www.ncbi.nlm.nih.
gov/projects/SNP).  Additional prevalences for the various polymorphisms in 
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sians 0.33 0.67 0.97 0.03 >0.92
up to 
0.08
Asians unknown unknown 0.997 0.003 >0.97 0-0.03
Blacks unknown unknown 0.998 0.002 0.975-1 0-0.025
Reference: http://www.ncbi.nlm.nih.gov/projects/SNP
A, C, G=DNA bases
SNPs single nucleotide polymorphisms
1.21.3.2 General anticipated effects of the three functional polymorphisms
The  BclI (C to G) polymorphism has been studied in relation to metabolic and 
various inflammatory or autoimmune conditions, following the observation that 
the polymorphism may be associated with enhanced cortisol sensitivity.448 The 
ER22/23EK (GAG AGG to GAA AAG) polymorphism has been reported to display 
decreased sensitivity to dexamethasone, with significantly greater levels of post 
dexamethasone cortisol, and it has also been studied in relation to metabolic 
profiles.450 The N363S (A to G) polymorphism is associated with increased GC 
sensitivity following various studies of low-dose dexamethasone, which evoked 
increased cortisol suppression.439 443
1.21.4 Phenotypic differences conferred by glucocorticoid receptor (GCR) 
polymorphisms
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haplotypes, producing variations in phenotype. GCR polymorphisms may be 
associated with alteration in body composition and metabolic parameters,433  which 
are not clinically easily recognisable thus the dexamethasone suppression test 
may be useful in assessing the clinical phenotype, defined by the concentration 
of early morning cortisol after administration of dexamethasone on the night 
before. The major problem with identifying the impact of the GCR polymorphisms 
on measurable variables such as glucose, lipids, lipoproteins and bone, is that 
these clinical parameters are affected by so many factors it is uncertain whether 
the GCR imparts different effects in different tissues.
1.21.4.1 Exogenous glucocorticoid response
It may be expected that individuals exhibiting increased central sensitivity to 
GCs through sensitising polymorphisms of the GCR that they may produce less 
total cortisol and suppress production to lower levels of cortisol.  However, the 
basal cortisol levels in the morning prior to dexamethasone suppression were 
no different between the heterozygous or homozygous carriers of the  BclI (C to 
G allele), compared with non-carriers.436 Moreover, fasting cortisol levels prior 
to dexamethasone suppression were no different between N363S (G allele) 
and non-carriers.443 Similarly, it could be expected that the subjects with the 
ER22/23EK (GAA AAG) polymorphism may exhibit increased basal cortisol levels 
to overcome a degree of resistance, yet these concentrations were no different 
between carriers and non-carriers.450 It is, however, conceivable that the total 
daily cortisol production might be altered, whereas a single random fasting basal 
cortisol, may not be affected.
Dexamethasone is used to test for negative feedback inhibition of cortisol. 
Individuals harbouring either the  BclI (G allele) or the N363S (G allele) 
polymorphisms,443 have increased suppression of cortisol in the morning, which 
is compatible with enhanced sensitivity to GCs. Healthy subjects exhibiting the 
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corroborating the concept of increased sensitivity with exogenous GCs.433 For 
the carriers of the BclI  (G allele), both the 1 mg and 0.25 mg dexamethasone 
resulted in significant cortisol reduction, with heterozygotes exhibiting a mean 
absolute reduction of 10 nmol/L and homozygotes approximately 15 nmol/L in the 
former dose category, compared with the wild-type. The absolute difference in the 
latter dose category was approximately 50 nmol/L and approximately 75 nmol/L 
respectively.436 By contrast, the ER22/23EK (GAA AAG allele) variant results 
in decreased sensitivity, as measured by higher post dexamethasone cortisol 
levels.451 The absolute reduction in serum cortisol following 1 mg and 0.25 mg of 
dexamethasone in relation to the ER22/23EK polymorphism was 467.0 nmol/L 
compared with 484.5 nmol/L in non-carriers and 259.7 nmol/L versus 285.89 
mmol/L in non-carriers respectively.450  The N363S (G allele) polymorphism carriers 
had a mean absolute reduction of cortisol following a 0.25 mg dexamethasone 
suppression test of 373 nmol/L, compared with 280.5 nmol/L in healthy controls 
However, the 1 mg dexamethasone suppression test failed to demonstrate any 
difference in cortisol concentration.443
The sensitising effect of the N363S (G allele) polymorphism is further 
corroborated by Di Blasio et al, who reported that healthy carriers of the N363S 
(G allele) polymorphism exhibited increased sensitivity to low-dose (0.25 mg) 
dexamethasone suppression testing. This was particularly evident in overweight 
subjects whose BMI was <28 kg/m2) and in those individuals with the N363S 
(G allele) polymorphism who had higher mean BMI compared to non-carriers.452 
A significant correlation between the N363S (G allele) polymorphism and 
prednisolone-induced ocular hypertension was found in patients undergoing a 
photorefractive keratectomy.453 Duchene’s muscular dystrophy patients exhibited 
a variable response to steroids, and in the analysis of the GCR polymorphisms, 
the N363S (G allele) polymorphism demonstrated a trend towards latest onset 
loss of mobility.454   Szczepankiewicz A et al showed that there was no association 
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GCs for asthma.440
1.21.4.2 Body mass index and obesity
Young adult male carriers of alleles inducing mild to moderate cortisol resistance 
are reportedly on average taller and have greater lean mass, while female 
carriers have a tendency to exhibit lower fat masses, and smaller waist and 
hip circumferences.455 It appears that this clear sexual dimorphism seen in the 
aforementioned study may be modulated by sex steroids. Age may also influence 
the phenotype. For example in the study,  BclI sensitising polymorphism an 
elevated BMI among middle aged subjects was induced456 whereas an elderly 
population may demonstrate a lower BMI436 which to some degree underpins the 
unpredictability of the net effect of the GCR polymorphisms.
Recent work has shown that the  BclI (G allele) polymorphism is associated with 
BMI, conferring an effect size over four successive visits of 1.4 kg/m² and 2.0 
kg/m² for heterozygotes and homozygotes respectively, as well as increased fat 
mass in boys, not preselected for leanness, aged between 8 years and 14 years 
either pre- or peri-pubertal. These findings were not reproducible in a similar group 
aged between 13 years and 36 years of age who were leaner, but not preselected 
for their leanness.432 The  BclI (G allele) polymorphism is also thought to influence 
the prevalence of metabolic derangements, with heterozygotes having a greater 
BMI than wild-type homozygotes. However, Di Blasio et al identified that an 
increase in BMI in this study population was associated with the combination of 
both BclI (G allele) and N363S carriers.452 Nevertheless, there are several studies 
that fail to demonstrate an association between the  BclI (G allele) polymorphism 
and obesity.457 458 The presence of the  BclI (G allele) and overfeeding, studied 
in 12 pairs of identical twin men has been associated with increased body 
weight, LDLC and abdominal visceral fat.459 In another study, abdominal visceral 
fat increased slightly in obese women and men in the presence of the G allele 
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the  BclI (G allele) has been associated with an increased cortisol response to 
a standard meal and visceral obesity, but not generalised obesity, in another 
study. Individuals harbouring the  BclI (G allele) polymorphism, demonstrated 
a higher systolic blood pressure and increased visceral obesity, compared with 
non-carriers of this polymorphism.461
Overall, the data available for the  BclI polymorphism, and its link with BMI and 
obesity are inconsistent, implying that this polymorphism may only exert a small 
influence or the control of BMI and obesity is subject to multiple and complex 
pathways.
Lower median mass gain of 2 kg and consequently lower BMI during pregnancy, 
has been reported among Hungarian women with the ER22/23EK (GAA AAG 
allele) polymorphism, compared to non-carriers.462 There was no difference 
between the BMI of elderly subjects harbouring ER22/23EK polymorphism 
compared to the wild-type.458 van Rossum et al showed that some male carriers 
of the ER22/23EK (GAA AAG allele) polymorphism had greater longitudinal 
height, equivalent BMI and fat mass, but the lean body mass was increased in 
male carriers, compared to the wild-type.455 The ER22/23EK polymorphism did 
not appear to be universally protective against an elevated BMI or obesity.
It could be expected, that since the N363S (G allele) enhances GC sensitivity 
that it may be associated with an increased BMI, but available data have been 
inconsistent. In 375 European subjects examined for the presence of the N363S 
(G allele), the overall prevalence was 3%, and it conferred a greater waist-to-
hip ratio in men, but not in women.434 Among Australians, the N363S (G allele) 
polymorphism was shown to confer an elevated BMI.444 In a heterogeneous 
population of South Asians, the prevalence of the N363S (G allele polymorphism) 
was only 0.3% in patients with the metabolic syndrome, indicating that it is a poor 
marker of obesity.446  A meta-analysis failed to yield convincing results that the 
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higher in the population carrying the N363S (G allele) polymorphism when the 
BMI was less than 27 kg/m2. This finding was not replicated  when combining 
data from both the Spanish and German cohort studies.460  Rosmond et al also 
reported no association with either BMI or sensitivity to GCs among 284 Swedish 
men with the N363S (G allele) polymorphism.463 In middle-aged males with 
juvenile onset obesity the N363S (G allele) was counter-intuitively associated with 
lower fat mass at a given BMI, as measured by DEXA scan.464  The studies have 
shown an inconsistent relationship between the N363S (G allele) polymorphism 
and the development of obesity, suggesting that this polymorphism too has a 
minor impact on obesity or that the development of obesity is highly complex.
Similarly, Echwald in 2001, showed no association between BMI, waist-hip-ratio 
or weight gain among 741 obese Danish men and 854 non-obese controls with 
the N363S (G allele) polymorphism.465 Another negative study by Halsall et al 
showed no association between BMI and the N363S (G allele) polymorphism. 
In 56 obese and 43 non-obese pre-menopausal women, hyperinsulinaemia in 
obese homozygotes was found, but hyperinsulinaemia was not evident among 
non-obese homozygous GG carriers of the N363S polymorphism.433  Individuals 
with the N363S (G allele) variant conferring increased GC sensitivity, have 
been shown to be more likely to develop obesity and CVD, compared to their 
homozygous wild-type carrier counterparts.434 443 466
1.21.4.3 Dysglycaemia
Among homozygote carriers with the  BclI (G allele), a significant increase in BMI, 
abdominal obesity, fasting glucose insulin and homeostasis model assessment-
insulin resistance (HOMA-IR) was identified, over a 5-year follow-up period.460 
Weaver et al showed a significant association between homozygous obese 
carriers of the  BclI (G allele) polymorphism and hyperinsulinaemia.459 In a group 
of Swedish men born in 1944 who were homozygous for the  BclI (G allele) 
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HOMA-IR was identified.460
One prospective study that involved children from the age of 13 years, showed 
that carriers of the ER22/23EK (GAA AAG allele) polymorphism have a lower 
tendency to develop impaired glucose tolerance or T2DM.433 455   Among elderly 
subjects over the age of 85 years of age, the presence of the ER22/23EK (GAA 
AAG allele) polymorphism was counter-intuitively associated with higher levels 
of glycosylated haemoglobin A1C (HbA1C), considering that this polymorphism 
ostensibly reduces sensitivity to GCs. The explanation suggested for this 
unexpected finding was that the GCR polymorphisms may have an altered 
response in elderly subjects.458  Pre-term birth is associated with an increased 
risk of developing the metabolic syndrome. However, among adults who were 
born prematurely, the ER22/23EK (GAA AAG allele) polymorphism has been 
found to decrease the risk of developing the metabolic syndrome, possibly due 
to its reduction of insulin and lower HOMA-IR.455  Moreover, in severely pre-term 
subject carriers of the ER22/23EK variant, who were followed up from birth until 
the age of 19 years of age, appeared to be partially protected against developing 
the metabolic syndrome, by virtue of a lower HOMA-IR, lower fasting insulin and 
taller stature, compared to non-carriers of this polymorphism.467
The glucose tolerance status in British subjects of European origin was not 
affected by the N363S (G allele) polymorphism434 yet in individuals who were 
administered dexamethasone. this polymorphism was associated with greater 
suppression of cortisol, but higher insulin levels.443
1.21.4.4 Lipids and cardiovascular risk
TThe absolute changes conferred by GCR polymorphisms on lipid and lipoprotein 
parameters are shown in Table 8. Investigation of GCR polymorphisms in patients 
with familial hypercholesterolaemia (a sub-group of patients at significantly 
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had a 34% increased risk for CVD, compared to the remaining cohort who were 
negative for the  BclI (C allele) polymorphism.  However, this was not related 
to the severity of the lipid abnormalities after being extensively adjusted for 
conventional CVD risk factors, suggesting that mortality in this sub-group could 
be increased through some novel risk mechanism.420  Homozygotes for the G 
allele of the  BclI polymorphism had a greater intimal medial thickness of the left 
common carotid artery (examined for the purposes of consistency), compared to 
patients who carried at least one C allele.468 A study of elderly Dutch subjects over 
the age of 85 years, failed to demonstrate a relationship between the presence of 
the  BclI (G allele) and any of the lipid parameters studied.458
Although the ER22/23EK polymorphism ostensibly results in a reduction of 
GC sensitivity, the clinical findings of a number studies have inconsistently 
demonstrated this and consequently have shown a lack of metabolic protection 
in the presence of this polymorphism. Reduced fasting insulin and lower TC and 
LDLC have been reported in patients harbouring the ER22/23EK (GAA AAG 
allele) polymorphism.450 The ER22/23EK (GAA AAG allele) polymorphism has 
also been recorded as being associated with reduced hs-CRP and improved 
survival rates in elderly men.435 Koeijvoets et al found no association between the 
ER22/23EK (GAA AAG allele) polymorphism and CVD risk in patients with familial 
hypercholesterolaemia.469 The ER22/23EK (GAA AAG allele) polymorphism 
has been associated with reduced GC sensitivity and subjects with this variant, 
demonstrate lower fasting insulin, TC and LDLC.450
The N363S (G allele) polymorphism was not associated with elevated blood 
pressure, TC, TG, LDL or HDLC in British subjects of European origin.434  In a 
study of Caucasians older than 85 years of age in the Netherlands, the  N363S 
(G allele) polymorphism was associated with higher concentrations of LDLC and 
TG, compared to non-carriers.458 Dobson et al, showed no association between 
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associated with increased waist-to-hip ratio in male Caucasians.434  Lin in 2003 
showed that the N363S (G allele) polymorphism was associated with coronary 
artery disease (categorised as unstable angina, stable angina or no angina), 
elevated TC, TG and TC/HDL ratios. Interestingly, the risk for coronary artery 
disease was associated with the N363S (G allele) and was influenced by body 
mass, that is lean patients with CVD exhibited a three-fold higher frequency and 
obese patients had a five-fold higher frequency of harbouring this polymorphism, 
compared to non-carriers. This suggests that this genetic influence on coronary 
artery disease may be mediated to some degree by mass.470 Thus certain 
polymorphisms within the GCR gene that promote GC sensitivity may contribute 
to degrees of obesity, body fat distribution and enhanced CVD risk.418 The 
study by Di Blasio et al reveals that two sensitising GCR polymorphisms may 
act synergistically, such that the net effect is potentiated. The  BclI (G allele) 
polymorphism in combination with the N363S (G allele) showed significantly higher 
TC and LDLC, compared to the N363 carriers alone.452 Table 8 summarises some 
of the findings in the literature on the impact of three selected GCR polymorphisms 
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Table 8: Summary of the absolute lipid, lipoprotein and BMI differences (conferred by the presence 
of three glucocorticoid receptor polymorphisms
Polymorphism Lipid fraction/ BMI Absolute change Reference
ER22/23EK (rs6189) 
(GAA AAG allele) TC -0.74 mmol/L
Van Rossum EF 
Diabetes 2002 450
ER22/23EK (rs6189) 
(GAA AAG allele) LDL -0.8 mmol/L
Van Rossum EF 
Diabetes 2002 450
N363S (rs6195) 










(G allele) plus BclI 
(rs41423247) 








(G allele) plus BclI 
(rs41423247) (G allele) 
carriers versus N363S 
(G allele) alone
LDL +1.60 mmol/L






































Introduction to primary hypoadrenalism and its possible complications
Polymorphism Lipid fraction/ BMI Absolute change Reference






Lin RC, British Medical 
Journal 1999 444
N363S (rs6195) (G 
allele) BMI +0.18 kg/m²
Marti A, BMC Medical 
Genetics, 2006 471
TC: total cholesterol 
LDL: low density lipoprotein
TG: triglycerides
+: absolute increase
 -: absolute reduction 
A,C,G = DNA bases
BMI: body mass index
References provided in superscript
1.21.4.5 Reduced bone mineral density
Bone mineral density was reduced among patients with Cushing’s syndrome in 
two femoral regions among the carriers of the  BclI (G allele) homozygous form, 
compared to the wild-type, suggesting that the complications that may result 
from endogenous hypercortisolism are likely to be modified by the presence of 
GCR polymorphisms.472 In the Longitudinal Ageing Study Amsterdam (LASA), 
the serum fasting cortisol was associated with reduced bone mineral density at 
the femoral neck; in particular, female homozygous BclI (G allele) polymorphism 
carriers had the highest serum fasting cortisol, but the lowest bone mineral 
density at the lesser trochanter. These findings were not replicated in the male 
sub-group.473 As far as is known, there are no known data on the relationship 
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1.21.4.6 Longevity
None of the three aforementioned polymorphisms of the GCR in participants 
older than 85 years of age (Leiden 85-plus study), was associated with either 
CV or all-cause mortality.458 On the other hand, children with acute lymphoblastic 
leukaemia, treated with antineoplastic agents including steroids and homozygous 
for the  BclI (G allele) polymorphism, had reduced survival rates.474  van Rossum et 
al suggested that the ER22/23EK (GAA AAG) polymorphism may confer survival 
benefit following the observation that the prevalence of this polymorphism was 
highest in the oldest of an elderly population from the Netherlands, after 4 years 
of follow-up. Also of interest is that the carriers of the ER22/23EK (GAA AAG 
allele) polymorphism had 50% lower CRP levels.475
1.21.4.7 Psychiatric and psychological manifestations
The cortisol responses to psychological disorders or challenges in relation to 
the GCR polymorphisms are unpredictable and appear also to be affected by 
gender.  Wust et al showed that the salivary cortisol response was highest in 
carriers of the N363S (G allele) polymorphism, compared with the wild type (A 
allele) and the  BclI (G allele) carriers had by contrast, a diminished response 
following exposure to a psychosocial stress.476  Kumsta et al demonstrated highest 
cortisol responses among women with the  BclI (homozygous for the G allele) 
polymorphism to the Trier Social Stress Test (TSST), which is an experimental 
procedure used to induce stress under laboratory conditions. By contrast,  BclI (G 
allele) male homozygotes subjected to the same stress had the lowest salivary 
cortisol response when compared to their respective wild-types.477 Lower cortisol 
levels were found in Vietnam war veterans with post-traumatic stress disorder, 
harbouring the  BclI (G allele) polymorphism.478
Depression is biologically linked to excess levels of cortisol, and yet paradoxically 
in a cohort of subjects with major depression, the ER22/23EK (GAA AAG allele) 
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et al reported that ER22/23EK (GAA AAG allele) polymorphism was associated 
with recurrent major depression and a more rapid response to antidepressant 
therapy.479 
There are isolated studies examining the relationships between salivary cortisol 
and GCR polymorphisms. In a study by Wust et al the interaction between 
psychological stress and GCR polymorphisms revealed that N363S (G allele) 
carriers had the greatest cortisol response as measured by salivary cortisol. In 
a study comparing the salivary cortisol exposure response following a stressor, 
N363S (G allele) carriers had the greatest cortisol exposure taken at 2 min, 15 
min, 25 min, 45 min, 60 min, 75 min and 105 min after a TSST.476   Among 601 
healthy subjects subjected to the TSST, male carriers of the N363S (G allele) 
polymorphism exhibited the highest salivary cortisol response, but no increase was 
observed in women  participating in this study.477  Repeated noxious stimuli may 
induce habituation and in those carriers of the N363S (G allele) polymorphism, a 
weak trend towards lower excursions of salivary cortisol was observed, compared 
to the remaining genotypes.480
1.21.4.8 Autoimmune disease
Carriers of the  BclI (G allele) polymorphism appeared to have a less advanced 
stage of Graves’ ophthalmopathy, which may be explained by the likely enhanced 
sensitivity to endogenous GCs, with partial dampening of the immune response.483  
There are conflicting reports demonstrating a relationship with inflammatory 
bowel disease and these GCR polymorphisms. For example, Crohn’s disease 
demonstrated a greater frequency of subjects with BclI (G allele) polymorphism in 
one report, whereas another report showed no relationship.435  Further studies are 
required to resolve the precise relationship between this polymorphism and the 
development of inflammatory bowel disease.  The BclI (G allele) polymorphism 
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The ER22/23EK (GAA AAG allele) polymorphism was associated with a far more 
aggressive course of multiple sclerosis in contrast to no identifiable association 
with other autoimmune diseases.481-483 No association was identified between the 
ER22/23EK polymorphism and the risk for developing myasthenia gravis.484
The N363S (G allele) polymorphism in several studies did not appear to influence 
the risk of rheumatoid arthritis, whereas one Dutch study suggested a lower risk.434 
Overall, the association between autoimmunity as a sub-group of disorders and 
GCR polymorphisms is at best tenuous.
1.21.4.9 Miscellaneous
As elevated levels of cortisol have been implicated in the pathogenesis of 
dementia, the Rotterdam study442 found that the ER22/23EK (GAA AAG allele) 
polymorphism was associated with a reduced incidence, implicating a possible 
role of this polymorphism in protecting against dementia. The ER22/23EK (GAA 
AAG allele) polymorphism modified the relationships between serum cortisol and 
grip strength, but not after stratifying for the individual polymorphisms, possibly 
due to the small number of subjects.485
Decreased inhibition of interleukin-2 (IL-2) production is expected in the presence 
of GCs, thus homozygote carriers of the N363S (G allele) demonstrated higher 
concentrations of this cytokine.439  Peeters et al reported that higher salivary 
cortisol was associated with reduced grip strength, the carriers of the N363S (G 
allele) polymorphism in the middle serum cortisol quartiles had the highest grip 
strength.485
1.21.4.10 Hypothesis of GCR polymorphisms in Addison’s disease 
There is a dearth of information on whether GCR polymorphisms play a role in the 
development of GC-related side-effects in individuals receiving hydrocortisone 
replacement for Addison’s disease. In addition, there is uncertainty, as to whether 
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GCR polymorphisms.
1.22 Conclusions
Major advances in our understanding of the embryological development of the 
adrenal glands have occurred as a result of molecular biological techniques. 
This has provided insight into the various causes of congenital adrenal gland 
hypoplasia.
Addison’s disease occurs in 93-144 people per million people in the Western 
world, where autoimmunity is the most common underlying aetiology. This is in 
contrast to earlier studies that have attributed tuberculosis and idiopathic causes 
to be the most abundant underlying aetiologies.  It might be expected that certain 
HLA DQB1 alleles could be associated with autoimmune Addison’s disease, 
in which a wide array of autoantibodies is frequently seen due to disruption of 
global autoantibody production.  As there is a high prevalence of HIV in South 
Africa, specific adrenal infections with subsequent hypoadrenalism could occur 
more commonly than in other parts of the world where HIV is less prevalent and 
autoimmunity may be a less common cause of Addison’s disease.
GCs may modulate multiple pathways governing lipid and lipoprotein metabolism. 
It is thus expected that Addison’s patients could exhibit alterations in lipid and 
lipoprotein metabolism. If sufficiently adverse lipid profiles are identified in this 
sub-group of patients, it could explain the more than double risk of CVD and 
premature mortality.
There are multiple methods to monitor hydrocortisone replacement, none of 
which is ideal. Since salivary cortisol is easily accessible, and has been found to 
correlate with plasma cortisol, it meets the criteria for monitoring hydrocortisone 
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GCR polymorphisms may modulate the effects of circulating cortisol, and have 
been associated with metabolic abnormalities, the absolute changes are small. It 
is anticipated, that should metabolic differences be identified in association with 
these GCR polymorphisms, these are likely to be small.
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Chapter 2
Rationale, aims and objectives
2.1 Rationale
My long-standing interest in Addison’s disease was kindled by the awareness that 
this rare disease is life-threatening if not diagnosed and managed appropriately, 
and that there is a dearth of knowledge pertaining to Addison’s disease in South 
Africa.
In the early stages of my odyssey into investigating Addison’s disease, I read 
several reports of cancer autopsies that confirmed the high prevalence of 
adrenal metastases, yet few verified the presence of primary hypoadrenalism 
using conventional diagnostic criteria. I addressed this unresolved question by 
determining the prevalence of primary hypoadrenalism, using validated diagnostic 
criteria in 30 patients not pre-selected for adrenal metastases with advanced 
(stage III or IV) bronchogenic carcinoma. Two patients had definitive evidence for 
adrenal insufficiency, representing a 6.7% (95% confidence interval 0.8 - 22.1%) 
prevalence of adrenal insufficiency,1 which is substantially lower than the 33% 
reported by Redman et al.2 This study prompted the work covered by this thesis, 
since I was concerned about the possibility that primary hypoadrenalism, which 
is a highly treatable condition, could be under-diagnosed, inadequately managed 
and its finer nuances, overlooked. 
Despite the large body of evidence, that autoimmunity is the predominant cause 
for Addison’s disease in the developed world, uncertainty exists as to whether 
it is also the case in South Africa.3-6 This developing country is characterised by 
a heterogeneous population, lack of uniform access to healthcare, and multiple 
disease burdens, including epidemics of tuberculosis and HIV, both of which are 
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Given the heterogeneous ethnic background of South Africans, it is also unclear 
whether patients with autoimmune Addison’s disease share the same HLA 
DQB1 alleles described from the Western world. It was considered that a large 
multicentre cohort study could be instrumental in determining both the underlying 
aetiology of Addison’s disease in South Africa and the HLA DQB1 genotypes.
Until recently, it was believed that patients with Addison’s disease had a comparable 
survival rate to the background population. However, a Swedish study indicated 
that the risk of death was two-fold higher in treated Addison’s disease, due to 
predominantly CVD and cerebrovascular disease.9 Although Addison’s disease 
per se, could have contributed to this accelerated mortality, supra-physiological 
levels of GCs may have resulted in abnormal lipid and lipoprotein metabolism.
Oral hydrocortisone is the most commonly used therapy for GC replacement in 
Addison’s disease. Various methods have been used to monitor this therapy, 
but none is ideal. Salivary cortisol is easily accessible and can be studied in 
the comfort of patients’ own homes. Several studies in Addison’s disease have 
shown reasonably good correlation between plasma and salivary cortisol.10 11 
Some authors on the other hand, have debated the validity of salivary cortisol 
monitoring, due to its high variability.12 13 An area that has not been analysed 
much is whether patients on usual hydrocortisone replacement therapy have the 
equivalent cortisol exposure to healthy subjects’ endogenous cortisol profiles. If it 
turns out that patients on usual hydrocortisone replacement are exposed to higher 
cortisol concentrations than healthy control subjects’ endogenous exposure, it 
may predispose patients to metabolic derangements, which are well-known to 
occur with supra-physiological doses of GCs.
Replacement therapy in Addison’s disease has to a large extent been empirically 
determined. There has been some appreciation of the potential of GCR 
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GCR polymorphisms have been identified, two of which exert a sensitising effect 
and another that confers a degree of resistance to cortisol. It is uncertain as to 
what extent the presence of the GCR polymorphisms may either modulate empiric 
doses of hydrocortisone replacement therapy or induce metabolic alterations in 
the context of Addison’s disease.
2.2 Aims
The overall aim of this study was to determine the aetiopathogenesis, CV and 
metabolic complications, and pharmacogenomics, in a cohort of patients with 
Addison’s disease in South Africa
The primary and secondary objectives of this study were:
1. To examine the aetiopathogenesis of Addison’s disease in South Africa 
and to determine whether specific HLA DQB1 alleles are associated with 
autoimmunity.14
(i) To determine the underlying aeti logy of Addison’s disease in South 
Africa, using special investigations, acquired through collaboration with 
centres in the USA and Sweden.
(ii) To determine whether in this South African cohort, certain HLA DQB1 
alleles may predispose to autoimmunity.
2. To determine the cause for the reported increased CV mortality in Addison’s 
patients by examining lipids, lipoproteins and markers of CV inflammation.
(i) To establish whether patients with Addison’s disease have adverse 
lipid profiles, raised markers of inflammation and CVD Framingham 
risk than controls.
14  Title: Autoimmunity predominates in a large South African cohort with Addison’s disease of mainly European de-
scent, despite long-standing disease and is associated with HLA DQB*0201.
Ian Ross was the principal author who conceived the study, recruited patients, performed data analysis and wrote 
the manuscript.14 Co-authors of the paper included a doctoral supervisor, a statistician and overseas individuals, who 
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(ii) To determine if a correlation exists between doses of hydrocortisone 
replacement and the parameters of evaluating lipid and lipoprotein 
metabolism.
(iii) To compare lipids and lipoproteins in a sub-group of South African 
Addison’s patients matched with a Swedish Addison’s sub-group for 
age, gender, ethnicity and BMI.
3. To test the hypothesis that patients with Addison’s disease, who are fully 
replaced on hydrocortisone and fludrocortisone, may be subject to supra-
physiological doses of GCs, as examined using salivary cortisol AUC.
(i) To determine the salivary cortisol AUC for patients with Addison’s 
disease on full replacement, and compare these to healthy control 
subjects’ endogenous salivary cortisol concentrations.
(ii) To determine the optimum time of sampling of salivary cortisol in 
patients and healthy control to most accurately reflect the salivary 
cortisol peak and the AUC.
(iii) To determine whether an increased salivary cortisol AUC translates 
into abnormal lipid, lipoprotein and markers of CV inflammation.
4. To determine whether metabolic alterations are associated with GCR 
polymorphisms to warrant modifications of hydrocortisone replacement, 
the data for which have so far been empiric.
(i) To explore the role of GCR polymorphisms in influencing metabolic 
parameters among patients with Addison’s disease, by comparing or 
correlating GCR genotypes with clinical parameters including BMI, 
TC, TG, HDLC, LDLC, hs-CRP, NEFA, small dense LDL, TSH and 
hydrocortisone dose.
(ii) To determine whether clinical differences exist among patients who 
harbour GCR polymorphisms with either increased or decreased 
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Chapter 3 details the methods used for the collection of this cohort and 
describes their clinical and demographic features. Chapter 4 describes  the 
aetiopathogenesis of Addison’s disease, as well as genetic factors predisposing 
individuals to autoimmune Addison’s disease in South Africa. Chapter 5 describes 
the observed lipids, lipoproteins and markers of CVD in patients with primary 
hypoadrenalism. Chapter 6 introduces the concept of monitoring replacement 
therapy in Addison’s disease by using salivary cortisol day curve measurements. 
Chapter 7 is dedicated to describing the effect of GCR polymorphisms on the 
sensitivity to cortisol in patients with Addison’s disease. The concluding chapter, 
Chapter 8, summarises the major findings of these various studies, and provides 
recommendations that will impact on management of patients with Addison’s 
disease.
It is hoped that this body of work will contribute to raising awareness of this highly 
treatable condition amongst physicians working in our resource poor environment. 
If, in addition, it heralds an appreciation for the potential metabolic consequences 
that can occur with Addison’s disease, and lowers the threshold for initiating 
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Chapter 3
Methods and description of the cohort
3.1 Background
Several factors peculiar to the health-care system in South Africa influenced 
recruitment of patients in this study.  These are outlined below.
3.1.1 The health-care systems in South Africa
South Africa has a population of more than 47 million people. In the absence of 
national health insurance, there is unequal access to health-care. The health-
care system consists of a vast public sector and a small, but expanding private 
sector.1 The latter serves 18% of the population, while the public health sector 
serves 82% of the population, predominantly the poor working class indigent, 
and is oversubscribed. The public health sector is challenged by a significant 
human resource crisis, HIV and tuberculosis epidemics, and is also burdened 
by non-communicable diseases. Despite the end of apartheid, racial and gender 
discrimination, income inequalities, and extreme violence continue to impede its 
function.2 Health-care varies from the most basic care, offered free of charge by 
the state, through to highly specialised health services at quaternary level and 
private sectors for those individuals who are members of a medical insurance 
company or those who can afford to pay for it. There has been a steady increase 
in the number of private hospitals; in 2005, there were 161 and in 2010, there 
were approximately 238, with 142 of these situated in urban areas.3 4 The mining 
sector, which provides health-care for its employees, is responsible for a further 
60 hospitals around the country. Secondary care hospitals, or district general 
hospitals, are found in most of the larger towns throughout South Africa.2 While 
some secondary care hospitals have computerised data, many do not keep any 
records, highlighting some of the challenges faced in identifying patients with a 
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in association with a medical school or university, they do not have sub-specialist 
endocrinology facilities. Similarly, the eight medical schools in South Africa do not 
universally offer specialised endocrine services. There are perceptions among 
certain strata of the population that the current public health service offers inferior 
health-care.6
Five of the nine provinces in South Africa have quaternary hospitals (major 
teaching hospitals with sub-speciality facilities) with medical schools attached. 
However, four of the provinces do not have specialised endocrine clinics. The 
quaternary hospitals receive referrals from the neighbouring provinces that do 
not have quaternary centres.
3.2 Method of registry compilation
Since databases in South Africa were not available for Addison’s disease, a 
systematic approach was adopted of initially inviting patients attending quaternary 
hospitals, followed by patients attending tertiary hospitals and private health-care 
facilities. This was followed by inviting prospective participants attending both 
secondary and primary health-care facilities.
3.2.1 Ethics and informed consent
Approval to conduct the study was obtained from the Research and Ethics 
Committee of the University of Cape Town. Ethics approval was also obtained 
from the respective research and ethics committees overseeing the various 
faculties of health sciences including the Nelson Mandela School of Medicine, 
University of KwaZulu-Natal, University of Stellenbosch,  University of the Free 
State, University of Pretoria and the University of Witwatersrand. All participants 
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3.2.2 Patient enrolment
The outline of the procedure followed in order to identify cases of Addison’s 
disease is shown in Figure 11. As Addison’s disease is likely to be diagnosed 
and managed by endocrinologists rather than generalists, the first phase was to 
contact all quaternary hospitals to compile a registry of Addison’s patients.
Patients with Addison’s disease who attended the endocrine clinic at Groote 
Schuur hospital, which is affiliated to the University of Cape Town, were 
sequentially invited by the medical staff at their routine clinical appointments to 
participate in the study, as there were no databases to indicate their personal and 
clinical details.
In the next phase, all other endocrinology divisions attached to quaternary hospitals 
(Pretoria Academic hospital, Albert Luthuli hospital, Universitas hospital, Pelonomi 
hospital, Johannesburg General hospital, Chris Hani Baragwanath hospital and 
Tygerberg hospital) were contacted to invite their patients with Addison’s disease 
to enrol in this registry. In the subsequent phase, tertiary hospitals without 
endocrinology divisions were then also contacted to invite patients with Addison’s 
disease to participate in this study. These hospitals included Helen Joseph, 
Livingstone, Garankuwa, Paarl, George, Cecilia Makiwane and Nelson Mandela 
Academic hospitals. All private endocrinologists were contacted to enhance 
the referral base, using the society of endocrinology membership {Society for 
Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA)} database. 
All specialist physicians (internists) in the Western Cape were accessed using 
telephone directories, issued by the postal services, and letters were written to 
each of them. 
A private commercial database (MedPages) of medical specialists and general 
practitioners sent 9 600 personalised e-mails to all specialist physicians, 
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Specialist physicians or paediatricians were thought more likely to be involved in 
the management of Addison’s disease, compared with other disciplines.
As Addison’s disease is designated as a medical condition that enjoys the 
prescribed minimum benefit, it is a statutory requirement in South Africa 
that patients belonging to a medical aid have the total cost of their treatment 
reimbursed.7 Although the medical aid or medical insurance companies were 
able to access the names of the patients suffering from Addison’s disease, only 
the names of their treating physicians were communicated to the researcher, 
as divulging the names to a third party would have represented a breach of 
confidentiality. Thereafter, the treating physician was requested to invite his or 
her patients to participate in this study.
A facility database of both private and public health-care was constructed, which 
included all primary, secondary, tertiary and quaternary health-care in South Africa. 
This was created using the Internet and the following key words were entered 
into the search engine for each of the nine provinces: “hospitals”, “clinics”, “day 
hospitals”, “community healthcare centres”, “district hospitals”, “district general 
hospitals”, “secondary hospitals”, “private hospitals”, “Department of Health” 
“list of hospitals”, “primary care facilities”, “secondary care facilities”, “secondary 
tier facilities”, “tertiary care facilities”, “quaternary care facilities”, “rural doctors 
association”, “netcare”, “medical centre”, “lifecare”, “intercare”, “melomed”, “medi-
clinic”, “academic hospitals” “private doctors”, ”Hospital Association of South 
Africa“ and “private medical practitioners”.
From each of the websites, the following information was extracted where 
possible: the name of the hospital facility, the address and telephone number, 
the name of the superintendent or chief executive officer, the fax number and the 
name of the liaison officer. Medical practitioners, or in the case of facilities without 
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Addison’s disease. Letters were written to superintendents of hospitals, medical 
practitioners and specialists, asking them to identify patients with Addison’s 
disease. They were also asked to inform their staff of the Addison’s disease 
national registry. The diagnosis of Addison’s disease was made on the basis of 
a suggestive clinical presentation, low basal cortisol level and simultaneously 
elevated ACTH concentration, or where indicated, a peak cortisol, following 250 
μg ACTH stimulation, of less than 550 nmol/L associated with a basal raised 
plasma ACTH, exceeding 10.1 pmol/L. These criteria have been published 
previously.8
Although patients may have been recruited through their general practitioners, 
Addison’s disease was confirmed in each case by a specialist internist, 
paediatrician or endocrinologist. They were also only considered eligible if they 
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3.3 Pattern of referrals
Overall, the response rate was low, but this was expected in view of the rarity 
of this disease. As seen in Figure 12, the majority of cases (46.2%) were from 
tertiary referral centres, followed by quaternary (44.2%), secondary (6%) and 









Figure 12: Proportion of referrals from differing levels of health-care in South Africa
primary (3.4%), secondary (6%), tertiary (46.2%), quaternary (44.2%)
3.4 Data captured in the registry
The following data were entered onto a spreadsheet: age at enrolment, date of 
birth, gender, ethnicity, duration of symptoms prior to diagnosis and the symptoms 
at presentation, duration of Addison’s disease, time elapsed between diagnosis 
and onset of first symptoms, co-morbidity, associated autoimmune conditions, 
family history of autoimmune disease and treatment. Since European or North 
American Addison’s patients were most likely to have underlying autoimmune 
Addison’s disease, patients in this cohort were evaluated for the presence of 
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relative who was born in either USA or Europe. The presence of primary 
hypothyroidism, and in particular, the approximate time of its onset was noted.
The total daily doses of fludrocortisone and hydrocortisone replacement therapy 
were included in the database. The hydrocortisone dose was corrected for weight 
and body surface area. All chronic medication use and risk factors for CVD were 
noted, including smoking or tobacco exposure, history of lipid abnormalities, 
hypertension and diabetes.
3.4.1 Anthropometric data
Height and mass were obtained where possible, which allowed the body BMI 
and body surface area to be calculated for each patient and control subject. One 
blood pressure measurement was recorded for each patient, where possible.
3.4.2 Biochemical data included in the registry
The biochemical data were obtained by reviewing medical notes, obtaining 
transcripts of the source data and by examining archived results in the relevant 
pathology laboratories. The following biochemistry results at diagnosis of 
Addison’s disease were entered into the database where available: serum 
sodium, potassium, basal and stimulated plasma cortisol, basal plasma ACTH, 
serum aldosterone, plasma renin, thyroid stimulating hormone (TSH), thyroxine 
(T4), and hydroxycobalamin (Vitamin B12).
3.4.3 Investigations performed at enrolment
A number of investigations were performed at the time of patient enrolment. 
Their detailed methods are described in subsequent chapters. Autoantibodies, 
biochemical markers of CV risk, HLA DQB1 alleles and genotypes, salivary 
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3.4.3.1 Autoantibodies
ACA and 21-hydroxylase autoantibodies were assayed to confirm autoimmune 
primary adrenal gland failure. Other clinical autoimmune conditions known to 
coexist with Addison’s disease were screened using appropriate autoantibody 
tests including tissue transglutaminase, antithyroperoxidase, antithyroglobulin, 
parietal cell, ovarian, placental, testicular autoantibodies, islet cell and anti-
GAD65.  This panel of autoantibodies, excluding 21-hydroxylase and tissue 
transglutaminase autoantibodies was kindly measured by Professor William 
Winter’s laboratory, Department of Pathology, Immunology and Laboratory 
Medicine, University of Florida, Gainesville USA. Both 21-hydroxylase and tissue 
transglutaminase autoantibodies were kindly measured by Professor Anders 
Karlsson at the Department of Clinical Immunology, University hospital, Uppsala, 
Sweden.
3.4.3.2 Biochemical markers of cardiovascular risk
TC, TG and HDLC were measured, but LDLC was calculated using the Friedewald 
equation. In addition, LDL particle size was measured to determine additional CV 
risk in both the patients and controls. NEFA and random blood glucose (RBG) 
were performed in Professor David Marais’ laboratory at the University of Cape 
Town. Professor Gudmundur Johannsson kindly performed the hs-CRP levels in 
Gothenburg, Sweden.
3.4.3.3 Genetic analyses
The HLA DQB1 alleles and genotypes were recorded for each of the patients 
and controls. These were kindly performed by Dr She, Centre for Biotechnology 
and Genomic Medicine, Medical College of Georgia, USA. Screening for GCR 
polymorphisms took place in the inherited metabolic disease laboratory at the 
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3.4.3.4 Salivary cortisol analyses
This analysis was performed by the National Health Laboratory Service (NHLS) 
in Cape Town.
3.4.3.5 Serum thyroid stimulating hormone (TSH)
Serum TSH was assayed by a private, accredited pathology laboratory, Davies 
and partners in Cape Town.
3.4.3.6 Very long chain fatty acids (VLCFAs)
Screening for elevated VLCFA concentration was kindly performed by Professor 
Japie Mienie from the School of Biochemistry, Northwest University Potchefstroom, 
South Africa.
3.5 Healthy control recruitment
Healthy control subjects were enrolled in the blood donor clinic of the Western 
Cape.  Each control subject was matched as far as was possible to a patient in 
terms of age, gender, BMI and ethnicity.
3.6 Description of the cohort
There were 161 patients who were referred for enrolment in the South African 
Addison’s study. Seven patients with an original label of Addison’s disease 
were excluded: two had a normal ACTH stimulation (Synacthen®) test, two had 
secondary hypoadrenalism, one had a bilateral adrenalectomy for Cushing’s 
disease, and two had suppression of the HPA axis, related to previous steroid 
use for another indication. Three patients declined to participate, citing personal 
reasons and a further three patients were too late to be enrolled in this observational 
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ε
7 patients excluded
because of incorrect diagnosesф
3 patients declined to be enrolled,
citing personal reasons
148 patients were enrolled
in this observational analysIs
161 patients were referred for enrolment 
in the South African Addison’s study
3 patients too late
for enrolment
Figure 13: Pattern of enrolment for this observational analysis.
ΦSeven patients were excluded as two had a normal ACTH stimulation test, two had secondary 
hypoadrenalism, one had a bilateral adrenalectomy for Cushing›s disease, and two had 
suppression of the hypothalamic-pituitary adrenal (HPA) axis, related to previous steroid use for 
another indication.
3.6.1 Demographic Data
The majority of the cohort was women (62%). The median and interquartile age 
range (IQR) of patients at enrolment was 46.0 (32.0-61.0) years, with a wide range 
from 2.8-88.0 years. The median and IQR age at initial diagnosis of Addison’s 
disease however, was 34.0 (20.0-45.0) years (range 0.02-77.0 years), indicating 
that at the time of enrolment, the patients, on average, had been diagnosed with 
Addison’s disease 12 years previously or longer. The majority of the cohort was 
diagnosed with Addison’s disease at an age of age >20 years (Figure 14). White 
patients (66%) contributed to the majority of the cohort, followed by mixed ancestry 
participants (23%). There were few Asian (3%) and black participants (8%) in 
the cohort (Figure 15). This is in contrast to the background population in which 
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2.6% are Asian.9 Of these, 34% confirmed that either their first or second degree 
relatives were of foreign ancestry, according to the predetermined definition. The 
majority of patients lived in urban areas (87%) as shown in Figure 16, particularly 
Cape Town, Johannesburg and Durban, where most of the specialised clinics 
for endocrinology are situated. Isolated pockets of patients were identified in the 
northern part of the Western province, southern Cape and various districts of 
KwaZulu-Natal. Looking at the ethnic specific prevalence among white patients, 
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3.7 Clinical characteristics of Addison’s disease patients
In this section, the clinical presentation, delay in diagnosis, co-morbidity at 
enrolment, biochemistry at diagnosis and replacement therapy will be discussed.
3.7.1 Addison’s disease: clinical presentation
The clinical symptoms of the patients at presentation were elicited by interviewing 
them at the time of enrolment, and as such are subject to recall bias (Table 9). 
The most common presenting sign was hyperpigmentation (76%), followed by 
symptoms related to the gastrointestinal system, and with nausea and vomiting 
being reported by >40% of the participants. A significant number reported having 
suffered from loss of consciousness at presentation (20%), had a history of 
collapse (7%) and suffered from shock (5%). The latter symptom is the most 
suggestive of an Addisonian crisis. Backache occurred in 20%, while dizziness 
(11%) and salt craving occurred in 15%. The latter symptoms are suggestive of 
mineralocorticoid deficiency, but dizziness may also be a feature of GC deficiency. 
Non-specific symptoms such as malaise and lassitude were noted in 8% of the 
cohort and 3% of the cohort were noted to have hypoglycaemia. At least 7 (5%) 
had presented in an acute Addisonian crisis, which was suggested by a history of 
prior collapse, shock or hypoglycaemia. Some patients had experienced fainting 
spells and it was difficult to ascertain whether these episodes represented an 
acute Addisonian crisis. Thus, the true number of patients who presented with an 
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Table 9: Addison’s disease: clinical presentation
Presenting symptom N Proportion of the cohort (%)
Self reported increase in skin pigmentation 112 76
Nausea 76 51
Vomiting 63 43
Weight loss 37 25
Abdominal pain 31 21
Backache 29 20
Loss of consciousness 29 20
Diarrhoea 22 15
Salt craving 21 15
Dizziness 16 11
Malaise/lassitude 12 8





The proportion of 148 Addison’s disease patients who manifested with any of these symptoms at 
presentation
A comparison of the clinical presentation with three other studies is shown in Table 
10. Hyperpigmention was the most common presenting symptom in three studies, 
including the retrospective analysis of acute hypoadrenalism in South Africa.8 
Gastrointestinal disturbances appeared to predominate in the presentation of 
Addison’s disease in all the studies. Weight loss only occurred in 25% of patients 
in this study, in contrast to the other studies, where it was far more prevalent.  In 
this study and that of Soule, loss of consciousness and confusion were recorded 











Methods and description of the cohort
South Africa may present in a more advanced state of ill-health, compared to their 
first-world counterparts.8
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3.7.1.1 Delay in diagnosis
Overall, the median and IQR duration of symptoms, prior to diagnosis was 5 (316) 
months, with a range as long as 240 months. Although a recent cross-sectional 
study from Germany also found a significant delay in making the diagnosis, as 
20% of the subjects had had symptoms for longer than five years prior to being 
diagnosed,12 only 1% of South African Addison’s study patients had symptoms 
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reports attest to the prolonged interval between onset of symptoms and the 
diagnosis of Addison’s disease.13
3.7.1.2 Co-morbidity reported at enrolment
As seen from Table 11, hypertension, hypercholesterolaemia and T2DM were 
the most prevalent CV conditions. A prior history of pulmonary tuberculosis was 
the most common respiratory condition. There were numerous infrequently 
encountered co-morbid conditions (≤1%), such as steatosis of uncertain aetiology, 
prosthetic cardiac valve replacement, pulmonary emboli, chronic obstructive 
airways disease, bronchopulmonary dysplasia, asthma, emphysema, gastro-
oesophageal reflux disease, peptic ulcer disease, hepatitis, gastric atrophy, chronic 
renal failure, epilepsy, Bell’s palsy, Duchenne’s muscular dystrophy, depression, 
anxiety, premature menopause, prostate carcinoma, hysterectomy, polycystic 
ovarian syndrome, gout, rheumatoid arthritis, breast carcinoma, psoriasis, foetal 
alcohol syndrome, metabolic syndrome, erythrocytosis, melanomas, thyroid 
carcinoma and rheumatoid arthritis. The associated autoimmune conditions will 
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Table 11: Co-morbidity reported at enrolment
System Medical condition Σ n/N (%)
Cardiovascular system Hypertension 22/148 (15)
Type 2 diabetes mellitus Ώ 9/148 (6)
Hypercholesterolaemia 7/148 (5)
Ischaemic heart disease 4/148 (3)
Cerebrovascular disease 3/148 (2)
Respiratory system Tuberculosis 11/148 (7)
Rheumatological Osteoporosis 7/148 (5)
Antiphospholipid syndrome 4/148 (3)
Osteoarthritis 3/148 (2)
Other Type 1 diabetes mellitus 11/148 (7)
n: Number of patients found to have a co-morbid illness
N: Total number of Addison’s subjects
Σ: Excludes medical conditions occurring in less than 1% of the patients, for example, steatosis, 
prosthetic cardiac valve replacement, pulmonary emboli and chronic obstructive airways disease
Ω: Considered a cardiovascular risk factor
3.7.1.3 Biochemistry at diagnosis
As this was a retrospective study, in which the diagnosis of Addison’s disease 
was made in several cases, 20 or more years previously, the records of the 
admissions were frequently unavailable. There was adequate biochemistry 
for the diagnosis of Addison’s disease in 72% of the cases. The biochemistry 
was considered to be adequate by the presence of at least one of suggestive 
electrolytes (hyponatraemia and hyperkalaemia), low early morning cortisol and 
simultaneously elevated ACTH levels or an inadequate cortisol response to an 
ACTH stimulation test. The high proportion of patients (28%) with inadequate 
biochemical verification is likely to be due to the study design  (Table 12). 
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ACTH stimulation tests were available in 38 (26%) of the patients, early morning 
cortisol and simultaneously elevated ACTH levels in a further 52 (36%) patients 
and suggestive biochemistry in 15 patients (10%). The median basal morning 
plasma cortisol was 58 nmol/L.  The median stimulated cortisol was 82 nmol/L, 
range 5.9 to 476.0 nmol/L, in all patients with complete data. Levels of ACTH 
>10 pmol/L were considered appropriately elevated for this range of cortisol and 
corroborated the presence of primary hypoadrenalism. Of the 50 patients who had 
a TSH measured at initial diagnosis, 13 (26%) also had primary hypothyroidism, 
however this may represent an overestimate as cortisol deficiency per se could 
induce a TSH rise, TSH ranged from (6.76-100 mIU/L). A further 2 (4%) patients 
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(26) 110 /148 (74) 82.0 49.8-20.8 0–476
Plasma ACTH 
(pmol/L)** 1.0 - 10.1
50/148 
(34) 98/148 (66) 376 178-973
12.2–
1878
Serum Na (mmol/L)** 135.0 - 147.0
52/148 




















(pmol/L)** 110 - 860.0
23/148 
(16) 125/148 (84) 30.9 25-139
0.09–
344











Serum free T4 
(pmol/L) 11.5 - 22.7
37/148 
(25) 111/148 (75) 14.2 10.4-17.0
0.1-
26.8
n: Number of patients identified with available biochemical parameter
N: Total number of Addison’s patients
Plasma ACTH: plasma adrenocorticotrophic hormone
Serum Na: Serum sodium
Serum K: Serum potassium
Serum TSH: Serum thyroid stimulating hormone
Serum free T4: Serum free thyroxine
**Laboratory investigations are not mutually exclusive
NHLS: National Health Laboratory Services
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Reference ranges likely differed as different assays were used since diagnosis.
The 105 patients with adequate or suggestive biochemistry were compared to 
the 43 patients with insufficient biochemical verification data (Table 13). There 
was no difference between these two groups in terms of age of enrolment, age of 
initial diagnosis and proportion that were female. The ethnic distribution and the 
proportion with foreign ancestry of at least a first or second degree relative were 
also no different. The only difference in the presenting symptoms between the two 
groups was that a greater proportion in the group with adequate or suggestive 
biochemistry presented with vomiting. There was an almost identical delay in 
diagnosis and there were no differences in either the prevalence of co-morbidity 
or replacement doses of hydrocortisone. Overall, there were substantial clinical 
similarities between the subjects with adequate or suggestive biochemistry and 
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Table 13: Clinical characteristics of Addison’s patients with adequate or suggestive biochemistry 
compared to those with insufficient biochemical verification








Age of enrolment years 
(IQR) 51 (35-62) 41 (21.5-54.5) 0.12
Age at initial diagnosis 
years (IQR) 34 (20-46.8) 30 (16.3-42.5) 0.26
Gender
















Foreign ancestry N (%)1 36 (34) 15 (35) 0.498









































Delay in diagnosis months 
(IQR) 6 (3-18) 5 (2-13) 0.28
Co-morbidity at enrolment 
N (%)
Hypercholesterolaemia
























Total daily hydrocortisone 
dose (IQR) mg 
20 (20-30) 25 (20-30) 0.91
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IQR: Inter-quartile range
1: First or second degree foreign relative from United States of America or Europe
p <0.05 considered significant
*p <0.05
3.7.1.4 Replacement therapy
Most patients (81%) received a combination of fludrocortisone and hydrocortisone. 
Prednisone in combination with fludrocortisone was the next most common 
combination of steroid replacement administered (Table 14). The median total 
daily hydrocortisone dose was 20 mg and the total median dose of hydrocortisone 
corrected for body surface area (hydrocortisone/m2) was 12.4 mg. In this cohort, 
33% were receiving three daily doses, 52% were receiving two daily doses and 
15% were receiving a single daily dose of GC replacement therapy. The proportions 
of patients using once-daily hydrocortisone, cortisone acetate, prednisone and 
dexamethasone were 12%, 66%, 40% and 100% respectively. In addition, 38% 
of patients reported having had at least one lifetime Addisonian crisis and 58% 
of patients did not wear any form of medical alert identification. The only patient 
who used dexamethasone as replacement therapy, was receiving a significantly 
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Table 14: Glucocorticoid replacement therapy in South African Addison’s disease patients











Hydrocortisone 112 /126 (89) 20.0 (20-30.0) 0.33 (0.25-0.44) 12.4 (10.3-16.9)
Cortisone acetate 3/126 (2.0) 25.0 (25.0-32.5) 0.53 (0.50-0.55) 19.7 (18.3-21.0)
Prednisone 10 /126 (8) 8.75 (5.0-11.9) 0.42 (0.3-0.68) 11.4 (16.6-26.3)
Dexamethasone 1/126 (0.8) 5 1.31 62
n: Total number of patients identified using a specific form of glucocorticoid replacement therapy
N: Total number of Addison’s patients enrolled in this analysis
IQR: Interquartile range
Hydrocortisone dose/m2:  Total daily hydrocortisone dose, corrected for body surface area
Hydrocortisone dose/kg: Total daily hydrocortisone dose corrected for body weight
Equivalent doses derived from Meikle AW and Tyler FH. Potency and duration of action of 
glucocorticoids. Am J of Med 1977;63(2):200-20714
Missing data in 22/148 (15%), patients untraceable
a: in a single patient
3.8 Discussion
There are numerous cohort studies of Addison’s disease in the literature, but 
this is the only one conducted in sub-Saharan Africa and it can be considered to 
represent a large cohort as 148 patients were enrolled.15 17 Although an extensive 
effort was made to identify every person with Addison’s disease in South Africa, 
it is possible that some patients may not have been captured. Collecting the 
current cohort relied on referrals from primary, secondary, tertiary and quaternary 
centres in the country, where no databases for this disease are kept, except within 
the domains of the medical insurance companies. In most cohort studies, the 
participants were exclusively drawn from academic centres, with the exception 
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practitioners in the United Kingdom requesting information on patients with 
Addison’s disease. More recently, a German survey analysed data from patients 
attending either an academic endocrinology department or a private endocrine 
practice.12 The methods used for collecting the South African Addison’s disease 
cohort needed to consider the major private and public health-care delivery 
systems. Although the majority of cases were identified from academic centres, 
the cohort would have been reduced by 48% if patients were not enrolled from 
lower levels of care and private practitioners. Nevertheless, it is quite possible 
that some patients were not captured, as only two-thirds of the country’s medical 
practitioners were reached by the researcher.
Although the researcher attempted to obtain a complete biochemistry data 
set for each of the patients, this was not possible because in many instances 
patients had been diagnosed with Addison’s disease up to 20 years prior to being 
enrolled in the study and early clinical and biochemical records of their initial 
admissions were not available. Biochemical data compatible with the diagnosis of 
primary hypoadrenalism were available for at least 72% of the patients enrolled. 
Nevertheless, there is no reason to doubt the diagnosis of primary hypoadrenalism, 
since the diagnosis was made by experienced specialist physicians (internists), 
paediatricians and endocrinologists and the researcher verified that the clinical 
picture at presentation was compatible with this diagnosis. Moreover, the clinical 
characteristics were similar in the group of patients with adequate biochemistry 
and the group with inadequate biochemical verification data (apart from a greater 
prevalence of vomiting in the former group). Although it could be expected that 
patients with insufficient biochemical data may have had Addison’s disease for 
longer than the other group due to data being lost or discarded, this was not 
confirmed in this study.
 
Based on data from Løvås et al and Ten et al,18 19 the prevalence of Addison’s disease 
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144 per million.20 Even using conservative estimates, this is considerably higher 
than the 3 per million found in the current study. A number of factors suggest that 
this cohort may not have included all of the cases of Addison’s disease. Given the 
demographic profile of the South African population, the majority of participants 
would be expected to be black African, with similar numbers of white and mixed 
ancestry patients, and a small number of Asian patients. However, in the cohort 
there were small numbers of black Africans and Asians, while whites comprised 
the majority. The predominantly European ancestry (white) patients seen in this 
study may reflect that the evolution of Addison’s disease is dependent on certain 
HLA frequencies, genetic variations or environmental factors, creating favourable 
conditions that promote a greater prevalence among Europeans. This may be 
supported by a large study from North America and the UK, which examined 2 
624 vitiligo probands and found that 83% were white.21 On the other hand, this 
may merely reflect the demographic profiles of these countries, since the majority 
of these respective populations are not black African.
Another possible explanation is that patients with Addison’s disease may die 
with the disease unrecognised. Addison’s disease is regarded as one of the 
mimickers in medicine. Although hyperpigmentation is a significant clinical feature 
in whites, it may be much more subtle in darkly pigmented races, resulting in the 
diagnosis being overlooked.8 22 23 The disease may also be unrecognised due to 
the poor health-care system, which is challenged by the HIV/AIDS epidemic and 
insufficient numbers of skilled health-care workers, with some facilities having 
only 7% of the required number of doctors.24 Enhancing awareness of Addison’s 
disease may be achieved by providing annotations on chemical pathology reports 
and alerting clinicians to the possibility that primary hypoadrenalism may coexist 
with compatible biochemistry. This should be tempered by the fact that the recent 
audit of the Asia-Pacific region and Africa indicated that the quality of interpretive 
commenting was diverse, incorrect in some cases and potentially misleading.25 
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medical students. This can be accomplished through so-called scripts, which 
are temporary mental representations, consisting of existing knowledge and 
new information. There are three critical elements, namely: enabling conditions 
(features associated with the acquisition of an illness, for example, fatigue or 
hereditary factors), fault (malfunctions in illness) and the consequence of faults 
(signs and symptoms).26
A significant migration of South African doctors has occurred to countries 
with perceived better standards of living. Analogous to the explanation for the 
low incidence of Addison’s disease in rural settings, is the lower incidence of 
T1DM in rural Africa,27 where the ratio of medical practitioners to population is 
considerably less than in the cities. Nevertheless, some autoimmune conditions 
may demonstrate a predilection for rural versus urban areas; T1DM has shown a 
tendency to develop in rural areas in Finland, in contrast to the African scenario.28 
The distribution of SLE has also been found to vary, even within an urban district, 
suggesting that geographical factors may play a role in modifying an autoimmune 
process. Taken together, the few black patients enrolled in the study may reflect 
the sub-optimal health delivery in rural areas and the particular challenge in 
making this diagnosis in pigmented races.
In some respects, this cohort is congruent with the findings of previous studies, for 
example, multiple authors have confirmed the preponderance of women in their 
cohorts15 16 and the age of diagnosis is similar to many studies of adult Addison’s 
disease.17 29 31 As can be anticipated, the age of onset in the paediatric Addison’s 
disease population differs substantially, as the median age of onset was 7.7 years 
in the study by Simm et al.32
Multiple authors have attested to the fact that hydrocortisone is the preferred 
form of replacement therapy.19 33-35 In Italy, until 1999, cortisone acetate was the 
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prednisone and dexamethasone may have advantages over hydrocortisone, due 
to their low cortisol peaks; sustained cortisol levels potentially limiting symptoms 
of fatigue and the possibility of once daily administration. On the other hand, 
the extended half life conferred by prednisone and cortisone acetate may give 
rise to high non-physiological night-time cortisol levels and for this reason, 
hydrocortisone remains a frequently prescribed form of therapy.33 Hydrocortisone 
replacement is preferred among children, administered in doses of 10-20 mg/
m² in three divided doses, as it has less impact on longitudinal growth than the 
longer acting GC therapy.19
It is concerning that a significant number (58%) of patients did not wear any 
form of medical identification in this study, which is considerably higher than the 
40% of type 1 diabetic children, aged between 6 years and 17 years of age, who 
did not wear medical alert identification that indicated they were diabetic and 
required insulin.37 The barriers to wearing forms of medical identification were 
not examined, although anecdotally it is not uncommon for patients to break the 
chains or discs and lose their bracelets. It seems advisable to encourage the use 
of medical identification alerts at each clinic visit.
The patients in this study appeared to have significant co-morbidity, but it remains 
unclear whether this is greater than that experienced by the general population 
in South Africa. On the other hand, recent data from the United Kingdom indicate 
that aside from expected coexistent autoimmune disease, 65% of patients with 
Addison’s disease had an elevated BMI of >25 kg/m², 65% had TC of >5 mmol/L, 
17.9% had established spinal osteoporosis and 53.5% had spinal osteopaenia, 
corroborating the fact that Addison’s patients are burdened by co-morbidity.38
Mortality has not been assessed in patients with Addison’s disease in South 
Africa, but in Sweden, this has been examined by reviewing death registers. CVD 
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as the background population. Malignancy with no specific predilection for a 
specific sub-type and infectious diseases were also considerably greater than 
the background population. In the same study, diabetes, irrespective of the type, 
conferred an almost quadruple mortality in patients compared to the background 
population.39
This current study of South African Addison’s disease patients has several 
weaknesses. As it includes a cross-sectional analysis of the clinical characteristics 
of Addison’s disease, the diagnosis in many instances was made several years 
previously. This, together with the lack of uniform protocols for evaluating 
Addison’s disease and incomplete clinical notes in a diversely functional health-
care system, probably contributed to the incomplete biochemical data available. 
It has been noted that the prevalence of Addison’s disease in South Africa is 
considerably lower than in Western countries. Poor access to health-care in rural 
regions could have accounted for this low prevalence.
3.9 Conclusions
This large cohort from sub-Saharan Africa contained small proportions of black 
and Asian participants, which do not reflect the overall demographics of the 
country. The overall prevalence of Addison’s disease is considerably lower than 
Western countries and its diagnosis is considerably more common in urban 
regions that are close to quaternary teaching hospitals, compared to rural areas 
due to possible under-diagnosis. Raising awareness of this highly treatable 
condition is an important and potentially life-saving measure. In the next chapter, 
the aetiopathogenesis and genetic associations of Addison’s disease in South 
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Chapter 4
Aetiopathogenesis and genetics of Addison’s 
disease in South Africa
4.1 Introduction
Prior to the first half of the 20th century in developed countries, tuberculous 
adrenalitis was an important cause of primary hypoadrenalism. However, even 
today in developing countries, tuberculosis still accounts for a significant proportion 
of these cases.1-3 Currently when autoimmune aetiology is assessed by adrenal 
autoantibodies, it accounts for the vast majority of Addison’s disease in Western 
countries,4-12 and tuberculous adrenalitis has become a less prominent cause.13 
South Africa is at the epicentre of HIV and tuberculosis epidemics,14 and it is 
uncertain whether the background prevalences of these communicable diseases 
influence the underlying aetiology of Addison’s disease.
A single study of acute Addison’s disease from South Africa suggested an 
underlying autoimmune aetiology of onl  12%, with the majority of cases being 
idiopathic (42%) or tuberculosis related (34%). However, adrenal autoantibodies 
were not measured.1 T1DM has been extensively studied and serves as a 
prototype for the study of other autoimmune conditions. Islet-cell autoantibodies 
(ICA) titres decline following diagnosis and only 5 10% of T1DM patients remain 
ICA positive ten years after diagnosis. Thus, it is likely that a similar pattern may 
be seen in patients that were diagnosed with Addison’s disease many years 
previously, with a significant number of patients being adrenal autoantibody 
negative.15 People of African origin may also have a different autoantibody profile 
when compared to European patients, as only 4 in 10 African-Americans are ICA 
positive, with new onset T1DM.15-17
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large South African cohort, with the hypothesis that autoimmunity would be more 
common than previously described in the country. In addition, since HLA DQ 
alleles have previously been reported to associate with adrenal autoimmunity, 
especially in APS2 with Addison’s disease and T1DM,18 19  the cohort was examined 
to determine whether there was a predisposition to autoimmunity, based on HLA 
DQB1 genotypes.20
4.2 Patients and methods
The methods employed in this cross-sectional study design are outlined below.
4.2.1 Patients
The patients enrolled in the Addison’s disease cohort (described in Chapter 3) 
were eligible for inclusion in this study.
At enrolment, all patients had blood drawn for ACA, 21-hydroxylase autoantibodies, 
islet cell autoantibodies (ICA), thyroid microsomal antibodies, thyroglobulin 
autoantibodies  (anti-Tg), tissue transglutaminase autoantibodies (anti-TTG), 
StCAb (ovarian, testicular and placental antibodies) and parietal cell antibodies. 
All male patients had VLCFAs evaluated for confirmation or exclusion of ALD. In 
addition, HLA DQB1 genotypes were determined for each patient and healthy 
control subject that attended the blood donor clinic. Patients and control subjects 
were matched for gender and ethnicity.
4.2.2 Measurement of serum autoantibodies
Autoantibodies expected to occur in association with autoimmune Addison’s 
disease were assayed as discussed below.
4.2.2.1 Adrenocortical autoantibodies (ACA)
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sections of human adrenal glands.21 22 Within two hours of surgical removal, the 
substrate of human adrenal gland was snap frozen in isopentane, which had 
been cooled in a dry ice acetone bath. This was performed by the Department of 
Pathology, University of Florida, Gainesville, USA.
4.2.2.2  21-hydroxylase autoantibodies
21-hydroxylase autoantibodies were measured with a commercial 
immunoprecipitation assay based on 125I-labeled recombinant human 21-OH 
(RSR Ltd., Cardiff, UK). 21-hydroxylase autoantibody levels above 1 U/ml 
were considered positive.23 The assay has high specificity for 21-hydroxylase 
antibodies and is more sensitive than immunofluorescence assay for detecting 
adrenal antibodies in cases with overt adrenal failure.24
4.2.2.3 Islet-cell autoantibodies (ICA)
Islet-cell autoantibodies (ICA) were determined by the Department of Pathology 
in the University of Florida, Gainesville, USA in an indirect immunofluorescence 
assay, using cryostatic sections of human pancreas from patients with blood 
group O. Values of ≥10 Juvenile Diabetes Foundation (JDF) units were considered 
positive. In past Immunology of Diabetes Society (IDS) workshops, this ICA assay 
had a specificity of 100% and a sensitivity of 74.4% in patients with new-onset 
T1DM, who were less than 30 years of age.25 26 
4.2.2.4 Thyroid microsomal autoantibodies
Thyroid microsomal antibodies were measured using the kit, employing 
haemagglutination methodology, Thymune-M (Remel Europe Ltd, Dartford, Kent, 
UK). Results were considered positive if the titre exceeded 1:400.
4.2.2.5 Thyroglobulin autoantibodies
Thyroglobulin autoantibodies (anti-Tg) were measured using the kit, employing 
haemagglutination methodology, Thymune-T (Remel Europe Ltd, Dartford, Kent, 
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4.2.2.6 Tissue transglutaminase autoantibodies
Tissue transglutaminase autoantibodies (anti-TTG) IgA antibodies against 
tissue transglutaminase were determined with a routine in-house ELISA assay 
at the Department of Clinical Immunology, University Hospital, Uppsala, using 
commercially available guinea pig transglutaminase and rabbit anti-IgA antibodies. 
Microplates were coated with Sigma tissue transglutaminase or human tissue 
transglutaminase. After incubation plates were blocked with Tris-hydrochloride 
and washed. Patient sera were diluted and horseradish peroxidase-conjugated 
rabbit anti-human IgA antibodies were added. A substrate solution containing 
1,2-phenylenediamine-dihydrochloride and H2O2 was added. The absorbance 
was measured at 492 nm.  The upper normal reference range of the 95th 
percentile was 6 kUnits/L.
4.2.2.7 Steroid cell producing autoantibodies
Steroid cell producing autoantibodies (StCA) were measured at the Department 
of Pathology at the University of Florida by indirect immunofluorescence, using 
human placenta, human testes and pregnant rabbit ovary as substrate. StcA may 
react with syncytiotrophoblast in the placenta, Leydig cells in the testes, and/or 
the theca interna/granulosa cell layers of the Graafian follicles, and the corpora 
lutea of the ovaries. Some StcA-positive sera react with all tissues, whereas other 
sera may only react with one or two tissues.27 
4.2.2.8 Parietal cell antibodies
Parietal cell antibodies were measured at the Department of Pathology at the 
University of Florida by indirect immunofluorescence, using human stomach as 
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4.3 Very Long Chain Fatty Acids (VLCFAs)
The plasma VLCFA concentration was determined by capillary gas chromatography 
mass spectrometry, following procedures described previously.28 29  Normal values 
were previously determined in 50 healthy South African controls that were similar 
in age to the study population, {C26:0 (0.5-2.1μmol/L), C24:0 (12.6-46.0μmol/L) 
and C22:0 (33.9-157.5μmol/L}. Normal C24/C22 and C26/C22 ratios were 
calculated as 0.2-0.4 and 0.01-0.02 respectively. All abnormal results obtained 
were confirmed by an external laboratory (Lab. Genetic Metabolic Diseases, F0-
225, Academic Medical Centre, University of Amsterdam, The Netherlands).29 30
4.4 HLA DQB1 genotyping and aetiological classification
HLA DQB1 genotypes were determined using a previously described method.32 
Briefly, exon 2 of the DQB1 gene was amplified using polymerase chain reaction 
(PCR). The amplified PCR products were then separated by denaturing gradient 
gel electrophoresis (DGGE). DQB1 alleles were determined by comparing the 
migration of bands from samples to standards with known identity.  Individuals 
with DQB1* 0302.3 or DQB1* 0602.3.4 alleles on DGGE were further typed using 
sequence specific primer techniques. Alleles *0302 and*0303 were distinguished 
using a DQB1*0302 specific amplification. The DQ6 alleles were distinguished 
using three sequence-specific primers.
The aetiological classification of Addison’s disease is demonstrated in Table 15. 
Autoimmune Addison’s disease was diagnosed when subjects were positive for ACA 
and/or 21-hydroxylase autoantibodies. Tuberculosis-related adrenal insufficiency 
was diagnosed if there was a prior or current history of tuberculosis.8 Biopsy-proven 
or radiological evidence for metastatic disease indicated a metastatic aetiology of 
Addison’s disease, while patients with sarcoidosis or iron overload and no other clear 
cause of hypoadrenalism had Addison’s disease attributed to these conditions.33  
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irrespective of the autoantibody pattern.34 35   X-linked adrenal hypoplasia was 
diagnosed in boys with primary adrenal failure and salt loss in the first few weeks 
of life, which is associated with hypogonadotrophic hypogonadism. The diagnosis 
of ACTH-resistance syndrome was made based on primary hypoadrenalism and 
isolated GC deficiency, but with normal mineralocorticoid function.36 37  Patients 
with an AIDS-defining illness were classified as having AIDS-related Addison’s 
disease. The diagnosis of idiopathic Addison’s disease was reserved for patients 
in whom there was no obvious clinical cause and had no adrenal autoantibodies.6 
Sarcoidosis, iron overload and HIV were excluded clinically, using the appropriate 
laboratory studies.  
Table 15: Aetiological classification of Addison’s disease
Aetiology Diagnostic Criteria
Autoimmune Addison’s disease Presence of 21-hydroxylase autoantibodies or ACA
Adrenoleukodystrophy Increased plasma VLCFA, irrespective of autoantibody pattern
Tuberculosis
A compatible current clinical or past history of 
tuberculosis of lung, bone, pelvic-peritoneal 
or genitourinary; radiology compatible with 
tuberculosis
AIDS (related)
Presence of an AIDS defining illness for 
example  cytomegalovirus, Mycobacterium 
avium- intracellulare, Cryptococcus 
neoformans, Toxoplasmosis gondii, Kaposi’s 
sarcoma
Other causes Malignancy (biopsy proven), sarcoidosis, iron overload
X-linked Adrenal hypoplasia
Male patients with primary hypoadrenalism, 
salt loss in the first few weeks of life, 
and later frequently associated with 
hypogonadotrophic hypogonadism
ACTH resistance syndrome
Isolated glucocorticoid insufficiency, but 
normal mineralocorticoid function, may be 
associated with alacrimia, achalasia
Idiopathic
Adrenal autoantibody negative, normal 
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VLCFA: Very long chain fatty acids




Patient characteristics with non-normal distribution were described using the 
median and IQR for continuous variables and numbers of patients, and percentages 
for binary and categorical variables. Data were compared between autoantibody 
groups using the univariate linear regression Wald test for continuous variables, 
and Chi-squared tests for binary and categorical variables.
The relative risk for autoimmune Addison’s disease, compared to controls in HLA 
allele frequency, were described for European ancestry (white) patients without 
T1DM, in order to avoid any confounding that may arise due to ethnicity or known 
associations with T1DM. Factors associated with an autoimmune aetiology in the 
study cohort were explored in univariate and multivariate logistic regression models. 
The 21-hydroxylase autoantibody titres were transformed to a logarithmic scale, 
plotted and regressed against the duration of Addison’s disease at enrolment in a 
two-way scatter-plot. All analyses were conducted using Stata(TM) version 10.0 
(Stata Corp., College Station, Texas).
4.6 Results
As seen in Figure 17, 144 of the 161 patients referred for enrolment in the South 
African Addison’s study were included in the study of aetiopathogenesis  and 
genetics. The clinical characteristics of the patients enrolled in the study and the 
seven who were excluded because they were too late for enrolment, are shown in 
Table 16. The median and IQR age of enrolment was 46.5 (32.8-61.0) years and 
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years, indicating that most patients had had the disease for a long period of time 
(12.5 years; range 0-50 years). There was a greater preponderance of women, 
who constituted 61% of the cohort. Most patients (n = 109, 75%) were over the age 
of 20 years at diagnosis and 49% had been diagnosed more than ten years earlier. 
88% of patients were recruited from the major cities, often in close association with 
a major teaching hospital. The ethnicity of the cohort was heterogeneous: 65% 
European ancestry (white), 24% mixed ancestry, 3% Asian and 8% were black 
South Africans.
The seven patients who were not included in this study differed from the 144 who 
were enrolled. They were younger at initial diagnosis (17.0 years versus 34.0 
years; p = 0.048), had been suffering from Addison’s disease for a shorter period 
of time (they had predominantly either new-onset Addison’s disease or had been 
diagnosed between 1.0 and 4.9 years ago), were lighter (53.1 kg versus 70.0 kg; 
p = 0.04) and had a lower BMI (21.2 kg/m2 versus 25.2 kg/m2; p = 0.01). This 
















3 patients declined to
participate in the study144 patients with 
Addison’s disease
7 patients too late 
for enrolment










7 patients excluded because
of an incorrect label of
Addison’s disease
33 both ACA and
21-hydroxylase 
autoantibody positive
ε 39 21-hydroxylase 
autoantibody Positive, 
but ACA negative





8 with X-linked adrenal 
hypopisia 2 ACTH resistance
6 adrenoleukodystrophy
ε
Figure 17: Diagnostic categories of patients enrolled in the South African Addison’s disease study 
for evaluating underlying aetiopathogenesis and genetics
TB: Tuberculosis
X-linked: X-linked congenital adrenal hypoplasia
ACTH resistance: Adrenocorticotrophic hormone resistance syndrome
ACA: Adrenocortical autoantibodies
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Table 16: Clinical characteristics of Addison’s disease subjects enrolled and seven subjects too late 


















enrolment years median (IQR) 46.5 (32.8 -61.0) 38.5 (19.0-59.0) 0.30
Age at initial 



































































































































Mass available for 107 patients, height and BMI for 94
**: Categories are not mutually exclusive
CI: Confidence interval
BMI: Body mass index
ACTH: Adrenocorticotrophic hormone 
ALD: Adrenoleukodystrophy
p <0.05 considered significant
*p <0.05
As seen in Figure 17, 70% of the cohort (n = 101) had identifiable causes of 
Addison’s disease. Of these, 51% had autoimmunity based on the presence 
of 21-hydroxylase and/or ACA, 8% had a history of tuberculosis, 4% had ALD, 
1% had ACTH-resistance syndrome and 6% had X-linked adrenal hypoplasia. A 
presumptive diagnosis of tuberculous adrenalitis was made in 8% of the patients. 
Only two of the patients had CT scans and the results from both were suggestive of 
tuberculous adrenalitis. In 30%, no specific aetiology was uncovered. There were 
no patients with sarcoidosis, iron overload, metastatic disease or AIDS-related 
Addison’s disease.  As ALD and X-linked AHC occur almost exclusively in males 
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There were 111 patients (74%) with at least one associated autoimmune condition. 
Of these, 44 (29%) had two, 16 (11%) had three and 6 (4%) had four associated 
autoimmune conditions. Of the 74 patients with at least one adrenal autoantibody, 
72 (96%) had autoantibodies to 21-hydroxylase, 35 (48%) had ACA and 33 (45%) 
were positive for both antibodies (Table 17). Of the 74 patients with adrenal 
autoimmunity, clinical primary hypothyroidism was the most commonly associated 
autoimmune condition (47%), while POF (8%) and T1DM (7%) were the next most 
prevalent disorders. Hypoparathyroidism, pernicious anaemia, coeliac and Graves’ 
disease, immune thrombocytopenic purpura, ulcerative colitis, and vitiligo coexisted 
in 5% or fewer of the patients who were positive for 21-hydroxylase and/or ACA. 
As expected, the presence of associated autoantibodies did not always correlate 
with a concurrent clinical autoimmune condition in the study. For example, in the 
patients with adrenal autoantibodies, primary hypothyroidism was present in only 
20 of the 32 patients with positive thyroid microsomal, coeliac disease was present 
in 2 of the 6 patients with positive anti-TTG, pernicious anaemia was diagnosed 
in 2 of the 11 patients with positive anti-parietal cell antibodies and although 6 
patients had T1DM, only 4 of these patients had positive ICA. This suggests that 
this sub-group is at risk of future coexistent autoimmune conditions.
The proportions of the total 144 patient cohort with either APS1 or APS2 were 5 
(3%) and 66 (46%) respectively. A positive family history for autoimmune disease 
was noted in 26% of this cohort. A positive family history for Addison’s disease 
and T1DM occurred most frequently in 8% of patients, 10 (7%) of the patients had 
a first-degree relative with primary hypothyroidism disease, and Graves’ disease 
occurred in 5% of patients’ relatives, while pernicious anaemia (1%), vitiligo (0.7%), 
SLE (1%) and rheumatoid arthritis (1%) were less commonly encountered in the 
patients’ relatives.
When comparing Addison’s disease patients with autoimmunity to those defined 
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likely to have a positive family history of autoimmune disease. However, among 
the idiopathic Addison’s disease group, 20 patients (47%) had at least one other 
organ-specific autoantibody. It is possible that some of these subjects had lost 
serologic evidence of adrenal autoimmunity over time, and adding this group to 
the autoimmune group would increase the proportion of patients with autoimmune 
Addison’s disease in the entire cohort to 65%. The length of time for which the 
patients had the disease at enrolment was not different between the idiopathic 
group without antibodies and the autoimmune group.
The idiopathic group was older than the other two groups comprising the presence 
of at least one adrenal autoantibody and the group with an identifiable cause of 
Addison’s disease excluding autoimmune, (p = 0.002). Interestingly, none of the 5 
Asian or 11 black patients was positive for adrenal autoantibodies. Although more 
patients with adrenal autoantibodies had a positive family history of autoimmune 
disease and had a history of foreign ancestry (a first- or second-degree relative 
born in Europe or USA), the latter did not reach statistical significance. The mean 
total daily hydrocortisone replacement dose was higher in the autoimmune group 
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Table 17: Comparisons based on adrenal autoantibody status
ACA (+) and/or anti-21 
(+)
(Autoimmune)
ACA (-) and anti-21 (-)
(Idiopathic)
p - value
Patients in group (N) 74 43
Gender N (%)
Female 54 (73) 30 (70)    0.71
Age at diagnosis
Age in years (95% CI) 33.1 (29.3-36.9) 40.0 (34.6-45.5)    0.03*
Duration of Addison’s disease 
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   0.18
   0.25
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   0.73
   0.64
   0.44
   0.11
Prevalence of other 
autoimmune diseases N (%)
Any autoimmune disease
44 (59) 27 (63)    0.72
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GADA: Glutamic acid decarboxylase 65 antibodies
CI: Confidence interval
mg: Milligram
Univariate linear regression Wald test: used for continuous variables, Chi-squared statistic for 
proportion
†: Only done in 21-hydroxylase autoantibody positive patients
‡: Presence of autoimmune disease in first-degree relative
p < 0.05 considered significant
Hydrocortisone dose: Total daily hydrocortisone dose
Fludrocortisone dose: Total daily fludrocortisone dose
Hydrocortisone dose/m²: Total daily hydrocortisone dose in relation to total body surface area
Fludrocortisone dose/m²: Total daily fludrocortisone dose in relation to total body surface area
An inverse correlation was present between titres of 21-hydroxylase autoantibodies 
and duration of disease since diagnosis (Figure 18). The duration of Addison’s 
disease does not appear to account for the absence of adrenal autoantibodies in 
the Asian and black sub-groups, as it was no different compared to the remaining 
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Figure 18: Lowess (locally weighted scatterplot smoothing) plot showing the relationship between 
duration of Addison’s disease and log transformed titre of 21-hydroxylase autoantibodies. The 
histograms indicate a skewed distribution of antibodies, with the greatest number of patients having 
the lowest antibody titre (y-axis) and shortest duration of Addison’s disease at enrolment.
4.6.1 HLA alleles and autoimmune Addison’s disease
Compared to the controls, the HLA DQB1*0201 allele was positively associated 
with autoimmunity in European ancestry (white) patients without T1DM, while the 
*0601 allele was negatively associated (Table 18). All patients with T1DM had 
the alleles *0201, *0302 or *0301. Hence, these patients were excluded to avoid 
bias. In sensitivity analyses, these associations persisted in the entire cohort, 
and due to the small numbers, could not be adequately described in patients of 
mixed, black or Asian ancestry. When comparing all the patients with autoimmune 
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associations were present.
Table 18: Associations between autoimmune Addison’s disease and HLA subtypes









0201 55 36 (65) 26 (43) 1.5 0.02*
0302 55 20 (36) 17 (28) 1.3 0.36
0301 55 13 (24) 21 (35) 0.7 0.18
0402 55 8 (15) 8 (13) 1.1 0.85
0500 55 10 (18) 17 (28) 0.6 0.2
060x 55 15 (27) 22 (37) 0.7 0.30
0601 55 1 (2) 7 (12) 0.2 0.03*
1 Comparison of alleles in patients with autoimmune disease and healthy control subjects
p < 0.05 considered significant
4.6.2 HLA DQB1 genotypes and autoimmune Addison’s disease
The most common genotypes in all the patients with Addison’s disease were 
*0201/*0302 (19%) and *0201/*060x (10%). The *0201/*0302 genotype was 
more common in patients with autoimmune Addison’s disease (28%) compared to 
controls without Addison’s disease (8%; p = 0.002). This was also the only genotype 
associated with autoimmune Addison’s disease when compared to patients with 
Addison’s disease of other aetiology (unadjusted odds ratio [OR] 3.2, 95% CI 1.3–
8.3; p = 0.01). This information is summarised in Table 19.
None of the HLA alleles or heterozygous genotypes were significantly associated 
with autoimmune aetiology in a multivariate analysis that was adjusted for sex and 
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*0201/*0302 heterozygous genotype (adjusted odds ratio [AOR] 2.4; p = 0.105) as 
shown in Table 19.
Table 19: Associations with autoimmune Addison’s disease
Univariate analysesn Multivariate analyses
Characteristic OR 95% CI p - value OR 95% CI p - value
Female gender 2.9 1.4-5.7    0.003* 3.0 1.2-7.1    0.02*
Age of diagnosis 
(per 10 year increase) 1.0 0.9-1.2    0.86     
European ancestry (white) 10.2 4.4-23.7 <0.001* 10.1
3.9-
25.8 <0.001*
Any other associated 
autoimmune disease 2.1 1.1-4.0    0.03*




Foreign ancestry 2.5 1.3-5.1    0.008*
Pigmentation at diagnosis 2.3 1.1-5.0    0.03* 2.5 0.9-6.9    0.07
Severe presentation 2.6 1.3-5.2    0.005*
Any other autoantibodi s 3.6 1.7-6.7 <0.001* 2.3 1.0-5.4  0.045*






















   0.01*
   0.13
   0.49
   0.07
   0.15
   0.22
   0.007*
Presence of specific HLA 
combination 0201/0302 3.2 1.3-8.3    0.01* 2.4 0.8-7.1    0.1
OR: Odds ratio
CI: Confidence interval
n = 117 and excludes patients with known aetiology of Addison’s disease other than autoimmunity
HLA: Human leukocyte antigen
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4.7 Discussion 
This study is the largest cross-sectional study of Addison’s disease conducted in 
sub-Saharan Africa in a heterogeneous population of predominantly European 
descent (white ancestry). The study refutes an earlier report suggesting that 
autoimmunity is an uncommon aetiology for Addison’s disease in South Africa.1 
However, autoimmunity was previously assessed without the use of specific 
adrenal autoantibodies. It has been shown that ACA are not nearly as detectable 
as 21-hydroxylase antibodies when monitoring Addison’s disease a long time after 
its onset.   An inverse relationship exists between the length of time that a patient 
has had Addison’s disease and 21-hydroxylase antibody titres. Curiously, none 
of the Asian or black subjects, although both groups did have small numbers, 
demonstrated adrenal autoantibodies. It is likely that Addison’s disease is being 
under-diagnosed in South Africa, with potential grave consequences to some 
patients.
Over 50% of our cohort was classified as autoimmune on the basis of at least 
one positive adrenal autoantibody. If one considered long-standing Addison’s 
patients who were adrenal autoantibody negative, but had other autoimmune 
clinical conditions, as likely to have autoimmune Addison’s, then the prevalence 
of autoimmune Addison’s rose to 65%. There was an inverse correlation between 
the titres of 21-hydroxylase autoantibodies and the duration of the disease since 
diagnosis, which confirmed that the adrenal autoimmunity wanes with increasing 
time after diagnosis. Thus, consistent with Western studies, this study confirms that 
autoimmunity is the most common cause of Addison’s disease in South Africa in a 
cohort that was predominantly of European descent (white ancestry).5 On the other 
hand, very few black patients were enrolled and none of them had autoimmunity, 
which may explain the similarity in prevalence to Western countries.
The cross-sectional design and the measurement of autoantibodies, in many cases 
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studies have demonstrated a 20% decline in the prevalence of autoantibodies in 
subjects followed for two or more years after the diagnosis of Addison’s disease.5 
9 This study clearly demonstrates that 21-hydroxylase autoantibody titres decline 
with increasing duration of Addison’s disease. Therefore, the possibility exists 
that patients who were adrenal autoantibody positive at diagnosis were antibody 
negative at enrolment in the study, thus falsely reducing the reported prevalence of 
autoimmune Addison’s. A further limitation is that very few patients underwent a CT 
scan of the adrenal glands, an investigation of proven diagnostic utility, particularly 
in the setting of negative autoantibodies. The final limitation of the study relates to 
possible ascertainment bias. Although every effort was made to comprehensively 
identify patients with Addison’s disease, it was impossible to determine what 
proportion of cases were missed due to non-response, or whether there was any 
selection bias in the patients included in the cohort. It is relevant that the vast 
majority of the cohort were of European ancestry (white ancestry), and a minority 
were black African and Asian. This is in contrast to the demographics of the South 
African population, in which the majority are black Africans (79%) with smaller 
proportions of European ancestry (white ancestry) (10%), mixed races (9%) and 
Asians (2%). It is unclear whether the preponderance of European (white ancestry) 
patients with Addison’s disease represents a true higher prevalence of the disease 
in this population, or whether it is an artefact reflecting the more limited access that 
the black population has to health-care, with the result that there may be missed 
diagnoses and/or under-reporting.
The prevalence of tuberculosis and other known causes of Addison’s disease 
(8% and 11% respectively in this cohort), are in agreement with European (white) 
studies.5 11  It should be noted that the prevalence of TB in this study is 8%, which is 
considerably greater than the 1% background prevalence in South Africa. However, 
India is also a developing country like South Africa, and in a North Indian cohort 
with adrenal insufficiency, the prevalence of primary adrenal failure attributable to 
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the North Indian cohort of 38 Caucasians, the diagnosis of tuberculosis was made 
on the basis of enlarged or calcified adrenal glands seen by abdominal imaging. If 
the adrenal glands were enlarged, cytology and microbiological examination (inter 
alia Zeil Nielsen staining) were performed, as well as radiology of the chest in order 
to exclude pulmonary tuberculosis. Granulomatous disease, indicative of either 
tuberculosis (n = 18) or fungi (n = 1), was diagnosed in 19 out of the 38 patients. 
In the remaining 19 idiopathic patients, 4 (21%) had positive 21-hydroxylase 
autoantibodies, which were no different from those with granulomatous disease. 
Therefore, the prevalence was considerably lower than in the South African 
Addison’s study, where 50% had positive 21-hydroxylase autoantibodies. Moreover, 
as abdominal imaging was not routinely performed in the South African Addison’s 
disease study, it is possible that Addison’s disease attributable to tuberculosis could 
have been underestimated. This difference in the prevalence of 21-hydroxylase 
autoantibodies, may suggest that North Indian Caucasians could have had 
different HLA class II antigens, compared to patients with Addison’s disease from 
Western countries.2 The multivariate analysis in the South African Addison’s study, 
demonstrated that European ancestry (white) had an OR of 10.1, emphasising the 
likely similarity between the South African cohort and European cohort studies.
There have been a few other cohort studies from developing countries. For example, 
in a Tunisian paediatric population with Addison’s disease, 3 out of 6 patients had 
Allgrove’s syndrome, there was APS1 in one patient, ALD in one patient and the 
underlying aetiology could not be determined in the remaining patient.38 In another 
cohort from India, similar to that reported by Nigam et al, 2 47% of the patients had 
Addison’s disease attributable to tuberculosis. 17% of these patients had positive 
adrenal autoantibodies, indicating the potential for overlap in these two conditions.3 
In a small study from Ethiopia, in which three Addison’s patients were identified, 
two were considered to have autoimmune adrenal disease.39 
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study were higher, then the proportion of cases due to autoimmunity may have 
been different. There are several reports indicating that black South Africans have a 
reduced, but not negligible risk of developing autoimmune disease. In the absence 
of antibody confirmation, African subjects are at definite risk of developing T1DM, 
with incidences ranging from 1.5/100 000 in Tanzania to 20/100 000 in Morocco.40 
Initial reports of rheumatoid arthritis prevalence in black Africans indicated that it 
was a disease that rarely occurred.  However, recently, there is evidence that its 
prevalence is increasing, but not to the level that it occurs in Western societies.41 
The incidence of SLE among black South Africans has been reported at 12.2/100 
000, which is significantly higher than among Brazilians at 8.7/100 000, but is less 
than 19.7/100 000 for Saudi Arabians and 60/100 000 identified in Hong Kong.42 
Based on these data, which are in contrast to the findings of the South African study 
in which none of the black and Asian patients were found to have autoimmune 
Addison’s disease, it is highly likely that with increasing awareness for autoimmune 
Addison’s disease, it will be diagnosed more frequently in these two ethnic groups.
Given the high background prevalence of tuberculosis and HIV (tuberculosis case 
finding was 1 000/100 000 and antenatal HIV seroprevalence was 29% in South 
Africa in 2006), surprisingly few patients presented with either tuberculosis or 
HIV-related Addison’s disease in this study.43 44  However, an earlier study from 
a South African tertiary care hospital, determined that primary hypoadrenalism is 
uncommon in a cohort of acutely ill, hospitalised patients with active pulmonary 
tuberculosis. This supports the contention that tuberculosis-related primary adrenal 
failure is relatively uncommon.45 
The heterogeneity of the population group studied is likely to have contributed to 
the observed frequencies of adrenal autoimmunity. Consistent with most studies, 
the vast majority of these patients were of European ancestry (white ancestry), with 
black and Asian participants constituting a small minority. None of the black and 
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in sub-Saharan Africa have decreased frequencies of ICA, compared with their 
European ancestry counterparts. This suggests that there are genetic differences 
between these populations for the lack of antibody response in both T1DM and 
Addison’s disease, or that the aetiologies of these disorders are considerably 
different.16 17
 
It is expected that 50% of patients with autoimmune Addison’s disease will have 
coexistent APS. In a group of 239 Italian patients with autoimmune Addison’s 
disease, 41% were thought to have APS2, while 13% had criteria for APS1. The 
proportion of APS1 was 11% in an Italian cohort of 317 individuals with Addison’s 
disease, irrespective of the aetiology. This is significantly greater than the 3% 
recorded in the South African Addison’s disease patients. Addison’s disease is often 
associated with other autoimmune diseases, including T1DM and hypothyroidism, 
making it difficult to determine whether the observed HLA associations are due to 
the presence of other autoimmune diseases or to Addison’s disease specifically.46 
47 This South African Addison’s study excluded patients with autoimmune Addison’s 
disease and associated autoimmune conditions to eliminate this source of bias. The 
sample sizes in almost all studies are small, limiting study power and increasing 
the chance of a type 2 error. On the other hand, the observed associations could 
reflect random chance. In the regression analysis, a positive association between 
Addison’s disease and several HLA*DQB1 alleles, especially DQB1*0201 and 
*0302, and *0601 alleles and the *0201/*0302 genotype, was observed. The 
presence of T1DM in patients with APS2 is reportedly strongly associated with 
DQB1*0201 and DQB1*0302 alleles. However, even after excluding Addison’s 
patients with T1DM, an association with *0201 and *0302 persisted, confirming a 
previous report.48 The DQB1*0201 frequency of 40% in the healthy population is 
extremely high and raises concerns about the genotyping quality. Even though this 
study has a relatively large sample size compared to some previous studies, the 
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In contrast to this study, 21-hydroxylase autoantibodies titres did not decline with 
increasing duration of the disease among North Indian Caucasians.2 However, 
these patients were studied for a much shorter time {mean duration of Addison’s 
disease was 12 months (range 1-72 months), compared to 13.3 years (range 
0.03-50 years)} in the South African Addison’s disease study. 21-hydroxylase 
autoantibodies were twice as detectable, compared with ACA. Moreover, the 
clinical associations appear to be stronger with 21-hydroxylase autoantibodies 
than ACA, suggesting that the former antibody may be a far more reliable marker 
of autoimmunity than ACA a long time after the diagnosis has been made. The 
declining autoantibody titres over time has been attributed to diminished antigenic 
stimulation, due to progressive destruction of the adrenal cortex.2 At least two 
studies have documented a decline of 21-hydroxylase autoantibodies and ACA 
with increasing duration.49 50   A similar waning of autoimmunity occurs in coeliac 
disease where reduction of anti-TTG levels is observed after introducing a gluten-
free diet.51  Similarly, anti-Tg titres normalise once the thyroid is ablated for 
malignancy.52  Finally, in T1DM, ICA prevalence declines with time after diagnosis, 
so that only 5 10% are ICA positive ten years after diagnosis.15 
4.8 Conclusions
In summary, it has been shown, for the first time, that despite the high prevalence 
of tuberculosis and HIV in South Africa, autoimmune Addison’s disease is by far the 
most common cause of adrenal insufficiency. HLA DQB*0201 and *0302 correlate 
with adrenal autoimmunity, while a novel finding of this study is that *0601 may be 
protective. Despite measurement long after diagnosis, markers of autoimmunity 
persist in many patients with Addison’s disease. 21-hydroxylase autoantibodies 
identified twice as many autoimmune Addison’s disease patients as ACA and 
therefore appear to be a more sensitive marker of an autoimmune aetiology in 
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It is important to highlight the fact that the cohort studied was predominantly of 
European ancestry (white), and it is difficult to predict whether the same distribution 
of causes for Addison’s disease would be seen if the participants more closely 
reflected the demographic profile of the country, that is the majority being black 
African, as the black African group, although small, was negative for adrenal 
autoantibodies. Future studies should focus on identifying more patients with 
Addison’s disease in this group, in order to address this question.
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Chapter 5
Lipids and lipoproteins, and markers 
of cardiovascular disease in primary 
hypoadrenalism
5.1 Introduction
For several decades, clinicians have asserted that the survival of patients with 
Addison’s disease on replacement therapy has been similar to the background 
population. A Norwegian study corroborated the finding that the overall mortality 
rate was normal, but it found that the sub-group of males, younger than 40 years 
of age, suffered excess mortality due to adrenal failure, infection and sudden 
death.1 A Swedish publication has also contested the original finding that the 
survival rate is similar to the background population. The study found that the 
relative risk of premature death was 2.19 and the risk of death, due to CVD from 
ischaemic heart and cerebrovascular disease, was doubled.2 The reasons for 
this accelerated mortality were not investigated, but supra-physiological doses 
of GCs, resulting in dyslipidaemia and hypertension, could have contributed to 
this observed increased rate of mortality.3 There are a number of both human 
and animal studies that indicate GCs potential for adversely affecting the lipid 
profiles. Elevated TC,4-7 raised TG,8 9 increased LDLC5 6 10 and reduced HDLC6 
have been found in association with GCs. Thus, the accelerated mortality seen 
in Addison’s disease may be due to adverse lipid profiles as a consequence of 
supra-physiological GC replacement. Therefore, it is clinically relevant to describe 
the lipid, lipoprotein profiles and markers of CV inflammation associated with 
Addison’s disease, with a view to comparing these to healthy control subjects, as 
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5.2 Aims 
The purpose of this study is to establish whether patients with Addison’s disease 
have an adverse lipid profile, raised markers of inflammation and higher CVD 
Framingham risk than controls.
The specific objectives of this study are to determine:
i. whether patients with Addison’s disease have adverse lipid profiles
ii. if a correlation exists between doses of hydrocortisone replacement 
and the parameters used to evaluate lipid and lipoprotein metabolism
iii. whether markers of CVD inflammation are elevated in Addison’s 
disease
iv. the Framingham CVD risk in patients with Addison’s disease, compared 
with unaffected peers
v. how lipids and lipoprotein metabolism of any sub-group of South African 
Addison’s patients compare with a Swedish Addison’s sub-group that 
has been matched for age, gender, ethnicity and BMI.
5.3 Patients and methods
In this section the patients, healthy control subjects and assays for lipids, 
lipoproteins and biochemical markers of CVD, will be discussed. 
5.3.1 Patients
The patients enrolled in the Addison’s disease cohort, described in Chapter 
3, were eligible for inclusion in this study. All participants were sufficiently well 
to receive ambulatory care, and the clinical information was obtained from a 
combination of the referring physicians and the participants in the study. The 
assumption was made that the patients complied with their chronic replacement 
medication, as verification of compliance could not be carried out. However, poor 
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non-adherence to taking chronic medication in CV patients varied between 31% 
and 58%.11
5.3.2 Matching with healthy control subjects
Healthy control subjects were recruited from volunteer blood donors. They were 
matched for ethnicity, BMI, age and gender with Addison’s disease patients. As 
there were too few Asian subjects, and the black subjects were regarded as both 
too few and heterogeneous, comparison of the Addison’s disease cohort with 
controls was limited to white and mixed ancestry subjects. Even within these sub-
groups, matching was imperfect. As a generalisation, there was far more potential 
for choice in white healthy control subjects, compared to the other ethnic groups. 
Thus, white healthy control subjects could be selected from the blood donor clinic 
in a ratio of 1:10, while the mixed ancestry subjects were selected in a ratio of 1:4, 
indicating that for white healthy control subjects there were ten people to choose 
from for every one selected and in the case of mixed ancestry, there were four 
people to choose from to select one healthy control subject.
5.3.3 Matching with Swedish subjects
Fifty-seven Swedish patients with Addison’s disease were matched with South 
African Addison’s disease patients for age, gender, ethnicity and BMI. 
5.3.4. Study methods
Demographic and clinical data were collected at enrolment. Sera were used to 
determine the TC, HDLC and TG. LDLC was calculated using the Friedewald 
equation, as shown below.
Additional approval was obtained from the University of Cape Town and from 
local research committees, where required, to conduct this study. The ethics 
review board of the University of Gothenburg approved the sub-study of matched 
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Addison’s disease.  
5.3.5 Assays for lipids, lipoproteins and biochemical markers of CVD
The assays for TG, TC, NEFA and RBG were carried out with commercially 
available enzymatic kits, using standard curves and calibrators. The respective 
kits for TG, TC, NEFA and glucose were KAT triglycerides, category number 
T801, using a glycerol-3-phosphate oxidase method; KAT cholesterol, category 
number CH704, using cholesterol oxidase-phenol; peroxidase method, Roche 
free fatty acids category number 11383175001, using colorimetric assay; and KAT 
glucose, category number GP747, using a glucose oxidase method. The HDLC 
was performed according to the first step in the Gidez assay, which yields HDLC 
in the supernatant of a heparin-Mn precipitation of apoB-containing lipoproteins. 
LDL particle size measurement was performed, using non-denaturing gradient 
gel electrophoresis. The LDLC was calculated by the Friedewald equation, as 
shown below:12
LDLC = TC-HDLC-(TG/2.18), provided TG <4.5 mmol/L
The hs-CRP was performed using the high-sensitivity CRP immuno-turbidometric 
assay (Roche Diagnostics, GmbH, Mannheim, Tyskland), demonstrating a 
coefficient of variation (c.v.) of 4% and 3% at serum concentrations of 1 mg/L and 
15 mg/L respectively. The Framingham risk was calculated using the algorithm to 
include diabetes so that comparisons could be made across the entire cohort.13 
Currently, diabetes is regarded as a secondary prevention equivalent for CVD.14
5.3.6 Statistical methods
Variables were tested for their distribution using the Shapiro-Wilk test. TC and 
LDLC were found to be normally distributed, whereas the remaining variables 
were non-normally distributed Assessment of statistical significance among non-
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distributed variables were compared using the t-test.  Proportions were compared 
with Chi-squared tests and replaced by Fisher’s exact test for small samples. 
Associations were determined using Spearman or Pearson regression analyses. 
The predictors for TG and HDLC were calculated using univariate and multivariate 
Cox hazards regression analyses.  Significance was accepted when the p-value 
was <0.05.
5.4 Results
The results of this study are discussed below.
5.4.1 Description of the patients enrolled in the South African Addison’s 
study
As seen in Figure 19, 146 of the 161 patients referred for enrolment in the South 
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154 patients identied
with Addison’s disease
4 patients were too late
for enrolment
147 patients were enrolled in 
the analysis of lipids, 
lipoproteins and markers
of CVD in Addison’s disease
7 patients excluded 
because of an incorrect 
label of Addison’s diseaseф
161 patients were referred 
for enrolment in the South 
African Addison’s study
3 patients declined
to participate in 
this study
Figure 19: Flow diagram of South African Addison’s patients enrolled in the lipids, lipoproteins and 
markers of cardiovascular disease study. ΦSeven patients were excluded because of an incorrect 
diagnosis, two had normal ACTH stimulation tests, two had secondary hypoadrenalism, one had 
bilateral adrenalectomy for Cushing’s disease and one had suppression of the hypothalamic 
pituitary adrenal axis (HPA) axis related to previous steroid use for another indication. 
CVD: Cardiovascular disease
The clinical characteristics of this cohort, defined as all patients, subjects who 
were neither diabetic nor on lipid-lowering therapy and diabetics not on lipid-
lowering therapy are outlined in Table 20. The table depicts risk for myocardial 
infarction using an older risk-calculation algorithm, so that the absolute risk 
could be assigned to diabetic subjects. Recent guidelines classify diabetes as 
a secondary prevention equivalent and do not provide an absolute risk estimate 
for this latter group.15 The proportions of the cohort with coexistent CV risk 
factors are also shown. The most prevalent CV risk factor in the whole group 
was hypertension (15%), followed by diabetes mellitus (14%). About 13% of the 
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In examining the sub-groups of Table 20 the whole cohort of Addison’s patients 
included children. It explains the lower, but non-significant median age, compared 
with the other two groups, which comprised exclusively adults. As expected, there 
were more hypertensive patients in the diabetic sub-group on no lipid-lowering 
therapy compared to the sub-group without diabetes and also not on lipid-lowering 
therapy. There were no smokers in the diabetic sub-group, it is speculated that 
that these patients may have benefited from effective anti-smoking counselling. 
As expected, the median Framingham risk was greater in the diabetic subjects 
compared to the non-diabetics, with neither sub-group receiving lipid-lowering 
therapy. This was corroborated by a higher proportion of patients in the diabetic 
sub-group with a >20% Framingham risk of developing CVD in 10 years, compared 
to the non-diabetic sub-group. Nevertheless, the hs-CRP and the proportion of 
the cohort with predominant small dense LDL was no different between these two 
groups.
The patients on lipid-lowering therapy {(n = 19; median age (IQR) 57.0 (45.0-
67.5) years} and diabetics {(n = 20, median age (IQR) 52.0 (39.0-59.0) years}, 
appeared older than the remainder of the cohort not using lipid-lowering therapy 
{(n = 127, median 44.0 (30.5-60.0) years} and that were non-diabetic {(n = 126, 
median 45.0 (31.5-61.0) years, but the differences were not significant: p = 0.69 
and p = 0.42 respectively. There was a predominance of white and mixed ancestry 
patients in the sub-groups receiving lipid-lowering therapy and diabetic therapy, 
similar to the remaining cohort without these risk factors. The differential health-
care in South Africa could explain the predominance of lipid-lowering treatment 
in white ancestry patients. Interestingly though, the ethnic distribution of patients 
receiving lipid-lowering therapy was not statistically different between the white 
and mixed ancestry patients. The increase in median age in the diabetic group, 
compared to non-diabetics (61 versus 48 years) not receiving lipid-lowering therapy 
was not significant.  Among the diabetics, the ethnic make-up was different from 
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risk of developing hypertension with increasing age, and the high prevalence 
of hypertension associated with diabetes is a well recognised CVD cluster.16 17 
There was a significantly greater proportion of diabetics (55%) who received lipid-
lowering therapy than the remaining cohort (5.5%; p = 0.0001), reflecting the 
gravity of diabetes as a CVD risk factor. However, as this intervention was not 
uniformly implemented, it did not comply with recommendations that all diabetics 
should receive lipid-lowering therapy, apart from exceptional circumstances.
5.4.2 Cardiovascular risk
The Framingham 10-year risk was significantly higher in diabetics, compared to 
the remaining cohort, having excluded subjects on lipid-lowering therapy in both 
sub-groups (Table 20). Data from the Mamre study,  a community-based study 
of CVD risk in people of mixed ancestry from Cape Town were used to estimate 
the Framingham risk as a comparison to risk in Addison’s disease patients.18 
The CVD risk in the Mamre subjects was 14% for men and 8% for women in the 
same median age group of 46 years.18 For the whole Addison’s disease cohort, 
the risk was 12.1% and 14.5% for males and females respectively, which may 
be partly influenced by the younger median (IQR) ages of males, which was 
37.0 (17.8-54.0) years, compared to females, which was 54.0 (39.5-63.0) years. 
By excluding patients in the Addison’s disease cohort on lipid-lowering therapy 
and those with diabetes mellitus, the Framingham risk estimate of ≥20% for 10 
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Table 20: Description of the Addison’s disease patients: whole study population and sub-sets of 
non-diabetics and diabetics not receiving lipid-lowering therapy
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(%) 22 (15) 7 (6) 4 (37) 0.004*




25.0 (20.0 - 30.0) 25.0 (20.0 - 30.0) 20.0 (15 - 30.0) 0.32
Framingham 
CVD 10 - year 
risk (IQR) Ω




≥ 20% CVD for 
10 yearsΩ
N (%)
53 (36) 37 (32) 8 (70) 0.02*
Proportion of 
cohort with small 
dense LDL N (%)
22 (15) 15 (13) 2 (18) 0.97
NEFA μmol/L 
(IQR)
345.0 (140.8 - 
663.5)
329.0 (139.0 - 
589.0)
371.0 (356.0 - 
655.0) 1.0
hs-CRP mg/L 
(IQR) 2.2 (1.0 - 6.4) 2.85 (1.48 - 7.43) 3.3 (1.42 - 10.5) 0.83
Ω: Calculation of the absolute risk of myocardial infarction over 10 years in individuals without 
heart disease by combining several conventional risk factors in 87 non-diabetic on no lipid-lowering 
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the presence of diabetes and is only estimated in individuals greater than 30 years of age. Wilson 
PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary 
heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.13
N: Number 
‡: Females
Median: Age, total daily hydrocortisone dose, Framingham CVD 10-year risk, hs-CRP
IQR: Interquartile range
CVD: Cardiovascular disease
LDL: Low density lipoprotein
hs-CRP: Highly sensitive C-reactive protein
p < 0.05 considered significant
*p < 0.05
5.4.3 Descriptive lipid and lipoprotein data of South African Addison’s 
disease patients
The mean ± SD TC for the entire cohort was 5.7 ± 1.55 mmol/L. As seen in Table 
21, one subject had hypobetalipoproteinaemia (TC < 2.5 mmol/L) and 18 subjects 
(14%) had severe hypercholesterolaemia (TC >7.5 mmol/L). The possibility of a 
monogenetic disorder or secondary cause could not be clarified. Only 44 (35%) 
of the patients had a low risk TC of <5.0 mmol/L, and the remaining 63 patients 
(50%) had moderat  hypercholesterolaemia (TC ranging from >5.0 mmol/L to 
<7.5 mmol/L).19 The median and IQR TG level for the South African Addison’s 
disease patients was 1.67 (1.10-2.62) mmol/L. Of all the patients, 39 (31%) had 
a TG of ≥2.3 mmol/L, which distinguishes a Fredrickson IIa from a Fredrickson 
IIb hyperlipidaemia. A TG  of >1.7 mmol/L is not ideal, and 62 patients (49%) 
exceeded this threshold.20 Fredrickson type IV hyperlipidaemia, inferred by 
hypertriglyceridaemia (TG >5.0 mmol/L), was present in four patients. Agarose 
electrophoresis was not performed to distinguish between type IIb and type IV 
hyperlipidaemia, so that the remaining cohort of TG 2.3-5.0 mmol/L remains 
uncharacterised. There were 35 subjects (28%) who had a TG concentration 
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type IIb or type IV hyperlipidaemia.21 Four patients had hypertriglyceridaemia, 
meriting referral to a specialist lipid clinic and who may require medication other 
than 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGCo-A-reductase) 
inhibitors. No patients had severe hypertriglyceridaemia (>15 mmol/L) and thus 
overall, the risk for pancreatitis from hypertriglyceridaemia was low. 
The median plasma HDLC and IQR was 0.78 (0.52-1.08) mmol/L. The levels of 
HDLC ranged from 0.03-2.87 mmol/L. Hypoalphalipoproteinaemia, considered 
a CVD risk factor when the concentration is <1.0 mmol/L, was identified in 82 
patients (73%). Ten patients (9%) were identified as having extremely low HDLC 
with levels of <0.25 mmol/L. Theoretically, this may be compatible with genetic 
disorders of HDL metabolism or a severe acute phase response.22 However, when 
comparing male patients with their controls, and similarly, female patients with 
their controls, no difference in HDLC was found. Consideration needs to be given 
to prolonged storage of samples as a possible explanation for the unexpectedly 
low levels of HDLC.
The mean LDLC was 4.1 mmol/L, but hypobetalipoproteinaemia (LDLC <1.5 
mmol/L) was identified in only one patient. The ideal LDLC concentration of 
between 1.5 mmol/L and 2.5 mmol/L was present in 12 patients (11%). There 
were 14 patients (13%) that had an LDLC of between 2.5 mmol/L and 3 mmol/L, 
representing a low, but not a negligible risk of developing CVD, depending on the 
clinical context. There were 55 patients (51%) that had an LDLC of between 3.0 
mmol/L and 5.0 mmol/L, and 25 patients (23%) were deemed to have high risk 
LDLC (>5 mmol/L).20
Table 21 also shows the descriptive lipid and lipoprotein data for the sub-group 
with diabetes compared with the non-diabetic sub-group. The proportion with 
diabetes who had a TG of >2.3 ≤ 5.0 mmol/L and LDLC of >5.0 mmol/L was greater 
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p = 0.0006 respectively). Overall, diabetes was associated with higher LDLC 
levels and moderately raised TG, potentially in the same individuals. Interestingly, 
severely raised TG was present in some non-diabetic patients with Addison’s 
disease. Moderate hypercholesterolaemia and moderate LDL were slightly less 
prevalent in the diabetic cohort compared to the non-diabetic cohort; however 
severe LDL hypercholesterolaemia was more prevalent in the diabetic sub-group.
Table 21: Descriptive lipid and lipoprotein data of South African Addison’s disease patients, 
arbitrarily defined cut-off points for significant dyslipidaemia
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12 (11)       14 (13)
0.75               0.77
  49 (54)
  6 (35)





















HDLC: High density lipoprotein cholesterol
LDLC: Low density lipoprotein cholesterol
p < 0.05 considered significant
*p < 0.05
Among Addison’s patients, the sub-group of treated diabetics, all on oral 
hypoglycaemic agents or insulin or both, had similar concentrations of plasma 
NEFA as non-diabetics (p = 0.74). It is not clear whether the diabetic treatment 
counteracted the usual diabetes-induced rise of NEFA, or whether Addison’s 
disease per se or its treatment, blunts the expected rise in plasma NEFA 
concentrations. Other possible relationships and plasma NEFA concentrations 
were explored (Table 22). In the sub-group of diabetic Addison’s patients, NEFA 
was not correlated with any of the plasma lipids or lipoproteins (Spearman 
correlations for TC and LDLC; Pearson correlations for TG and HDLC). It was 
surprising that NEFA did not correlate with the concentration of TG in either the 
diabetic or the non-diabetic group . However, in the whole cohort, NEFA was 
positively associated with TC and LDLC, and there was a trend to a positive 
correlation with HDLC, in the non-diabetic sub-group, but not in the diabetic sub-
group. It is difficult to explain the observation that NEFA was positively correlated 
with TC and LDLC. It is assumed that preservation of samples is not involved 
in this positive association and that plasma contains no active lipoprotein lipase 
to hydrolyse TG. However, plasma may have some residual hepatic lipase or 
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Table 22: The correlations of plasma NEFA in Addison’s disease patients
Addison’s patients whole 
cohort
Non-diabetic Diabetic
TG r = -0.108       p = 0.25 r = - 0.162         p = 0.11 r = 0.296            p = 0.23
TC r = 0.252        p = 0.006* r = 0.287           p = 0.004* r = 0.049            p = 0.85
HDLC r = 0.187        p = 0.06 r = 0.267           p = 0.01* r = -0.197           p = 0.46
LDLC r = 0.255        p = 0.01* r = 0.270           p = 0.01* r = 0.096            p = 0.73
TG Triglyceride
TC: Total cholesterol
HDLC: High density lipoprotein cholesterol
LDLC: Low density lipoprotein cholesterol
r: Correlation coefficient
p < 0.05 considered significant
*p < 0.05
In order to establish whether the lipid profiles were different in diabetic patients 
compared to non-diabetic patients, subjects not using lipid-lowering therapy were 
compared (Table 23). Neither the TC, LDLC, TG, NEFA, random blood glucose 
(RBG) concentrations nor the proportion of small dense LDL was different 
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TG mmol/L (IQR) 1.57 (1.08 - 2.57)(N = 9)
1.65 (1.09 - 2.62)
(N = 97) 0.75
TC mmol/L (SD) 5.30 (1.62)(N = 11)
5.62 (1.50)
(N = 97) 0.53
HDLC mmol/L (IQR) 0.77 (0.73 - 0.86)(N = 11)
0.78 (0.50 - 1.02)
(N = 86) 1.0
LDLC mmol/L (SD) 3.72 (1.53)(N = 9)
4.04 (1.33)
(N = 82) 0.57
Proportion with small 
dense LDL n/N(%)
2/ 11 (18) 12/ 97 (12) 0.59
NEFA μmol/L (IQR) 371.0 (209.0 - 655.5) (N = 11)
308 (139.0 - 584.3)
(N = 90) 0.26
RBG mmol/L (IQR) 5.48 (4.87 - 12.13)(N = 11)
5.3 (4.75 - 6.15)
(N = 97) 0.22
Median: TG, HDLC, NEFA and RBG
Mean: TC and LDLC
TG: Triglyceride
TC: Total cholesterol
HDLC: High density lipoprotein cholesterol
LDLC: Low density lipoprotein cholesterol
NEFA: Non-esterified fatty acids
RBG: Random blood glucose
IQR : Interquartile range
N: Number of patients with either diabetes or not diabetic
SD: Standard deviation 
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The underlying two conditions least likely to induce derangements in lipids were 
deemed to be ALD and isolated autoimmune Addison’s disease. So, in order to 
assess whether the aetiology of Addison’s disease could be contributing to lipid 
abnormalities, these two conditions were compared to the remaining causes for 
Addison’s disease. The TG concentrations were found to be significantly lower 
among patients with ALD and isolated autoimmune Addison’s disease, compared 
to the remaining cohort. The small difference in TG is, however, not useful at the 
clinical level to discern the different causes of Addison’s disease.
5.4.4 Lipid and lipoprotein data in white and mixed ancestry patients 
compared to their respective controls
This analysis was performed on the cohort of white and mixed ancestry patients 
over the age of 30 years undergoing the Framingham risk calculation, irrespective 
of intervention for dyslipidaemia.  As seen in Table 24, the median ages and BMI 
confirm adequate matching between the patients and their respective controls. 
In both categories, the mean TC and LDLC did not differ between the patient 
and control groups. However, the median TG levels were significantly higher 
in the mixed ancestry patients versus the mixed ancestry controls, despite the 
former having a lower median BMI.18 There were no individuals with extreme TG 
deviations in either group. The explanation for this could lie in the elevation of 
TG by the cause(s) of Addison’s disease or its treatment. The median HDLC was 
lower in both the white patients and the patients of mixed ancestry versus their 
respective controls. The hs-CRP was increased compared to their respective 
controls. There was a significantly greater proportion of small dense LDL among 
the white and mixed ancestry patients versus their respective controls.
The NEFA levels were lower in the white patients compared to their controls, 
and although the levels were lower in the mixed ancestry patients compared to 
their controls, it was only of borderline significance. Due to their extreme values, 
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Addison’s patients. There was no difference in NEFA between the mixed ancestry 
patients and the control group (p = 0.05), although the trend remained. The median 
RBG concentrations were surprisingly higher among the white controls versus 
the white patients (5.93 mmol/L versus 5.36 mmol/L; p = 0.0001). The mixed 
ancestry patients also had a lower median RBG compared with their respective 
controls (5.7 mmol/L versus 5.9 mmol/L; p = 0.005).
Overall, a greater proportion of the Addison’s patients had small dense LDL 
particles, compared with the controls. The median TSH levels did not differ 
between the white {(1.51, IQR (0.57-2.00)} mIU/L and mixed ancestry {(1.16, IQR 
(0.85-1.80)} mIU/L patients (p = 0.17). As expected, the RBG was significantly 
greater in the white patients with diabetes compared to the white patients without.
The impact of diabetes mellitus was also analysed in white and mixed ancestry 
patients, compared to their respective controls. These results are summarised in 
Table 25. Diabetes mellitus in the mixed ancestry patients was associated with a 
greater LDLC concentration (4.89 mmol/L versus 3.66 mmol/L p = 0.04). Although 
inequalities exist in health care in South Africa, where whites in the private sector 
may have more access to lipid-modifying therapy than other groups in public 
health-care systems, diabetic white patients received lipid-lowering therapy as 
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Table 24: Comparisons of lipid profiles and atherosclerotic risk in the cohort of patients and their 






















































































































LDL n/N (%) 11/81 (14) 3/ 96 (3)
0.02*


























































































Median: Age, BMI, TG, HDLC, NEFA, RBG, hs-CRP and TSH
Mean: TC and LDLC
BMI: Body mass index
TG: Triglyceride
HDLC: High density lipoprotein cholesterol
LDLC: Low density lipoprotein cholesterol
NEFA: Non-esterified fatty acids
RBG: Random blood glucose
hs-CRP: Highly sensitive C-reactive protein




p1: Comparison between white patients and white controls
p2: Comparison between mixed ancestry patients and mixed ancestry controls
p < 0.05 considered significant
*p < 0.05
Φ: TSH was only measured in patients and not controls
5.4.5 The effect of diabetes on lipid and lipoprotein data in this cohort
There were no differences in any of the lipids and lipoproteins between the South 
African patients with Addison’s disease, with or without diabetes. As expected, 
the median RBG (IQR) was higher in the sub-group with diabetes mellitus (9.83 
mmol/L, range 5.86-12.58 mmol/L versus 5.27 mmol/L, range 4.74-6.30 mmol/L; 
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therapy compared with those diabetic patients on lipid-lowering therapy the 
median TG and IQR was {1.51 (0.90-2.6) mmol/L versus 1.83 (1.3-2.6) mmol/L; 
p = 0.36}, the mean (SD) {TC 5.30 (1.54) mmol/L versus 6.57 (2.14) mmol/L; p 
= 0.17}, median and IQR HDLC was {0.79 (0.73-1.03) mmol/L versus 0.65 (0.4-
1.6) mmol/L; p = 0.64} and mean (SD) LDLC was {3.72 (1.53) mmol/L versus 
4.81 (1.67) mmol/L ; p = 0.19}. The NEFA did not differ in these two groups; p = 
1.0. Overall there were no differences in the lipid and lipoprotein concentrations 
between the diabetic sub-groups on lipid-lowering therapy and those without. 
However, values before and after initiating lipid-lowering therapy were not 
available. These findings may be due to confusion caused by the lipid-lowering 
treatment, as there is an inherent bias towards treating diabetic patients with 
lipid-lowering therapy because it is a secondary prevention equivalent. Diabetics 
tended to have moderately raised TG levels and both moderate and severe LDLC 
elevation (Table 21). A mildly elevated TG level is expected with diabetes, along 
with lower HDLC, but this is not seen in this study, possibly because of the small 
numbers and other influences on lipid profiles. The reason for the elevated LDLC 
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Number N = 13 N = 83 N = 7 N = 27




























































































































Median: Age, BMI, TG, HDLC, LDLC, NEFA, RBG, hs-CRP and TSH
Mean: TC and LDLC
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TG: Triglyceride
TC: Total cholesterol
HDLC: High density lipoprotein cholesterol
LDLC: Low density lipoprotein cholesterol
NEFA: Non-esterified fatty acids
RBG: Random blood glucose
hs-CRP: Highly sensitive C-reactive protein
TSH: Thyroid stimulating hormone
IQR: Interquartile range
SD: Standard deviation
p1: Comparison between white patients and white controls
p2: Comparison between mixed ancestry patients and mixed ancestry controls
p < 0.05 considered significant
*p < 0.05
5.4.6. General applicability of white and mixed ancestry control data
The white control subjects were compared to the white community study (CORIS) 
and the mixed ancestry control subjects were compared to the mixed ancestry 
community study (Mamre).18 24 The mixed ancestry control subjects differed from 
the community study, in that they had higher TC, lower HDLC and higher LDLC 
levels. The proportion of subjects with high TG was greater in the mixed ancestry 
control subjects compared to the mixed ancestry community study. This may 
be due to considerably higher BMI levels in the mixed ancestry control subjects 
(31.2 kg/m2) compared to those in the Mamre community study (24.5 kg/m2). 
Therefore, the lipid and lipoprotein data from the mixed ancestry controls may not 
be applied to all the mixed ancestry in South Africa, while the data from the white 
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5.4.7 The description of lipid and lipoprotein data among black and Asian 
patients enrolled in the South African Addison’s study 
As there were few Asian and black patients among the South African Addison’s 
disease patients (n = 5 and n = 11 respectively), they were not matched to controls 
(Table 26). The mean TC of black patients with Addison’s disease appears to 
agree with the two separate community studies of black South Africans.25 26 The 
TG and HDLC levels among Asian patients were strikingly abnormal, with the 
median TG and HDLC being 2.83 mmol/L and 0.66 mmol/L respectively. All of the 
Asian patients had LDLC of >3.0 mmol/L, TG of >1.7 mmol/L and HDLC of <1.0 
mmol/L, and 75% had TC of >5 mmol/L. While the Asian sub-group of Addison’s 
patients was very small, a significant proportion had an adverse lipid profile, 
unlike the black patient cohort, in which 33-50% had abnormal lipid parameters. 
Formal statistical comparison with other ethnic groups is not of value because of 
the small numbers of Asian and black subjects. However, on inspection, the Asian 
sub-group was older than the white and mixed ancestry subjects, while the black 
sub-group were younger than both the white and mixed ancestry patients. The 
Asian patients appeared thinner than the white and mixed ancestry patients; while 
by comparison, the black patients were extremely lean. TG was elevated in Asian 
patients, compared to the black patients, but the TG in black patients was similar 
to both white and mixed ancestry patients. The TC in Asian patients appeared 
greater than in white patients, but similar to the mixed ancestry patients, whereas 
the TC of black patients was considerably lower than both the white and mixed 
ancestry patients. The HDLC of Asian patients was lower than that of both the 
white and mixed ancestry patients. The HDLC found in black patients appeared 
to be greater than the other ethnic sub-groups. LDLC was found to be higher in 
the Asian patients compared to white and mixed ancestry patients. Although there 
were only a few black patients, they exhibited much lower LDLC concentrations 
than the other ethnic sub-groups. While no Asian patients with small dense LDL 
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LDL was similar to both the white and mixed ancestry patients. 
The RBG of Asian patients was higher than the sub-groups of the white and mixed 
ancestry patients, even though none of the Asians was known to be diabetic, 
but the black patients exhibited similar RBG to the white and mixed ancestry 
patients. The hs-CRP appeared to be markedly elevated in the Asian sub-group 
compared to the other sub-groups, while the black sub-group demonstrated the 
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Table 26: Description of lipid and lipoprotein data in the Asian and black sub-groups with Addison’s 
disease
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Median: Age, BMI, TG, HDLC, LDLC, NEFA, RBG, hs-CRP and TSH
Mean: TC and LDLC
BMI: Body mass index
TG: Triglyceride
TC: Total cholesterol
HDLC: High density lipoprotein cholesterol
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NEFA: Non-esterified fatty acids
RBG: Random blood glucose
hs-CRP: Highly sensitive C-reactive protein
TSH: Thyroid stimulating hormone




n: Total number of patients failing to achieve lipid targets
N: Total number of patients in these two ethnic groups
σ: Numbers too few to calculate median, therefore individual values are provided
5.4.8 Comparisons between patients and controls, according to the targets 
of the NCEP ATP III criteria
As shown in Table 27 the proportions of patients not achieving TG, TC, LDLC 
targets, according to NCEP ATP III guidelines,20 were no different in white and 
mixed ancestry  patients compared to their respective controls. The proportions of 
patients whose HDLC was <1.0 mmol/L were significantly higher in white patients 
compared to their respective controls only, while greater proportions of the mixed 
ancestry patients had abnormal hs-CRP levels, compared to their respective 
controls. 
As mixed ancestry patients were previously disadvantaged and may not have 
enjoyed the same level of health-care as white patients, the extent to which these 
ethnic groups differed in failing to achieve NCEP ATP III targets were compared 
and  no differences were noted in control of TG, TC, HDLC and RBG.  The 
proportion with an abnormal hs-CRP was greater in the mixed ancestry patients, 
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Table 27: Comparisons of the proportion of patients and their respective controls, according to 
the cutpoints of the NCEP ATP III recommendations,20 as well as RBG and hs-CRP
Variable Proportion of white patients 
n/N (%)  versus white controls 
n/N (%)
Proportion of mixed ancestry 
patients n/N (%) versus mixed 
ancestry controls  n/N (%)
TG > 1.7 mmol/L 41/87 (47) vs. 34/97 (36)
p = 0.1
16/30 (53) vs. 10/32 (31)
p = 0.1
TC > 5 mmol/L 59 /86 (69) vs. 81/ 97 (84)p = 0.43
19/30 (63) vs. 18/34 (53)
p = 0.56
HDLC < 1.0 mmol/L 56/77 (72) vs. a 18/63 (29)
p = 0.0001*
20/26 (77) vs. 16/28 (57)
p = 0.21
LDLC > 3 mmol/L 55/74 (74) vs. 52/63 (83)
p = 0.34
21/26 (81) vs. 20/28 (71)
p = 0.23
RBG > 11.1 mmol/L 6/85 (7) vs. 1/96 (1)p = 0.08
4/30 (13) vs. 0/33 (0)
p = 0.09
hs-CRP > 4.5 mg/L 25/97 (26) vs. 15/97 (15)p = 0.11




HDLC: High density lipoprotein cholesterol
LDLC: Low-density lipoprotein cholesterol
RBG: Random blood glucose
hs-CRP: Highly sensitive C-reactive protein
vs.: versus
p < 0.05 considered significant
*p < 0.05
NCEP: National Cholesterol Education Programme
ATP III: Adult Treatment Panel III
n: Total number of patients who failed to achieve recommended lipid targets
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5.4.9 Patients using lipid-lowering therapy failing to achieve NCEP ATP III 
targets
Bias was likely because the patients using lipid-lowering therapy also received 
their medical care through private, rather than state facilities. 88% of the patients 
on lipid-lowering therapy had persistent levels of TC >5.0 mmol/L and 81% had 
persistent LDLC of >3.0 mmol/L, indicating that treatment for CV risk was not 
aggressively undertaken or that treatment compliance was incomplete (Table 
28). Achievement of TG and LDLC targets did not differ in patients using or not 
using lipid-lowering therapy. On the other hand the proportion of patients who 
failed to achieve target TC was greater in those on lipid-lowering therapy than 
those patients not on this treatment. Patients not on lipid-lowering therapy had 
a higher proportion whose HDLC was <1.0 mmol/L. All patients not on lipid-
lowering therapy should be assessed for their global CV risk because adverse 
lipid profiles are highly prevalent in this disease group. It is speculated that the 
lipid-lowering therapy may have been initiated in patients with poorer baseline 
lipid concentrations, than those who were not on this medication.
Table 28: Comparison of the lipid data of patients using lipid-lowering therapy versus those 
patients not on lipid-lowering therapy, using NCEP ATP III guideline criteria20
Variable Lipid - lowering therapy
n/N (%)
Not on lipid - lowering 
therapy n/N (%)
p - value
TG >1.7 mmol/L 12/18 (67) 50/108 (46) 0.17
TC > 5.0 mmol/L 16/18 (88) 68/108 (63) 0.03*
HDLC < 1.0 mmol/L 7/17 (41) 71/95 (75) 0.006*
LDLC > 3.0 mmol/L 13/16 (81) 67/91 (74) 0.11
TG: Triglycerides
TC: Total cholesterol
HDLC: High density lipoprotein cholesterol
LDLC: Low-density lipoprotein cholesterol
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ATP III: Adult Treatment Panel III
n: Total number of patients failing to achieve lipid targets
N: Total number of patients with available data either on or not on lipid-lowering therapy
p < 0.05 considered significant
*p < 0.05
5.4.10 The relationship between hydrocortisone and lipid fractions and 
other markers of cardiovascular risk
The relationship between the hydrocortisone dose, lipid fractions and other 
parameters of CV risk was assessed  by linear regression analyses. As has 
been previously demonstrated in the literature, HDLC is also positively correlated 
with hydrocortisone in this study (r = 0.3; p = 0.003). Glucose is also positively 
correlated with hydrocortisone dose (r = 0.32; p = 0.001), but TSH is negatively 
correlated with hydrocortisone dose (r = -0.20; p = 0.03). These relationships 
of total daily hydrocortisone dose with HDLC, RBG and TSH are expected 
physiologically. When the dose of hydrocortisone was corrected for body weight, 
TG (r  =  -0.24; p = 0.01) and hs-CRP (r =  -0.3; p = 0.001) were negatively 
associated for hydrocortisone, while HDLC remained positively associated, (r = 
0.38; p = 0.0001).  
5.5 Comparison of the sub-group of South African Addison’s disease 
patients matched with the Swedish cohort
As seen in Table 29, the sub-group of South African Addison’s disease patients, 
who were matched for ethnicity, gender, age and BMI with the Swedish Addison’s 
patients, demonstrated an adverse lipid profile with lower doses of hydrocortisone. 
When patients on lipid-lowering therapy were excluded, TC, LDLC and HDLC 
remained different, while TG did not. The other CVD risk factors were however, 
similar in both cohorts. Although quality control should ensure comparability of 
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this could influence the findings. The implication is that South African Addison’s 
disease subjects could have a much higher CV risk, as each of the lipid and 
lipoprotein parameters is far worse. The general applicability of this comparison 
to the whole study of matched Swedish and South African patients was assessed 
between the South African white patients who were included and those who were 
excluded. Although only age differed significantly, the general findings are likely 
applicable.














Age (years) 53.1 14.5 53.1 13.3 0.97
BMI (kg/m2) 25.8 4.1 25.6 3.6 0.72
TG (mmol/L) 1.9 1.1 1.3 0.8 0.002*
TC (mmol/L) 6.0 1.5 5.2 0.9 0.001*
HDLC (mmol/L) 0.8 0.4 1.9 0.5 0.001*








0.08 0.05 0.08 0.04 0.59
Disease duration 
(years) 14.8 11.6 17.8 11.7 0.17
Smoking N (%) 5 (9) 4 (7) 0.72
Hypertension N (%) 11 (19) 11 (19) 0.1
Diabetes N (%) 12 (21) 10 (18) 0.64
Lipid-lowering 
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N = 57 
N: Number
SD: Standard deviation
BMI: Body mass index
TG: Triglyceride
TC: Total cholesterol
HDLC: High density lipoprotein cholesterol
LDLC: Low-density lipoprotein cholesterol
α: Swedish patients were matched with South African patients by age, gender, ethnicity and BMI
p < 0.05 considered significant 
*p < 0.05
Ψ: Means are used, irrespective of the distribution, in order to enable comparisons with the 
Swedish data set
5.6 The associated factors for a low HDLC in the cohort of South African 
Addison›s patients
The associations of a low HDLC for the entire cohort were youth, low hydrocortisone 
dose and small dense LDL (Table 30). 
Table 30: Comparison of clinical characteristics with respect to HDLC of <1.0 mmol/L
Characteristic HDLC  < 1.0 mmol/L HDLC  ≥ 1.0 mmol/L p-value
HDLC <1.0 mmol/L 
versus
HDLC ≥1.0 mmol/L
Age years (IQR) 43.0 (31.5-61.0) 54.0 (40.3-62.0) 0.04*
Gender
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Median: age, BMI and total daily dose of hydrocortisone
BMI: Body mass index
HDLC: High density lipoprotein cholesterol
IQR: Interquartile range
N: Number
p < 0.05 considered significant
*p < 0.05
In the multivariate model examining the predictors of HDLC <1.0 mmol/L, age 
and LDL particle size remained independently significant, but hydrocortisone 
dose was no longer significant (Table 31).



















0.95 (0.91-0.99) 0.04* 0.95 (0.93-1.00) 0.05
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5.7 Predictors for elevated triglyceride (TG) levels in the South 
African Addison’s disease patients
The associations for TG >1.7 mmol/L were small/intermediate dense LDL particle 
size, elevated BMI and increased age (Table 32). 
Table 32: Comparison of clinical characteristics, with respect to TG level of >1.7 mmol/L
Characteristic TG > 1.7 mmol/L TG ≤ 1.7 mmol/L p-value





































21.25 (15.0-30.0) 22.5 (20.0-30.0) 0.64
Median: Age, BMI and total daily hydrocortisone dose
TG: Triglyceride
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In the multivariate model examining the predictors of TG >1.7 mmol/L, age and 
LDL particle size were independently predictive of TG >1.7 mmol/L, but the BMI 
was no longer independently significant (Table 33).
Table 33: Univariate and multivariate Cox hazards regression analyses of predictors of TG >1.7 
mmol/L
Variable Univariate analysis 
odds ratio (95% CI)
p1-value Multivariate 
analysis
odds ratio (95% CI)
p2-value
Age 1.02 (1.00-1.04)    0.02* 1.03 (1.01-1.05) 0.02*














CI:  Confidence interval
p < 0.05 considered significant
*p < 0.05
**p < 0.0001
The atherogenic profile of a low HDLC, higher TG and small dense LDL is similarly 
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5.8 Discussion
5.8.1 Summary of findings
The findings of this study may be summarised as follows:
1. The lipid profiles of the South African patients with Addison’s disease 
were highly variable, reflecting a heterogeneous group. Although 
few (n = 19) of the patients were on lipid-lowering therapy, of these, 
88% had a TC of ≥5 mmol/L and 81% had a LDLC of >3.0 mmol/L, 
indicating incomplete control. In the entire group of Addison’s patients, 
almost 50% had hypertriglyceridaemia, defined as TG >1.7 mmol/L, 
since less than 1.7 mmol/L is considered ideal. Approximately 65% 
had hypercholesterolaemia (>5.0 mmol/L) and about 75% had low 
HDLC (<1.0 mmol/L), with many individuals having strikingly low 
levels. Approximately 75% had higher than ideal LDLC (>3.0 mmol/L). 
The proportions in these categories were similar in white and mixed 
ancestry sub-groups. Other ethnic groups were too small to analyse.
2. Among the diabetics, there was an increase in moderate 
hypertriglyceridaemia and an increase in severe LDL 
hypercholesterolaemia. Diabetic patients not receiving lipid-lowering 
therapy were no different in their manifestation of dyslipidaemia from 
those that were receiving lipid-lowering therapy, indicating only partial 
correction. Peculiar to the mixed ancestry subjects, diabetes was 
associated with higher LDLC concentrations (Table 25).
3. Ethnic differences were identified. White patients with Addison’s 
disease had decreased HDLC, increased small LDL and increased 
hs-CRP, compared to white controls. In the mixed ancestry patients, 
increased TG, decreased HDLC, both small LDL and hs-CRP were 
increased, compared to their mixed ancestry control subjects.
4. GC treatment appeared to influence some of the metabolic parameters. 
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body size, TG and hs-CRP were negatively correlated, but HDLC was 
positively correlated.
5. When comparing the South African sub-group of Addison’s patients 
with the matched Swedish sub-group, the former group displayed 
higher TG, TC and LDLC, but lower HDLC. However, importantly, they 
were managed on lower hydrocortisone doses.
6. A large portion of patients and their respective controls did not achieve 
recommended lipid and lipoprotein NCEP ATP III targets, as analysed 
in the sub-group on lipid-lowering therapy and those not using lipid-
lowering therapy. A greater proportion of white patients, compared with 
their controls failed to achieve an HDLC >1.0 mmol/L.
Some of the cardinal findings and other issues are discussed below.
5.8.2 The dyslipidaemias
The wide range of dyslipidaemias identified within this cohort is not surprising, 
given the variability of environmental and genetic factors, as well as secondary 
influences, which can modulate the lipid profiles. Evaluation is further complicated 
by some patients’ treatment. The doctors who referred their patients for the study 
did not assess them for causes and treatment of dyslipidaemia, so that detailed 
analysis on this topic is not possible. As discussed below, there are also limited 
data on healthy free-living individuals’ lipid profiles in South Africa. Additionally, an 
effort was made to obtain the best possible controls for patients, but this matching 
process was imperfect as the controls were selected from the blood donor clinic, 
which represents a restricted pool from which healthy subjects could be chosen. 
Taking these difficulties into account, the findings of interest are discussed below.
5.8.3 Normative lipid data in South Africa
A number of community-based studies for each of the white, mixed ancestry, 
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studies were relatively small and were also conducted a long time ago. Since that 
time, many socio-economic changes have occurred.  Although it could be said 
that there are no current normative values for appropriate and comprehensive 
comparisons,  the CORIS, CRISIC, BRISK and Mamre studies were the only 
studies available  to contrast patients with Addison’s disease to people without 
the disease. Additionally, other controls were enrolled to match with the patients 
in a more deliberate fashion to ascertain whether real differences exist.
The mean HDLC was considerably lower in the white Addison’s disease subjects 
compared to healthy controls. This could powerfully raise the risk of accelerated 
atherosclerosis within the usual population range of LDLC. Among white patients, 
the fundamental difference was that the hs-CRP was higher than their controls. 
When the mixed ancestry participants in the South African Addison’s study were 
compared to their respective controls, the most important differences were higher 
TG, hs CRP concentrations and lower HDLC levels in the patient population 
compared to their controls. These changes promote atherosclerosis.
5.8.3.1 The importance of low HDLC
The finding that 75% of the cohort had an HDLC of <1.0 mmol/L is striking. This 
finding is generalised across the ethnic spectra. A systematic problem such as 
aged or improper handling of samples from the Addison’s patients may apply, 
but the same laboratory was also used for controls, making the method used an 
unlikely explanation. HDLC metabolism is complex and is altered by the acute 
phase response. Low levels of HDLC have been found in critically ill patients 
with adrenal dysfunction. ApoAI concentration is also reduced, along with HDLC 
in the acute phase.28 Adrenal function relies, at least in part, on HDL as the 
source of cholesterol for cortisol synthesis.29 Acute phase response has been 
shown to increase HDL catabolism, producing a decreased plasma HDL level. 
A higher TG concentration also occurs typically in the acute phase response, 
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into HDL and subsequent lipolysis by hepatic lipase, accounting for lower HDLC 
concentration and small particle size.28 30 A plausible mechanism for the observed 
reduction in HDLC was offered by Beentjes et al. He showed that hypopituitary 
patients who were not supplemented with growth hormone, and were evaluated 
before and after receiving GC replacement, had a decreased plasma cholesterol 
esterification, and thus, HDL production could be impaired in Addison’s disease 
patients. The action of GC replacement to decrease LCAT activity largely explains 
this phenomenon.31
Other endocrine deficiencies or factors may also influence lipoprotein metabolism. 
Hypothyroidism does not explain the low HDLC concentration in this Addison’s 
disease cohort, since the majority (82%) were euthyroid. Only a minority of 
patients were diabetic, making this disorder an unlikely contributor to low HDLC. 
Smoking has been found to reduce levels of HDLC, but the prevalence of smoking 
was only 8% in this cohort, and thus, cannot account for the very low HDLC 
levels. Nevertheless, smoking cessation should be encouraged as HDLC may be 
increased by 0.1 mmol/L.32 Although visceral obesity is a powerful determinant 
of low HDLC,33 this parameter was not evaluated specifically. The patients and 
controls were matched for BMI, which is a guide to visceral obesity, making this 
parameter an unlikely explanation for the reduced HDLC. It is known that HDLC 
is lower in the male gender, and for this reason, HDLC was analysed separately 
in males and females. No gender differences were found in this study. Other 
influences such as TG, dysglycaemia, alcohol consumption (not assessed in this 
study) and postmenopausal status should also be considered.34
Despite the expected pharmacological consequences of GCs of raising HDLC,8 
10 31 35-41 strikingly low HDLC was observed. Nevertheless, a positive correlation 
between hydrocortisone dose and HDLC was found in this study, however, HDL 
still remains responsive to GC doses, indicating that there is an explanation for 
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hydrocortisone, but there is insufficient evidence for this. Particularly in elderly 
subjects, endogenous cortisol levels were also positively correlated with HDLC.42 
In the univariate analysis of the South African Addison study, lower age, lower 
total daily hydrocortisone doses and increased small dense LDL were associated 
with low HDLC. The latter is a well-known association. Younger age may be 
associated with different underlying aetiology of Addison’s disease, although it 
is not obvious why this should influence HDLC (Chapter 4). In the multivariate 
analysis that incorporated these factors, hydrocortisone dose was no longer 
independently associated with a decreased HDLC. On the other hand, the small 
dense LDL is likely to have an association with low HDLC due to the metabolic 
mechanism(s), rather than being causal, because TG exchange will provide a 
mechanism for both particles to be modulated by hepatic lipase.43
The explanation for the protective mechanism of HDLC against atherosclerosis lies 
in its reverse cholesterol transport action. In this action, cholesterol is transferred 
from the peripheral cells to the liver, where cholesterol, as well as its product 
bile acid, are ultimately excreted into the gastrointestinal tract.44 Additionally, 
HDL has anti-inflammatory properties, and thus, acts to reduce atherosclerosis. 
Experimentally, endothelial function is also modulated by HDL.45 Visceral obesity 
appears to be a powerful influence on HDLC. A meta-analysis revealed an 
increase of 0.007 mmol/L of HDLC for every 1 kg of body mass lost. Diets high 
in saturated and omega-3 fatty acids, but low in carbohydrates, may contribute 
to increasing HDLC.33 46 The benefits of mild to moderate alcohol intake are well-
established and include the raising of HDL.47 Recently, pharmacological therapy 
has been directed at raising HDLC by CETP inhibition, but this did not lower the 
CVD event rate. HDLC elevation by this mechanism should not be endorsed to 
raise HDL until further insights are gained.48
The low HDLC in patients with Addison’s disease is unexplained and certainly not 
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favourably. If this association is confirmed in the future, detailed studies are 
required to understand the reason for the low HDLC implications of the disease 
and CV prognosis.
A low level of HDLC is an independent risk factor for the development of CVD. 
HDLC levels of <1 mmol/L are strongly predictive of CVD events.49 50 A reduction 
of HDLC by 0.03 mmol/L, increases the risk of a CVD event by 23%, and by 
implication, the low HDLC on its own could accord a 20% increase in CVD events 
in this South African cohort of Addison’s patients.51 A low HDLC concentration 
has also been recognised as an independent CVD risk factor by the NCEP, which 
advises a HDLC threshold of <1.03 mmol/L as a potential target for therapy.20
5.8.3.2 The finding of hypertriglyceridaemia among South African Addison’s 
disease patients
Half of the South African Addison’s disease patients had TG concentrations that 
were not ideal, representing another independent risk factor of CVD.52 There are 
multiple studies corroborating the direct link between an elevated TG concentration 
and CVD. In the Prospective Cardiovascular Münster Heart (PROCAM) study, 
4 849 middle-aged men were followed for up to 8 years, and a significant 
association between coronary heart disease and TG, independent of LDLC and 
HDLC, was found.53 A meta-analysis of 21 population-based prospective studies, 
involving 65 863 men and 11 089 women has provided credence to the dogma 
that a relationship exists between CVD and TG levels. In this relationship, each 
1 mmol/L of TG conferred a 32% and 76% increase in coronary heart disease 
risk among men and women respectively, adjusted for TC, LDLC, HDLC, BMI, 
blood pressure and diabetes mellitus, which are all potential factors known to 
influence TG.54 The multivariate analysis of this study of Addison’s disease in 
South Africa confirmed that age and LDL species were independently predictive 
for a raised TG level. Plasma TG, along with CETP and hepatic lipase, will result 
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BMI, was no longer independently predictive for TG in the study of Addison’s 
disease in South Africa. A population-based survey in the USA confirmed that 
30% of participants, in a total cohort of 8 814 who were all older than 20 years 
of age, had TG levels of >1.69 mmol/L. In participants older than 50 years of 
age, the prevalence of hypertriglyceridaemia was 42.8%.56 In addition to age, TG 
levels are influenced by increasing BMI, waste-to-hip ratio, dysglycaemia, drugs 
and hypothyroidism.57 As the majority of the Addison’s patients were matched for 
age and BMI (in the white and mixed ancestry groups), these factors could not 
account for this elevation in TG. Moreover, the patients with diabetes showed no 
differences in their lipid profiles compared to the rest of the cohort. Similarly, it is 
unlikely that the hypertriglyceridaemia is attributable to primary hypothyroidism, 
as only 5% of the cohort had a TSH above the upper range of normal (4.94 
mIU/L). While the metabolic syndrome, renal disease, T2DM and obesity may all 
result in hypertriglyceridaemia,58 specific evidence for renal disease in this cohort 
was not sought, but it was unlikely to be present to a significant extent.
Although increased VLDL production may account for an elevated TG level resulting 
from hydrocortisone excess,4 7-10 59 there is no overt evidence for excessive GC 
replacement in this cohort, as hydrocortisone dose was not associated with TG 
levels. The presence of small dense LDL remained independently predictive for 
an elevated TG, but this is likely to be an association by mechanism, rather than 
being causal.43
Certain genetic defects may account for elevated TG levels, for example, apoE2/
E2 status, which occurs in 1:50 of the general population, can result in markedly 
elevated TG levels and low LDLC associated with small dense LDL species upon 
metabolic stress.60 When a metabolic stress occurs, lipoprotein lipase deficiency 
will manifest with elevated TG, low LDLC and small dense LDL, including an 
especially high dose of hydrocortisone. A genetic deficiency in hepatic lipase will 
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concentrations.61 The aforementioned genetic defects have not been tested in 
this cohort, and these uncommon or rare genes are neither expected to have a 
selection bias in this cohort nor influence the average significantly.62
The recommended interventions for borderline high TG (1.69-2.25 mmol/L) are 
lifestyle changes e.g. weight loss, regular physical activity, smoking cessation, 
restriction of calories and limitation of carbohydrate intake.20  When the TG 
levels are 2.26-5.63 mmol/L, HMG-CoA reductase inhibitors may be indicated 
to reduce non-HDLC, if the person is at high risk.  Fibrates are indicated when 
the levels of TG are higher, having excluded all the usual secondary causes for 
hypertriglyceridaemia.54
5.8.3.3 Small dense LDL among South African Addison’s disease patients
A significantly greater proportion of South African Addison’s disease patients 
had small dense LDL, compared to their controls. This may reveal yet another 
contributory factor in explaining the excess CV mortality associated with 
Addison’s disease. The ease with which small dense LDL can enter arterial tissue, 
compared to larger LDL particle sizes, may explain its link with the development of 
atherosclerosis,63 along with the greater susceptibility to oxidation and the metabolic 
milieu, which predisposes to small dense LDL. In the Quebec Cardiovascular 
Study, the combination of LDL size, apoB and LDL had a significant positive 
predictive value for CVD events, emphasising the importance of small dense 
LDL, in association with other lipid parameters, as a CV risk marker. When small 
dense LDL predominates, it confers about a 3-7-fold increased risk of coronary 
artery disease.63 Evidence indicates that LDL particle size is not an independent 
risk factor for CVD, but rather it is its association with low HDLC, high TG and 
the presence of hypertension, which in combination confer the greatest risk.64 
Similarly, the multivariate analyses in this study of Addison’s disease confirm that 
an independent predictor for both HDLC < 1.0 mmol/L and TG >1.7 mmol/L is a 
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factors and that a sub-set of Addison’s disease patients is at a particularly high 
risk of CVD.
In one review, the prevalence of small dense LDL was between 30% and 35% 
in adult men, between 5% and 10% in men older than 20 years of age, and 
between 5% and 10% in premenopausal women. The prevalence of small dense 
LDL in postmenopausal women in the same review was 15-25%.65 The estimated 
frequency of the putative gene(s) (Mendellian inheritance) related to small dense 
LDL was 15% in a USA cohort, but small dense LDL occurred in 25% of 61 
nuclear families, indicating that the clustering can occur within at-risk families.66 
The prevalence of small LDL particle size among the South African Addison’s 
disease patients was considerably greater than their respective controls (14% 
versus 3% among age-, gender-, ethnicity- and BMI-matched white patients, and 
17% versus 0% among mixed ancestry patients, compared to their respective 
controls). Among the South African Addison’s disease patients, 15% were found 
to have small dense LDL particle size, and in the corresponding categories as 
described by Rizzo et al,65 the prevalence was 12% among premenopausal 
women, 16% in postmenopausal women and 16% among men over the age 
of 20 years. Although the prevalence of small dense LDL in the general South 
African population is not known, it is expected to be about 15%66 and may double 
in people with diabetes. In this study of South African Addison’s disease, the 
proportion of patients with small dense LDL was 18% among diabetics not using 
lipid lowering therapy, raising the possibility that Addison’s disease may confer 
some protection against the formation of small dense LDL in diabetics, or that 
autoimmune diabetes may have a lower prevalence of small dense LDL.
5.8.3.4 The effect of diabetes on lipid abnormalities
Despite the relatively small number of patients with diabetes in this cohort, 
the presence of diabetes contributed to some of the abnormal findings. As 
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hypertriglyceridaemia (>2.3 ≤ 5.0 mmol/L). Elevated LDLC levels of >5.0 mmol/L 
is somewhat unexpected until a nephrotic syndrome sets in. Although diabetes 
became a secondary prevention equivalent in 2003,67 it was only accepted as 
such by cardiologists in South Africa in 2006.68 International and local guidelines 
for the management of lipids were not uniformly adhered to for diabetics in this 
South African study, irrespective of whether the patients were funded by the 
state or by private medical insurance. The observation that small dense LDL 
was increased in the general Addison’s subjects, but not in diabetic Addison’s 
disease subjects is of interest, albeit that it constituted a small group. This could 
be due to a fundamental derangement in lipoprotein modulation, caused by 
hypoadrenalism and/or its treatment. As indicated in the description of the whole 
study population, {(small dense LDL among South African Addison’s disease 
occurred in 22 patients (15%)}. There could be interesting differences in diabetics 
with Addison’s disease, favouring T1DM on an autoimmune basis and modulation 
of diabetes and complications by supra-physiological hydrocortisone therapy.
5.8.3.5 hs-CRP among South African patients with Addison’s disease
CRP is an acute-phase reactant protein that dramatically increases with tissue 
necrosis, as part of a generalised acute-phase response. Increases detected at 
low levels with highly sensitive assays can indicate CV risk.69 As far as is known, 
no previous study has examined hs-CRP status in Addison’s disease, except 
when the influence of DHEA was evaluated. In the study no change in hs-CRP 
was found and the mean hs-CRP was 1.4 (0.2-13.1) mg/L.70 The proportion of 
patients with elevated hs-CRP was considerably greater in the white and mixed 
ancestry patients compared to their respective controls. The high levels of hs-
CRP found in the South African Addison’s disease patients did not correlate with 
age, any of the lipid fractions, BMI, or Framingham risk. 
In the white and mixed ancestry Addison’s patients, the hs-CRP was higher than 
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such a way that the CRP production is down-regulated when a tissue necrotic event 
is encountered.38 71 In contrast to rheumatoid arthritis or SLE, Addison’s disease 
does not manifest with an overt inflammatory state.72 73 Autoimmune primary 
hypothyroidism is akin to Addison’s disease as there is no overt inflammation and 
much of the process has burned out by the time the diagnosis has been made. 
Among euthyroid Hashimoto’s thyroiditis sufferers, SAA, fibrinogen and ESR were 
elevated, but CRP was not. Therefore, it is not expected that the autoimmune 
process of Addison’s disease will raise the hs-CRP significantly. In this cohort, it 
remains difficult to elucidate whether the low-grade inflammatory state reflected 
by hs-CRP is a consequence of a systemic problem or the Addison’s disease per 
se, or relates to the treatment with GCs.72
There are also known ethnic differences with respect to hs-CRP, as African-
American women exhibit higher levels than white women. Nazmi et al showed that 
increased poverty and socio-economic factors may also account for increased 
hs-CRP levels.73 Higher levels were documented among mixed ancestry patients 
compared to white patients, and in the small Asian group, these levels were 
strikingly elevated, which may represent either ethnic differences or increased 
inflammation in this study of Addison’s disease. Appropriate cut-offs are unknown, 
as no population-based study of hs-CRP has been carried out in South Africa.
Anecdotal observations from this study revealed that a few patients died soon 
after recording strikingly elevated CRP. While the reliability of this finding for 
predicting death in this cohort remains to be determined, it is potentially a useful 
modality to detect a high risk immunocompromised individual, which a person 
with Addison’s disease represents. This has been corroborated by an analysis 
of death registers in Norway, in which 10% of deaths were ascribed to infection 
and secondary to adrenal gland failure per se.1  Addison’s disease patients may 
present with occult sepsis, as they often fail to manifest with the usual signs 
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severe, but unrecognised illnesses that require treatment, including increases 
of hydrocortisone supplementation. The significance of finding an elevated hs-
CRP will need to be investigated in long-term studies of Addison’s patients to 
determine if it translates into accelerated CVD morbidity and mortality.
5.8.3.6 NEFA among South African Addison’s disease patients
NEFA was significantly lower in white patients compared to their respective 
white controls. The association with NEFA release and sympathetic tone is 
well-established.74 In many cases of long-standing Addison’s disease, adrenal-
medullary destruction occurs, making the lower level of NEFA that was found 
in our cohort, compared to their controls, not altogether surprising.75 Though 
hormone-sensitive lipase may not be suppressed in diabetics, leading to increased 
NEFA flux to the liver and consequent overproduction of VLDL, diabetic white 
and mixed ancestry subjects did not have higher NEFA concentrations compared 
to non-diabetic Addison’s patients (Table 26). There could be blunting of NEFA 
release in Addison’s disease. Despite the lower levels of NEFA in Addison’s 
patients compared to controls, NEFA was positively associated with TC and 
LDLC. Plasma cholesterol esterase activity is also positively correlated with 
TC and LDLC. Therefore, it is entirely plausible that ongoing enzymatic action 
of cholesterol esterase could have continued in the samples of the Addison’s 
patients that may have been incorrectly frozen to account for the NEFA association 
with TC and LDLC.23 Low concentrations and mismatch of GCs to stress could 
influence the endothelial cells to promote atherosclerosis in the setting of co-
existing risk and contributing factors. While NEFA levels are correlated with CVD 
death, the findings in this study demonstrate levels that are lower than healthy 
control subjects. However, it has not yet been determined whether a low NEFA 
concentration is protective against CVD. Even if this is proven to be the case, the 
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5.8.3.7 Comparison of the lipid and lipoprotein data of Swedish and South 
African Addison’s disease patients
South African Addison’s disease patients demonstrated an adverse lipid profile. 
They also took lower replacement doses of hydrocortisone compared to their 
Swedish counterparts. Relative to the Swedes, the South African cohort had 
higher TC (13%), TG (32%), LDLC (39%) and lower HDLC (137%) levels (Table 
30). Whilst some of these changes may be within the range of variation of 
laboratory analyses, the TG, LDLC and HDLC differences are striking. The only 
expected difference was in TG concentration, because unlike the Swedes who 
fasted, the South African cohort had random samples. This is the first study to 
examine the lipid profiles of patients with Addison’s disease in two geographically 
distinct cohorts. The adverse profile documented in the South African Addison’s 
disease patients is seen despite careful matching of patients with respect to age, 
gender, ethnicity and BMI. The prevalences of smoking, hypertension, diabetes 
and lipid-lowering therapy were similar in both groups, but it is uncertain to what 
extent lifestyle, socio-economic status, genetics and levels of health-care factors 
may have contributed to this adverse lipid profile.
A potential weakness of this sub-study is the fact that the lipid analyses were 
conducted in two separate laboratories. Although the differences in the results 
between the two laboratories were not analysed by exchanging samples, 
results should be comparable by using internationally accepted calibrators. 
The differences between the different laboratories in Sweden and South Africa 
should be small if proper quality control was exercised. The University of Cape 
Town laboratory used Precinorm (Boehringer Mannheim GmbH, Mannheim, 
Germany), which has international consensus values for plasma lipids, but 
the magnitude of the potential difference is acceptable at 10% for the range of 
accepted readings, as stated in the package insert. Compared to the other lipid 
fractions, the potential variability in HDLC is the greatest and it is also likely to 
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as well as that in non-fasted TG, may also influence the LDLC calculation. The 
heparin-Mn chloride methodology of HDLC evaluation produces lower values, 
compared to homogenous assays used in automated machines. The magnitude 
of variance between the two cohorts is too great to be explained by the differences 
in methodology alone. A prospective study using a single laboratory is advised in 
the future, to confirm and investigate this finding.
The prevalence of primary hypercholesterolaemia and significant 
hypertriglyceridaemia is 14% and 3% respectively in the sub-group of South African 
patients that were matched for the Swedish patients. Interestingly, the mean 
TC identified in the Swedish cohort is considerably more favourable compared 
to the MONICA population-based survey in Northern Sweden.76 Nevertheless, 
it appears that the South African Addison’s disease patients have a greater 
proportion with neglected levels of cholesterol. Poor lifestyle may significantly 
contribute to the dyslipidaemia and CV risk. Reddy et al predicted a rise in burden 
of CVD in the Third World, in association with early-onset vascular events.77 The 
Scandinavian countries by comparison, have enjoyed long-standing emphasis on 
reducing CV risk factors. The 4S study has been pivotal in raising awareness and 
detection of lipid abnormalities in Northern Europe,78 and could have influenced 
the Swedish population favourably. Mass screening of patients in South Africa for 
lipid abnormalities has not been encouraged and it represents a deficiency in this 
health system. Specifically, lifestyle factors such as exercise and diet were not 
analysed in this study, but it is conceivable that in First World countries, greater 
willingness exists among the public to pursue physical activity and healthier food 
options.
It is possible that the higher doses of GCs in Sweden, relative to the South African 
cohort, may increase the HDLC through a reduction of hepatic lipase and CETP 
activity.39 South Africa has been identified as an important geographical area for 
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Afrikaans-speaking citizens.79 Thus, by random selection and by virtue of the 
sporadic nature of Addison’s disease, finding a significant number of patients 
with genetic dyslipidaemias among this small cohort is unlikely. The observation 
that the South African cohort had, on average, a lower exposure to GCs, could 
not account for the wide array of lipid abnormalities. In the Swedish-South 
African comparative study, the proportion of subjects treated with lipid-modifying 
drugs was similar in the two groups and could not clarify the differences seen in 
these respective lipid profiles. It is possible that the South African and Swedish 
cohorts may include minor genetic traits, which could potentially influence the 
lipid profiles. However, this again is not subject to selection bias. The difference 
found between the Swedish and the South African Addison’s disease patients 
is most likely explained by the economic and lifestyle differences. The diet is 
likely to be different between the Swedish and the South African cohorts, with the 
South African cohort consuming more saturated fat and cholesterol.80-82 Lack of 
education, economic reasons and availability of certain foods may account for this 
difference. Detailed dietary questionnaires in the future may assist in unravelling 
the reasons for these striking differences.
5.8.3.8 Cardiovascular risk
The way that an artery responds to an atherogenic process that involves 
lipoproteins and oxidative stress could be influenced by Addison’s disease per se. 
Cholesterol esterase may have modified NEFA concentration in vitro, but its effect 
in vivo should also be considered, as it influences the processing of lipoproteins 
and sphingomyelin-ceramide signalling systems. Not only is cholesterol esterase 
expressed in endothelial cells,83 but it may also have a GC response element.84 
Therefore, as atherosclerosis is an inflammatory process, a deficiency of GCs, 
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The findings of this study may explain the findings of an earlier single study 
emanating from Sweden. In this study, Addison’s patients on stable doses of 
hydrocortisone replacement have twice the CVD mortality compared to the 
background population.2 The lipid and lipoprotein data of patients disclose variable, 
but often atherogenic profiles, which compared unfavourably with their respective 
controls and limited South African normative data. Additionally, compared with 
Swedish Addison’s disease patients that were matched for gender, ethnicity and 
BMI, South African Addison’s disease patients had considerably more atherogenic 
lipid profiles. The Framingham risk was negatively correlated with hydrocortisone 
doses, which suggests that hydrocortisone may either ameliorate risk or that a 
lack of hydrocortisone promotes risk.
This is one of the first studies that attempts to determine the reason(s) for the 
significant CVD mortality among Addison’s disease patients. In a recent study,85 
Addison’s patients, compared to controls whose glucose levels were no different, 
had a higher proportion who were hypercholesterolaemic (18% vs. 8%) and had 
hypertriglyceridaemia (18% vs. 8%). However, none of these Addison’s patients 
demonstrated an HDL of <1.036 mmol/L or an LDL of >5.51 mmol/L, which 
is in sharp contrast to this South African Addison’s disease study, in which a 
significant proportion had either abnormally elevated LDL or reduced HDL levels. 
Gurnell et al86 investigated the effect of DHEA supplementation in patients with 
Addison’s disease and did not find abnormalities in lipid profiles before or after 
DHEA supplementation. The combination of small dense LDL, low HDLC and an 
elevated TG has been designated as the atherogenic lipoprotein phenotype.85 
Both white and mixed ancestry patients had more small dense LDL compared to 
local controls. Whilst there was no significant difference in TG in white patients 
compared to controls, the mixed ancestry patients displayed raised TG. Both 
white and mixed ancestry patients, when compared to controls, displayed low 
HDLC. It is thus possible that the atherogenic lipoprotein phenotype applies to 
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The proportion of the cohort with Framingham risk of >20% CVD risk in 10 years 
was 36%. The average cohort 10-year interval risk of CVD for a median age of 
46 years was 13.3% and was worse for diabetics (25.4%). This is considerably 
greater than the available comparative data from the USA, which reflects a 8% risk 
for men and 3% for women in the age group approximately 46 years of age.13 The 
Framingham risk is derived from data that was probably collected in the absence 
of Addison’s disease and it may not be applicable to Addison’s disease patients. 
Judging from the increased mortality in the Swedish study,2 the risk calculation 
is likely to underestimate CVD. Although the Framingham risk prediction has 
not been formally validated in South Africa, the prediction will reflect the trend, 
even if it lacks accuracy. In a follow-up study of the Framingham cohort, hs-
CRP predicted the risk of death, but not of major CV events, and only showed 
moderate improvement over the conventional risk factors.87 A few patients in this 
South African Addison’s disease study with severe elevations of CRP suffered 
imminent death, the causes of which were likely to be conditions other than 
vascular disease, although in one patient, the cause was due to a cerebrovascular 
accident. It is therefore questionable whether hs-CRP in Addison’s disease is 
reliable for predicting CV risk.
It remains difficult to unravel the precise cause or causes for the atherogenic 
dyslipidaemia in this cohort. There are multiple factors that could account for 
increased CVD. It is clear that Addison’s patients demonstrate multiple CV risk 
factors, but only CV endpoint and mechanistic studies can confirm this. Addison’s 
disease patients with moderate dyslipidaemia should be considered for lipid-
modifying therapy, as they may have a higher than expected CVD risk than 
predicted by the Framingham risk scores. Other parameters such as vascular 
imaging should be used as an adjunct to assessing risk. While the HDLC was 
lower than expected, there is a correlation with total daily hydrocortisone dose and 
this may need mechanistic and therapeutic assessment. The changes in lipids 
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hydrocortisone, but several other influences could also be operating.
There is sufficient evidence, based on this Addison’s disease study, for clinicians 
involved in the management of patients with Addison’s disease to consider that 
they are at a higher than average risk of CVD. Although the Framingham risk for 
CVD may be determined by meticulous assessment, this may be an underestimate. 
Pharmacotherapy permits the treatment of risk factors, for example, hypertension 
and hypercholesterolaemia, which should be used in conjunction with lifestyle 
modification.88 In addition, evaluation of the lipid and lipoprotein profiles should 
be a fundamental component of care for patients with Addison’s disease. This 
particularly applies in the South African context, where dietary indiscretions may 
contribute to some degree to the adverse lipid profiles; healthy eating habits 
should be taught to this sub-set of patients. The longitudinal effect of reducing 
lipid abnormalities by using lipid-modifying therapy, has not been undertaken in 
Addison’s disease, but there is sufficient circumstantial evidence to warrant its 
use, when it is indicated. The sub-group of Addison’s patients using lipid-lowering 
therapy failed to achieve lipid and lipoprotein targets, and so remain at risk 
for a CV event. This is alarming, as the CV risk may be underestimated using 
conventional CV risk factors, and so by implication, Addison’s disease patients as 
a group would necessitate intensive modification of CVD risk factors. Treatment 
of other risk factors such as hypertension, diabetes and encouraging smoking 
cessation should be the routine.
It is concerning to note that the hs-CRP was higher than control subjects, and this 
on its own should necessitate vigilant attention to modifiable CV risk factors, even 
though it may not be applicable due to altered immune status. The anecdotal 
observation that a minority of patients died soon after an elevated hs-CRP was 
assayed, may compel it to be routinely assayed at the time of inter-current illness 
or concern about health in general, but currently its recommendation would be 
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5.8.3.9 Future directions for the management of dyslipidaemia and 
cardiovascular (CV) risk of South African Patients with Addison’s disease
Addison’s disease is rare and primarily managed by endocrinologists, who should 
be conversant with dyslipidaemia, but may not be trained for atherosclerotic 
risk inferences. The initial consultation is crucial in order to establish baseline 
clinical and biochemical parameters. Given the relatively slow evolution  of 
atherosclerosis, time is available to re-evaluate patients following correction 
of hormone deficiencies. It is sound clinical practice to introduce lipid-lowering 
therapy early among patients with Addison’s disease, considering that the life 
expectancy is generally good. This contention is supported by the work in this 
area that demonstrates that Addison’s disease patients have increased (twice) 
the CV risk compared to healthy individuals. The applicability of the Framingham 
risk calculations for CVD may not be perfect and may underestimate the true CVD 
risk because other factors, aside from those used in the Framingham calculations, 
may operate. With detailed information about CV outcomes in large cohorts, a 
correction factor could be derived to enhance the accuracy of the Framingham or 
other risks scores.
A prospective observational study to examine the effect of addressing CVD 
among Addison’s disease patients would require an extremely large sample size, 
because Addison’s disease is uncommon and atherosclerosis is multi-factorial 
in pathogenesis. Surrogate markers, for example, intimal-medial thickness 
evaluation, are useful adjuncts to standard CV disease risk factors, but again 
may not be similar in their implications owing to changes that may occur, due to 
Addison’s disease per se or its cause. The longitudinal population-based studies 
examining carotid intimal-medial thickness (CIMT) of >1 mm and/or discrete 
plaques to subsequent myocardial infarction event rates from Finland, Italy, USA 
and Holland, indicate that the relative risk varies from 2.1-6.3, and the greatest 
risk is exhibited in individuals with focal plaque.89 This is likely to apply in Addison’s 
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assessment of Addison’s patients for CVD risk. Thus, it becomes more important 
to harbour awareness and attention to modifying conventional CV risk factors in 
South Africa.
The retrospective data available for study in this thesis indicate that CV risk 
and dyslipidaemia may be increased in a similar way to that found in Sweden. 
Although this study did not show a relationship between hydrocortisone dose 
and lipid abnormalities, there are no specific recommendations with respect to 
hydrocortisone supplementation and dyslipidaemias. Management of an acute 
CVD event in Addison’s disease is also not directed by previous studies. The 
lack of an acute cortisol response to such a stress may also influence outcome. 
It is not known whether Addison’s disease patients are at greater risk of acute 
mortality in the context of an acute coronary event, and therefore this represents 
an area of research that should be undertaken in the future.
It still remains uncertain to what extent the atherosclerotic lesion of the vessel 
wall is modulated, by either insufficient or excessive hydrocortisone doses. 
While one author suggests that there is no change in endothelial flow-mediated 
dilatation in response to GCs,91 the question of whether Addison’s patients have 
abnormal physiological responses to flow represents an area of possible further 
research. It is clear that Addison’s patients will require support of at least tertiary 
care to ensure the most favourable outcome for CVD. The role of cholesterol 
esterase should be explored for its activity in Addison’s disease, its response to 
GC replacement and possible atherogenesis.
5.8.3.10 Conclusions
This is the first comprehensive study in South Africa that examines the lipogram 
and markers of CV risk in Addison’s disease patients, in order to verify the 
excessive CVD risk shown by mortality among patients in Sweden with Addison’s 
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been demonstrated. HDLC is markedly abnormal in this cohort of patients, but 
this requires confirmation and further research for its implications. Whilst some 
patients were treated (albeit not to target) for LDL, more can be done to achieve 
target values in the current guidelines. Pharmacological therapy directed at 
modulating HDL is still under investigation. A local registry is recommended for 
South Africa to increase its awareness of dyslipidaemia and risk.
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Chapter 6
Monitoring hydrocortisone replacement therapy 
using salivary cortisol day curve measurements
6.1 Introduction
Salivary cortisol is a non-invasive, accurate measure of endogenous free cortisol 
production. It has been utilised in fields such as sports physiology, endocrinology, 
immunology and psychology,1 and has demonstrated good correlation with serum 
in Addison’s disease.2 3 Therefore, it would be interesting to determine the degree 
of salivary cortisol exposure in Addison’s patients on their usual hydrocortisone 
replacement versus healthy controls, and to correlate this level with the evolution 
of side-effects. 
Moreover, it has not yet been ascertained which time point after hydrocortisone 
ingestion is the most reliable in predicting salivary cortisol peaks. Following 
hydrocortisone ingestion, supra-physiological peaks of serum and salivary 
cortisol are generated in patients with Addison’s disease and hypopituitarism, 
in contrast to healthy controls’ ndogenous levels.4-10 It is uncertain whether the 
total exposure to cortisol (AUC) or the supra-physiological peaks are responsible 
for the deleterious effects of hydrocortisone. 
6.2 Aims
The purpose of this study is to test the hypothesis that patients with Addison’s 
disease, who are fully replaced on hydrocortisone and fludrocortisone, may be 
subject to supra-physiological doses of GCs, as examined using salivary cortisol 
AUC.
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i. to determine the salivary cortisol AUC for patients with Addison’s disease 
on full replacement and compare these results to healthy control subjects’ 
endogenous salivary cortisol concentrations
ii. to determine the optimum time to sample the salivary cortisol in patients 
and healthy controls that would reflect most accurately the salivary cortisol 
peak and the AUC
iii. to determine whether an increased salivary cortisol AUC translates into 
abnormal lipids, lipoproteins and markers of CV inflammation
6.3 Patients and methods
The methods are described below under the headings of patients, procedures, 
salivary cortisol test principle, expected cortisol levels in saliva, automated 
measurement of salivary cortisol, collection method for salivary cortisol and 
statistics.
6.3.1 Patients
The patients enrolled in the Addison’s disease cohort, described in Chapter 3, 
were eligible for inclusion in this study.11 Approval from the University of Cape Town 
Research and Ethics Committee was obtained for this sub-study. All participants 
in the South African Addison’s study were sent a letter that explained the purpose 
of this study and 31 patients with Addison’s disease agreed to participate. Healthy 
control subjects, comprising mostly medical students, were recruited through the 
university website. Both participants and healthy control subjects were excluded 
if they were pregnant, using medication that could interfere with salivary cortisol 
analysis or taking hormonal therapy. Examples of medications that were deemed 
to be an exclusion criterion included oestrogens or hormonal therapy, histamine-2 
receptors antagonists, antidepressants and asthma medication.12 All participants 
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6.3.2 Procedures
Since the salivary cortisol study was performed in both the patients’ and the 
healthy control subjects’ homes, counselling was performed both telephonically 
and by letter to ensure the maximum adherence to the study protocol. The saliva 
was obtained using a straw and drained into a 1.5 ml microcentrifuge tube, by 
passive drool technique. 
The patients and controls were asked to collect their saliva at 08h00 (immediately 
before the first hydrocortisone dose in the case of patients), at 08h30, 09h00, 
09h30, 10h00, 10h30, 11h00, 12h00, 14h00, 16h00, 16h30, 17h30, 19h00, 21h00, 
22h00 and at midnight (16 samples per participant) in a home environment. 
Patients were asked to continue their usual hydrocortisone maintenance therapy, 
but to indicate the precise times of these doses. In order to prevent contamination 
with food and drink, participants were advised only to eat at certain times of the 
day, that is, have breakfast at 06h45 for 15-20 minutes, lunch between 12h30 
and 13h00, dinner between 19h30 and 20h00, and not to snack at other times 
or drink alcohol for 24 hours before collecting saliva and on the day of collection. 
In addition, the participants were requested to avoid dairy products, for example, 
cheese, yoghurt and milk. Fizzy drinks, oranges, lemons, pineapples, sweets and 
chocolates were also to be avoided. Participants also had to limit brushing their 
teeth, as there was a chance that injury to the gums could allow blood to pass 
into the saliva collection and falsely increase cortisol levels. Similarly, chewing 
gum or bubblegum or flossing teeth was not permitted during the day of sampling. 
Participants were presented with sealed straws for maintaining hygiene and were 
advised to cut the straw 6 cm from the pointed edge. They were then asked to 
chew on the back of the straws to encourage saliva production and pass as 
much saliva as possible through the straws while their head was facing forward 
and down to the floor. Each microcentrifuge tube was marked with the patient’s 
initials and the time point of each collection. The participant was advised to use a 
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prevent contamination with a previous sample.
In order to enhance adherence to the protocol, patients and control subjects were 
told that they would be contributing significantly to science and medicine. A review 
in 2000 by Shumaker et al suggested ways to promote adherence in clinical trials 
through the combination of a written record and informing each of the subjects of 
the importance of their contribution.13
All participants were counselled regarding measures to prevent contamination 
with blood, for example, brushing teeth at designated times, followed by oral 
rinses. On completion of the collection, the participants were advised to refrigerate 
or freeze the samples. The samples were returned either by hand or by express 
mail to limit exposure to room air. The specimens were stored at -70 °C.
6.3.3 Salivary cortisol test principle
The assay used was a competitive electrochemi-luminescence immunoassay that 
used a sheep polyclonal antibody. Endogenous cortisol in the sample is freed from 
binding proteins by danazol, which competes with a cortisol derivative (cortisol-
peptide-tris bipyridyl ruthenium complex) for the binding sites of biotinylated 
antibody. The second incubation follows, with the addition of streptavidin-coated 
paramagnetic microparticles and the entire complex binds to the solid phase. 
This entire reaction mixture is then drawn into a measuring unit, where the 
microparticles are magnetically captured onto the surface of the electrode. These 
unbound complexes are then removed. A potential difference to the electrode is 
applied, which induces a chemi-luminescent emission and which is quantified by 
a photomultiplier. The amount of cortisol is determined using a calibration curve. 
The sample volume for the assay is 20 μl.14
6.3.3.1 Expected cortisol levels in saliva
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provided with the Elecsys (Roche) cortisol assay kit, having been derived from 
154 healthy individuals and sampled in the morning hours between 08h00 and 
10h00, and 14h30 and 15h30, revealed ranges of 1.90–19.1 nmol/L and 2.05–
11.9 nmol/L respectively. A population-based study to determine the reference 
range in the normal population in South Africa was not undertaken as part of this 
investigation.
6.3.3.2 Automated measurement of salivary cortisol 
The Elecsys (Roche) random access analyser has been shown to offer good 
performance in the low nmol/L range that is required for evaluating salivary cortisol 
and it demonstrates low cross-reactivity with cortisone (0.3% at 2.7 μmol/L). The 
lower limit of detection for salivary cortisol is 0.5 nmol/L and a 20% inter-assay 
c.v. was reported, using this methodology.14  
6.3.4 Collection method for salivary cortisol
In this study, the salivary cortisol samples were collected by the passive drool 
technique, because the literature suggests that it has a superior yield for salivary 
cortisol compared to salivettes.15 However, salivettes were recommended as 
the preferred collection device in the assay package insert. For this reason, the 
correlation between salivary cortisol collected in microcentrifuge tubes by the 
passive drool technique, by salivettes, and by passive drool technique and instilled 
on to salivettes, was examined. The degree of agreement was determined in ten 
healthy control subjects, providing three salivary samples collected sequentially 
at 08h00, using the aforementioned collection methods. There was a poor 
correlation between salivary cortisol obtained from microcentrifuge tubes directly, 
compared to salivary cortisol obtained using salivettes (r = 0.37) {personal 
communication, John Stanfliet, National Health Laboratory Services (NHLS) 
2008}. On the other hand, the correlation between salivary cortisol collected in 
microcentrifuge tubes and instilled onto salivettes was r = 0.96, which although 
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nmol/L was calculated between these latter two methods for collecting saliva, 
which is clinically insignificant.
6.3.5 Statistics
Data were analysed using Stata version 11.0 (College Station, Texas, USA.) 
Salivary cortisol fluctuations are presented graphically for each participant, with 
grouped comparisons of median salivary cortisol levels at different time points for 
patients versus controls. AUC and clearance were calculated using WinNonlin® 
version 6 software, Pharsight corporation Mountainview California USA. The 
distributions are described as means with standard deviations, medians with 
interquartile ranges, or percentages, as appropriate. Distributions of continuous 
variables were compared using student’s t-test, replaced by rank-sum tests for 
non-normally distributed variables. Proportions were compared with Chi-squared 
tests, replaced by Fisher’s exact tests for small samples. Repeated measures 
ANOVA were used to examine the differences between salivary cortisol 
concentrations between patients and controls. Spearman’s correlation was used 
to examine the association between the overall AUC for salivary cortisol and 
cortisol concentrations at different time points. Throughout, 2-sided statistical 
tests with p <0.05 indicating significance, were used.
6.4 Results
As seen in Figure 20, there were 31 patients who agreed to participate in this study 
and 113 patients who were not enrolled. Of these, 12 patients were excluded 
because of concomitant medication, three patients declined to participate in 
the salivary cortisol study and 98 patients did not respond. The large number 
of non-responders was attributed to a lack of interest in the study and a largely 
mobile society, which meant that the postal addresses at the time may have been 
incorrect. It was suggested that this study may have been excessively rigorous, 
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subjects, who were not matched for any of the patient parameters.
7 patients excluded
because of an incorrect 
label of Addison’s diseaseф
3 patients declined to








31 patients agreed to 
participate in this study
98 patients 
no response






Figure 20: Process for enrolling Addison’s disease patients in the salivary cortisol study.
Patients were excluded because of concomitant therapy, including sex steroid therapy, depression 
and using antidepressants, supplemental steroid use for asthma, and anticonvulsants. The 
reasons for the poor response have not been ascertained, but it is speculated that the lack of 
interest in the study and a largely mobile society meant that the postal addresses at the time 
may have been incorrect. It was suggested, that this study may have been excessively rigorous, 
dissuading potential participants from enrolling.
6.4.1 Baseline characteristics of the Addison’s disease subjects who 
participated in the salivary cortisol sub-study
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subjects differed from the 31 Addison’s patients, as they were younger and there 
was a predominance of both males and black subjects. The 31 participants of 
this sub-study were compared to the remaining 113 Addison’s patients who did 
not have their salivary cortisol monitored (Table 34). An equivalent proportion 
of the sub-study participants was female (74% versus 57%; p = 0.07) and the 
ethnic distribution was different, which can be explained by the absence of black 
patients participating in the sub-study (p = 0.0003). On the other hand, age, total 
daily hydrocortisone dose, the hydrocortisone dose/m2 and BMI were no different 
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Table 34: Comparisons between patients who underwent salivary cortisol examination and the 
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88 (61)
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N/A 14.3 (10.6-17.0) N/A 0.85
12.8 
(10.4-6.8)
Median: Age, total daily hydrocortisone dose, total daily hydrocortisone dose/m2 and BMI
IQR interquartile range, 
N number, 
SD standard deviation
BMI: Body mass index
p-value: Comparison of patients who underwent salivary cortisol examination with the remaining 
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p < 0.05 considered significant
*p < 0.05
**p < 0.0001
The individual-timed salivary cortisol concentration plots for healthy volunteers 
and patients with Addison’s disease are shown in Figure 21. It is evident from 
these that no salivary cortisol measurements were performed between the 
hours of 00h00 and 08h00, limiting the appraisal of the day curves to 16 hours. 
Moreover, significant variability is identified for both patients and controls, with the 
former exhibiting far greater excursions compared to the healthy control subjects’ 
endogenous cortisol concentrations. In the salivary cortisol day curves for healthy 
volunteers, no consistent peaks were identified at the time points 08h00 and 16h00 
when endogenous serum cortisol levels are expected to demonstrate an initial 
peak, followed by a secondary peak respectively.17 The CAR was not assessed 
in this study, as salivary cortisol at the time points 15 minutes, 30 minutes and 45 
minutes post awakening were not sampled, which traditionally has been used to 
investigate psychological influences on the HPA axis.19  
The median salivary cortisol concentrations during the day curve measurements 
in patients and healthy control subjects are depicted graphically, without the IQR, 
as there is considerable overlap at all time points (Figure 22). For the entire day 
curve, the median salivary cortisol concentration was greater in patients than in 
controls, but the difference was greatest between these two groups during the 






































Salivary cortisol concentrations (nmol/L) in healthy control subjects (N=30)
time
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Figure 22: Comparison of the median salivary cortisol in patients and controls. The interquartile 
ranges (IQR) for each of the time points indicated in clock time are not shown, because of the 
substantial overlap that exists between patients and controls.
The Addison’s patients demonstrated significantly higher first and second peak 
salivary cortisol concentrations, as well as longer time to peak levels, compared 
to healthy subjects’ endogenous cortisol profiles (Table 35). Considerable inter-
individual variability of salivary cortisol concentrations was noted in the spaghetti 
plots, in both healthy control volunteers and Addison’s patients. The median (IQR) 
salivary cortisol AUC was 15-fold higher in patients compared to the controls. The 
AUC correlated with the peak cortisol concentrations both in patients (r = 0.87; 
p = 0.0001) and controls (r = 0.74; p = 0.0001), which is expected as there is 
ordinarily a strong correlation between AUC and peak concentrations, as shown 
in the evaluation of different drugs in plasma.20–22 Moreover, the peak correlates 
well with the AUC for salivary ofloxacin. Taken together, there is evidence for the 
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median (IQR) clearance rates of cortisol were significantly lower among patients 
with Addison’s disease who enrolled in the salivary cortisol study, as 0.02 (0.01–
0.05) litres/hour (L*h-1) versus 0.37 (0.28–0.45) (L*h-1) for the healthy control 
subjects (p = 0.0001). 
Table 35: Salivary cortisol excursions in Addison’s patients on hydrocortisone and endogenous 








































Trough cortisol nmol/L (IQR) <0.50 <0.50










Median: Peak cortisol, time to peak cortisol, first peak cortisol, time to first peak cortisol, second 
peak cortisol, time to second peak cortisol, trough cortisol, time to first trough and AUC
AUC: Area under curve
IQR: Interquartile range
N: Number
p-value: Comparison of patients’ salivary cortisol on hydrocortisone compared with healthy control 
subjects’ endogenous cortisol
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The greatest difference in median salivary cortisol between patients and controls 
were 23- and 25-fold at 09h00 and 09h30 respectively. The magnitude of the 
difference in the median cortisol levels between Addison’s patients and healthy 
control subjects falls during the period from 14h00 until midnight, where the 
difference varies from almost 10- to 4.4-fold higher in the Addison’s patients. 
Among patients and controls, the p-value was <0.0001 at each time point apart 
from 08h00, using repeated measures analysis of variance (ANOVA) test. The 
concentration of salivary cortisol also differed by the time point measured (p < 
0.0001). In summary, Addison’s patients are exposed to a higher median cortisol 
level throughout a 16-hour day curve, compared to control subjects. 
6.4.2 Correlation between hydrocortisone dose and peak salivary cortisol 
concentrations
There was no correlation between hydrocortisone dose and peak salivary cortisol 
levels (r = 0.18; p = 0.32). The median salivary cortisol of the Addison’s patients 
was significantly greater than that of the controls at each time point, with the 
exception of 08h00 (Figure 22). This is of relevance, since it is expected that the 
median cortisol level at 08h00 represents the basal concentration in patients with 
Addison’s disease. Although the first sample was ostensibly taken prior to the 
usual dose of hydrocortisone in several patients, it was greater than the healthy 
subjects’ endogenous salivary cortisol concentrations, suggesting that patients 
may exhibit residual endogenous cortisol concentrations or that patients may not 
have complied with the study requirement that their initial salivary cortisol be 
sampled immediately prior to their first usual dose of hydrocortisone.
6.4.3 Sampling time of salivary cortisol, hydrocortisone dose and correlation 
with AUC
It is expensive and cumbersome to take multiple salivary samples from individual 
patients on hydrocortisone replacement therapy. Therefore, should a single 
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for AUC and consequently, be enough to indicate either adequate, under- or 
over-replacement. The time point that showed the best correlation with AUC 
was 08h30 (r = 0.67), representing Cmax, which could potentially indicate the 
best surrogate marker for AUC. The most ideal time points to sample salivary 
cortisol concentrations in healthy control subjects appeared to be 08h00 and 
08h30, by virtue of their strong correlation with AUC (Table 36). The scatterplots 
demonstrate a lack of correlation between total daily dose of hydrocortisone, 
hydrocortisone dose/kg, total dose of hydrocortisone/m2 and AUC (Figure 23). 
The Spearman correlations were not significant and remained non-significant, 
even after adjusting for gender, age, race and foreign ancestry (Table 37).
Table 36: Time points reflecting sampling of salivary cortisol, showing the strongest correlations 
with AUC for healthy control subjects
Time Point Correlation coefficient (r) p-value
08h00 0.53 0.003*
08h30 0.66 0.0001*
AUC: Area under the curve
p-value: Correlation of salivary cortisol at time points with AUC
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Figure 23: Scatterplots showing the relationship between AUC and hydrocortisone dose
The scatterplots above demonstrate a lack of correlation between AUC and dose of 
hydrocortisone, expressed as total daily hydrocortisone dose, total daily hydrocortisone dose/kg 
and hydrocortisone/m2 (total daily hydrocortisone dose adjusted for body surface area) 
Table 37: Correlation of hydrocortisone dose with salivary cortisol AUC (unadjusted) and adjusted 
for gender, age, race and foreign ancestry in 31 Addison’s patients
Spearman (unadjusted) Adjusted
Dose r p-value p-value
Total daily hydrocortisone dose   0.0336 0.86 0.77
Total daily hydrocortisone dose/kg -0.2043 0.27 0.70
Total daily hydrocortisone dose/m2 -0.0567 0.77 0.92
Total daily hydrocortisone dose/kg: Total hydrocortisone dose per kilogram
Total hydrocortisone/m²: Total daily hydrocortisone dose per square metre of body surface area
r: Correlation coefficient
AUC: Area under the curve
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6.4.4 Quantification of the variability of salivary cortisol in both patients 
and controls
As the sample was not normally distributed, the median value was used as a 
central measure of the analyte. The IQR was used to express the dispersion of 
the analyte in patients and controls. The dispersion of salivary cortisol was overtly 
greater in the Addison’s patients compared to the controls (Table 38).
Table 38: Quantification of the variability of the salivary cortisol assay using interquartile ranges 
for each time point
Time 
Point
Median cortisol levels nmol/L (IQR)
(Addison’s patients, N = 31)
Median cortisol levels nmol/L (IQR)
(Healthy control subjects, N = 30)
08h00 1.32 (0.72-9.94) 4.89 (2.95-4.89)
08h30 55.35 (21.39-534.93) 4.05 (2.28-5.22)
09h00 60.12 (26.5-130.68) 2.59 (1.56-4.69)
09h30 47.53 (26.60-101.48) 1.86 (0.93-3.03)
10h00 40.76 (27.15-66.7) 1.31 (0.72-3.00)
10h30 24.46 (19.0-67.90) 1.2 (0.62-2.41)
11h00 19.09 (11.23-35.86) 0.81 (0.50 -1.69)
12h00 12.09 (7.66-20.55) 0.80 (0.50 -1.34)
14h00 7.07 (2.22-13.76) 1.24 (0.74-2.03)
16h00 4.64 (1.69-12.85) 0.58 (0.50 -1.42)
16h30 4.91 (2.56-11.84) 0.50 (0.50 -1.10)
17h30 4.37 (1.82-12.57) 0.50 (0.50 -0.96)
19h00 2.68 (0.69-4.45) 0.50 (0.50 -0.62)
21h00 2.2 (0.85-4.19) 0.50 (0.50 -0.78)
22h00 2.92 (0.89-4.4) 0.50 (0.50 -0.63)
00h00 2.17 (0.49-6.16) 0.50 (0.50 -0.50)
N: Number
IQR: Interquartile ranges
Significant variability is detected at each time point using interquartile ranges, but it is exaggerated 
among the patients, particularly in the morning time points. Substantially less variability is noted in 
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0.05 nmol/L represents the lower limit of detection.
In the individual timed salivary cortisol concentration plots for the patients on 
hydrocortisone replacement, there was considerable variability (Figure 24). 
Despite the fact that the largest dose of hydrocortisone was taken immediately 
after the 08h00 sample, the highest saliva cortisol peak is not invariably observed 
in the first part of the day. The salivary cortisol concentrations at 08h00 for each 
of the patients do not uniformly represent the nadir. In addition, several patients 
demonstrated incomplete salivary cortisol day curve data, for example, subject 





















































































































































































































































































































































08h00 11h00 16h00 19h00 00h00
Figure 24: The individual timed salivary cortisol concentration plots for each of the patients.
There is a lack of uniformity for each of the salivary cortisol concentration plots. Considerable 
variability is also observed. Despite the fact that the largest dose of hydrocortisone was taken 
immediately after the 08h00 sample, the highest salivary cortisol peak is not invariably observed 
in the first part of the day. The salivary cortisol concentration at 08h00 do not uniformly represent 
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6.4.5 Examination of the salivary cortisol reference range
The National Health Services Laboratory (NHLS) at Groote Schuur hospital set 
up the salivary cortisol assay using the Elecsys (Roche) system. The endogenous 
cortisol concentrations from 30 normal healthy subjects were evaluated. The 
purpose of this was to compare the results with those from Addison’s patients on 
their usual hydrocortisone replacement therapy.
Using the package insert supplied by the manufacturer of the Elecsys (Roche) 
automated analyser, the proportions of patients and controls whose salivary cortisol 
was either lower than or in excess of the reference ranges, were calculated (Table 
39). For the afternoon, the manufacturer had supplied reference ranges for the 
time interval between 14h30 and 15h30, but it was deemed that since sampling in 
this study occurred at 14h00 and 16h00, these time points were sufficiently close 
for comparison. Interestingly, none of the healthy controls exhibited a salivary 
cortisol above the reference range supplied by the manufacturer.  As many as 
73% at the 14h00 time point demonstrated a salivary cortisol below the reference 
range, in contrast, a substantial proportion exhibited a salivary cortisol below the 
reference range for the predetermined time points. However, the majority of patients 
exhibited salivary cortisol concentrations above the reference range for each of 
the time points and only a minority of patients demonstrated a salivary cortisol 
below the reference range, except at the 08h00 time point. The manufacturer’s 
reference range is derived from the 5th to the 95th percentile, so within this 
reference range, it would be expected that 90% of the controls would exhibit 
salivary cortisol in this range. As none of the control subjects exhibited salivary 
cortisol concentrations above the reference range, and all outliers were below 
the reference range, it may indicate that the reference range was too high for the 
population sampled in this study. Therefore, the manufacturer’s reference range 
could not be validated for these healthy control subjects and so the reference range 
supplied by the manufacturer, by inference, is not transferable. It should be stated 











Monitoring hydrocortisone replacement therapy using salivary cortisol day curve measurements
as it included an additional step of instilling saliva from a microcentrifuge onto a 
salivette, which could account for the substantial proportion of healthy controls 
who exhibited salivary cortisol levels lower than the recommended lower limit of 
the reference range.
The fact that there were very few samples from healthy controls and that they 
were not normally distributed, represented an obstacle in determining a reference 
range in the study. Ideally, a minimum of 120 samples are needed to determine the 
5th to the 95th percentile in a non-parametric data set. Nevertheless, the CI was 
calculated for the 5th and the 95th percentiles at each time point. For example, at 
08h00, the lower reference range was 0.96 nmol/L, with a CI of 0.79-1.01 nmol/L, 
whereas the upper reference range was 10.47 nmol/L with a wide CI of 8.58-15.27 
nmol/L using the 90% confidence intervals for each value suggesting uncertainty 
as to the true ranges. At midnight for example, the upper limit appeared to be 2.35 
nmol/L with a CI of 1.12-4.62 nmol/L.  A lower reference range for midnight could 
not be determined because 0.50 nmol/L probably represents the limit of detection 
for the assay. The 90% CI is utilised by convention to express the certainty of the 
95% reference range.  In view of the small numbers, these limits are unlikely to be 
reliable. Notably, there are discrepancies between the manufacturer’s reference 
range and the healthy ranges, suggesting that the former may not be applicable in 
this healthy population. It was also confirmed that the Addison’s patients exhibited 
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Table 39: Proportion of Addison’s disease patients and controls, whose salivary cortisol levels fell 
outside the recommended reference range, using the Elecsys (Roche) assay

















































































n: numbers of patients and controls identified with salivary cortisol outside the reference range
N: Total number of patients and control subjects 
p-value patients versus controls












Monitoring hydrocortisone replacement therapy using salivary cortisol day curve measurements
6.4.6 Lipids, lipoproteins and biochemical markers of cardiovascular 
inflammation in the salivary cortisol sub-study, and the remaining cohort 
of Addison’s patients
The median levels of TSH, RBG, TC, TG, HDLC, LDLC, NEFA and hs-CRP were 
comparable in both the salivary cortisol study and the remainder of the Addison’s 
disease cohort. No association was identified between AUC and any of the 
aforementioned metabolic characteristics.
6.5 Discussion 
The principal finding of this study was that Addison’s disease patients, irrespective 
of the dose of hydrocortisone used, had a significantly greater exposure to cortisol 
than healthy control subjects, when assessed using AUC or peak salivary cortisol 
measurements. Additionally, the degree of salivary cortisol exposure, as shown 
by AUC, did not correlate with measured metabolic abnormalities.
Although this study sample size is small, the differences in salivary cortisol levels 
between healthy control subjects and patients were large, and there is less than 
1% likelihood that these differences were due to chance alone. This study is 
unique in many respects. First, it examines salivary cortisol in one of the largest 
exclusively primary hypoadrenal cohorts. Many other similar studies included 
patients with both pituitary and adrenal disease. Second, in contrast to previous 
studies, it has generated credible evidence for excess exposure using AUC, 
with what is believed to be physiological replacement of hydrocortisone therapy. 
Third, apart from the report by Lovas et al, this study of South African Addison’s 
disease patients’ salivary cortisol, which analysed a day curve over 16 hours with 
multiple sampling, is considerably longer than many others.9 Fourth, it confirms 
that an intensive survey of cortisol excursions in the comfort of patients’ homes 
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The patients who participated in the salivary cortisol study differed from the entire 
Addison’s disease cohort in terms of ethnicity and differed from healthy control 
subjects in terms of ethnicity, gender and age. Nevertheless, it is speculated 
that most of the findings can be generalisable to the entire cohort. Although 
cortisol production rates are higher in men compared to women,24 when using 
steady-state stable isotope tracer infusion deuterated cortisol, this was no 
longer significant when adjusted for body surface area. Additionally, increased 
metabolites of cortisol have been found in men compared to women, which may 
offset the higher cortisol production rates.25 Moreover, black and white women 
did not differ in the evaluation of the HPA axis using the 24-hour urinary excretion 
of cortisol and dexamethasone suppressability, matched for age, weight, BMI 
and body surface area.26 Despite some literature indicating differences in cortisol 
production between genders and among various ethnic groups, it is likely that 
the findings from those enrolled in the salivary cortisol study are applicable to 
the remaining group of Addison’s patients. The vast differences observed in the 
salivary cortisol excursions between patients and healthy control subjects are not 
likely due to these factors.
This study has clearly demonstrated that exposure to cortisol is significantly 
greater in patients with Addison’s disease on hydrocortisone therapy compared 
to endogenous cortisol secretion in healthy control subjects. This was shown 
by the median AUC, which was 15-fold greater in magnitude than that seen in 
healthy control subjects. Only one other study used salivary cortisol AUC as a 
measure of hydrocortisone exposure in Addison’s disease and hypopituitarism. 
The study’s purpose was to examine the correlation between saliva and plasma 
exposure, following hydrocortisone administered both intravenously and orally 
in hypoadrenal patients. Although the correlation was poor, it was not designed 
to compare exposure of cortisol in hypoadrenalism on replacement therapy to 
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The vast difference in AUC is likely to be true as possible causes for spuriously 
elevated cortisol levels were minimised. Drugs and interfering substances may 
cause spurious elevations of salivary cortisol. However, drugs that potentially 
could raise salivary cortisol concentrations were exclusion criteria in this study. 
As cross-reactivity of cortisol and cortisone is known to occur in some automated 
assays, the cross-reactivity with cortisone, using the Elecsys (Roche) analyser, 
is limited to 0.3% at 74.5 nmol/L of cortisol and so it represents an attractive 
assay methodology.14 Several AUC levels were very high and the sample size 
was small, none of the outliers was eliminated from the analysis. If the very high 
levels were removed, it could have reduced the sample size considerably, but 
the large differences would remain. A number of conditions are associated with 
elevated salivary cortisol levels. Salivary cortisol was found to be elevated in 
patients with anorexia nervosa, whether treated or untreated, but not in patients 
with obesity compared to controls.28 As none of the patients in the current study 
was anorexic, this factor could not account for the remarkably elevated AUC 
levels. The role of the fasting or fed state on AUC is unclear. Aanderud et al 
showed that AUC was greater if patients had breakfast prior to their cortisone dose 
compared to taking it after an overnight fast, while Barbhaiya et al reported that 
cortisol levels were lower after eating.29–32 Johannsson et al, utilising a modified-
release hydrocortisone tablet in healthy volunteers, demonstrated a significantly 
greater plasma cortisol AUC in the fed state compared to the fasting state, and 
this finding suggests that food accelerates the solubility and the dissolution rate 
in the gastrointestinal system.33 In this study of Addison’s patients, it is uncertain 
whether sampling the cortisol levels in a fasting state would have significantly 
altered the outcome of the AUC levels.
The body of evidence, with respect to hydrocortisone replacement therapy in 
Addison’s disease and hypopituitarism, points to the supra-physiological peaks 
of cortisol following ingestion, followed by the inexorable decline of cortisol 
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150 nmol/L (tmax 50 minutes) following usual oral hydrocortisone doses,27 which 
was similar to the 174.5 nmol/L (tmax 60 min) found in this study. Among patients 
with anorexia nervosa, the total AUC for plasma cortisol was approximately 1.5 
times greater than that of healthy controls.35 In alcohol-dependent persons who 
are going through alcohol withdrawal, the mean daily salivary cortisol levels, 
as calculated by AUC, was 2.56 nmol*min*L-1 compared to control levels of 0.5 
nmol*min*L-1.36 Similarly, the AUC for patients with chronic fatigue syndrome was 
2.3 nmol*min*L-1.37 Taken together, the AUC for salivary cortisol determined in 
Addison’s disease patients using hydrocortisone is considerably greater than 
in patients with anorexia nervosa and alcohol withdrawal. On the other hand, 
chronic fatigue syndrome appears to induce lower AUC for salivary cortisol than 
controls,37 and it is therefore expected that Addison’s patients have higher AUC 
for salivary cortisol than chronic fatigue syndrome sufferers.
Some studies of salivary cortisol in Addison’s disease have confirmed a high 
degree of correlation between plasma and salivary cortisol,2 3 10 while Wong et 
al showed a poor correlation attributed to the rapid changes of free cortisol in 
plasma, which occur soon after administration of hydrocortisone. These levels 
rise sharply due to saturation of CBG. It raises some uncertainty as to whether 
the serum cortisol AUC in these Addison’s patients was also elevated.10 The 
significantly elevated AUC for salivary cortisol, and thus increased exposure to 
GCs, may translate into unwanted side-effects. Specifically among individuals 
aged between 50–70 years of age, the higher AUC for salivary cortisol was 
associated with impairment of cognitive function.38 The endogenous total salivary 
cortisol exposure, as measured by AUC, was found to be positively correlated with 
the number of plaques in the carotid arteries, having been adjusted for associated 
CV risk and socio-demographic factors in an elderly population group.39 It was 
suggested that the accelerated atherosclerosis resulted from the propensity of 
cortisol to induce diabetes, hypertension and lipid derangements.30 39 Furlan et al 
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AUC, depression and BMD.40 The impaired quality of life and feelings of fatigue 
identified in patients with Addison’s disease have been attributed to the low levels 
of cortisol during the day and late evening, but it is equally conceivable, since high 
cortisol concentrations are associated with depression, that this symptom may be 
accounted for by the high salivary cortisol AUC seen in this cohort of the South 
African Addison’s disease patients. Moreover, a link has been demonstrated 
between elevations of salivary cortisol AUC and diabetes mellitus among Jewish 
Immigrants.41
The only adverse effects examined in this small study were those of lipids, 
lipoproteins and markers of CV inflammation. It is not surprising that there is a lack 
of association between salivary cortisol exposure and metabolic derangement, 
since the study size limited its power. Salivary cortisol levels were highly variable, 
and although the salivary cortisol was sampled frequently during the day curve in 
this study, the finding of increased salivary cortisol may fail to reflect that which 
transpires on a cellular level. Lipid and lipoprotein values in a given individual 
are the result of multiple co-existing metabolic processes, and only a few 
endpoints have been examined in the current study. The effects of, inter alia, 
ageing, menopause, personal diets and genetic factors were not considered in 
the evaluation of this cohort.42–45 It is also entirely plausible that patients may have 
individual sensitivities to cortisol. Previous work has confirmed the presence of 
multiple GCR polymorphisms, which may have a role to play, whether patients 
manifest with metabolic derangements or not.46–48 These receptors are known to 
induce either enhanced or reduced sensitivity, and the finding of either a high or a 
low AUC may fail to reflect the post-receptor exposure to cortisol. Thus, a degree of 
cortisol receptor resistance may be protective in those individuals with excessive 
AUC for cortisol. These GCR polymorphisms are known to occur sporadically 
and are unlikely, on their own, to account for the mismatch between high cortisol 
exposure levels and failure to demonstrate metabolic changes. Indeed, work by 
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only modestly elevated and this has been ascribed to alterations in the enzyme 
11 beta-hydroxysteroid-dehydrogenases, which may alter GC action on fat tissue 
either by enhancing its sensitivity or by reducing its efficacy at tissue level.49 
Alterations in the kinetics of the enzyme 11 beta-hydroxysteroid-dehydrogenase 
were not examined in this cohort, but may account for the reduced sensitivity 
seen in relation to salivary cortisol concentrations and consequent absence of 
metabolic derangements. It is most likely that a large sample will finally resolve 
whether a relationship exists between AUC for salivary cortisol and metabolic 
derangements.
A considerable degree of inter-individual variability in salivary cortisol concentration 
was noted in both the patients and controls, as determined by the wide IQR 
to express the dispersion of the analyte. It is conceivable that factors relating 
to sample collection may have played a role in this degree of inter-individual 
variability. This variability has previously been documented.6 10 29 These factors 
include the possibility of mislabelled tubes, incorrect recording times and 
contamination of saliva with the hydrocortisone tablets. Additionally, one cannot 
ignore the heterogeneity of the group with respect to age range and that the 
cause of Addison’s disease, as well as unknown factors, may be contributing to 
this variability, for example, gastro-intestinal factors.50 The additional step, not 
specifically recommended by the manufacturer, of instilling saliva on to salivettes 
following passive drool collection, could have also contributed to the variability.
The median salivary cortisol of Addison’s patients was significantly greater than in 
controls at each time point, with the exception of 08h00. This is relevant since the 
patients were requested to take their morning hydrocortisone dose immediately 
after collecting the 08h00 sample. Smans et al reported partial recovery of cortisol 
secretion in a patient with autoimmune adrenalitis having been observed for 7 
years and deciding on his own volition to stop replacement therapy.51 Other authors 
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caused by lymphomatous infiltration could be reversed following successful 
chemotherapy.53 It is not clear whether the phenomenon of partial recovery may 
account for the higher than expected basal cortisol levels found in the present 
study, or alternatively that erroneous sampling of salivary cortisol, following the 
hydrocortisone dose instead of immediately prior to it, may play a role.
In many cases, the healthy control subjects’ salivary cortisol did not fall within 
the manufacturer’s reference range; especially as a significant proportion had 
salivary cortisol levels below the reference range. It was therefore deemed that 
this reference range was not transferable to this dataset. Since the salivary 
cortisols of the healthy controls exhibited a non-normal distribution and were too 
few in number, it was appreciated that a reference range from this data could not 
be generated. The theoretical minimum sample size required for the estimation 
of the 100α and 100 (1 – α) percentiles is equal to 1/α. The estimation of the 2.5 
percentile requires at least 1/0.025 = 40 observations. The precision of percentiles 
increases with increasing numbers of observations and a reduction of CI. It has 
been suggested that a minimum of 120 reference values are required and even 
more are necessary when the distribution of data is non-normal.54 55
The observation that the 08h30 time point for sampling salivary cortisol correlated 
well with the AUC, suggests that this may serve as a surrogate marker for AUC 
and peak cortisol levels. It may in time serve as a useful indicator of either under- 
or over-replacement with hydrocortisone therapy. On the other hand, Mah et al 
found that the 4-hour single plasma measurement after the initial hydrocortisone 
dose correlated reliably with the AUC.29 The difference is probably due to the study 
being performed using plasma cortisol, which may take time to equilibrate with 
CBG, unlike salivary cortisol, which is an instantaneous measure of free cortisol. 
Indeed, salivary cortisol may have a specific advantage in its correlation with 
AUC, as it can be sampled half an hour after hydrocortisone ingestion, provided 
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cortisol taken 120 min and 360 min after the morning dose would be the best 
samples to determine whether patients are either under- or over-treated by virtue 
of the cortisol excursions following replacement therapy.56 However, this should 
ideally be used in conjunction with the clinical features to confirm either over- or 
under-replacement. While plasma cortisol has been used to assess adequacy of 
replacement, salivary cortisol may in time gain the scientific credence for routine 
use.
As the cortisol exposure appears to be markedly supra-physiological in patients 
on hydrocortisone replacement therapy, it begs the question of whether these 
patients require the hydrocortisone replacement to be escalated during times of 
stress. Despite the high observed concentrations of cortisol, escalating therapy 
during stressful conditions is still advised until further research demonstrates the 
contrary.
In the preliminary studies of salivary cortisol, a poor correlation was obtained 
from saliva collected by passive drool into microcentrifuge tubes and salivettes 
(r = 0.37). Subsequent analysis showed that a sub-optimal correlation of r 
= 0.96 (r = 0.975 is considered a perfect correlation) exists between salivary 
cortisol collected in microcentrifuge tubes and then being instilled onto salivettes 
compared to salivettes alone. Although this relationship is acknowledged as 
sub-optimal for method comparisons, it was considered adequate for general 
comparisons.55  All salivary cortisol samples were collected by initial passive drool 
into microcentrifuge tubes throughout the study and were subsequently instilled 
onto salivettes.
6.5.1 Weaknesses of this study
This study has a number of weaknesses. A significant degree of inter-individual 
variability in salivary cortisol levels was noted. Although this is well described, 
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utilisation of mislabelled tubes or eating at the incorrect times could not be 
excluded. The addition of a pre-analytical step could have contributed to the 
higher than expected concentrations seen in Addison’s patients. The sample size 
was small and so limited the power of the study to examine the relationships 
with metabolic parameters.  It would have been preferable to perform salivary 
analyses in hospital. On the other hand, the widespread geographical distribution 
of the patients precluded admission to hospital.  It is acknowledged that choosing 
medical students as a control population may have inherent problems as they 
have likely a higher degree of compliance to a medial study. Moreover as the first 
salivary cortisol sample was taken at 08h00, it is conceivable that the peak could 
have been missed if it were earlier.
6.5.2 Conclusions and future recommendations
A significantly elevated cortisol exposure has been confirmed in the Addison’s 
patients. This may represent entirely artifactually high concentrations with no 
deleterious effects, or, it is more likely that the inordinately high concentrations 
may be directly harmful. It is conceivable that salivary cortisol reflects tissue 
exposure much more closely than serum cortisol, since the former is free cortisol. 
Potentially, the 30 minute salivary sample taken after hydrocortisone ingestion is 
a likely candidate as a surrogate marker for AUC and this should be confirmed in 
further studies. A future line of investigation would be to examine the correlation 
between AUC for salivary cortisol and metabolic parameters, especially lipids 
and markers of bone turnover in considerably larger samples. Once this has 
been accomplished and the association with metabolic consequences excluded, 
only then can we confidently deduce that current forms of routine replacement in 
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Chapter 7
The effect of glucocorticoid receptor 
polymorphisms on the sensitivity to cortisol in 
Addison’s disease
7.1 Introduction
Addison’s patients require lifelong hydrocortisone replacement therapy, but there 
is uncertainty as to the ideal dose of hydrocortisone. Despite the impression 
that patients are adequately supplemented, many Addison’s patients report 
subjectively impaired health quality.1 Clinicians often respond by raising the 
doses of hydrocortisone in an attempt to reverse this subjective health impairment 
with potentially deleterious effects on multiple systems.1–6 It has not yet been 
established whether the presence of specific GCR alleles induce a degree of 
GC resistance, necessitating increased doses of hydrocortisone. On the other 
hand, if deleterious metabolic c nsequences are identified in association with 
sensitising GCR polymorphisms, it may provide impetus to modify the dose of 
hydrocortisone in accordance with the specific GCR polymorphism. 
There is a dearth of information as to whether GCR polymorphisms play a role in 
the development of GC-related side-effects in individuals receiving hydrocortisone 
replacement for Addison’s disease. In addition, there is uncertainty as to whether 
the empiric dose of hydrocortisone needs to be altered in the presence of certain 
GCR polymorphisms.
7.2 Aims
The purpose of this study is to determine whether metabolic alterations are 
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hydrocortisone replacement. This so far has been empiric. 
The objectives of this study are to:
i. explore the role of GCR polymorphisms in influencing metabolic parameters 
among patients with Addison’s disease by comparing or correlating GCR 
genotypes with clinical parameters including BMI, TC, TG, HDLC, LDLC, 
hs-CRP, NEFA, small dense LDL, TSH and hydrocortisone dose
ii. determine whether clinical differences exist among patients who harbour 
GCR polymorphisms with either increased or decreased sensitivity 
compared to those with wild type.
7.3 Patients and methods
One hundred and forty seven (n = 147) patients with Addison’s disease were age, 
gender, ethnicity and BMI matched with 147 control subjects who attended a blood 
donor clinic. As there were limited numbers of healthy control subjects available, 
their selection was based on the closest possible match with the Addison’s 
disease patients. As a generalisation, there were far more potential white healthy 
control subjects available compared with other ethnic groups. Thus, the white 
healthy control subjects could be selected in a ratio of 1:10, whereas the mixed 
ancestry controls could only be selected in a ratio of 1:4 basis and for the black 
controls, 11 were selected from a possible 15 subjects. White and mixed ancestry 
patients were far better matched to their respective controls compared to the 
black and Asian patients. These latter two ethnic groups were represented by too 
few healthy volunteers and overall the matching was imperfect. The majority of 
the South African Addison’s disease cohort (95%) was enrolled in this study after 
signing written informed consent. 
7.3.1 Genotyping for glucocorticoid receptor polymorphisms
In this section the methods for DNA extraction and detection of GCR polymorphisms 
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7.3.1.1 DNA extraction
Genomic DNA purification was performed using a Promega Wizard Kit from 
Wisconsin, USA. 900 μl of cell lysis buffer was added to a 1.5-ml eppendorf tube, 
to which 300 μl of blood had been previously added. Once the tube had been 
inverted five to six times to mix the solution, it was left standing at room temperature 
for 10 minutes, during which time it was inverted twice. The entire mixture was 
centrifuged at 14 000 centrifugal accelerations related to gravity (xg) for 1 minute 
in a microcentrifuge tube. The supernatant was then poured off, leaving a small 
amount of residual liquid. Excess liquid was removed by blotting the inverted tube 
onto tissue. If the pellet was very red, 300 μl of lysis buffer was added and further 
lysis buffer was added. The pellet was resuspended by vigorously vortexing it in 
300 μl of nuclei lysis solution. Mixing was performed by sucking the suspension 
up and down, using a 1-ml Gilson pipette. 100 μl of protein precipitation solution 
was added, which was followed by a 15–20 seconds of vigorous vortex. This was 
followed by 14 000 xg of centrifuging for 3.5 minutes at room temperature. The 
supernatant was then decanted and the remaining liquid was blotted onto tissue. 
The pellet was then washed with 300 μl of 70% ethanol. This was inverted to 
mix the solution and followed by 3 minutes of further centrifuging, after which the 
supernatant was discarded. The tube was then drained upside down onto tissue 
for 30 minutes and 100 μl of DNA rehydrating solution was added and incubated 
overnight at room temperature. The DNA was stored at 4 °C for hours and at 
–20°C for longer periods.
7.3.1.2 Detection of the GCR single nucleotide polymorphisms: BclI, 
E22/23EK and N363S
The genotyping of the GCR gene for detecting the single nucleotide changes BclI 
G/C (rs41423247), ER22/23EK AA/GG (rs6189) and N363S G/A (rs6195) was 
performed by PCR amplication, followed by restriction length fragment length 
analysis. The primer pairs used in the PCR amplification were 5’-GCA GTG AAC 
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GCC TCT TAC TAA TCG GAT CA-3’ / 5’-TTT AAG TCT GTT TCC CCC GAG-3’ 
and 5’-TTT AAT GTC ATT CCA CCT ATT CCC-3‘ / 5’-AGC CAT TAG AAA AAA 
CTG TTC GAC-3’ respectively. The primers were designed by using Oligo.exe 
version 3.4 (National Bio-sciences, Hamel, Minnesota USA) (Table 40). Each 
PCR contained approximately 100–500 ng/μl genomic DNA, 1 × PCR buffer, 
1.5 mM MgCl2, 200μM of deoxyribonucleotide triphosphate (dNTP), 15 pM of 
each primer and 0.75U Thermus aquaticus (Taq) DNA polymerase (Promega–
Go Taq Flexi DNA Polymerase) in a final volume of 30 μl. The PCR conditions 
for all reactions were the same. The denaturation step was performed at 98 °C 
for 2 minutes, followed by 35 cycles of denaturation at 94 °C for 30 seconds 
and annealing was carried out at 52 °C for 30 seconds. Elongation occurred 
at 72 °C for 30 seconds and a final extension occurred at 72 °C for 8 minutes. 
The rs41423247 PCR products were digested using BclI restriction enzyme (C 
allele = 146 + 86 base pairs (bp), G allele = 232 bp), rs6189 PCR products were 
digested using Mn1 restriction enzyme (GAG AGG allele = 201 + 143 + 50 + 35 
+ 15 + 11 + 3 bp, GAA AAG allele = 201 + 178 + 50 + 15 + 11 + 3 bp) and rs6195 
PCR products were digested, using Tsp 5091 (A allele 91 + 36 bp, G allele = 127 
bp), according to manufacturers’ instructions. The products were separated on 
an agarose gel, visualised with ethidium bromide and the sizes of the fragments 
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Table 40: Primer pairs used for the detection of single nucleotide polymorphisms (SNPs) of the 
GCR
Polymorphism SNP Forward primer
Reverse primer
BclI G/C rs41423247 5’-GCA GTG AAC AGT GGT ACC AGA CC-3’5’-AAA GAG AAA AAT CAA ACG AAA GC-3
ER22/23EK AA/GG rs6189 5’-GCT GCC TCT TAC TAA TCG GAT CA-3’5’-TTT AAG TCT GTT TCC CCC GAG-3’
N363S G/A rs6195 5’-TTT AAT GTC ATT CCA CCT ATT CCC- 3‘5’-AGC CAT TAG AAA AAA CTG TTC GAC-3’
GCR: Glucocorticoid receptor
SNP: Single nucleotide polymorphism
rs: Reference SNP
A, C, G, T = DNA bases




BclI Restriction enzyme digest was separated on 2% agarose gel, lane 1 heterozygous, lane 
2 wild type, lane 3 heterozygous, lane 4 wild type, lane 5 homozygous, lane 6 wild type, lane 
7 heterozygous, lane 8 wild type, lane 9 heterozygous, lane 10 homozygous, lanes 11 and 12 
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ER22/23EK polymorphism (rs6189) Restriction enzyme digest  was separated on 4% agarose 
gel lane 1 heterozygous, lanes 2-13 wild type, lane 15 1KB plus marker (wild type GAG AGG/ 
GAG AGG, heterozygous GAG AGG/GAA AAG alleles)
300
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
200
100
N363S polymorphism (rs6195) Restriction enzyme digest was separated on a 2% agarose 
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wild type, lane 14 positive control, 15 1KB plus marker. (wild type AA allele, heterozygous AG, 
homozygous GG allele)
Figure 25: Agarose gel pictures showing digestion patterns for the three glucocorticoid receptor 
(GCR) polymorphisms
The genotyping quality was verified using the Hardy Weinberg Equilibrium (HWE) 
calculation on the controls and it was observed that none of the genotypes 
deviated from HWE, as shown by their respective p-values in parentheses: BclI 
(0.113), N363S (1.00) and ER22/23EK (1.00). None of the samples obtained was 
sequenced. The HWE test was also performed in ethnic sub-groups of healthy 
control subjects to determine whether there were problems with the genotyping 
methods. In the groups with sufficient sample size, the genotypes were also 
in HWE, suggesting that no problems were encountered with the genotyping 
methodology employed (Table 41).
Table 41: Hardy Weinberg equilibrium (HWE) test for controls (p-value), examined in relation to 
ethnicity
Polymorphism White Mixed Ancestry Asian Black
BclI (C to G allele) 0.45 0.56 0.709 _____*
ER22/23EK (GAG AGG to 
GAA AAG allele) 0.67 0.93 _____* 0.88
N363S (A to G allele) 0.75 0.93 _____* ______*
In the groups with sufficient sample size, the genotypes were in Hardy Weinberg equilibrium, 
suggesting no problems with the genotyping methods. 
p < 0.05 is considered significant
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7.3.2 Statistical methods
Clinical characteristics of patients and controls were compared, regardless of 
ethnicity.  Nonparametric and parametric data were compared, using the Mann-
Whitney and student-T tests, respectively.  The prevalences of polymorphisms 
between patients and their respective controls were compared.  Mixed-effects 
logistic regression was used to compare the genotype distributions between 
patients and controls, while simultaneously controlling for ethnicity and matched 
pairs.  Samples were analysed to determine whether the genotype had an 
effect on phenotype in healthy control subjects. Analysis was also undertaken 
to determine whether the genotype had an effect on phenotype in the Addison’s 
patients. Further analysis was undertaken to determine whether the effect of 
the polymorphisms differed between patients and controls (interaction). These 
analyses were carried out using logistic mixed regression models, adjusting for 
BMI, gender, age and ethnicity in both patients and controls, while in Addison’s 
patients foreign ancestry and hydrocortisone/m2 were additionally adjusted for. For 
all analyses a p-value <0.05 was interpreted as indicating statistical significance. 
7.4 Results
The pattern of enrolment of the 147 Addison’s disease patients who participated 
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154 patients identied
with Addison’s disease
4 patients were too late
for enrolment
147 patients were enrolled in 
the analysis of glucocorticoid 
receptor polymorphisms 
in Addison’s disease
7 patients excluded 
because of an incorrect 
label of Addison’s diseaseф
161 patients were referred 
for enrolment in the South 
African Addison’s study
3 patients declined
to participate in 
this study
Figure 26: Pattern of enrolment of patients in the study of glucocorticoid receptor polymorphisms.
ΦThere were seven patients who were not included in the study because of an incorrect label of 
Addison’s disease as two had normal ACTH stimulation test, two had secondary hypoadrenalism, 
one had bilateral adrenalectomy for Cushing’s disease and two had suppression of the 
hypothalamic-pituitary adrenal (HPA) axis related to previous steroid use for another indication. 
Three patients declined to participate in this study citing personal reasons, and four were enrolled 
after DNA was analysed for glucocorticoid receptor polymorphisms. There were 147 patients 
who were ultimately enrolled in the study of glucocorticoid receptor polymorphisms in Addison’s 
disease.
7.4.1 Baseline clinical characteristics were compared between patients and 
controls
Comparison between patients and controls of baseline clinical characteristics 
showed that all parameters were significantly different, except for LDLC, TC, 
ethnicity and gender. The patients were older, the median BMI was lower and they 
had a significantly worse atherogenic profile, as deduced by a preponderance 
of small dense LDL, higher TG, lower HDLC and higher hs-CRP levels (Table 
42). As discussed in Chapter 5, a small sub-group was on lipid-lowering therapy, 
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initiated on lipid-lowering therapy or who had failed to achieve adequate lipid and 
lipoprotein targets on lipid-lowering therapy. On the other hand, patients had a 
lower BMI and lower NEFA levels, which may to some degree mitigate against 
the atherogenic potential from an adverse lipid profile. All the samples in both 
patients and healthy control subjects were taken in a non-fasted state, eliminating 
the postprandial state as a cause for the significant differences observed between 
these two groups. In view of these obvious differences, all future analyses were 
adjusted for BMI, age, gender and ethnicity for healthy control subjects, and in 
the case of patients, the analyses were adjusted for BMI, age, gender, ethnicity, 
foreign ancestry and hydrocortisone dose/m². For those parameters that were 
adjusted for, unadjusted comparisons are provided.

































BMI kg/m2 (IQR) 24.7 (22.1-30.3) 26.4 (24.1-31.2)    0.007*
TG mmol/L (IQR) 1.67 (1.1-2.61) 1.39 (0.97-2.13)    0.004*
TC mmol/L (SD) 5.70 (1.55) 5.77 (1.26)    0.64
HDLC mmol/L (IQR) 0.78 (0.53-1.07) 1.08 (0.93-1.27) <0.0001**
LDLC mmol/L (SD) 4.07 (1.37) 3.89 (1.17)    0.29
Proportion of small 
dense LDL N (%) 17/147 (12) 5/147 (3)    0.01*
NEFA μmol/L (IQR) 341.0 (142.5-654) 467 (325.8-644.0)    0.001*
Proportion on lipid 





















hs-CRP mg/L (IQR) 2.2 (0.97-6.38) 1.5 (0.64-3.25)    0.01*
Median: Age, BMI, TG, HDLC and hs-CRP
Mean: TC and LDLC
BMI: Body mass index
TG: Triglyceride
TC: Total cholesterol
HDLC: High-density lipoprotein cholesterol
LDLC: Low-density lipoprotein cholesterol
LDL: Low-density lipoprotein




p-value: Patients versus controls
p < 0.05 considered significant
*p < 0.05
**p < 0.0001
The observed genotype counts and frequencies, stratified by ethnicity and 
Addison’s disease status, are shown in Table 43. While there were no differences 
observed for the ER22/23EK and N363S polymorphisms in patients and controls, 
there were significant differences in the distribution of the BclI genotypes (p = 
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Table 43: Observed genotype counts and frequencies, stratified by ethnicity and Addison’s 
disease status 
Patients Controls
Polymorphism Ethnicity Genotype N freq N freq
BclI
C/C White Wild Type 34 0.38 43 0.45
G/C Heterozygote 47 0.52 40 0.42
G/G Homozygote 9 0.10 13 0.14
C/C Mixed ancestry Wild Type 18 0.53 22 0.65
G/C Heterozygote 15 0.44 10 0.29
G/G Homozygote 1 0.03 2 0.06
C/C Asian Wild Type 2 0.40 2 0.4
G/C Heterozygote 2 0.40 2 0.4
G/G Homozygote 1 0.20 1 0.2
C/C    Black Wild Type 8 0.73 10 0.91
G/C Heterozygote 3 0.27 0 0
G/G Homozygote 0 0.00 1 0.09
p-value 0.02*a 0.21b
ER22/E23EK
GAG AGG/ GAG AGG White Wild Type 84 0.93 88 0.92
GAA AAG/ GAG AGG Heterozygote 6 0.07 8 0.08
GAG AGG/ GAG AGG Mixed ancestry Wild Type 33 0.97 33 0.97
GAA AAG/ GAG AGG Heterozygote 1 0.03 1 0.03
GAG AGG/ GAG AGG Asian Wild Type 5 1.00 5 1
GAA AAG/ GAG AGG Heterozygote 0 0.00 0 0
GAG AGG/ GAG AGG Black Wild Type 11 1.00 10 0.91
GAA AAG/ GAG AGG Heterozygote 0 0.00 1 0.09
p-value 0.68c 0.60d
N363S
A/A White Wild Type 81 0.90 90 0.94











The effect of glucocorticoid receptor polymorphisms on the sensitivity to cortisol in Addison’s disease
Patients Controls
A/A Mixed ancestry Wild Type 33 0.97 33 0.97
G/A Heterozygote 1 0.03 1 0.03
A/A Asian Wild Type 5 1.00 5 1
G/A Heterozygote 0 0.00 0 0
A/A Black Wild Type 11 1.00 11 1




p < 0.05 considered significant
*p < 0.05
A,C,G = DNA bases
rr: Comparison of the distribution of the BclI genotypes among patients of different ethnic origins
rs: Comparison of the distribution of the BclI 1 genotypes among controls of different ethnic origins
rt: Comparison of the distribution of the ER22/23EK genotypes among patients of different ethnic 
origins
ru: Comparison of the distribution of the ER22/23EK genotypes among controls of different ethnic 
origins
rv: Comparison of the distribution of the N363S genotypes among patients of different ethnic 
origins
rw: Comparison of the distribution of the N363S genotypes among controls of different ethnic 
origins
7.4.2 Race distribution among patients with BclI (C to G) polymorphism 
A significant ethnicity-genotype association with BclI cases was observed, 














































Figure 27: Mosaic plot of BclI genotype frequencies according to ethnicity in Addison’s patients. 
The width of the blocks is proportional to the numbers of patients tested. Even taking into 
consideration the fact that white ethnicity represented the largest group tested, there was a still 
a greater frequency with which homozygous or heterozygous BclI polymorphism occurred.
MM: homozygous GG allele
WM: heterozygous GC allele
WW: wild type CC allele
The impact of gender, age and race (ethnicity) were explored in relation to the 
genotypes in both patients and controls, while the effect of foreign ancestry on the 
genotype of patients was examined (Table 44). Foreign ancestry was defined as 
any individual with a first- or second-degree relative from either Europe or USA. 
It is acknowledged that the vast majority of whites in South Africa have European 
ancestry, therefore it is expected that the genetic make-up of these subjects may 
mirror those of their European counterparts more closely compared to the other 
ethnic sub-groups. Gender and age did not influence the prevalence of any of the 
three polymorphisms examined in either patients or controls. On the other hand, 
race influenced the prevalence of the BclI polymorphism. Foreign ancestry did 
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Table 44: Gender, age, ethnicity and foreign ancestry associations with 3 glucocorticoid receptor 














Patients Controls Patients Controls Patients Controls Patients
BclI 
(C to G 
allele)
0.56 0.81 0.19 0.67 0.02* 0.21 0.66
N363S 
(A to G 
allele)






0.25 0.74 0.99 0.34 0.68 0.86 1
1: Comparisons made using Fisher exact test
2: Comparisons made using linear models
3: Foreign ancestry was only available for patients, thus no comparisons were made between 
patients and controls
A,C,G = DNA bases
p < 0.05 considered significant
*p < 0.05
7.4.3 Linkage disequilibrium
Linkage disequilibrium is when two alleles occur more commonly than is likely 
by random effects. It is known that linkage disequilibrium can differ between 
populations. Linkage disequilibrium (D’) was calculated using a standard method 
in the programme R (obtainable from www.r-project.org).
There was significant linkage disequilibrium between BclI (G allele) and the 
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observed in controls (p = 0.93) (Table 45). On the other hand, there is a weak 
association for the G allele of the BclI and the GAA AAG allele of the ER22/23EK 
polymorphism in Addison’s patients (p = 0.07). There was no linkage of the G 
allele of the N363S and the GAA AAG allele of the ER22/23EK in either the 
Addison’s disease patients or their controls.
It is acknowledged that the results come from a small data set, comprising 
heterogeneous groups, and random effects may be seen. While significant 
linkage was identified with two alleles as shown above, the significance of this is 
uncertain and the results of this analysis should not be over-interpreted, as it is 
unlikely to confer meaningful significance.
Table 45: Linkage disequilibrium for three glucocorticoid receptor (GCR) polymorphisms in 
Addison’s patients and controls
N363S (A to G allele) ER22/23EK (GAG AGG to GAA AAG allele).
Patients Controls Patients Controls
BclI (C to G allele) D -0.01 -0.00 -0.00 0.00
BclI (C to G allele) D’  1.0  0.05  1.0 0.01
BclI (C to G) allele Corr. -0.13 -0.00 -0.11 0.00
BclI (C to G allele) Chi²  4.72  0.00  3.25 0.00
BclI (C to G allele) p1-value  0.03*  0.93  0.07 0.95
N  141β  147  141β 147
N363S (A to G allele) D -0.00 0.00
N363S (A to G allele) D’  0.91 0.08
N363S (A to G allele) Corr. -0.02 0.07
N363S (A to G allele) Chi²  0.22 1.37
N363S (A to G allele) p2-value  0.04 0.24
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D: Distance between two loci
D’: The amount of linkage between two loci
p1 : Comparison of the linkage disequilibrium observed between the BclI G allele and N363S G 
allele and ER22/23EK GAA AAG allele
p2: Comparison of the linkage disequilibrium observed between the N363S G allele and the 
ER22/23EK GAA AAG allele
N: Number
Chi²: Chi-squared test
A,C,G = DNA bases
p < 0.05 considered significant
*p < 0.05
β: 6 patients with missing data
7.4.4 Comparisons of the prevalences of these polymorphisms between 
patients and controls
There were no gender, age or foreign ancestry related differences in the 
prevalences of the polymorphisms between patients and controls. The prevalence 
of the BclI (G allele) polymorphism analysed by race, differed between patients 
and controls (Table 45).
7.4.5 Frequencies of haplotype BclI-N363S-ER22/23EK
The frequencies of the various haplotype permutations are shown in Table 46. The 
combined wild type for each of the three polymorphisms was inferred in 62% of 
the patients and in 65% of the controls. The second most prevalent haplotype was 
BclI (G allele)/N363S (A allele)/ER22/23EK (GAG AGG allele), which occurred 
in 32% of patients and 29% of controls. All other haplotypes were observed at 
frequencies below 5%. The remaining possible permutations did not occur in this 
data set. There were no differences in the prevalences of the haplotypes between 
the patient and control groups.
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Polymorphism Haplotype frequency
BclI N363S ER22/23EK Patients N (freq) Controls N (freq) p-value
W (C) W (A) W (GAG AGG) 91 (0.62) 96 (0.65) 0.53
M (G) W (A) W (GAG AGG) 47 (0.32) 43 (0.29) 0.51
W (C) M (G) W (GAG AGG) 6 (0.04) 3 (0.02) 0.50





A, C, G = DNA bases
p-value: Comparison of haplotype frequencies in patients and healthy control subjects
p < 0.05 considered significant
7.4.6 Clinical characteristics of the BclI (G allele) polymorphism in healthy 
control subjects and patients
Clinical characteristics were explored in healthy controls and patients with 
Addison’s disease in relation to the BclI polymorphism (Table 47). The age and 
gender were no different among healthy controls of different BclI genotypes. 
In healthy controls, there were ethnic differences in the distribution of the BclI 
genotypes, as seen previously. For example, among white healthy controls, 
the most prevalent genotype was the wild type CC allele in 44%, while among 
healthy Asian and black controls, the heterozygous genotype (CG allele) 
was observed significantly less often than in their white and mixed ancestry 
counterparts. There were no ethnic differences in the distribution of the BclI 
genotypes among patients. However, when all the patients were compared to all 
the controls, there were differences in the distribution of the BclI genotypes. The 
clinical traits of BMI, gender, age and ethnicity were adjusted in both patients and 
controls. However, foreign ancestry and hydrocortisone/m2 were adjusted only 
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extreme value of 31.2 mIU/L, in a single patient due to possible non-compliance 
with thyroxine replacement. Among healthy control subjects, there were no 
differences detected in TC, TG, HDLC, LDLC, NEFA, hs-CRP and the proportion 
with small dense LDL among those individuals who carried at least one G allele 
for the BclI polymorphism, compared to the wild type (two C alleles). In Addison’s 
patients, there were no differences in the prevalence of hypertension, diabetes 
and use of lipid-lowering therapy, TC, TG, HDLC, LDLC, the proportion with 
small dense LDL, NEFA, hs-CRP, Framingham risk and AUC for salivary cortisol 
between those individuals who harbour at least one allele (G allele) for the BclI 
polymorphism and the wild type. Moreover, the total daily hydrocortisone dose 
did not differ between Addison’s patients who harbour at least one G allele for 
the BclI polymorphism and the wild type (two C alleles). Comparison between 
Addison’s patients and healthy controls, with respect to the BclI polymorphism, 
revealed that the TC, LDLC, small dense LDL, TG, HDLC, NEFA and hs-CRP 
did not differ when appropriately adjusted. On the other hand, there was a trend 
towards a greater BMI in the controls compared to the patients with respect to 
at least one G allele for the BclI polymorphism. In summary, the BclI (G allele) 
polymorphism had minimal effect on the clinical phenotype in both patients and 
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Table 47: Analysis of the effect of the BclI (C to G base change) in healthy control subjects and 
patients with Addison’s disease





















controls females N (freq)







0.77 α 0.54β 0.42γ
Ethnicity N (freq)
White                         controls
patients
Mixed ancestry      controls
patients
Asian                          controls
patients



































0.23 α 0.11 β 0.05γ
HypertensionΦ N (freq) 0(0) 14 (0.64) 8 (0.36) N/A 0.33 N/A









































Proportion of small dense 




















lipid lowering therapyΦ N 
(freq)











Total daily hydrocortisone 
dose mgΦ (IQR)
25.0 (13.1-30.0) 23.8 (20.0-30.0) 20.0 (15.0-30.0) N/A 0.742 N/A
Framingham risk (IQR) Φ 12.0 (5.3-22.0) 14.4 (8.0-27.4) 13.0 (4.3-21.9) N/A 0.39 N/A
TSH mIU/L (IQR)Φ 1.23 (0.90-2.46) 1.21 (0.50-1.91) 1.66 (0.93-2.18) N/A 0.2 N/A
AUC nmol*min*L-1 (IQR)Φ 431.0 (24.0-160.0) 271.0 (150.0-624.0) 760.0 (575.0-945.0) N/A 0.24 N/A
Median: Age BMI, TG, HDLC, NEFA, hs-CRP, total daily hydrocortisone dose, TSH and AUC
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BMI Body mass index
TG: Triglyceride
TC: Total cholesterol
HDLC: High-density lipoprotein cholesterol
LDLC: Low-density lipoprotein cholesterol
LDL: Low-density lipoprotein
NEFA: Non-esterified fatty acids
hs-CRP: Highly sensitive C-reactive protein
mg: Milligrams
TSH: Thyroid stimulating hormone
AUC: Area under the curve (salivary cortisol)
Φ: parameter examined in patients only




IQR: Interquartile range 
α: Unadjusted p-values for controls
β: Unadjusted p-values for patients
γ: Unadjusted p-Values for comparison of patients with controls
N/A: Not applicable
p-values for total number, age, gender and ethnicity were unadjusted 
p1-value: Comparing BclI genotypes among control subjects, adjusted for BMI, age, gender and 
ethnicity
p2-value: Comparing BclI genotypes among Addison’s patients, adjusted for BM), age, gender, 
ethnicity, foreign ancestry and hydrocortisone dose per metre squared
p3-value: Simultaneous/joint comparison between BclI genotypes, and between Addison’s patients 
and healthy control subjects (interaction), adjusted for BMI, age, gender and ethnicity
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7.4.7 Clinical characteristics of the ER22/23EK (GAA AAG base changes) 
polymorphisms in healthy controls and in patients with Addison’s disease
Clinical characteristics were explored in both the healthy control subjects and 
patients with Addison’s disease in relation to the ER22/23EK polymorphism 
(Table 48). There were no ethnic differences in the distribution of the ER22/23EK 
(GAA AAG base changes) polymorphism in patients and controls, and between 
patients and controls. There was no difference in age and gender among healthy 
controls, among Addison’s patients, and between healthy control subjects and 
patients of different ER22/23EK genotypes. The clinical traits of BMI, gender, 
age and ethnicity were adjusted in both patients and controls. However, foreign 
ancestry and hydrocortisone/m² were adjusted only in the patients.
In both the healthy control group and the Addison’s disease patient group, the 
BMI was considerably greater in the heterozygote subjects compared to the wild 
types and there was no difference when the patients were compared to all the 
healthy controls in relation to the ER22/23EK polymorphism. The LDL was lower 
in the heterozygote sub-group compared to the wild type group of healthy control 
subjects, but this relationship was not observed in Addison’s patients. Moreover, 
there was no difference in LDL when all the patients were compared to all the 
healthy controls.
The TC, TG HDLC, NEFA and the proportion of small dense LDL were not affected 
by the presence of the ER22/23EK polymorphism among healthy control subjects 
when adjusted for BMI, age, gender, ethnicity and foreign ancestry. Similarly, the 
TC, TG HDLC, NEFA, proportion of small dense LDL and hs-CRP were not affected 
by the presence of the ER22/23EK polymorphism among Addison’s patients when 
appropriately adjusted. One patient was excluded from the analysis because of 
a very high TSH due to non-compliance with thyroxine replacement for primary 
hypothyroidism. The prevalence of hypertension, diabetes and the use of lipid-
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of this polymorphism when adjusted. Within the context of this polymorphism, the 
HDLC was lower in all the patients compared to all the controls. However, the 
proportion with small dense LDL, TC, LDLC, TG, NEFA, Framingham risk and hs-
CRP did not differ between patients and controls in relation to this polymorphism. 
In summary, the BMI was higher in the heterozygote versus wild types in both 
patients and controls. The LDLC was lower among heterozygote controls compared 
to the wild type healthy control subjects, and the HDLC was lower in patients 
compared to healthy control subjects examined in relation to the presence of the 
ER22/23EK polymorphism. In summary, the GAA AAG base changes resulting 
in the ER22/23EK polymorphism was associated with an increased BMI in both 
controls and patients compared to the wild type. This polymorphism was also 
associated with a reduction in LDLC in healthy controls and HDLC was found to 
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Table 48: Analysis of the effect of the presence of the ER22/23EK (GAG AGG to GAA AAG base 
changes) polymorphism in healthy controls and patients with Addison’s disease
Heterozygotes Wild type p1-value p2-value p3-value
controls N (freq)















controls females N (freq)







Whites                       controls
patients
Mixed Ancestry      controls 
patients
Asians                        controls 
patients


























HypertensionΦ N (freq) 0 (0) 22 (1.0) N/A 0.21 N/A
DiabetesΦ N (freq) 0 (0) 20 (1.0) N/A 0.98 N/A































Proportion of small dense 

























Total daily hydrocortisone dose 
mgΦ (IQR) 30.0 (25.0-30.0) 20.0 (20.0-30.0) N/A 0.32 N/A
Framingham risk (IQR) Φ 9.0 (3.1-16.7) 13.3 (5.9-25.7) N/A 0.94 N/A
TSHΦ mIU/L (IQR) 1.10 (0.56-1.38) 1.46 (0.78-2.16) N/A 0.88 N/A
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Median: Age, BMI, TG, HDLC, NEFA, hs-CRP, total daily hydrocortisone dose, TSH and AUC
Mean: TC and LDLC
BMI: Body mass index
TG: Triglyceride
TC: Total cholesterol
HDLC: High-density lipoprotein cholesterol
LDLC: Low-density lipoprotein cholesterol
LDL: Low-density lipoprotein
NEFA: Non-esterified fatty acids
hs-CRP: Highly sensitive C-reactive protein
mg: Milligrams
TSH: Thyroid stimulating hormone
AUC: Area under the curve (salivary cortisol)
Φ: Parameter examined in patients only





α: Unadjusted p-values for controls
β: Unadjusted p-values for patients
γ: Unadjusted p-values for comparison of patients with controls
N/A: Not applicable
p-values for total number, age, gender and ethnicity were unadjusted 
p1-value: Comparing ER22/23EK genotypes among control subjects adjusted for BMI, age, 
gender and ethnicity
p2-value: Comparing ER22/23EK genotypes among Addison’s patients adjusted for BMI, age, 
gender, ethnicity, foreign ancestry and hydrocortisone dose per metre squared
p3-value: Simultaneous/joint comparison between ER22/23EK genotypes, and between Addison’s 














The effect of glucocorticoid receptor polymorphisms on the sensitivity to cortisol in Addison’s disease
7.4.8 Clinical characteristics of the N363S (A to G base change) polymorphism 
in healthy control subjects and patients with Addison’s disease
Clinical characteristics were explored in the healthy control subjects and in 
patients with Addison’s disease in relation to the N363S polymorphism (Table 
49). The distribution of N363S polymorphism did not differ between the patients 
and controls. The unadjusted age and gender were no different among healthy 
controls, among Addison’s patients, and between healthy control subjects and 
patients of different N363S genotypes. Ethnicity did not influence the distribution 
of the N363S genotype in either healthy control subjects or Addison’s patients. 
Moreover, when all the patients were compared to all the controls, no differences 
in ethnic distribution of the N363S polymorphism were discerned. The clinical 
traits of BMI, gender, age and ethnicity were adjusted in both patients and controls. 
However, foreign ancestry and hydrocortisone/m2 were only adjusted in patients. 
As before, TSH values were trimmed in the patients because of an extreme value 
of 31.2 mIU/ml from a single subject, likely due to non-compliance of thyroxine 
replacement for primary hypothyroidism. Among healthy control subjects, there 
were no differences in TC, TG, HDLC, the proportion with small dense LDL, 
NEFA and hs-CRP among those individuals who carried at least one G allele 
for the N363S polymorphism, compared to the wild type (two A alleles) when 
appropriately adjusted. In Addison’s patients, there were no differences in the 
prevalence of hypertension, diabetes and the use of lipid-lowering therapy, TC, 
TG, HDLC, LDLC, proportion with small dense LDL, NEFA, hs-CRP, Framingham 
risk and AUC for salivary cortisol between those individuals who harbour at 
least one allele (G allele) for the N363S polymorphism and the wild type with 
appropriate adjustment. Moreover, hydrocortisone dose/m2 did not differ between 
Addison’s patients who harbour at least one G allele for the N363S polymorphism 
and the wild type (two A alleles). Also, when all the patients were compared with 
all the healthy controls, the TC, LDLC, small dense LDL, TG, HDLC, NEFA and 
hs-CRP, when appropriately adjusted, did not differ with respect to the N363S 
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any of the clinical characteristics that were examined in this study.
Table 49: Analysis of the effect on the presence of N363S (A to G base change) polymorphisms 
in healthy controls and patients with Addison’s disease
Heterozygotes Wild type p1-value p2-value p3-value
Controls N (freq)














‡Gender               
controls females N (freq)







White                                     controls 
patients
Mixed ancestry                   controls
patients
Asian                                      controls
patients


























Hypertension N (freq) Φ 2 (0.09) 20 (0.91) N/A 0.07 N/A
Diabetes frequency N (freq) Φ 0 (0) 20 (1.0) N/A 0.084 N/A












































Proportion on lipid lowering therapy N 
(freq) Φ
2 (0.11) 17 (0.89) N/A 0.79 N/A







Total daily hydrocortisone dose mg (IQR) Φ 25.0 (20.0-30.0) 20.0 (20.0-30.0) N/A 0.20 N/A
Framingham risk (IQR) Φ 8.7 (7.4-26.2) 13.7 (3.5-22.3) N/A 0.31 N/A
TSH mIU/L (IQR) Φ 1.63 (0.94-1.84) 1.38 (0.76-2.15) N/A 0.18 N/A
AUC nmol*min*L-1 (IQR) Φ 131.0 (118.0-143.0) 404.0 (203.0-126.0) N/A 0.20 N/A
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Mean: TC and LDLC
BMI: Body mass index
TG: Triglyceride
TC: Total cholesterol
HDLC: High-density lipoprotein cholesterol
LDLC: Low-density lipoprotein cholesterol
LDL: Low-density lipoprotein
NEFA: Non-esterified fatty acids
hs-CRP: Highly sensitive C-reactive protein
mg: Milligrams
TSH: Thyroid stimulating hormone
AUC: Area under the curve (salivary cortisol)
Φ: Parameter examined in patients only





α: Unadjusted p-values for controls
β: Unadjusted p-values for patients
γ: Unadjusted p-values for comparison of patients with controls
N/A: Not applicable
p-values for total number, age, gender and ethnicity were unadjusted 
p1-value: Comparing N363S genotypes among control subjects adjusted for BMI, age, gender 
and ethnicity
p2-value: Comparing N363S genotypes among Addison’s patients adjusted for BMI, age, gender, 
ethnicity, foreign ancestry and hydrocortisone dose per metre squared
p3-value: Simultaneous/joint comparison between N363S genotypes, and between Addison’s 
patients and healthy control subjects (interaction) adjusted for BMI, age, gender and ethnicity
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7.5 Discussion
This is the first study to examine the effect of the common GCR polymorphisms 
in patients with hypoadrenalism and to correlate polymorphisms with either dose 
of hydrocortisone or with metabolic parameters.
The principal metabolic alteration conferred by the GCR polymorphisms was an 
elevated unadjusted BMI in healthy controls and patients, in the presence of the 
ER22/23EK polymorphism. However, the LDLC was reduced in heterozygous 
healthy control subjects when adjusted for BMI, foreign ancestry, gender and 
ethnicity. The ER22/23EK polymorphism was associated with a lower HDLC in 
patients compared to controls. Neither the BclI nor the N363S polymorphisms 
were associated with any significant alteration in any of the metabolic clinical 
traits examined in this study.
Since the prevalence of these GCR polymorphisms was similar among patients 
and healthy control subjects, no role for this gene in the pathogenesis of Addison’s 
disease in this South African Addison’s disease cohort was inferred. However, 
there were significant differences in the distribution of the BclI genotypes among 
patients of different ethnic origins, with a greater proportion of white ancestry 
subjects harbouring the G allele compared to the other ethnic groups. The small 
sample size could have influenced the distribution of this polymorphism among 
white ancestry subjects. The observed G allele frequency for BclI polymorphism 
in the NCBI database was 67%,7 whereas in the Addison’s patients and controls, 
the G allele frequency was 60% and 53% respectively.  The reduced frequency 
in Asian and black races, in both the patients and controls, may account for the 
disparity observed between the NCBI database and the Addison’s patients and 
their respective controls. In addition, the small sample sizes could have accounted 
for the observed low frequency. The observed GAA AAG allele frequency for 
the ER22/23EK polymorphism in the NCBI database varied between 0.02% 
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was 5% and 7% respectively, which is substantially greater than the available 
data from the NCBI database. The G allele frequency observed for the N363S 
polymorphism in the NCBI database varied between 0% and 8.3%, whereas in the 
Addison’s patients and controls, the observed G allele frequency was 5% and 7% 
respectively. In keeping with the NCBI database, the greatest frequency of the G 
allele was observed among the white patients. It is likely that the heterogeneous 
ethnic make-up accounts for the differences observed in this South African cohort 
study compared to the NCBI database.7 Further population-based studies are 
warranted to confirm these findings.
The ER22/23EK polymorphism appeared to have the greatest impact in its 
association with an elevated BMI among both healthy control subjects and 
the Addison’s disease patients. The effect and magnitude of the ER22/23EK 
polymorphism on elevating the BMI in the study of Addison’s disease is intriguing 
and has not been reported previously. If this is a true association, it would have 
been revealed in other studies of obesity, especially since a difference of 2 kg/
m2 in BMI was observed in this study. Similarly, a genome-wide scan for obesity 
showed that single nucleotide polymorphisms (SNPs), located on chromosome 
16, were most likely to affect BMI, hip circumference and mass.8 While a genome-
wide scan assessing susceptibility for T2DM in obese and non-obese subjects 
demonstrated four loci, none of them was related to chromosome 5, indicating 
that the SNP ER22/23EK was not associated with obesity in previous studies.9 
As far as could be determined, previous genome-wide association scans failed to 
demonstrate an association between obesity and any of the GCR polymorphisms. 
It was expected that this polymorphism should have resulted in a reduced in either 
a reduced or unchanged BMI. Therefore, the implication is that the presence of 
this polymorphism does not confer either an obligatory metabolically protective 
or reduced GC sensitivity phenotype. This finding of an elevated BMI, and in 
particular the magnitude of its effect size, in association with this polymorphism, 
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association, substantiation of this unforeseen association is warranted in future 
studies.
Additionally, the ER22/23EK (GAA AAG allele) polymorphism was associated with 
a reduction in LDLC in healthy control subjects but not in Addison’s patients. The 
absolute LDLC reduction was 0.47 mmol/L which was less than the 0.80 mmol/L 
observed by van Rossum et al.10 The explanation for the greater reduction in LDLC 
may lie in the age difference (average age of 40.5 years for the healthy control 
subjects versus 69.2 years in the study by Rossum et al) and discrepant mean 
LDL levels (3.46 mmol/L in the healthy control subjects versus 4.31 mmol/L in the 
elderly Dutch population study).10 There is evidence to support an increasing LDL 
with age, and it is conceivable that a higher baseline LDL may be modified to a 
greater degree by the ER22/23K polymorphism.11
It remains a challenge to reconcile the differential effect of this polymorphism on 
healthy control subjects, in which a reduction in LDL was observed compared 
to Addison’s patients, who demonstrated no change in LDL. As there were few 
subjects who were heterozygous for the ER22/23EK polymorphism, the possibility 
of a lack of statistical power needs to be entertained. Addison’s patients who 
were heterozygous for this polymorphism also exhibited lower LDL levels than 
the wild type, but this did not reach statistical significance. Patient LDL levels 
were scattered more widely (higher standard deviations), possibly impairing the 
ability to detect a statistical significance.
Pharmacological or supra-physiological doses of GCs could cause an increase 
in LDL,12-14 and the beneficial effect of the ER22/23EK polymorphism may be 
negated by the possibility of supra-physiological hydrocortisone replacement. On 
the other hand, no correlation was found in this study between hydrocortisone 
dose and LDL (as seen in Chapter 5), invoking the possibility that the reduction 
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Addison’s patients, is through an entirely different mechanism. In this cohort of 
both patients and controls, there was no evidence for coexistent competing GCR 
polymorphisms in the same patient, that is, sensitising and resistant haplotypes, 
ruling this out as a potential mechanism for selective LDL reduction in the healthy 
control subjects. Some studies have confirmed a favourable metabolic profile in 
relation to the ER22/23EK polymorphism. This beneficial effect on LDLC was 
not always universal, and one study confers benefit by trend and fails to reach 
statistical significance.10 15-17 There are no clear explanations for the difference 
in LDLC response between Addison’s patients and controls. Overall, these 
polymorphisms were very poorly predictive for a specific clinical or metabolic 
phenotype.
The ER22/23EK (GAA AAG allele) polymorphism was also associated with 
a decreased HDLC in patients compared to healthy controls. However, this 
observation was seen neither in the healthy controls nor the Addison’s patients 
as independent groups. Already, prior to examining the GCR polymorphisms, the 
Addison’s patients exhibited a significantly lower HDLC compared to their healthy 
controls, which suggests that this discrepant relationship may be exaggerated 
when examining the polymorphisms. As the ER22/23EK polymorphism is 
associated with decreased GC sensitivity, it is speculated that it in turn may result 
in lower HDLC levels18 due to possible coexistent inflammation. However, the 
ER22/23EK polymorphism is associated with decreased GC sensitivity and a 
favourable CV lipid profile, and thus the lower HDLC is counterintuitive.19 It is 
not clear whether this polymorphism may have a greater influence in Addison’s 
patients, as they may have a greater coexistent acute phase response compared 
to healthy control subjects, which accounts for the marked differences in HDL.18 
The study by van Rossum et al did not show a difference in HDL in relation to the 
ER22/23EK polymorphism, and as far as is known, there are no previous studies 
to support the finding of a low HDL associated with this polymorphism.17  The 
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The BclI and the N363S polymorphisms did not appear to alter the clinical traits 
significantly. The small sample of patients may have contributed to the lack of 
association. As these polymorphisms only modestly alter the phenotype, it is 
not surprising that this study failed to show an association with the BclI and 
the N363S polymorphism. There are several negative studies examining the 
influence of these three polymorphisms in different clinical scenarios. Donn et al 
showed no association between the ER22/23EK polymorphism and rheumatoid 
arthritis.20 Decorti et al and De Iudicibus et al similarly found no association with 
inflammatory bowel disease and both the ER22/23EK and N363S polymorphisms 
respectively.21 22  Spijker et al failed to find association with the latter polymorphism 
and bipolar affective disorder.23 Lee et al identified no association between the 
BclI polymorphism and rheumatoid arthritis in Korean subjects.24
Harbouring a polymorphism does not invariably give rise to a clinically significant 
alteration or abnormal phenotype. There are a number of negative studies that 
show no metabolic derangements in association with polymorphisms that are 
expected to enhance GC sensitivity. In a study by van Rossum et al, elderly 
Dutch individuals who demonstrated increased sensitivity to dexamethasone, 
counterintuitively had lower BMI and a tendency towards lower lean mass, 
whereas fat mass was no different in individuals harbouring the BclI polymorphism 
compared to the wild type genotype.25 The incongruity of these studies may 
corroborate the tenuous effect that these polymorphisms confer on modifying the 
clinical phenotype.
A strong linkage disequilibrium exists between BclI (G allele) and N363S (G allele) 
in the South African Addison’s patients. This has not been observed previously. 
As the combination of these alleles could contribute to enhance glucocorticoid 
sensitivity, it is difficult to reconcile how the combination of these alleles may 
predispose to either the development or the progression of Addison’s disease. 
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risk for the development of Addison’s disease. Since this data comes from a 
small group, which was heterogeneous and random effects may be seen, 
it is unlikely to be of any meaningful clinical significance. On the other hand, 
researchers have examined the relationship between ACTH-secreting tumours 
and GCR polymorphisms. The N363S polymorphism occurred in 17% of ACTH-
secreting tumours in one study, but this was unlikely to be pathogenic as the latter 
polymorphism resulted in increased sensitivity of cortisol, and a polymorphism 
inducing resistance would more likely explain the molecular defect, which was 
not detected.26 
There are isolated studies that have explored the relationships between steroid 
dose and GCR polymorphisms. Szczepankiewicz et al showed that there was no 
association between any of the GCR polymorphisms and the need for increased 
doses of GCs for asthma.27 Similarly, in this cohort of South African Addison’s 
disease patients, no association was found between hydrocortisone dose and 
the various GCR polymorphisms, even when adjusting for hydrocortisone/m2. In 
addition, the AUC for salivary cortisol was not associated with any of the GCR 
polymorphisms examined. Intracellular cortisol accumulation, as measured by 
3H-cortisol, is substantially lower than the amount with which neuronal tissue was 
incubated, but the major intracellular cortisol is unbound to the GCR.28 Therefore, 
as the amounts of cortisol that bind to the receptors are very small compared 
to the levels in the circulation, it was considered unlikely therefore that the AUC 
for salivary cortisol would be affected by the GCR polymorphisms.29 Further, the 
main clearance of plasma cortisol is via hepatic (production of glucuronides) and 
renal metabolism, where the 11 beta-hydroxysteroid-dehydrogenase-II converts 
cortisol to cortisone, in addition to the production of 17-hydroxycorticoids.30  
Very few studies have examined the association between AUC for cortisol exposure 
and GCR polymorphisms. Similarly, no previous studies, to my knowledge, have 
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in primary hypoadrenalism. In two of these three alleles which occur at low 
frequencies, the possibility of false negative results should be considered.
There are a number of potential pitfalls in performing association studies with 
polymorphisms and phenotyping. Accuracy can be enhanced by increasing 
the sample size and thereby minimising inter-research variation. Indeed, the 
possibility of performing a type I error can occur with multiple testing. Additionally, 
it has been suggested that these polymorphisms can exert different effects in 
different ethnic groups, and ideally, a homogenous population should be selected 
in order to determine the true effect.31
It was assumed that patients harbouring a sensitising GCR polymorphism may 
require lower doses of hydrocortisone, whereas individuals with a polymorphism 
inducing a degree of GC resistance may require higher doses of hydrocortisone, by 
virtue of persistent symptoms of GC insufficiency.32 Nevertheless, no relationship 
between GCR polymorphisms and hydrocortisone doses was found in this study. 
This may possibly be explained by the fact that hydrocortisone doses were 
prescribed on a totally empiric basis by their treating doctor.
7.5.1 Weaknesses of this study
The small number of participants with this rare condition may have contributed to 
the lack of associations found. The 9β polymorphism of the GCR gene has been 
associated with an increased risk of myocardial infarction, especially in an elderly 
sub-group.  Those who were homozygous for this polymorphism had increased 
intima media thickness and an almost threefold increased risk of CVD,33  therefore 
analysis of this polymorphism may have yielded interesting data in the South 
African Addison’s disease patients. 
7.5.2 Conclusion
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in healthy controls and patients harbouring the ER22/23EK polymorphism. This 
was in contrast to what was expected, considering that it normally reduces 
cortisol sensitivity. Additionally, no relationship was found between the doses of 
hydrocortisone and the presence of any of the BclI, N363S and ER22/23EK GCR 
polymorphisms. Further work is required to confirm whether these findings can 
be corroborated in a larger series of Addison’s patients on replacement doses of 
GCs.
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Chapter 8
Final discussion, recommendations and 
concluding remarks
8.1 Summary of the major findings
Utilising a systematic classification of Addison’s disease, it was possible to 
confirm that autoimmune Addison’s disease occurred in more than 50% of this 
cohort, contradicting an earlier study suggesting that autoimmune Addison’s 
disease is uncommon in South Africa.1 2  In keeping with several research groups, 
HLA DQB1*0201 and *0302 alleles were associated with APS2 when patients 
with T1DM were excluded.3-6 Despite the burden of the two epidemics that South 
Africa is currently facing, tuberculosis as a cause for Addison’s disease7 8 was 
remarkably uncommon and none of the Addison’s disease in this cohort was 
caused by either HIV or AIDS.9 10 Although there were few black or Asian South 
Africans in the cohort, none had adrenal autoantibodies. Further as found by 
Tanaka et al, ACA were less detectable than 21-hydroxylase autoantibodies, long 
after the onset of Addison’s disease.11
Several lipid and lipoprotein parameters were worse in patients compared to 
controls, indicating that Addison’s disease patients may have a predisposition 
to abnormal lipids and lipoproteins. Approximately 65% of patients exhibited 
hypercholesterolaemia of >5.0 mmol/L, hypertriglyceridaemia >1.7 mmol/L 
was identified in approximately 50%, about 75% of patients had an HDLC <1.0 
mmol/L and 75% demonstrated an LDLC >3.0 mmol/L. Coexistent diabetes 
mellitus increased moderate levels of hypertriglyceridaemia and further raised 
severely elevated LDL levels. South African Addison’s patients demonstrated 
a more adverse lipid profile than the matched Swedish patients. An increased 
incidence of small dense LDL and elevated hs-CRP concentrations was identified. 
This comprehensive analysis has established a probable causal link between 
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to the body of knowledge in this area.
Based on the salivary cortisol data, Addison’s disease patients had a much 
greater cortisol exposure than that generated by the healthy control subjects’ 
endogenous cortisol production. The median dose of hydrocortisone was 12 mg/
m2 and as such is likely to represent supra-physiological concentrations given 
that the normal daily cortisol production is 6-11 mg/m2.13 The peak salivary cortisol 
correlated well with the AUC in both patients and healthy control subjects. Thus 
the peak concentration may be used as a surrogate marker for monitoring AUC in 
both Addison’s patients and healthy control subjects, limiting the need for multiple 
sampling and reducing the attendant expense. 
The predominant metabolic changes associated with the ER22/23EK GCR 
polymorphism were an elevated BMI in Addison’s disease patients and 
healthy control subjects. These findings were entirely counterintuitive as this 
polymorphism ostensibly confers a degree of GC resistance.14  A lower LDLC 
was associated with the ER22/23EK polymorphism in healthy control subjects 
only, and may be partially explicable by GCR resistance. Neither the BclI nor 
the N363S polymorphisms were associated with alterations in any of the studied 
metabolic clinical characteristics.
8.2 Strengths of the study
The relatively large size of this cohort is a strength of the study. The cohort 
was derived from several sources, including databases from medical insurance 
companies, a database generated by the researcher of private and public health-
care and a commercial database. It sought to enrol patients from all geographical 
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Sera were subjected to a large panel of appropriate autoantibodies and DNA was 
collected for genetic studies. At least two confirmatory adrenal autoantibodies 
were screened for, as it is known that 21-hydroxylase autoantibodies are more 
sensitive than the immunofluorescence assay of ACA in cases with overt primary 
adrenal failure.11 Addison’s patients were compared to healthy control subjects 
and several cohort studies of lipids and lipoproteins in the community,15-18 
providing at least two strata for comparison with healthy subjects. Unlike the 
study by Giordano et al, the South African Addison’s disease study elucidated 
in detail the impact of the combination of Addison’s disease and diabetes on 
lipids and lipoproteins.19 Three biochemical markers of CVD were also examined 
in this study including small dense LDL, hs-CRP and NEFA; two of these have 
established roles in evaluating patients for CVD risk.20 21 
The salivary cortisol was measured 16 times in a 16 hour period in this study, 
which is considerably longer than many others in an exclusively primary adrenal 
cohort.22-27 It also showed that it is possible to monitor replacement therapy in 
rural and isolated regions of a vast country, where infrastructure is poor.
The study of GCR polymorphisms in Addison’s disease is novel and provides an 
insight, as to how this polymorphism could be altering the clinical phenotype in 
this condition.
8.3 Weaknesses of the study
The study has a number of weaknesses. Its cross-sectional design ensured that 
several cases were included many years after the diagnosis was made. There 
were missing biochemical data, confirmatory of Addison’s disease in a proportion 
of the study participants and the symptoms at original diagnosis are likely to have 
been subject to recall bias. The contribution of autoimmunity to the aetiology of 
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autoantibody positive at diagnosis, have become autoantibody negative at enrolment 
in the study.7 8
 
In the absence of a national registry, the prevalence of Addison’s disease may 
have been underestimated. Most patients’ lived in close proximity to major 
teaching hospitals, indicating a likely degree of ascertainment bias. Although the 
study does show ethnic heterogeneity, the black and Asian participant numbers 
do not reflect the relative proportions of these groups in the country.28 Additionally, 
the study is underpowered to examine HLA differences in these ethnic groups. 
This study design also precluded an analysis of lipids and lipoproteins, at 
diagnosis and in the long-term. It provided a survey of lipid and lipoproteins as 
a snapshot rather than evaluating the consequences of hypoadrenalism per se 
and GC replacement therapy, both of which have the potential to influence lipid 
and lipoprotein metabolism. The TG levels could have been elevated because 
the samples of South African subjects’ lipid profiles were taken in the non-fasted 
state.29 In the comparison of the Swedish and South African Addison’s patients, 
lipid analyses were performed in two separate laboratories and exchange of 
samples was not carried out. Ideally method comparison studies to determine 
the relative agreement between two different methods should have been carried 
out.30
The healthy South African control subjects were not selected from a central 
subject pool who meet carefully defined selection criteria, but were recruited from 
the blood donor clinic. This resulted in inadequate matching, for example there 
were insufficient black and Asian healthy control subjects and may also have 
introduced a degree of volunteer bias.31 
The salivary cortisol study was performed at the participants’ homes and was thus 
unsupervised, allowing for the possibility of erroneous sampling of saliva or failure 











Final discussion, recommendations and concluding remarks
insufficiently powered to determine an association with metabolic derangements. 
This relatively large cohort is likely to have been too small and/or too heterogeneous, 
to find metabolic associations with GCR polymorphisms. Healthy control subjects 
were limited, precluding perfect matching. As the Addison’s patients were 
receiving empiric GC replacement therapy, selected by their physicians this 
could have contributed to the lack of association of the GCR polymorphisms and 
hydrocortisone replacement doses.
8.4 Major implications of this study
It is highly likely that Addison’s disease is being under-diagnosed in South 
Africa given that the prevalence is considerably lower than reported in Western 
countries.32-34 and people may be dying despite it being an eminently treatable 
condition. There should be widespread emphasis on the constellation of specific
symptoms to alert physicians to the possibility of Addison’s disease and in so 
doing raise the awareness for this life-threatening disease. The combination 
of hyperpigmentation, nausea, vomiting and weight loss should suggest 
Addison’sdisease, as confirmed by three previous studies and corroborated in 
this study of Addison’s disease.2 35-37 There is a need to develop mindfulness of 
Addison’s disease, which has been referred to as one of the great mimickers of 
medicine. 
A German retrospective study of adrenal insufficiency showed that in 45% of 
cases a false diagnosis was made, of which psychiatric disorders were thought 
to be the aetiology in 27%, gastrointestinal disorders in 5% and the remainder 
were non-classified.35 The probable explanations for the under-diagnosis include
hyperpigmentation which could be overlooked in darkly pigmented races.38 
The large populations of HIV and tuberculosis-infected patients in South Africa 
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rather than to primary hypoadrenalism. Under-diagnosis may also be explained 
by patients having unequal access to health-care, particularly those living in 
ruralareas. Health delivery is also hindered by the small secondary and tertiary 
hospital sectors, relative to the need in South Africa.39 40
Since Addison’s disease occurs even at the highest recorded prevalence at fewer
than 5 cases per 10 000 people in the overall population, it may be considered 
a rare or orphan disease.41 Most physicians do not see a single patient with a 
life-threatening rare disease in their entire careers. The European Organisation 
for Rare Diseases (EURODIS), estimates that there are between 5000 and 8000
distinct rare conditions affecting between 6 and 8% of the population and notes 
that frequently there are no health policies for these. In addition, there is a paucity
of expertise which translates into delayed diagnosis and difficulty in accessing 
health-care. The benefits of establishing a patient organisation are to create 
awareness among physicians, to strengthen co-operation with non-governmental
organisations and to improve quality of life.42 Education may be disseminated 
through websites and local meetings in which patients, their family members, 
physicians, non-governmental organisation workers and government officials can
meet with a view to inform and educate citizens about rare diseases.43
Even in the USA, black men suffer worse clinical outcomes compared with 
other ethnic and gender counterparts. Socio-economic status, masculinity, 
discrimination on the basis of ethnicity, lack of awareness to seek primary health-
care, religious beliefs and influences by peers have been identified as barriers for
this sub-group to obtain appropriate and timeous treatment.44 This phenomenon 
could have also contributed to the disparity in ethnic representation in the 
South African Addison’s study. Health-care providers and the media could also 
contribute by raising awareness of either specific illnesses or that all individuals 
regardless of their ethnicity or gender should be encouraged to seek medical 
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it is the political endorsement of state and national strategies, which is needed 
to ensure that all ethnic groups and genders do not feel awkward in respect of 
accessing health-care.44
Another possible way to increase recognition of primary hypoadrenalism is to 
emphasise this condition to medical students. Clinical reasoning is dependent 
upon two processes: an analytic process which refers to a deductive approach 
and a non-analytic method or pattern-based recognition, which relies on past 
clinical experience or illness scripts. Advanced clinicians have inevitably a far more 
extensive library of illness scripts and rely on pattern recognition.45 Diagnostic 
errors have been hypothesised to result from either faulty detection of clinical 
features or faulty triggering of diagnostic hypotheses. The history and physical 
examination led to the correct diagnosis in 70%, compared to 35% for radiological 
techniques in one study, emphasising clinical knowledge and competent reasoning 
abilities as being pivotal in order to arrive at a correct diagnosis.46 It was found 
in 1991 found that 58% of patients attending a rural ambulatory clinic in the USA
were subject to a diagnostic error.45 Checklists, informing colleagues of diagnostic
errors, automated decision-making for unusual clusters of signs and symptoms 
may be helpful in avoiding diagnostic error.47
The vital implication of the finding of abnormal lipids, lipoproteins and markers of
CVD in primary hypoadrenalism, is that it has elucidated plausible arguments for
accelerated CVD mortality in this disease. Addison’s disease may now represent
an independent CVD risk factor, akin to rheumatoid arthritis, which demands 
surveillance and intervention.48 There are several coexistent lipid, lipoprotein 
and biochemical markers of CVD which corroborate that Addison’s disease is 
at increased risk for CV events. As these markers indicate independent risk, it 
could attest to the fact that Addison’s disease patients may be vulnerable for 
CVD through multiple concurrent mechanisms. For example, a high proportion 
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strongly predictive for CVD events. By implication a reduction of HDLC by 0.03 
mmol/L could accord a 20% increase in CVD events.49 Moreover, approximately
50% of Addison’s disease patients exhibited TG >1.7 mmol/L which represents 
an independent risk factor for CVD. There was a greater proportion of patients, 
compared to their healthy control subjects, who had predominant small dense 
LDL, which confers a 3-7 fold increased risk of coronary artery disease.21
Physicians should be cognisant of this risk and pay particular attention to screening 
for CVD risk. This should be incorporated in the usual care of patients, as required 
in the usual care of a diabetic patient.50 Lifestyle modification, exercise and dietary 
recommendations should be the norm and a low threshold for introduction of 
lipid-modifying therapy and a preparedness to confirm that the
NCEP ATP III targets are being achieved.51 The patients who have both diabetes
and Addison’s disease will require meticulous surveillance and intervention to 
ensure that their additional CVD risk factors, such as adequate glycaemic and 
blood pressure control, are addressed.
This study should serve as a reminder to clinicians that replacement doses 
of hydrocortisone may induce supra-physiological concentrations of cortisol, 
potentially placing patients at risk for the cluster of GC related side-effects. A 
systematic evaluation for possible GC excess should include evaluation of emotional 
lability, weight gain, insomnia, evolution of diabetes mellitus, hypertension, peptic 
ulcer disease, impaired wound healing, increased susceptibility to infections, 
atherosclerosis, fatty liver, osteoporosis, glaucoma and mood disturbance.52
As the ER22/23EK polymorphism was associated with an elevated BMI, this 
could contribute to the increased CVD risk. Analysis of the Framingham data 
identified that the relative risk for CVD for the overweight category was 1.20 and
the relative risk for the obese males and females was 1.46 and 1.64 respectively,
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CV risk factor. Routine assessment of body mass and anthropometry at patient 
follow-up visits should be recommended in Addison’s disease patients.
8.5 Recommendations for future study
As Addison’s disease is rare, collaboration with established research groups 
may provide sufficient numbers of patients and thus greater statistical power to 
address research questions in relation to CVD risk, salivary cortisol exposure and
the influence of GCR polymorphisms, raised by this study. Several international 
Addison’s disease registries have already contributed substantially to the body 
of knowledge relating to this disease. For example Euradrenal is the European 
patient registry, representing multiple European nations’ cohorts of autoimmune 
Addison’s disease and incorporating several national networks. From 2009 
to 2010, at least 17 publications were identified from this registry, covering 
immunology, autoimmunity, metabolic and CV profiles, clinical features of primary
hypoadrenalism and complications related its replacement.54 Registries such as 
these would provide ideal platforms with which to collaborate.
8.5.1 Suggestions for further evaluation of CVD risk 
Further evaluation of CVD risk in Addison’s patients should be undertaken using
the national registry and in collaboration with international research groups. 
Utilising a national database, dietary evaluation could elucidate dietary influences
on lipids and lipoprotein and may explain the vast differences between the 
Swedish and South African cohorts. Dietary patterns have been used to examine
the relationship of health outcomes and the total usual food intake in individuals 
and groups. Multiple diet-record days, 24-hour recalls or the Healthy Eating 
Index score may be used to assess consumption.55 The latter score allocates 
points for saturated fat intake, and intake of fruit, vegetables, grains, milk and 
dairy products. The Mediterranean diet score evaluates the intake of non-refined 
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fat dairy products and alcohol. Statistical analyses examine actual intake patterns
and have been shown to offer good reproducibility in diverse populations.55 Such
analysis could be useful in understanding if lifestyle contributes to worse lipid and
lipoprotein profiles in South Africa compared to Sweden. On the other hand, it should 
be appreciated that dietary analyses require large numbers of participants for the 
association of CV risk with eating patterns to be demonstrated. The association 
in several studies was attenuated after adjusting for several factors including 
smoking, physical activity, education level, BMI and alcohol consumption.56 
Although collaboration with international research groups could improve follow-up 
and documentation of CVD events and it may permit the derivation of a conversion
factor for the Framingham risk assessment of Addison’s disease patients, a 12 
year follow-up possibly is warranted with several thousand Addison’s patients. 
Identification that hs-CRP is elevated in Addison’s disease in this cohort should 
be a catalyst to study whether this translates into imminent risk for CVD events or
whether it is a signal for emerging serious infection. In the setting of community 
acquired pneumonia for example, hs-CRP has an important role in distinguishing
bacterial from non-bacterial and non-infectious causes of respiratory symptoms, 
supporting its role as an early warning system for serious infection.57 Particularly,
when examining CVD events large numbers of participants in association with 
Addison’s disease are required to generate meaningful data, but designers of 
these kinds of studies should be mindful of the local background event rates and
adjustaccordingly.
There are several further areas of study relating to CVD which warrant evaluation
requiring large-scale cooperation with international research groups. In order 
to gain insights as to whether the lipid abnormalities may be associated with 
Addison’s disease and/or its treatment, it would be crucial to evaluate lipids 
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studies once established on maintenance GC therapy. Ridker et al, in 2003 
showed that the relative risk for first-ever myocardial infarction or stroke as well 
as the onset of symptomatic peripheral arterial disease relates to baseline hs-
CRP.58 Epidemiological studies have confirmed a strong relationship between 
hs-CRP and carotid intimal medial thickness, warranting confirmation whether 
this relationship also occurs in Addison’s disease, to account for this increased 
CV mortality.59 The implication of NEFA concentrations should also be examined 
in future studies to determine if lower concentrations have a protective effect 
against future CV events.
8.5.2 Suggestions for further evaluation of salivary cortisol 
Larger international studies are required to corroborate the discrepant cortisol 
exposure in Addison’s disease patients on hydrocortisone and healthy control 
subjects’ endogenous cortisol concentrations noted in this study, and whether 
this excessive exposure predisposes to the evolution of complications. Further 
studies are warranted to assess whether a dose reduction of hydrocortisone could
minimise the development of side-effects. As the peak salivary cortisol correlates
well with the AUC, this relationship should also be explored to determine if a 
correlation exists with metabolic consequences.
While Addison’s disease patients have subjective impaired health quality attributed 
to the prolonged nadir of sub-physiological concentrations of serum cortisol,60 
depression has also been linked to increased salivary cortisol exposure.
In the context of Addison’s disease patients exhibiting higher salivary cortisol 
concentrations it would be important to establish whether there is a correlation 
between salivary cortisol concentrations and depression scores.61 Psychological
well being scores and correlation with salivary cortisol AUC could clarify, whether
supra-physiological doses of hydrocortisone may be contributing to depression, 
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performed using both an available national registry of Addison’s disease and in
collaboration with others.
As there is progress in the development of newer modified prolonged release 
preparations for replacing GCs in hypoadrenal individuals as reported by 
Johannsson et al,62 salivary cortisol could be an additional modality in which to 
evaluate whether the exposure to cortisol is more physiological.
8.5.3 Suggestions for further genetic analyses
International larger studies could confirm the phenotypic findings in relation to 
the GCR polymorphisms. Determination as to whether the GCR polymorphisms 
confer subtle derangements in insulin sensitivity parameters could be of interest 
as insulin resistance may potentiate CVD risk.63 Enzyme kinetics of 11 beta- 
hydroxysteroid-dehydrogenase-I may influence the clinical phenotype. Two 
polymorphisms rs846910 and rs13306421 have an in vitro effect of raising 
this enzyme activity and evaluation should be undertaken as to whether these 
polymorphisms associate with metabolic abnormalities in Addison’s disease. 
Potentially they can enhance the GC side-effect profile of replacement doses, by
reducing metabolism to cortisone.64 Larger cohort studies will make inferences of 
genetic conclusions far more credible.
8.5.4 Novel forms of therapy
While there is ongoing research aimed at improving replacement therapy for
patients with Addison’s disease,62 these novel forms of therapy may need to be
evaluated with GCR or 11 beta-hydroxysteroid-dehydrogenase-I polymorphisms,
with the view of developing individualised, rather than empiric therapy.
8.5.5 Broader consequences of this study 
The methodology employed in this study to identify patients with a rare disease 
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databases are actualised. This study has underscored that there is a failure to 
institute global recommendations, for example, initiating lipid-modifying therapy in 
diabetics and it has documented that even when this therapy was administered, 
the minority achieved targets. Studies have shown that although patients were 
prescribed lipid-lowering agents, many patients failed to achieve adequate goals
due to poor adherence, affordability of therapy and factors relating to health-care 
provision including either not following or understanding the guidelines, inadequate 
follow-up with laboratory testing, and insufficient dose-titration. Despite these 
barriers, a recent study revealed that close follow-up and point of care testing of 
lipids and lipoprotein fractions resulted in 68% of participants maintaining target 
lipid levels for three years compared to only 30% in other national surveys.65 
The South African Addison’s study has also highlighted the significant deficiencies
in current local available normative lipid data. This should be prioritised and 
should include populations of HIV-infected patients. These patients are prone 
to decreases in HDLC and LDLC and those who are treated with highly active 
anti-retroviral therapy have a propensity to exhibit elevations in TC, LDLC and 
HDLC with first-generation nonnucleoside reverse transcriptase inhibitors, while 
the second generation nonnucleoside reverse transcriptase inhibitors have less 
effect than the first generation. The nucleoside reverse transcriptase inhibitors 
impact on both TG and TC and protease inhibitors have led to enhanced VLDL 
secretion.66 Therefore HIV positive patients and those who are on antiretroviral 
therapy should be screened for lipid and lipoprotein abnormalities, as they 
represent a large population which could influence national averages.
While hypopituitarism has enjoyed extensive recognition as a condition associated
with CVD risk, there have been very few reports of the relationship between 
lipid abnormalities and CVD in Addison’s disease and CAH.67-69 Appreciation for 
repeat lipid and lipoprotein evaluation in Addison’s disease and a low threshold 
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disease patients, compared with healthy control subjects’ endogenous cortisol 
concentrations, this study should be extended to evaluate CAH, hypopituitarism 
and asthma sufferers. Similarly, GCR polymorphisms should also be evaluated 
and correlated with hydrocortisone dose, in the setting of hypopituitarism and 
CAH to determine if they have an impact on metabolic parameters or doses of 
hydrocortisone.
8.6 Final conclusions
An extensive analysis of Addison’s disease in South Africa has been undertaken 
and has yielded novel data. It has highlighted the need for improved education 
of medical students and practising doctors so that the diagnosis of Addison’s 
disease is not missed. There should be emphasis on the constellation of 
symptoms suggestive of primary hypoadrenalism to remind clinicians of this 
disorder. Moreover it should alert the clinician to consider Addison’s disease as 
a condition, requiring surveillance and intervention to limit CV risk. It highlighted 
that the cortisol exposure in hydrocortisone replaced patients is many-fold higher 
than healthy control subjects, necessitating both further studies and appreciation 
for the potential harm. Further studies, incorporating cohorts from different parts 
of the world should be undertaken to corroborate and extend the findings of this 
body of work.
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